WO2013036835A1 - Neuroactive steroids, compositions, and uses thereof - Google Patents

Neuroactive steroids, compositions, and uses thereof Download PDF

Info

Publication number
WO2013036835A1
WO2013036835A1 PCT/US2012/054261 US2012054261W WO2013036835A1 WO 2013036835 A1 WO2013036835 A1 WO 2013036835A1 US 2012054261 W US2012054261 W US 2012054261W WO 2013036835 A1 WO2013036835 A1 WO 2013036835A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
certain embodiments
compound
alkyl
Prior art date
Application number
PCT/US2012/054261
Other languages
French (fr)
Inventor
Ravindra B. Upasani
Boyd L. Harrison
Benny C. ASKEW Jr.
Jean-Cosme DODART
Francesco G. Salituro
Albert J. Robichaud
Original Assignee
Sage Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201280054927.2A priority Critical patent/CN103958540B/en
Priority to SI201232034T priority patent/SI2753632T1/en
Application filed by Sage Therapeutics, Inc. filed Critical Sage Therapeutics, Inc.
Priority to CA2848212A priority patent/CA2848212C/en
Priority to FIEP12766766.5T priority patent/FI2753632T3/en
Priority to HRP20230747TT priority patent/HRP20230747T1/en
Priority to ES12766766T priority patent/ES2951664T3/en
Priority to PL12766766.5T priority patent/PL2753632T3/en
Priority to AU2012304412A priority patent/AU2012304412A1/en
Priority to JP2014529913A priority patent/JP6205362B2/en
Priority to LTEPPCT/US2012/054261T priority patent/LT2753632T/en
Priority to DK12766766.5T priority patent/DK2753632T3/en
Priority to BR112014005373-1A priority patent/BR112014005373B1/en
Priority to EP23171488.2A priority patent/EP4245369A3/en
Priority to US14/343,603 priority patent/US20150158903A1/en
Priority to RU2014113548A priority patent/RU2665571C2/en
Priority to RS20230525A priority patent/RS64332B1/en
Priority to EP12766766.5A priority patent/EP2753632B1/en
Publication of WO2013036835A1 publication Critical patent/WO2013036835A1/en
Priority to HK15100472.0A priority patent/HK1200173A1/en
Priority to AU2017204452A priority patent/AU2017204452B2/en
Priority to US16/114,791 priority patent/US10759828B2/en
Priority to AU2019227507A priority patent/AU2019227507B2/en
Priority to US16/942,235 priority patent/US20210147470A1/en
Priority to AU2021204183A priority patent/AU2021204183B2/en
Priority to US17/707,303 priority patent/US20230192756A1/en
Priority to AU2023203028A priority patent/AU2023203028A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Definitions

  • Brain excitability is defined as the level of arousal of an animal, a continuum that ranges from coma to convulsions, and is regulated by various neurotransmitters.
  • neurotransmitters are responsible for regulating the conductance of ions across neuronal membranes.
  • the neuronal membrane At rest, the neuronal membrane possesses a potential (or membrane voltage) of approximately -70 mV, the cell interior being negative with respect to the cell exterior.
  • the potential (voltage) is the result of ion (K + , Na + , CI " , organic anions) balance across the neuronal semipermeable membrane.
  • Neurotransmitters are stored in presynaptic vesicles and are released as a result of of neuronal action potentials.
  • an excitatory chemical transmitter such as acetylcholine will cause membrane depolarization (change of potential from -70 mV to -50 mV).
  • membrane depolarization change of potential from -70 mV to -50 mV.
  • This effect is mediated by postsynaptic nicotinic receptors which are stimulated by acetylcholine to increase the membrane permeability of Na + ions.
  • the reduced membrane potential stimulates neuronal excitability in the form of a postsynaptic action potential.
  • NMDA receptors are highly expressed in the CNS and are involved in excitatory synaptic transmission and synaptic plasticity as well as excitotoxicity. These receptors are ligand-gated ion channels that admit Ca 2+ after binding of the neurotransmitter glutamate and are fundamental to excitatory neurotransmission and normal CNS function.
  • NMDA receptors are heteromeric complexes comprised of NR1, NR2, and/or NR3 subunits and possess distinct recognition sites for exogenous and endogenous ligands. These recognition sites include binding sites for glycine, and glutamate agonists and modulators.
  • modulators may be useful as therapeutic agents with potential clinical uses as cognitive enhancers and in the treatment of psychiatric disorders in which glutamatergic transmission is reduced or defective (see, e.g., Horak et ah, J. ofNeuroscience, 2004, 24(46), 10318-10325).
  • Neuroactive steroids such as pregnenolone sulfate (PS) have been shown to exert direct modulatory effects on several types of neurotransmitter receptors, such as GABA A , glycine, AMPA-kainate, and NMDA receptors.
  • NMDA receptors are positively modulated by PS; however, the degree of modulation varies considerably.
  • New and improved neuroactive steroids are needed that modulate brain excitability for the prevention and treatment of CNS-related conditions.
  • the compounds, compositions, and methods described herein are directed toward this end.
  • New 3-CC and 3 -hydroxy steroids described herein are potential NMDA receptor modulators and thus are useful for preventing and/or treating a broad range of CNS- related conditions, including but not limited to schizophrenia, depression, bipolar disorder ⁇ e.g., I and/or II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, compulsive disorders, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive compulsive disorder (OCD), pain ⁇ e.g., a painful syndrome or disorder), sleep disorders, memory disorders, dementia, Alzheimer's Disease, a seizure disorder ⁇ e.g., epilepsy), traumatic brain injury, stroke, addictive disorders ⁇ e.g., addiction to opiates, cocaine, and/or alcohol), autism, Huntington's Disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus. These compounds are expected to show improved in vivo
  • Z is a group of the formula (i), (ii), (iii), (iv), or (v):
  • R 14 , R 17 , R 19 , R 20 , R 23a , R 23b , and R 24 are as defined herein; and the group -XR 3b at the C3 position is alpha or beta.
  • the compound of Formula (I) is of
  • Z is a group of the formula (i), (ii), (iii), (iv), or (v):
  • L is a substituted or unsubstituted Ci-C 6 alkylene, a substituted or unsubstituted C 2 - C alkenylene, substituted or unsubstituted C 2 -C6 alkynylene, a substituted or unsubstituted hetero Ci-C 6 alkylene, a substituted or unsubstituted hetero C 2 -C 6 alkenylene, or a substituted or unsubstituted hetero C 2 -C 6 alkynylene;
  • each instance of X and X is independently -0-, -S-, or -NH-;
  • R 1 is hydrogen or substituted or unsubstituted alkyl
  • R 3b is hydrogen
  • R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
  • each of R 6a and R 6b is independently hydrogen, halo, or substituted or unsubstituted alkyl, and represents a single or double bond, provided if a double bond is present, then one of R 6a or R 6b is absent, and provided if a single bond is present, then the hydrogen at C5 is in the alpha or beta position;
  • each instance of R 19 and R 20 is independently hydrogen or -C3 ⁇ 4;
  • R 23a and R 23b are independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R 23a and R 23b are joined together to form substituted or
  • R 24 is hydrogen or substituted or unsubstituted alkyl
  • Y is -0-, -S-, or -NR Z5 -;
  • R is independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR 25 , -SR Z5 , or -N(R Z5 ) 2 ;
  • each instance of R Z5 is independently hydrogen or substituted or unsubstituted alkyl
  • each instance of R z6 is independently hydrogen or substituted or unsubstituted alkyl, or two R z6 groups are joined to form a C 3 _ 6 carbocyclic ring;
  • n 0 or 1
  • Z is a group of formula: (iii), R Z6 (iv), or YR Z5 (v).
  • R and R are, independently, hydrogen, halo, substituted or unsubstituted C ⁇ alkyl, or -OR Z5.
  • L 3 is a group of formula:
  • R Z7 and R Z8 is independently hydrogen, halo, substituted or unsubstituted Ci 5
  • L is a group of formula
  • Z is of formula
  • the group R Z4 is of the formula
  • Z is of formula
  • Y is -O- and L 3 is an alkylene or heteroalkylene group.
  • Z is of formula YR b .
  • Y is -O- and L 3 is an alkylene or heteroalkylene.
  • the group Y YR is of the formula:
  • R 3a is hydrogen. In certain embodiments, R 3a is substituted or unsubstituted alkyl. In certain embodiments, R 6b is halogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 . In certain embodiments, R l lb is hydrogen or -OR B1 , and R lla is hydrogen. In certain embodiments, R lla and R llb together form an oxo group. In certain embodiments, represents a single bond, and the hydrogen at C5 is in the alpha position. In certain embodiments, represents a double bond. In certain embodiments,
  • R 19 is -CH 3 .
  • a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier.
  • the compound of the present invention is provided in an effective amount.
  • the compound of the present invention is provided in a therapeutically effective amount.
  • the compound of the present invention is provided in a prophylactically effective amount.
  • compounds of the present invention are provided as negative allosteric modulators (NAM) of NMDA receptor and thus are useful for preventing and/or treating a broad range of CNS conditions including but not limited to schizophrenia, depression, bipolar disorder (I and II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, compulsive disorders, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive compulsive disorder (OCD), all pain syndromes and disorders, sleep disorders, memory disorders and dementia including Alzheimer's Disease, epilepsy and any seizure disorders, traumatic brain injury (TBI), stroke, addictive disorders including opiates and cocaine and alcohol, autism, Huntington's Disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus.
  • NAM negative allosteric modulators
  • NMDA receptor modulation comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
  • a method of modulating CNS-activity comprising administering an effective amount of acompound of the present invention to a subject in need thereof.
  • a method of modulating brain excitability comprising administering an effective amount of acompound of the present invention to a subject in need thereof.
  • Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers.
  • the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
  • Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
  • HPLC high pressure liquid chromatography
  • analogue means one analogue or more than one analogue.
  • Alkyl refers to a radical of a straight-chain or branched saturated
  • an alkyl group has 1 to 12 carbon atoms ("Ci_ 12 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms ("Q-io alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms ("Q-9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“Ci-8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“Ci_7 alkyl”).
  • an alkyl group has 1 to 6 carbon atoms ("Ci_6 alkyl", also referred to herein as "lower alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“Ci_5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms ("C ⁇ alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“Ci_ 3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“Ci_ 2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“Ci alkyl”).
  • an alkyl group has 2 to 6 carbon atoms ("C 2 _ 6 alkyl").
  • Ci_ 6 alkyl groups include methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2- butanyl (C 5 ), tertiary amyl (C 5 ), and n-hexyl (C 6 ).
  • alkyl groups include n-heptyl (C 7 ), n-octyl (Cg) and the like.
  • each instance of an alkyl group is independently optionally substituted, i.e. , unsubstituted (an "unsubstituted alkyl") or substituted (a "substituted alkyl") with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
  • the alkyl group is unsubstituted C ⁇ o alkyl (e.g., -CH ).
  • the alkyl group is substituted Ci-w alkyl.
  • alkylene refers to a divalent radical of an alkyl, alkenyl, and alkynyl group, respectively.
  • alkylene refers to the range or number of carbons in the linear carbon divalent chain.
  • alkylene refers to the range or number of carbons in the linear carbon divalent chain.
  • alkylene refers to the range or number of carbons in the linear carbon divalent chain.
  • alkylene refers to the range or number of carbons in the linear carbon divalent chain.
  • alkylene alkenylene
  • alkynylene may be substituted or unsubstituted with one or more substituents as described herein.
  • Alkylene refers to an alkyl group wherein two hydrogens are removed to provide a divalent radical, and which may be substituted or unsubstituted.
  • Unsubstituted alkylene groups include, but are not limited to, methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -), butylene (-CH 2 CH 2 CH 2 CH 2 -), pentylene (-CH 2 CH 2 CH 2 CH 2 CH 2 - ), hexylene (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -), and the like.
  • substituted alkylene groups e.g., substituted with one or more alkyl (methyl) groups, include but are not limited to, substituted methylene (-CH(CH 3 )-, (-C(CH 3 ) 2 -), substituted ethylene (-CH(CH 3 )CH 2 -,- CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 -,-CH 2 C(CH 3 ) 2 -), substituted propylene (-CH(CH 3 )CH 2 CH 2 -, - CH 2 CH(CH 3 )CH 2 -, -CH 2 CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 CH 2 -, -CH 2 C(CH 3 ) 2 CH 2 -, - CH 2 CH 2 C(CH 3 ) 2 -), and the like.
  • alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds), and no triple bonds ("C 2 _ 2 o alkenyl”).
  • an alkenyl group has 2 to 10 carbon atoms ("C ⁇ io alkenyl”).
  • an alkenyl group has 2 to 9 carbon atoms (“C 2 _g alkenyl”).
  • an alkenyl group has 2 to 8 carbon atoms (“C 2 _g alkenyl”).
  • an alkenyl group has 2 to 7 carbon atoms ("C 2 _7 alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C 2 _6 alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms ("C 2 _5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms ("C 2 ⁇ alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C 2 _ 3 alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms ("C 2 alkenyl”).
  • the one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
  • Examples of C 2 ⁇ alkenyl groups include ethenyl (C 2 ), 1-propenyl (C 3 ), 2- propenyl (C 3 ), 1-butenyl (C 4 ), 2-butenyl (C 4 ), butadienyl (C 4 ), and the like.
  • Examples of C 2 6 alkenyl groups include the aforementioned C 2 ⁇ alkenyl groups as well as pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), and the like.
  • alkenyl examples include heptenyl (C 7 ), octenyl (Cg), octatrienyl (Cg), and the like.
  • each instance of an alkenyl group is independently optionally substituted, i.e., unsubstituted (an "unsubstituted alkenyl") or substituted (a "substituted alkenyl") with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
  • the alkenyl group is unsubstituted C 2 _ 10 alkenyl.
  • the alkenyl group is substituted C 2 _ 10 alkenyl.
  • Alkenylene refers to an alkenyl group wherein two hydrogens are removed to provide a divalent radical, and which may be substituted or unsubstituted.
  • substituted alkenylene groups e.g., substituted with one or more alkyl (methyl) groups
  • Alkynyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds), and optionally one or more double bonds (e.g., 1, 2, 3, or 4 double bonds) ("C 2 _ 2 o alkynyl").
  • An alkynyl group that has one or more triple bonds and one or more double bonds is also referred to as an "ene-yene” group.
  • an alkynyl group has 2 to 10 carbon atoms ("C 2 _io alkynyl").
  • an alkynyl group has 2 to 9 carbon atoms ("C 2 _g alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms ("C 2 _8 alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C 2 _7 alkynyl”). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C 2 _6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms ("C 2 _5 alkynyl").
  • an alkynyl group has 2 to 4 carbon atoms ("C 2 ⁇ alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C 2 _ 3 alkynyl”). In some embodiments, an alkynyl group has 2 carbon atoms ("C 2 alkynyl”).
  • the one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1- butynyl).
  • Examples of C 2 ⁇ alkynyl groups include, without limitation, ethynyl (C 2 ), 1- propynyl (C 3 ), 2-propynyl (C 3 ), 1-butynyl (C 4 ), 2-butynyl (C 4 ), and the like.
  • Examples of C 2 _6 alkenyl groups include the aforementioned C 2 ⁇ alkynyl groups as well as pentynyl (C 5 ), hexynyl (C 6 ), and the like. Additional examples of alkynyl include heptynyl (C 7 ), octynyl (Cg), and the like.
  • each instance of an alkynyl group is independently optionally substituted, i.e. , unsubstituted (an "unsubstituted alkynyl") or substituted (a "substituted alkynyl") with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
  • the alkynyl group is unsubstituted C 2 _ 10 alkynyl.
  • the alkynyl group is substituted C 2 -io alkynyl.
  • Alkynylene refers to a linear alkynyl group wherein two hydrogens are removed to provide a divalent radical, and which may be substituted or unsubstituted.
  • Exemplary divalent alkynylene groups include, but are not limited to, substituted or unsubstituted ethynylene, substituted or unsubstituted propynylene, and the like.
  • heteroalkyl refers to an alkyl group, as defined herein, which further comprises 1 or more (e.g. , 1, 2, 3, or 4) heteroatoms (e.g. , oxygen, sulfur, nitrogen, boron, silicon, phosphorus) within the parent chain, wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment.
  • a heteroalkyl group refers to a saturated group having from 1 to 10 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroQ-io alkyl").
  • a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroCi-9 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1, 2, 3, or 4
  • heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroC ⁇ alkyl”).
  • a heteroalkyl group is a group having 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms ("heteroCi-6 alkyl”).
  • a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms ("heteroQ-s alkyl”).
  • a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and lor 2 heteroatoms ("heteroC ⁇ alkyl”).
  • a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom (“heteroCi-3 alkyl”).
  • a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom ("heteroCi-i alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom (“heteroCi alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms ("heteroC 2 -6 alkyl"). Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an "unsubstituted heteroalkyl") or substituted (a "substituted heteroalkyl") with one or more substituents.
  • heteroalkyl group is an unsubstituted heteroCi-io alkyl. In certain embodiments, the heteroalkyl group is a substituted heteroQ-io alkyl.
  • heteroalkenyl refers to an alkenyl group, as defined herein, which further comprises one or more (e.g. , 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment.
  • one or more heteroatoms e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus
  • a heteroalkenyl group refers to a group having from 2 to 10 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2 - io alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 9 carbon atoms at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2 -9 alkenyl"). In some
  • a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2 -8 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2 -7 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1, 2, or 3 heteroatoms ("heteroC 2 -6 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2
  • heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and lor 2 heteroatoms ("heteroC 2 ⁇ alkenyl”).
  • a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom (“heteroC 2 -3 alkenyl”).
  • a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms ("heteroC 2 -6 alkenyl”).
  • each instance of a heteroalkenyl group is independently unsubstituted (an "unsubstituted heteroalkenyl") or substituted (a "substituted heteroalkenyl") with one or more substituents.
  • the heteroalkenyl group is an unsubstituted heteroC 2 -io alkenyl.
  • the heteroalkenyl group is a substituted heteroC 2 -io alkenyl.
  • heteroalkynyl refers to an alkynyl group, as defined herein, which further comprises one or more (e.g. , 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment.
  • one or more heteroatoms e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus
  • a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2 - 10 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2 -9 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2 -8 alkynyl").
  • a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC 2 -7 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1, 2, or 3 heteroatoms ("heteroC 2 -6 alkynyl"). In some embodiments, a
  • heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms ("heteroC 2 -5 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and lor 2 heteroatoms ("heteroC 2 ⁇ alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom (“heteroC 2 -3 alkynyl").
  • a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms ("heteroC 2 -6 alkynyl"). Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an "unsubstituted heteroalkynyl") or substituted (a "substituted heteroalkynyl") with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted heteroC 2 io alkynyl. In certain embodiments, the heteroalkynyl group is a substituted heteroC2-io alkynyl.
  • alkylene alkenylene
  • alkynylene alkynylene
  • heteroalkylene alkenylene
  • heteroalkenylene and “heteroalkynylene,” refer to a divalent radical of an alkyl, alkenyl, alkynyl group, heteroalkyl, heteroalkenyl, and heteroalkynyl group respectively.
  • alkylene alkenylene
  • alkynylene a divalent radical of an alkyl, alkenyl, alkynyl group, heteroalkyl, heteroalkenyl, and heteroalkynyl group respectively.
  • alkynylene "heteroalkylene,” “heteroalkenylene,” or “heteroalkynylene,” group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain.
  • alkylene "alkenylene,” “alkynylene,” “heteroalkylene,”
  • heteroalkenylene and “heteroalkynylene” groups may be substituted or unsubstituted with one or more substituents as described herein.
  • '"Aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 ⁇ electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ("Ce-u aryl").
  • an aryl group has six ring carbon atoms ("C 6 aryl”; e.g., phenyl).
  • an aryl group has ten ring carbon atoms ("Qo aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms ("C 14 aryl”; e.g., anthracyl).
  • Aryl also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
  • Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene.
  • aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl.
  • each instance of an aryl group is independently optionally substituted, i.e. , unsubstituted (an "unsubstituted aryl") or substituted (a "substituted aryl") with one or more substituents.
  • the aryl group is unsubstituted C 6 -i4 aryl.
  • the aryl group is substituted Ce_ 14 aryl.
  • R and R may be hydrogen and at least one of R and R is each independently selected from C Cs alkyl, C Cs haloalkyl, 4-10 membered heterocyclyl, alkanoyl, C Cs alkoxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR 58 COR 59 , NR 58 SOR 59 NR 58 S0 2 R 59 , COOalkyl, COOaryl, CONR 58 R 59 , CONR 58 OR 59 , NR 58 R 59 , S0 2 NR 58 R 59 , S-alkyl, SOalkyl, S0 2 alkyl, Saryl, SOaryl, S0 2 aryl; or R 56 and R 57 may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or more heteroatoms selected from the group N, O, or S.
  • R 60 and R 61 are independently hydrogen, C Cs alkyl, CrC 4 haloalkyl, C3-C 10 cycloalkyl, 4- 10 membered heterocyclyl, C 6 -Cio aryl, substituted C 6 -Cio aryl, 5- 10 membered heteroaryl, or substituted 5- 10 membered heteroaryl .
  • each W is selected from C(R ) 2 , NR , O, and S; and each Y is selected from carbonyl, NR 66 , O and S; and R 66 is independently hydrogen, C Cg alkyl, C3-Q0 cycloalkyl, 4-10 membered heterocyclyl, C6-Cio aryl, and 5-10 membered heteroaryl.
  • fused aryl refers to an aryl having two of its ring carbon in common with a second aryl or heteroaryl ring or with a carbocyclyl or heterocyclyl ring.
  • Alkyl is a subset of alkyl and aryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group.
  • Heteroaryl refers to a radical of a 5-10 membered monocyclic or bicyclic
  • 4n+2 aromatic ring system (e.g., having 6 or 10 ⁇ electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-10 membered heteroaryl").
  • heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings.
  • Heteroaryl includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system.
  • Heteroaryl also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system.
  • Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
  • the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
  • a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl").
  • a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl").
  • a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heteroaryl").
  • the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
  • each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an "unsubstituted heteroaryl") or substituted (a "substituted heteroaryl") with one or more substituents.
  • the heteroaryl group is unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is substituted 5-14 membered heteroaryl.
  • Exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl.
  • Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
  • Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
  • Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl.
  • Exemplary 6-membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl.
  • Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.
  • Exemplary 7-membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl.
  • Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
  • Exemplary 6,6- bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
  • each Y is selected from carbonyl, N, NR , O, and S; and R is independently hydrogen, Q-Cg alkyl, C3-Q0 cycloalkyl, 4-10 membered heterocyclyl, C6-Cio aryl, and 5-10 membered heteroaryl.
  • Heteroaralkyl is a subset of alkyl and heteroaryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group.
  • Carbocyclyl or “carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms ("C ⁇ o carbocyclyl") and zero heteroatoms in the non-aromatic ring system.
  • a carbocyclyl group has 3 to 8 ring carbon atoms ("C 3 _g carbocyclyl”).
  • a carbocyclyl group has 3 to 6 ring carbon atoms ("C 3 _6 carbocyclyl”).
  • a carbocyclyl group has 3 to 6 ring carbon atoms ("C 3 _6 carbocyclyl”).
  • a carbocyclyl group has 3 to 6 ring carbon atoms ("C 3 _6 carbocyclyl”).
  • carbocyclyl group has 5 to 10 ring carbon atoms ("Cs-io carbocyclyl").
  • Exemplary C 3 _6 carbocyclyl groups include, without limitation, cyclopropyl (C 3 ), cyclopropenyl (C 3 ), cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like.
  • Exemplary C 3 _g carbocyclyl groups include, without limitation, the aforementioned C 3 _ 6 carbocyclyl groups as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (Cg), cyclooctenyl (Cg), bicyclo[2.2.1]heptanyl (C 7 ), bicyclo[2.2.2]octanyl (Cg), and the like.
  • Exemplary C 3 _ 10 carbocyclyl groups include, without limitation, the
  • the carbocyclyl group is either monocyclic ("monocyclic carbocyclyl") or contain a fused, bridged or spiro ring system such as a bicyclic system ("bicyclic
  • Carbocyclyl also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system.
  • each instance of a carbocyclyl group is independently optionally substituted, i.e., unsubstituted (an "unsubstituted carbocyclyl") or substituted (a "substituted carbocyclyl") with one or more substituents.
  • the carbocyclyl group is unsubstituted C 3 _io carbocyclyl.
  • the carbocyclyl group is a substituted C 3 _ 10 carbocyclyl.
  • “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms ("C ⁇ o cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C 3 _g cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C 3 _6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("Cs_6 cycloalkyl").
  • a cycloalkyl group has 5 to 10 ring carbon atoms ('3 ⁇ 4_ 1 ⁇ 2 cycloalkyl").
  • C 5 _6 cycloalkyl groups include cyclopentyl (C 5 ) and cyclohexyl (C 5 ).
  • Examples of C 3 _6 cycloalkyl groups include the aforementioned C 5 _6 cycloalkyl groups as well as cyclopropyl (C 3 ) and cyclobutyl (C 4 ).
  • C 3 _8 cycloalkyl groups include the aforementioned C 3 _ 6 cycloalkyl groups as well as cycloheptyl (C 7 ) and cyclooctyl (Cg). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an
  • the cycloalkyl group is unsubstituted C 3 _io cycloalkyl. In certain embodiments, the cycloalkyl group is substituted C 3 _io cycloalkyl.
  • Heterocyclyl or “heterocyclic” refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("3-10 membered heterocyclyl").
  • the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • a heterocyclyl group can either be monocyclic ("monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system ("bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated.
  • Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings.
  • Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system.
  • each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted (an "unsubstituted heterocyclyl") or substituted (a "substituted heterocyclyl") with one or more substituents.
  • the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3-10 membered heterocyclyl.
  • a heterocyclyl group is a 5-10 membered non- aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("5-10 membered heterocyclyl").
  • a heterocyclyl group is a 5- 8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heterocyclyl").
  • a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heterocyclyl").
  • the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
  • Exemplary 3-membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl.
  • Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl.
  • Exemplary 5-membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl,
  • Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
  • Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
  • Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
  • Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl.
  • Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl.
  • Exemplary 7-membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl.
  • Exemplary 8- membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl.
  • Exemplary 5-membered heterocyclyl groups fused to a C 6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl,
  • Exemplary 6-membered heterocyclyl groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
  • each W is selected from CR , C(R ) 2 , NR , O, and S; and each Y is selected from NR 67 , O, and S; and R 67 is independently hydrogen, Ci-C 8 alkyl, C 3 -C 10 cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 aryl, 5-10 membered heteroaryl.
  • heterocyclyl rings may be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl (carbamoyl or amido), aminocarbonylamino, aminosulfonyl, sulfonylamino, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, halogen, hydroxy, keto, nitro, thiol, -S-alkyl, -S-aryl, -S(0)-alkyl,-S(0)-aryl, -S(0) 2 -alkyl, and -S(0) 2 -aryl.
  • groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, amino
  • Substituting groups include carbonyl or thiocarbonyl which provide, for example, lactam and urea derivatives.
  • Hetero when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, aryl, e.g,. heteroaryl, cycloalkenyl, e.g,. cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.
  • alkyl e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, aryl, e.g,. heteroaryl, cycloalkenyl, e.g,. cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.
  • Acyl refers to a radical -C(0)R 20 , where R 20 is hydrogen, substituted or unsubstitued alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstitued heteroaryl, as defined herein.
  • “Alkanoyl” is an acyl group wherein R 20 is a group other than hydrogen.
  • R 21 is Ci-C % alkyl, substituted with halo or hydroxy; or C 3 -C 10 cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted Q- C 4 alkyl, halo, unsubstituted C C 4 alkoxy, unsubstituted C C 4 haloalkyl, unsubstituted Q- C 4 hydroxyalkyl, or unsubstituted CrC 4 haloalkoxy or hydroxy.
  • Acylamino refers to a radical -NR 22 C(0)R 23 , where each instance of R 22 and
  • R23 is independently hydrogen, substituted or unsubstitued alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstitued heteroaryl,, as defined herein, or R 22 is an amino protecting group.
  • acylamino include, but are not limited to, formylamino, acetylamino,
  • acylamino groups are -NR 24 C(0)-Ci-C8 alkyl, -NR 24 C(O)-(CH 2 ) t (C 6 -C 10 aryl), -NR 24 C(O)-(CH 2 ) t (5-10 membered heteroaryl), -NR 24 C(0)- (CH 2 ) t (C 3 -Cio cycloalkyl), and -NR 24 C(O)-(CH 2 ) t (4-10 membered heterocyclyl), wherein t is an integer from 0 to 4, and each R 24 independently represents H or Q-Cg alkyl.
  • R 25 is H, Q-Cg alkyl, substituted with halo or hydroxy; C 3 -Cio cycloalkyl, 4- 10 membered heterocyclyl, C 6 -C 10 aryl, arylalkyl, 5-10 membered heteroaryl or
  • heteroarylalkyl each of which is substituted with unsubstituted Q-C 4 alkyl, halo,
  • R 26 is H, Q-Cg alkyl, substituted with halo or hydroxy; C 3 -C 10 cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted Q- C 4 alkyl, halo, unsubstituted C C 4 alkoxy, unsubstituted C C 4 haloalkyl, unsubstituted Q- yl, or unsubstituted Q xyl; provided at least one of R 25
  • R 26 is other than H.
  • Acyloxy refers to a radical -OC(0)R 27 , where R 27 is hydrogen, substituted or unsubstitued alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstitued heteroaryl, as defined herein.
  • R 28 is Q- Cg alkyl, substituted with halo or hydroxy; C3-Cio cycloalkyl, 4-10 membered heterocyclyl, C6-Q0 aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted CrC 4 alkyl, halo, unsubstituted Q-C 4 alkoxy, unsubstituted Q-C 4 haloalkyl, unsubstituted C C 4 hydroxyalkyl, or unsubstituted Q-C 4 haloalkoxy or hydroxy.
  • Alkoxy refers to the group -OR 29 where R 29 is substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or
  • alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n- hexoxy, and 1,2-dimethylbutoxy.
  • Particular alkoxy groups are lower alkoxy, i.e. with between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 and 4 carbon atoms.
  • R 29 is a group that has 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent, selected from the group consisting of amino, substituted amino, C 6 -C 10 aryl, aryloxy, carboxyl, cyano, C3-Q0 cycloalkyl, 4-10 membered heterocyclyl, halogen, 5-10 membered heteroaryl, hydroxyl, nitro, thioalkoxy, thioaryloxy, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(0) 2 - and aryl-S(0) 2 -.
  • substituents for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent, selected from the group consisting of amino, substituted amino, C 6 -C 10 aryl, aryloxy, carboxyl, cyano, C3-Q0 cycloal
  • Exemplary 'substituted alkoxy' groups include, but are not limited to, -O-(CH 2 ) t (C 6 -C 10 aryl), -O-(CH 2 ) t (5-10 membered heteroaryl), -O-(CH 2 ) t (C 3 -C 10 cycloalkyl), and -O-(CH 2 ) t (4-10 membered heterocyclyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocyclyl groups present, may themselves be substituted by unsubstituted Q-C 4 alkyl, halo, unsubstituted Q-C 4 alkoxy, unsubstituted Q- C 4 haloalkyl, unsubstituted Q-C 4 hydroxyalkyl, or unsubstituted Q-C 4 haloalkoxy or hydroxy.
  • Particular exemplary 'substituted alkoxy' groups are -OCF 3 , -OCH 2 CF , -OCH 2 Ph, -OCH 2 -cyclopropyl, -OCH 2 CH 2 OH, and -OCH 2 CH 2 NMe 2 .
  • Amino refers to the radical -NH 2 .
  • Substituted amino refers to an amino group of the formula -N(R 38 ) 2 wherein
  • R 38 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstitued heteroaryl, or an amino protecting group, wherein at least one of R 38 is not a hydrogen.
  • each R 38 is independently selected from hydrogen, Q-Cg alkyl, C 3 -Cg alkenyl, C 3 -Cg alkynyl, C6-Q0 aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl, or C 3 -C 10 cycloalkyl; or Q-Cg alkyl, substituted with halo or hydroxy; C 3 -Cg alkenyl, substituted with halo or hydroxy; C 3 -Cg alkynyl, substituted with halo or hydroxy, or - (CH 2 )t(C 6 -Cio aryl), -(CH 2 ) t (5-10 membered heteroaryl), -(CH 2 ) t (C 3 -Ci 0 cycloalkyl), or - (CH 2 ) t (4-10 membered heterocyclyl), wherein t is an integer between 0 and 8, each of which is substituted by unsubsti
  • Exemplary "substituted amino" groups include, but are not limited to, -NR 39 -
  • substituted amino includes the groups alkylamino, substituted alkylamino, alkylarylamino, substituted alkylarylamino, arylamino, substituted arylamino, dialkylamino, and substituted dialkylamino as defined below.
  • Substituted amino encompasses both mono substituted amino and disubstituted amino groups.
  • Carbamoyl or “amido” refers to the radical -C(0)NH 2 .
  • Substituted carbamoyl or “substituted amido” refers to the radical -
  • each R 62 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or
  • R 62 is selected from H, Q-Cg alkyl, C3-Q0 cycloalkyl, 4-10 membered heterocyclyl, C 6 -Q 0 aryl, aralkyl, 5- 10 membered heteroaryl, and heteroaralkyl; or Ci-Cg alkyl substituted with halo or hydroxy; or C 3 -Cio cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 aryl, aralkyl, 5-10 membered heteroaryl, or heteroaralkyl, each of which is substituted by unsubstituted Q-C4 alkyl, halo, unsubstituted Q-C 4 alkoxy, unsubstituted C C 4 haloalkyl, unsubstit
  • Exemplary "substituted carbamoyl” groups include, but are not limited to, -
  • Carboxy refers to the radical -C(0)OH.
  • Cyano refers to the radical -CN.
  • Halo or "halogen” refers to fluoro (F), chloro (CI), bromo (Br), and iodo (I).
  • the halo group is either fluoro or chloro.
  • Haldroxy refers to the radical -OH.
  • Nonro refers to the radical -N0 2 .
  • Cycloalkylalkyl refers to an alkyl radical in which the alkyl group is substituted with a cycloalkyl group.
  • Typical cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, and cyclooctylethyl, and the like.
  • Heterocyclylalkyl refers to an alkyl radical in which the alkyl group is substituted with a heterocyclyl group.
  • Typical heterocyclylalkyl groups include, but are not limited to, pyrrolidinylmethyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyrrolidinylethyl, piperidinylethyl, piperazinylethyl, morpholinylethyl, and the like.
  • Cycloalkenyl refers to substituted or unsubstituted carbocyclyl group having from 3 to 10 carbon atoms and having a single cyclic ring or multiple condensed rings, including fused and bridged ring systems and having at least one and particularly from 1 to 2 sites of olefinic unsaturation.
  • Such cycloalkenyl groups include, by way of example, single ring structures such as cyclohexenyl, cyclopentenyl, cyclopropenyl, and the like.
  • Fused cycloalkenyl refers to a cycloalkenyl having two of its ring carbon atoms in common with a second aliphatic or aromatic ring and having its olefinic
  • Ethylene refers to substituted or unsubstituted -(C-C)-.
  • Neitrogen-containing heterocyclyl means a 4- to 7- membered non- aromatic cyclic group containing at least one nitrogen atom, for example, but without limitation, morpholine, piperidine (e.g. 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (e.g. 2-pyrrolidinyl and 3-pyrrolidinyl), azetidine, pyrrolidone, imidazoline, imidazolidinone, 2-pyrazoline, pyrazolidine, piperazine, and N-alkyl piperazines such as N- methyl piperazine. Particular examples include azetidine, piperidone and piperazone.
  • Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted (e.g., "substituted” or “unsubstituted” alkyl, "substituted” or “unsubstituted” alkenyl, "substituted” or “unsubstituted” alkynyl,
  • substituted means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
  • a "substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
  • substituted is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound.
  • the present invention contemplates any and all such combinations in order to arrive at a stable compound.
  • heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
  • Exemplary carbon atom substituents include, but are not limited to, halogen, -
  • R aa is, independently, selected from Ci-w alkyl, Ci-w perhaloalkyl, C 2 _io alkenyl, C 2 _ 10 alkynyl, C 3 _ 10 carbocyclyl, 3-14 membered heterocyclyl, C 6 -i4 aryl, and 5-14 membered heteroaryl, or two R aa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocycl
  • each instance of R cc is, independently, selected from hydrogen, C ⁇ o alkyl, C ⁇ o perhaloalkyl, C 2 _io alkenyl, C 2 _io alkynyl, C 3 _io carbocyclyl, 3-14 membered heterocyclyl, C 6 -i4 aryl, and 5-14 membered heteroaryl, or two R cc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;
  • each instance of R ee is, independently, selected from d_6 alkyl, d_6 perhaloalkyl, C 2 6 alkenyl, C 2 _ 6 alkynyl, C 3 _ 10 carbocyclyl, C 6 -io aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups;
  • each instance of R is, independently, selected from hydrogen, d_6 alkyl, d_6 perhaloalkyl, C 2 -6 alkenyl, C 2 _ 6 alkynyl, C 3 _ 10 carbocyclyl, 3-10 membered heterocyclyl, C 6 - ff
  • each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups;
  • a "counterion” or “anionic counterion” is a negatively charged group associated with a cationic quaternary amino group in order to maintain electronic neutrality.
  • exemplary counterions include halide ions (e.g., F ⁇ , CT, Br , ⁇ ), N0 3 , C10 4 , OH ⁇ , H 2 P0 4 , HS0 4 , sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene-l-sulfonic acid-5-sulfonate, ethan-l-sulfonic acid-2-sulfonate, and the like), and carboxylate ions (e.g., acetate, ethanoate, propano
  • Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quarternary nitrogen atoms.
  • the substituent present on a nitrogen atom is an amino protecting group (also referred to herein as a nitrogen protecting group).
  • Amino protecting groups such as sulfonamide groups include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,- trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5, 6-tetramethyl-4- methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6- trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7, 8-pentamethylchroman-6-sulfonamide (Pmc), methane
  • Ts p-toluenesulfonamide
  • Mtr 2,
  • amino protecting groups include, but are not limited to, phenothiazinyl-
  • benzenesulfenamide o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide,
  • triphenylmethylsulfenamide triphenylmethylsulfenamide
  • 3-nitropyridinesulfenamide Npys
  • the substituent present on an oxygen atom is an oxygen protecting group (also referred to as a hydroxyl protecting group).
  • Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • oxygen protecting groups include, but are not limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl,
  • DPMS diphenylmethylsilyl
  • TMPS i-butylmethoxyphenylsilyl
  • the substituent present on an sulfur atom is an sulfur protecting group (also referred to as a thiol protecting group).
  • Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
  • “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts.
  • such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2- naphthalenesulfonic acid, 4-toluenesulf
  • Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • pharmaceutically acceptable cation refers to an acceptable cationic counter- ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like (see, e.g., Berge, et al, J. Pharm. Sci. 66(1): 1-79 (Jan.”77) .
  • “Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.
  • “Pharmaceutically acceptable metabolically cleavable group” refers to a group which is cleaved in vivo to yield the parent molecule of the structural Formula indicated herein.
  • Examples of metabolically cleavable groups include -COR, -COOR,-CONRR and - CH 2 OR radicals, where R is selected independently at each occurrence from alkyl, trialkylsilyl, carbocyclic aryl or carbocyclic aryl substituted with one or more of alkyl, halogen, hydroxy or alkoxy.
  • Specific examples of representative metabolically cleavable groups include acetyl, methoxycarbonyl, benzoyl, methoxymethyl and trimethylsilyl groups.
  • Prodrugs refers to compounds, including derivatives of the compounds of the invention,which have cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N- alkylmorpholine esters and the like. Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but in the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
  • Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides.
  • Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are particular prodrugs.
  • double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
  • Ci to alkyl, C 2 -C 8 alkenyl, C2-C 8 alkynyl, aryl, C7-C 12 substituted aryl, and C 7 -C 12 arylalkyl esters of the compounds of the invention are particularly the Ci to alkyl, C 2 -C 8 alkenyl, C2-C 8 alkynyl, aryl, C7-C 12 substituted aryl, and C 7 -C 12 arylalkyl esters of the compounds of the invention.
  • Solvate refers to forms of the compound that are associated with a solvent or water (also referred to as "hydrate”), usually by a solvolysis reaction. This physical association includes hydrogen bonding.
  • solvents include water, ethanol, acetic acid and the like.
  • the compounds of the invention may be prepared e.g. in crystalline form and may be solvated or hydrated.
  • Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non- stoichiometric solvates. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • “Solvate” encompasses both solution-phase and isolable solvates.
  • Representative solvates include hydrates, ethanolates and methanolates.
  • a "subject" to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or a non-human animal, e.g. , a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs.
  • the subject is a human.
  • the subject is a non- human animal.
  • the terms "human,” “patient,” and “subject” are used interchangeably herein.
  • an “effective amount” means the amount of a compound that, when administered to a subject for treating or preventing a disease, is sufficient to effect such treatment or prevention.
  • the “effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.
  • a “therapeutically effective amount” refers to the effective amount for therapeutic treatment.
  • a “prophylatically effective amount” refers to the effective amount for prophylactic treatment.
  • Preventing or “prevention” or “prophylactic treatment” refers to a reduction in risk of acquiring or developing a disease or disorder ⁇ i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject not yet exposed to a disease- causing agent, or predisposed to the disease in advance of disease onset.
  • prophylaxis is related to "prevention,” and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease.
  • prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization; and the administration of an anti-malarial agent such as chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.
  • Treating” or “treatment” or “therapeutic treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder ⁇ i.e., arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof).
  • “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject.
  • “treating” or “treatment” refers to modulating the disease or disorder, either physically, ⁇ e.g., stabilization of a discernible symptom), physiologically, ⁇ e.g., stabilization of a physical parameter), or both.
  • “treating” or “treatment” relates to slowing the progression of the disease.
  • isotopic variant refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such
  • an "isotopic variant" of a compound can contain one or more non- radioactive isotopes, such as for example, deuterium ( 2 H or D), carbon- 13 ( 13 C), nitrogen- 15 ( 15 N), or the like. It will be understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be 2 H/D, any carbon may be 13 C, or any nitrogen may be 15 N, and that the presence and placement of such atoms may be determined within the skill of the art. Likewise, the invention may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies.
  • radioactive isotopes tritium, i.e., 3 H, and carbon- 14, i.e., 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • compounds may be prepared that are substituted with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N, and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. All isotopic variants of the compounds provided herein, radioactive or not, are intended to be encompassed within the scope of the invention.
  • enantiomers and those that are non-superimposable mirror images of each other are termed "enantiomers.”
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory ⁇ i.e., as (+) or (-)-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".
  • Tautomers refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of ⁇ electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
  • a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess).
  • an "S" form of the compound is substantially free from the "R” form of the compound and is, thus, in enantiomeric excess of the "R” form.
  • enantiomerically pure or “pure enantiomer” denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the enantiomer.
  • the weights are based upon total weight of all enantiomers or stereoisomers of the compound.
  • the term “enantiomerically pure R-compound” refers to at least about 80% by weight R-compound and at most about 20% by weight S-compound, at least about 90% by weight R-compound and at most about 10% by weight S-compound, at least about 95% by weight R-compound and at most about 5% by weight S-compound, at least about 99% by weight R-compound and at most about 1% by weight S-compound, at least about 99.9% by weight R-compound or at most about 0.1% by weight S-compound.
  • the weights are based upon total weight of compound.
  • the term “enantiomerically pure S-compound” or “S-compound” refers to at least about 80% by weight S-compound and at most about 20% by weight R-compound, at least about 90% by weight S-compound and at most about 10% by weight R-compound, at least about 95% by weight S-compound and at most about 5% by weight R-compound, at least about 99% by weight S-compound and at most about 1% by weight R-compound or at least about 99.9% by weight S-compound and at most about 0.1% by weight R-compound.
  • the weights are based upon total weight of compound.
  • an enantiomerically pure compound or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof can be present with other active or inactive ingredients.
  • a pharmaceutical composition comprising enantiomerically pure R-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure R-compound.
  • enantiomerically pure R-compound in such compositions can, for example, comprise, at least about 95% by weight R-compound and at most about 5% by weight S-compound, by total weight of the compound.
  • a pharmaceutical composition comprising enantiomerically pure S-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure S-compound.
  • the enantiomerically pure S-compound in such compositions can, for example, comprise, at least about 95% by weight S-compound and at most about 5% by weight R-compound, by total weight of the compound.
  • the active ingredient can be formulated with little or no excipient or carrier.
  • the compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof.
  • heterocyclic ring may have one to four heteroatoms so long as the hetero aromatic ring is chemically feasible and stable.
  • 3-CC and 3 -hydroxy steroid compounds as NMDA receptor modulators and thus, useful for preventing and/or treating a broad range of CNS conditions, among them, schizophrenia, depression, bipolar disorder (e.g., I and/or II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, compulsive disorders, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive compulsive disorder (OCD), pain (e.g., a painful syndrome or disorder), sleep disorders, memory disorders, dementia, Alzheimer's Disease, a seizure disorder (e.g., epilepsy), traumatic brain injury, stroke, addictive disorders (e.g., addiction to opiates, cocaine, and/or alcohol), autism, Huntington's Disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus. These compounds are expected to show improved in vivo potency
  • Z is a group of the formula (i), (ii), (iii), (iv), or (v):
  • L and V are selected from a group consisting of a bond, a substituted or
  • L is a substituted or unsubstituted C ⁇ -Ce alkylene, a substituted or unsubstituted C 2 - C 6 alkenylene, substituted or unsubstituted C 2 -C 6 alkynylene, a substituted or unsubstituted hetero C ⁇ - e alkylene, a substituted or unsubstituted hetero C 2 -C 6 alkenylene, or a substituted or unsubstituted hetero C 2 -C 6 alkynylene;
  • each instance of X and X is independently -0-, -S-, -N(R )-, wherein each instance of R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group;
  • R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • R CI is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R CI groups are joined to form an substituted or unsubstituted heterocyclic ring; and R C2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or un
  • each of R 6a and R 6b is independently hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, and represents a single or double bond, provided if a double bond is present in Ring B, then one of R 6a or R 6b is absent, and provided if a single bond is present in Ring B, then the hydrogen at C5 is in the alpha or beta position;
  • R 14 is hydrogen or substituted or unsubstituted alkyl
  • R D1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -OR D1 , wherein R D1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group;
  • each instance of R , R , and R is independently hydrogen or substituted or unsubstituted alkyl
  • R 23a and R 23b are independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R 23a and R 23b are joined together to form substituted or
  • R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting
  • R is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • Y is -0-, -S-, or -NR Z5 -;
  • R Z5 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR 25 , -SR Z5 , or -N(R Z5 ) 2 ; each instance of R Z5 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group
  • each instance of R z6 is independently hydrogen or substituted or unsubstituted alkyl, or two R z6 groups are joined to form a C 3 _ 6 carbocyclic ring;
  • n 0, 1, 2, or 3.
  • R 3a when R 3a is H, n is 1, and R 19 is Me; then R 1 is other than H, alkyl, alkenyl, or alkynyl.
  • R 3a when R 3a is H, R 3b is -COMe, R 19 is Me, and n is 0; then R 1 is OH.
  • R 3a when R 3a is H, n is 0, and R 20 is alkyl; then R 1 is other than OH.
  • R 19 when R 19 is Me; then R 1 is other than H, alkyl, alkenyl, or alkynyl.
  • R 1 is H; and R 19 is other than Me.
  • each R 1 and R 3a is H; and R 19 is other than Me.
  • R 1 is other than H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl.
  • R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. It is generally understood that R 3a may be in the alpha (down) or beta (up) position. In certain embodiments, R 3a is alpha. In certain embodiments, R 3a is beta. [00129] In certain embodiments, R 3a is hydrogen.
  • R 3a is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted C 4 _ 5 alkyl, or substituted or unsubstituted Cs ⁇ alkyl.
  • R 3a C ⁇ a cyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3- pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n- hexyl (C 6 ), C ⁇ alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g., -CF 3 , -CH 2 F, -CHF 2> difluoroethyl, and 2,2,2-trifluoro groups
  • R 3a is substituted alkyl, e.g., R 3a is haloalkyl, alkoxyalkyl, or aminoalkyl.
  • R 3a is Me, Et, n-Pr, n-Bu, i-Bu, fluoromethyl, chloromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, difluoroethyl, 2,2,2-trifluoro- 1,1 -dimethyl-ethyl, methoxymethyl, methoxyethyl, or ethoxymethyl.
  • R 3a is Me, Et, n-Pr, n-Bu, or i-Bu. In certain embodiments, R 3a is
  • R 3a is trifluoromethoxymethyl.
  • R 3a is fluoromethyl, chloromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, or 2,2,2-trifluoro- 1,1 -dimethyl-ethyl. In certain embodiments, R 3a is trifluoromethyl.
  • R 3a is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C 2 _ 6 alkenyl, substituted or unsubstituted C 2 _ 3 alkenyl, substituted or unsubstituted C 3 ⁇ alkenyl, substituted or unsubstituted C ⁇ salkenyl, or substituted or unsubstituted Cs_ 6 alkenyl.
  • R 3a is ethenyl (C 2 ), propenyl (C 3 ), or butenyl (C 4 ), unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxyl.
  • R 3a is ethenyl, propenyl, or butenyl, unsubstituted or substituted with alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxy.
  • R 3a is ethenyl.
  • R 3a is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C 2 _ 6 alkynyl, substituted or unsubstituted C 2 _ 3 alkynyl, substituted or unsubstituted C 3 ⁇ alkynyl, substituted or unsubstituted C ⁇ salkynyl, or substituted or unsubstituted Cs_ 6 alkynyl.
  • R 3a alkynyl groups include, but are not limited to, ethynyl, propynyl, or butynyl, unsubstituted or substituted with alkyl, halo, haloalkyl (e.g., CF 3 ), alkoxyalkyl, cycloalkyl (e.g., cyclopropyl or cyclobutyl), or hydroxyl.
  • R 3a is selected from the group consisting of
  • R 3a is ethynyl (C 2 ), propynyl (C 3 ), or butynyl (C 4 ), unsubstituted or substituted with one or more substituents selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, and substituted or unsubstituted heterocyclyl.
  • R 3a is ethynyl (C 2 ), propynyl (C 3 ), or butynyl (C 4 ) substituted with substituted phenyl.
  • the phenyl substitutent is further substituted with one or more substituents selected from the group consisting of halo, alkyl, trifluoroalkyl, alkoxy, acyl, amino or amido.
  • R 3a is ethynyl (C 2 ), propynyl (C 3 ), or butynyl (C 4 ) substituted with substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, or tetrazolyl.
  • R 3a is ethynyl, propynyl, or butynyl, unsubstituted or substituted with alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxyl. In certain embodiments, R 3a is ethynyl or propynyl, substituted with substituted or unsubstituted aryl. In certain embodiments, R 3a is ethynyl or propynyl, substituted with phenyl unsubstituted or substituted with halo, alkyl, alkoxy, haloalkyl, trihaloalkyl, or acyl.
  • R 3a is ethynyl or propynyl, substituted with substituted or unsubstituted carbocyclyl. In certain embodiments, R 3a is ethynyl or propynyl, substituted with substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In certain embodiments, R 3a is ethynyl or propynyl, substituted with substituted or unsubstituted heteroaryl.
  • R 3a is ethynyl or propynyl, substituted with substituted or unsubstituted pyridinyl, or pyrimidinyl. In certain embodiments, R 3a is ethynyl or propynyl, substituted with substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl.
  • R 3a is ethynyl or propynyl, substituted with substituted or unsubstituted heterocyclyl. In certain embodiments, R 3a is ethynyl or propynyl, substituted with substituted or unsubstituted pyrrolidinyl, piperidinyl, piperazinyl, or mopholinyl. In certain embodiments, R 3a is propynyl or butynyl, substituted with hydroxyl or alkoxy. In certain embodiments, R 3a is propynyl or butynyl, substituted with methoxy or ethoxy. In certain embodiments, R 3a is ethynyl or propynyl, substituted with CI. In certain embodiments, R 3a is ethynyl or propynyl, substituted with trifluoromethyl.
  • R 3a is substituted or unsubstituted carbocyclyl, e.g. , substituted or unsubstituted C 3 _ 6 carbocyclyl, substituted or unsubstituted C 3 ⁇ carbocyclyl, substituted or unsubstituted C 4 _ 5 carbocyclyl, or substituted or unsubstituted C 5 _ 6 carbocyclyl.
  • R 3a is substituted or unsubstituted heterocyclyl, e.g., substituted or unsubstituted 3-6 membered heterocyclyl, substituted or unsubstituted 3-4 membered heterocyclyl, substituted or unsubstituted 4-5 membered heterocyclyl, or substituted or unsubstituted 5-6 membered heterocyclyl.
  • R 3a is substituted or unsubstituted aryl. In certain embodiments, R 3a is substituted or unsubstituted phenyl.
  • R 3a is substituted or unsubstituted heteroaryl, e.g. , optionally substituted 5- to 6-membered heteroaryl.
  • R 3a As a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl groups, are depicted below:
  • each instance of R is hydrogen, halo, or -OR , wherein R is substituted or unsubstituted alkyl; and each instance of R 3d is hydrogen, halo, or substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl.
  • At least one R 3c is hydrogen. In certain embodiments, at least two R 3c is hydrogen. In certain embodiments, each R 3c is hydrogen. In certain embodiments, at least one R 3c is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, at least two R 3c are halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each R 3c is halogen (e.g., fluoro, to provide the group -CF 3 ). In certain embodiments, at least one R 3c is -OR F1 (e.g., OMe or OEt).
  • At least two R 3c is -OR F1 (e.g., OMe or OEt). In certain embodiments, at least one R 3c is hydrogen, F, -OMe, or -OEt. In certain embodiments, one of R 3c is F, -OMe, or OEt; and the rest are H. [00140] In certain embodiments, at least one R 3d is hydrogen. In certain embodiments, each R 2c is hydrogen. In certain embodiments, at least one R 3d is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each R 3d is halogen (e.g., fluoro, chloro, bromo, iodo).
  • each of R 3d is alkyl, e.g., each of R 2c is Me. In certain embodiments, one of R 3d is alkyl; and the other is hydrogen, e.g., one of R 3d is Me; and the other is hydrogen. In certain embodiments, one of R 3d is substituted or unsubstituted carbocyclyl, e.g., cyclopropyl or cyclobutyl, and the other is hydrogen. In certain
  • At least one R 3d is hydrogen, -F, -Br, -CI, -I, -CH 3 , -CF 3 , cyclopropyl, or cyclobutyl.
  • each instance of R 3d is H.
  • each instance of R 3d is halogen (e.g., fluoro, chloro, bromo, iodo).
  • each instance of R 3d is alkyl, e.g., -CH 3 , -CF 3 , -CH 2 CH 2 CI.
  • each instance of R 3d is substituted or unsubstituted carbocyclyl, e.g., cyclopropyl or cyclobutyl. In certain embodiments, R 3d is substituted or unsubstituted cyclopropyl. In certain embodiments,
  • each instance of R 3d is hydrogen, -F, -Br, -CI, -I, -CH 3 , -CF 3 , -CH 2 CH 2 C1, cyclopropyl, or cyclobutyl.
  • R 3d is Me or CI.
  • R 3d is substituted or unsubstituted heterocyclyl.
  • R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R CI groups are joined to form an substituted or unsubstituted heterocyclic ring.
  • the group -X ⁇ R 313 may be in the alpha (down) or beta (up) position.
  • the group -X 1 -R 3b is alpha.
  • the group -X ⁇ R 313 is beta.
  • X 1 is -0-. In certain embodiments, X 1 is -S-. In certain embodiments, X is -N(R )-. In certain embodiments, R is alkyl. In certain embodiments, R X is Me, Et, or i-Pr. In certain embodiments, R X is H, i.e., wherein XI is - NH-.
  • R 3b is hydrogen.
  • the group - ⁇ 3 ⁇ 4 is -OH. In certain embodiments, the group - ⁇ 3 ⁇ 4 is -SH. In certain embodiments, the group -X 1 ⁇ is -NH 2 or -NHR X .
  • At least one instance of R C 1 is hydrogen or a protecting group, i.e., an oxygen protecting group when attached to an oxygen atom, sulfur protecting group when attached to an sulfur atom, or a nitrogen protecting group when attached to a nitrogen atom.
  • at least one instance of R CI is hydrogen.
  • R C 1 is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C ⁇ a cyl, substituted or unsubstituted Ci_ 2 alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted C 4 _ 5 alkyl, or substituted or unsubstituted Cs ⁇ alkyl.
  • alkyl e.g., substituted or unsubstituted C ⁇ a cyl, substituted or unsubstituted Ci_ 2 alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted C 4 _ 5 alkyl, or substituted or unsubstituted Cs ⁇ alkyl.
  • R Ci_ 6 alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso- butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n-hexyl (C 6 ), Ci_ 6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g., -CF , -CH 2 F, -CHF 2> difluoroethyl, and 2,2,2-trifluoro-l,l-
  • R C 1 is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C 2 _ 6 alkenyl, substituted or
  • At least one instance of R is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C 2 _ 6 alkynyl, substituted or unsubstituted C 2 _ 3 alkynyl, substituted or unsubstituted C 3 ⁇ alkynyl, substituted or
  • At least one instance of R is substituted or unsubstituted carbocyclyl, e.g., substituted or unsubstituted C 3 _ 6 carbocyclyl, substituted or unsubstituted C 3 ⁇ carbocyclyl, substituted or unsubstituted C 4 _ 5 carbocyclyl, or substituted or unsubstituted C 5 _ 6 carbocyclyl.
  • At least one instance of R is substituted or unsubstituted heterocyclyl, e.g. , substituted or unsubstituted 3-6 membered heterocyclyl, substituted or unsubstituted 3-4 membered heterocyclyl, substituted or unsubstituted 4-5 membered heterocyclyl, or substituted or unsubstituted 5-6 membered heterocyclyl.
  • At least one instance of R is substituted or unsubstituted aryl, e.g., substituted or unsubstituted phenyl.
  • At least one instance of R is substituted or unsubstituted heteroaryl, e.g. , optionally substituted 5- to 6-membered heteroaryl.
  • two R groups are joined to form a substituted or unsubstituted heterocyclic ring, e.g., a substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl ring.
  • a substituted or unsubstituted heterocyclic ring e.g., a substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl ring.
  • R cl is, for example, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), is
  • R 3b is e.g., for example, wherein R cl is, for example, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), or n-hexyl (C 6 ).
  • R cl is, for example, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-buty
  • R cl is, for example, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), iso
  • R is, for example, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ),
  • tertiary amyl C 5
  • n-hexyl C 6
  • each R cl is, for example, independently hydrogen, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), or n-hexyl (C 6 ), or substituted or unsubstituted phenyl.
  • each R cl is, for example, independently hydrogen, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C
  • Z is a group of formula (i):
  • Z is a group of formula (ii):
  • L and L is a bond (i.e., in other words, is absent) or is a substituted or unsubstituted C -C alkylene, a substituted or unsubstituted C 2 -C6 alkenylene, substituted or unsubstituted C 2 -C6 alkynylene, a substituted or unsubstituted hetero Ci-Ce alkylene, a substituted or unsubstituted hetero C 2 -C 6 alkenylene, or a substituted or unsubstituted hetero C 2 -C 6 alkynylene.
  • L or L is a bond.
  • L or L is a substituted or unsubstituted Ci-Ce
  • L or L is a substituted or unsubstituted Ci-C 4 alkylene.
  • L or L is a substituted or unsubstituted Ci-C3 alkylene.
  • L or L is a substituted or unsubstituted C 1 -C 2 alkylene.
  • L or L is a substituted or unsubstituted C alkylene. In certain embodiments,
  • L or L is a substituted or unsubstituted C 2 alkylene. In certain embodiments, L or L is a
  • L or L is a substituted or
  • L or L is a substituted or unsubstituted
  • L or L is a substituted or unsubstituted C 6 alkylene.
  • L or L is an alkylene group, as described above, substituted with one or more substituents selected from the group consisting of substituted or unsubstituted
  • L or L is -CH 2 -, -CHMe-, -CMe 2 -, -CH 2 -CH 2 -, - CF 2 -CH 2 -, -CH 2 -CMe 2 -, -CH 2 -CH 2 -CH 2 -, or -CH 2 -CH 2 -CMe 2 -.
  • L or L is a substituted or unsubstituted C 2 -C 6
  • L or L is a substituted or unsubstituted C 2 -C 5
  • L or L is a substituted or unsubstituted C 2 -C 4
  • L or L is a substituted or unsubstituted C 2 -C 3
  • L or L is a substituted or unsubstituted C 2 alkenylene. 1 2
  • L or L is a substituted or unsubstituted C 3 alkenylene.
  • L or L is a substituted or unsubstituted C 4 alkenylene.
  • L or L is a substituted or unsubstituted C 5 alkenylene.
  • L or L is a substituted or unsubstituted C 6 alkenylene.
  • L or L is an alkenylene group, as described above, substituted with one or more substituents selected from the group consisting of substituted or unsubstituted alkyl and halo.
  • L or L is a substituted or unsubstituted C 2 -C6
  • L or L is a substituted or unsubstituted C 2 -C 5
  • L or L is a substituted or unsubstituted C 2 -C 4
  • L or L is a substituted or unsubstituted C 2 -C 3
  • L or L is a substituted or unsubstituted C 2 alkynylene.
  • L or L is a substituted or unsubstituted C 3 alkynylene.
  • L or L is a substituted or unsubstituted C 4 alkynylene.
  • L 1 is a substituted or unsubstituted C 5 alkynylene. In certain embodiments, L 1
  • L is a substituted or unsubstituted C 6 alkynylene.
  • L or L is an alkynylene group, as described above, substituted with one or more substituents selected from the group consisting of substituted or unsubstituted alkyl and halo.
  • L or L is substituted or unsubstituted heteroCi-ealkylene, e.g., substituted or unsubstituted heteroC ⁇ alkylene, substituted or unsubstituted heteroC 2 _ 3 alkylene, substituted or unsubstituted heteroC 3 ⁇ alkylene, substituted or unsubstituted heteroC 4 _salkylene, or substituted or unsubstituted heteroCs_ 6 alkylene.
  • substituted or unsubstituted heteroCi-ealkylene e.g., substituted or unsubstituted heteroC ⁇ alkylene, substituted or unsubstituted heteroC 2 _ 3 alkylene, substituted or unsubstituted heteroC 3 ⁇ alkylene, substituted or unsubstituted heteroC 4 _salkylene, or substituted or unsubstituted heteroCs_ 6 alkylene.
  • L or L is substituted or unsubstituted heteroC 2 _ 6 alkyenlene, e.g. , substituted or unsubstituted heteroC 2 _ 3 alkenylene, substituted or unsubstituted heteroC 3 _ 4 alkenylene, substituted or unsubstituted heteroC 4 _salkenylene, or substituted or unsubstituted
  • L or L is substituted or unsubstituted heteroC 2 _ 6 alkynylene, e.g. , substituted or unsubstituted heteroC 2 _ 3 alkynylene, substituted or unsubstituted heteroC 3 ⁇ alkynylene, substituted or unsubstituted heteroC 4 _salkynylene, or substituted or unsubstituted heteroCs_ 6 alkynylene.
  • substituted or unsubstituted heteroC 2 _ 6 alkynylene e.g. , substituted or unsubstituted heteroC 2 _ 3 alkynylene, substituted or unsubstituted heteroC 3 ⁇ alkynylene, substituted or unsubstituted heteroC 4 _salkynylene, or substituted or unsubstituted heteroCs_ 6 alkynylene.
  • L or L is heteroalkylene, heteroalkenylene, or hetero alkynylene unsubstituted or substituted with halo (e.g. , fluoro) or substituted or unsubstituted Ci_ 6 alkyl.
  • halo e.g. , fluoro
  • R 1 is hydrogen
  • R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl. In certain embodiments, R 1 is substituted or unsubstituted alkyl, e.g., Me, Et, or i-Pr. In certain embodiments, R 1 is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted ethenyl or substituted or unsubstituted propenyl. In certain embodiments, R 1 is substituted or unsubstituted alkynyl.
  • R 1 is selected from substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl.
  • R 1 is substituted or unsubstituted aryl, e.g., phenyl.
  • R 1 is substituted or unsubstituted heteroaryl, e.g., a substituted or unsubstituted heteroaryl selected from pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, quinazonyl, quinoxilinyl, naphthyridinyl, indolyl, indazolyl, benzimidazloyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyridopyrimidinyl, or purinyl.
  • a substituted or unsubstituted heteroaryl selected from
  • the heteroaryl group is substituted with one or more groups selected from substituted or unsubstituted alkyl, haloalkyl, alkenyl, substituted or unsubstituted alkynyl, oxo, hydoxy, halo, alkoxy, -S-alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -SO- alkyl, substituted or unsubstituted -S0 2 -alkyl, substituted or unsubstituted -SO-aryl, substituted or unsubstituted -S0 2 -aryl, substituted or unsubstituted -SO-heteroaryl, substituted or unsubstituted -S0 2 -heteroaryl, amino, cyano, and acyl.
  • substituted or unsubstituted alkyl substituted or unsubstitute
  • R 1 is imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, or tetrazolyl; each unsubstitued or substituted with one or two groups independently selected from oxo, Me, F, CI, -CN, and -CF 3 .
  • R 1 is quinolinyl, isoquinolinyl or purinyl; each unsubstitued or substituted with one or two groups independently selected from oxo, Me, F, CI, -CN, and -CF 3 .
  • R 1 is -OR A1 .
  • R 1 is -O- quinolinyl, -O-isoquinolinyl,- O-purinyl, each unsubstitued or substituted with one or two groups independently selected from Me, F, CI, -CN, and -CF .
  • R 1 is -OH or -0-CO-CH 2 -CH 2 -C0 2 H.
  • R 1 is -SR A1 .
  • R 1 is S- quinolinyl, -S-isoquinolinyl, or -S-purinyl, each unsubstitued or substituted with one or two groups independently selected from Me, F, CI, -CN, and -CF .
  • R 1 is -SH.
  • OS( 0) 2 OR A1 ; e.g., -0-S0 3 H.
  • R 20 is independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 20 is hydrogen. In certain embodiments, R 20 is substituted or unsubstituted alkyl ⁇ e.g., -CH ).
  • each instance of R 23a and R 23b is independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R 23a and R 23b are joined together to form substituted or unsubstituted C 3 -C 6 cycloalkyl.
  • each instance of R 23a and R 23b is hydrogen.
  • one of R 23a and R 23b is halo gen, e.g., fluoro
  • the other of R 23a and R 23b is hydrogen, halogen, or substituted or unsubstituted alkyl.
  • each instance of R 23a and R 23b is halogen, e.g., fluoro.
  • each instance of R 23a and R 23b is independently substituted or unsubstituted alkyl.
  • each of R 23a and R 23b is Me.
  • one of R 23a and R 23b is H.
  • one of R 23a and R 23b is H; and the other is substituted or unsubstituted alkyl.
  • one of R 23a and R 23b is H; and the other is Me or Et.
  • R 23a and R 23b are joined
  • R and R 23b are joined together to form a substituted or unsubstituted cyclopropyl.
  • X 2 is independently -0-, -S-, or -N(R X )-, wherein each instance of R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group.
  • X 2 is -0-. In certain embodiments, X 2 is -S-. In
  • X is -N(R )-. In certain embodiments, R is alkyl. In certain embodiments,
  • R is Me, Et, or i-Pr. In certain embodiments, R is hydrogen.
  • X is -O- and X is -0-. In certain embodiments, X
  • X is -O- and X is -S-. In certain embodiments, X is -O- and X is -N(R )-. In certain
  • X is -S- and X is -0-. In certain embodiments, X is -S- and X is -S-. In
  • X is -S- and X is -N(R )-. In certain embodiments, X is -N(R )-
  • X is -0-.
  • X is -N(R )- and X is -S-.
  • X 1 is -N(R X )- and X 2 is -N(R X )-.
  • R 24 is hydrogen
  • R 24 is substituted or unsubstituted alkyl. In certain embodiments, R 24 is alkyl unsubstituted or substituted with one or more substituents selected from the group consisting of halo or and hydroxyl. In certain embodiments, R 24 is substituted or unsubstitued alkenyl. In certain embodiments, R 24 is substituted or unsubstituted alkynyl.
  • R 24 is substituted or unsubstituted carbocyclyl.
  • R 24 is substituted or unsubstituted heterocyclyl. In certain embodiments, R 24 is substituted or unsubstitued aryl. In certain embodiments, R 24 is substituted or unsubstituted heteroaryl.
  • n is 0, 1, 2, or 3. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3.
  • Z is a group of formula (Hi), (iv), or (v)
  • Z is a group of formula (iii), (iv), or (v): (v).
  • L 3 is substituted or unsubstituted C ⁇ alkylene, e.g. , substituted or unsubstituted C ⁇ alkylene, substituted or unsubstituted C 2 _ 3 alkylene, substituted or unsubstituted C 3 ⁇ alkylene, substituted or unsubstituted C 4 _ 5 alkylene, or substituted or unsubstituted Cs ⁇ alkylene.
  • L is substituted or unsubstituted C 2 _ 6 alkyenlene, e.g., substituted or unsubstituted C 2 _ 3 alkenylene, substituted or unsubstituted C 3 ⁇ alkenylene, substituted or unsubstituted C 4 _ 5 alkenylene, or substituted or unsubstituted Cs ⁇ alkenylene.
  • L is substituted or unsubstituted C 2 6 alkynylene, e.g., substituted or unsubstituted C 2 _ 3 alkynylene, substituted or unsubstituted C 3 4 alkynylene, substituted or unsubstituted C ⁇ alkynylene, or substituted or unsubstituted C 5 6 alkynylene.
  • L is alkylene, alkenylene, or alkynylene unsubstituted or substituted with halo (e.g., fluoro), substituted or
  • L 3 is substituted or unsubstituted heteroCi-ealkylene, e.g., substituted or unsubstituted heteroC ⁇ alkylene, substituted or unsubstituted heteroC 2 _ 3 alkylene, substituted or unsubstituted heteroC 3 ⁇ alkylene, substituted or unsubstituted heteroC 4 _salkylene, or substituted or unsubstituted heteroCs_ 6 alkylene.
  • L is substituted or unsubstituted heteroC 2 _ 6 alkyenlene, e.g.
  • L is substituted or unsubstituted heteroC 2 _ 6 alkynylene, e.g.
  • L is heteroalkylene, heteroalkenylene, or hetero alkynylene unsubstituted or substituted with halo
  • At least one of the above or below instances in certain embodiments, at least one
  • R is hydrogen
  • At least one of the above or below instances in certain embodiments, at least one of the above or below instances, at least one of the above or below instances, at least one of the above or below instances, at least one of the above or below instances, at least one of the above or below instances, at least one of the above or below instances, at least one of the above or below instances, at least one of the above or below instances, at least one of the above or below instances, at least one of the above or below instances, at least one
  • R is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted Q_ 6 alkyl, substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted C ⁇ salkyl, or substituted or
  • R C ⁇ alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n-hexyl (C 6 ), Q_ 6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g., -CF 3 , -CH 2 F, -CHF 2> difluoroethyl
  • At least one instance of R Z5 is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C 2 6 alkenyl, substituted or unsubstituted C 2 _ 3 alkenyl, substituted or unsubstituted C 3 ⁇ alkenyl, substituted or unsubstituted C 4 _salkenyl, or substituted or unsubstituted Cs ⁇ alkenyl.
  • At least one instance of R Z5 is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C 2 6 alkynyl, substituted or unsubstituted C 2 _ 3 alkynyl, substituted or unsubstituted C 3 ⁇ alkynyl, substituted or unsubstituted C 4 _ 5 alkynyl, or substituted or unsubstituted Cs ⁇ alkynyl.
  • At least one instance of R Z5 is substituted or unsubstituted carbocyclyl, e.g., substituted or unsubstituted C 3 _ 6 carbocyclyl, substituted or unsubstituted C 3 ⁇ carbocyclyl, substituted or unsubstituted C 4 _ 5 carbocyclyl, or substituted or unsubstituted C 5 _ 6 carbocyclyl.
  • At least one instance of R Z5 is substituted or unsubstituted heterocyclyl, e.g., substituted or unsubstituted 3-6 membered heterocyclyl, substituted or unsubstituted 3-4 membered heterocyclyl, substituted or unsubstituted 4-5 membered heterocyclyl, or substituted or unsubstituted 5-6 membered heterocyclyl.
  • At least one instance of R Z5 is substituted or unsubstituted aryl, e.g., substituted or unsubstituted phenyl.
  • At least one instance of R Z5 is substituted or unsubstituted heteroaryl, e.g., optionally substituted 5-6 membered heteroaryl.
  • R Z5 is a protecting group, e.g., an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom.
  • substituted or unsubstituted heterocyclic ring e.g., a substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl ring.
  • each instance of R z6 is independently hydrogen, substituted or unsubstituted alkyl, or two R z6 groups are joined to form a C 3 _ 6 carbocyclic ring.
  • At least one instance of R z6 is hydrogen.
  • R z6 is substituted or unsubstituted alkyl, e.g. , substituted or unsubstituted C ⁇ a cyl, substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted C 4 _ 5 alkyl, or substituted or unsubstituted Cs ⁇ alkyl.
  • alkyl e.g. , substituted or unsubstituted C ⁇ a cyl, substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted C 4 _ 5 alkyl, or substituted or unsubstituted Cs ⁇ alkyl.
  • R Ci_ 6 alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso- butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n-hexyl (C 6 ), Ci_ 6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g.
  • Q_ 6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups e.g., -CH 2 C1, -CHC1 2
  • Q- 6 alkyl substituted with alkoxy groups e.g. , -CH 2 OCH 3 and -CH 2 OCH 2 CH 3 ).
  • two R z6 groups are joined to form a C 3 _ 6 carbocyclic ring, e.g. , for example, a substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, or substituted or unsubstituted cyclohexyl ring.
  • R 24 is substituted or unsubstituted alkyl, e.g. , substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted C 4 _ 5 alkyl, or substituted or unsubstituted Cs ⁇ alkyl.
  • R C ⁇ alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3- pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n- hexyl (C 6 ), Ci_ 6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g., -CF 3 , -CH 2 F, -CHF 2> difluoroethyl, and 2,2,2-trifluoro-l,
  • R 24 is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C 2 - 6 alkenyl, substituted or unsubstituted C 2 _ 3 alkenyl, substituted or unsubstituted C 3 ⁇ alkenyl, substituted or unsubstituted C ⁇ alkenyl, or substituted or unsubstituted Cs_ 6 alkenyl.
  • R 24 is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C 2 - 6 alkynyl, substituted or unsubstituted C 2 _ 3 alkynyl, substituted or unsubstituted C 3 ⁇ alkynyl, substituted or unsubstituted C ⁇ alkynyl, or substituted or unsubstituted Cs_ 6 alkynyl.
  • R 24 is substituted or unsubstituted carbocyclyl, e.g., substituted or unsubstituted C 3 _6carbocyclyl, substituted or unsubstituted C 3 ⁇ carbocyclyl, substituted or unsubstituted C 4 _ 5 carbocyclyl, or substituted or unsubstituted C 5 _ 6 carbocyclyl.
  • R 24 is substituted or unsubstituted heterocyclyl, e.g., substituted or unsubstituted 3-6 membered heterocyclyl, substituted or unsubstituted 3-4 membered heterocyclyl, substituted or unsubstituted 4-5 membered heterocyclyl, or substituted or unsubstituted 5-6 membered heterocyclyl.
  • R 24 is substituted or unsubstituted aryl, e.g., substituted or unsubstituted phenyl.
  • R 24 is substituted or unsubstituted heteroaryl, e.g., optionally substituted 5- to 6-membered heteroaryl.
  • R Z4 is -OR Z5 , wherein R Z5 is as defined herein, e.g.,
  • R is hydrogen, methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), or n-hexyl (C 6 ).
  • R Z4 is -SR Z5 , wherein R Z5 is as defined herein, e.g.,
  • R is hydrogen, methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), or n-hexyl (C 6 ).
  • R 24 is -N(R 25 ) 2 , e.g. , R 24 is -NH 2 , or -NHR 25 , wherein R Z5 is as defined herein, e.g., for example, R Z5 is hydrogen, methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n- pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), or n-hexyl (C 6 ), or R Z4 is -N(R Z5 ) 2 wherein the two R Z4 is -N(R Z5
  • L is an alkylene group of the formula: wherein p is 1, 2, or 3; and each instance of R Z7 and R Z8 is, independently, hydrogen, halo, substituted or unsubstituted Ci Z5
  • p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3.
  • L 3 alkenylene groups are also contemplated herein.
  • L is an alkenylene group of the formula:
  • R Z7 and R Z8 are, independently, hydrogen, halo, substituted or unsubstituted Ci Z5
  • q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2.
  • L 3 heteroalkylene groups are also contemplated herein, e.g., for example, in certain embodiments, L is a heteroalkylene group of the formula:
  • R' and R Z8 is independently hydrogen, halo, substituted or unsubstituted Ci_6 alkyl, or -OR Z5.
  • p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, w is 0. In certain embodiments, w is 1. In certain embodiments, w is 0, and p is 1. In certain embodiments, w is 0, and p is 2. In certain embodiments, w is 0, and p is 3. In certain embodiments, w is 1, and p is 1. In certain embodiments, w is 1, and p is 2. In certain embodiments, w is 1, and p is 3. [00220] For example, in certain embodiments wherein w is 0, provided is an L 3 heteroalkylene group of the formula:
  • At least one instance of R Z7 is hydrogen.
  • At least one instance of R is halo, e.g. , fluoro.
  • At least one instance of R is substituted or unsubstituted Ci_6 alkyl, e.g. , substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted
  • R C ⁇ alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3- pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n- hexyl (C 6 ), C ⁇ alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g.
  • Ci_ 6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups e.g. , -CH 2 C1, -CHC1 2
  • Ci_6 alkyl substituted with alkoxy groups e.g. , -CH 2 OCH 3 and -CH 2 OCH 2 CH 3 ).
  • At least one instance of R is -CH , -CF , - CH 2 CH (Et), or -CH(CH ) 2 (iPr). In any of the above instances, in certain embodiments, at
  • R is -OR , e.g. , -OH.
  • At least one instance of R Z8 is hydrogen.
  • At least one instance of R is halo, e.g. , fluoro.
  • At least one instance of R is substituted or unsubstituted Ci_6 alkyl, e.g. , substituted or unsubstituted Ci_ 2 alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted
  • R C h alky! groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3- pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n- hexyl (C 6 ), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g.
  • Ci_ 6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups e.g. , -CH 2 C1, -CHC1 2
  • Ci_6 alkyl substituted with alkoxy groups e.g. , -CH 2 OCH 3 and -CH 2 OCH 2 CH 3 ).
  • At least one instance of R is -CH 3 , -CF 3 , - CH 2 CH (Et), or -CH(CH ) 2 (iPr). In any of the above instances, in certain embodiments, at
  • R is -OR , e.g. , -OH.
  • Exemplary L 3 alkylene groups include, but are not limited to:
  • L heteroalkylene groups include, but are not limited to: [00227] In certain embodiments, the group wherein L is an alkylene or heteroalkylene group, is of the formula:
  • the group , wherein Y is -O- and L ylene or heteroalkylene group is of the formula:
  • L is an alkylene or heteroalkylene group, is of the formula
  • an alkylene or heteroalkylene group is of the formula:
  • each instance of R 2 , R lla , and R llb is
  • R 2 is H. In certain embodiments, R 2 is substituted or unsubstituted alkyl. In certain embodiments, R is substituted or unsubstituted alkenyl. In certain embodiments, R 2 is substituted or unsubstituted alkynyl. In certain embodiments, R 2 is
  • R 2 is -SRB1. In certain embodiments, R 2 is -N(RB 1 ) 2 . In certain embodiments, R is H, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -OR B 1 , -SR B 1 , or -N(R B 1 ) 2 .
  • R is F, CI, Me, Et, n-Pr, methoxy, ethoxy, propoxy, butoxy, ethynyl, hydroxybutynyl, methoxypropynyl, chloroethynyl, or cyclopropynyl.
  • R 2 is CF 3 , amino, or dimethylamino. In certain embodiments, R 2 is a non-hydrogen group in the alpha position. In certain embodiments, R is a non-hydrogen group in the beta position.
  • each instance of R l la and R llb is hydrogen.
  • one of R l la and R l lb is hydrogen.
  • one of R l la and R llb is hydrogen; and the other is -OR B 1 , -SR B 1 , or -N(R B 1 ) 2 .
  • one of R l la and R l lb is H; and the other is -OH, -OMe, amino, or dialkylamino.
  • R llb is a non-hydrogen group, and R lla is hydrogen.
  • R l la is a non-hydrogen group, and R l lb is hydrogen.
  • R l la and R l lb together form an oxo group.
  • each instance of R 4a and R 4b is hydrogen. In certain embodiments, one of R 4a and R 4b is hydrogen. In certain embodiments, one of R 4a and R 4b is hydrogen; and the other is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. In certain embodiments, one of R 4a and R 4b is hydrogen; and the other is Me, Et, ethenyl, ethynyl, propenyl, or propynyl. In certain embodiments, each of R 4a and R 4b is independently substituted or unsubstituted alkyl. In certain embodiments, each of R 4a and R 4b is Me.
  • each instance of R 7a and R 7b is hydrogen.
  • each of R 6a and R 6b is independently hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, and represents a single or double bond, provided if a double bond is present in Ring B, then one of R 6a or R 6b is absent, and provided if a single bond is present in Ring B, then the hydrogen at C5 is in the alpha or beta position.
  • each instance of R 6a and R 6b is hydrogen. In certain embodiments, each instance of R 6a and R 6b is halo, e.g., fluoro.
  • R 6a is hydrogen
  • R 6b is halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl.
  • R 6a is hydrogen
  • R 6b is halo (e.g., fluoro).
  • R 6a is hydrogen
  • R 6b is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C ⁇ alkyl, substituted or unsubstituted C 2 _ 3 alkyl, substituted or unsubstituted C 3 ⁇ alkyl, substituted or unsubstituted C 4 _salkyl, or substituted or unsubstituted C 5 _ 6 alkyl, e.g., methyl, ethyl, propyl, or isopropyl.
  • R 6a is hydrogen
  • R 6b is substituted or unsubstituted alkenyl.
  • R 6a is hydrogen
  • R 6b is substituted or unsubstituted alkynyl.
  • R 6b is hydrogen, and R 6a is halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl.
  • R 6b is hydrogen, and R 6a is halo (e.g., fluoro).
  • R 6b is hydrogen, and R 6a is substituted or unsubstituted alkyl, e.g.
  • R 6b is hydrogen, and R 6a is substituted or unsubstituted alkenyl. In certain embodiments, R 6b is hydrogen, and R 6a is substituted or unsubstituted alkynyl.
  • R 6a is hydrogen. In certain embodiments, wherein represents a double bond, R 6a is halo, e.g., fluoro. In certain embodiments, wherein represents a double bond, R 6a is substituted or unsubstituted alkyl, e.g.
  • R 6a is substituted or unsubstituted alkenyl. In certain embodiments, wherein
  • R 6a represents a double bond
  • R 6a is substituted or unsubstituted alkynyl.
  • R is hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or
  • R is hydrogen. In certain embodiments, R is halo. In certain embodiments,
  • R is substituted or unsubstituted alkyl. In certain embodiments, R is substituted or
  • R is substituted or unsubstituted alkynyl.
  • R is substituted or unsubstituted carbocyclyl. In certain embodiments,
  • R is substituted or unsubstituted heterocyclyl. In certain embodiments, R is substituted or
  • R 14 is H or substituted or unsubstituted alkyl. In certain embodiments, R 14 is H. In certain embodiments, R 14 is substituted or unsubstituted alkyl ⁇ e.g., -CH 3 ).
  • R 18 is independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 18 is hydrogen. In certain embodiments, R 18 is substituted or unsubstituted alkyl ⁇ e.g., -CH ).
  • R 19 is independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 19 is hydrogen. In certain embodiments, R 19 is substituted or unsubstituted alkyl ⁇ e.g., -CH ).
  • R 14 is hydrogen
  • R 18 is -CH 3
  • R 19 is -CH 3 .
  • R 14 is hydrogen
  • R 18 is -CH 3
  • R 19 is hydrogen
  • the compound of Formula (I) is of Formula (I- w):
  • R 3b is hydrogen.
  • the group - ⁇ 3 ⁇ 4 at the C3 position is beta.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B1 .
  • R lla is hydrogen and R l lb is hydrogen or - OR B1 .
  • R 5 is alpha (down)
  • R 6a is hydrogen.
  • R 6a and R 6b are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen.
  • R 6a and R 6b are both halo, e.g., fluoro.
  • R 19 is methyl.
  • the group - OH at the C3 position is beta.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B 1. In certain
  • R lla is hydrogen and R llb is hydrogen or -OR B1 .
  • R 5 is alpha (down) and R 6a is hydrogen.
  • R 6a is hydrogen.
  • R 6a and R 6b are both hydrogen.
  • R a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen.
  • R 6a and R 6b are both halo, e.g., fluoro.
  • R 19 is methyl.
  • the compound of Formula (I) is of Formula (I-y):
  • the group OH at the C3 position is beta.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B 1. In certain
  • R lla is hydrogen and R llb is hydrogen or -OR B1 .
  • R 5 is alpha (down) and R 6a is hydrogen.
  • R a represents a double bond.
  • R a and R are both hydrogen.
  • R ) 6a is halo, e.g., fluoro, or alkyl.
  • RR 6b iiss hhaalloo,, ee..gg..,, fflluuoorrco, or alkyl, and R a is hydrogen.
  • R a and R are both halo, e.g., fluoro.
  • the compound of Formula (I) is of Formula (I-z):
  • the group - OH at the C3 position is beta.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B 1. In certain
  • R lla is hydrogen and R llb is hydrogen or -OR B1 .
  • R 5 is alpha (down) and R 6a is hydrogen.
  • R 6a is hydrogen.
  • R 6a and R 6b are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen.
  • R 6a and R 6b are both halo, e.g., fluoro.
  • the compound of Formula (I) is of Formula (I-al), (I- a2), or (I-a3):
  • R is hydrogen.
  • the group -OR at the C3 position is beta.
  • R a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B1 .
  • R l la is hydrogen and R l lb is hydrogen or - OR B 1 .
  • R 6a and R 6b are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl
  • R 6a is hydrogen.
  • R 6a and R 6b are both halo, e.g., fluoro.
  • the compound of Formula (I) is of Formula (I-bl), (I- b2), or (I-b3):
  • R 3b is hydrogen.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B 1 .
  • R l la is hydrogen and R l lb is hydrogen or -OR B1 .
  • R 6a and R 6b are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl
  • R 6a is hydrogen.
  • R 6a and R 6b are both halo, e.g., fluoro.
  • the compound of Formula (I) is of Formula (I-cl), (I- c2), or (I-c3):
  • R 3b is hydrogen.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B1 .
  • R lla is hydrogen and R l lb is hydrogen or -OR B1 .
  • R 6a and R 6b are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl
  • R 6a is hydrogen.
  • R 6a and R 6b are both halo, e.g., fluoro.
  • the compound is of Formula (I-d):
  • R 3b is hydrogen.
  • the group - ⁇ 3 ⁇ 4 at the C3 position is beta.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B1 .
  • R lla is hydrogen and R l lb is hydrogen or - OR B1 .
  • R 5 is alpha (down)
  • R 6a is hydrogen.
  • R 6a and R 6b are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen.
  • R 6a and R 6b are both halo, e.g., fluoro.
  • R 19 is methyl.
  • each R 26 is independently hydrogen or methyl.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R is hydrogen or - OR B1 .
  • R lla is hydrogen and R llb is hydrogen or -OR B1 .
  • represents a single bond R 5 is alpha (down) and R 6a is hydrogen.
  • R 6a and R 6b are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl
  • R 6a is hydrogen
  • R 6a and R 6b are both halo, e.g., fluoro
  • R 19 is methyl
  • each R 26 is independently hydrogen or methyl.
  • the compound is of Formula (I-f):
  • R 3b is hydrogen.
  • the group - ⁇ 3 ⁇ 4 at the C3 position is beta.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B1 .
  • R lla is hydrogen and R l lb is hydrogen or - OR B1 .
  • R 5 is alpha (down)
  • R 6a is hydrogen.
  • R a and R are both hydrogen.
  • R a is halo, e.g., fluoro, or alkyl.
  • R is halo, e.g., fluoro, or alkyl, and R a is hydrogen.
  • R 6a and R 6b are both halo, e.g., fluoro.
  • R 19 is methyl.
  • each R z6 is independently hydrogen or methyl.
  • R Z5 is hydrogen or methyl.
  • the compound is of Formula (I-g):
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R is hydrogen or - OR B1 .
  • R lla is hydrogen and R llb is hydrogen or -OR B1 .
  • represents a single bond R 5 is alpha (down) and R 6a is hydrogen.
  • R 6a and R 6 are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R is halo, e.g., fluoro, or alkyl, and R D 6 a a i ⁇ s hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro. In certain embodiments, R 19 is methyl. In certain embodiments, each R 26 is independently hydrogen or methyl. In certain embodiments, R 25 is hydrogen or methyl.
  • the compound is of Formula (I-h):
  • R 3b is hydrogen.
  • the group - ⁇ 3 ⁇ 4 at the C3 position is beta.
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R 2 is hydrogen or -OR B1 .
  • R l la is hydrogen and R l lb is hydrogen or - OR B1 .
  • R 5 is alpha (down)
  • R 6a is hydrogen.
  • R 6a and R 6b are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl, and R 6a is hydrogen.
  • R 6a and R 6b are both halo, e.g., fluoro.
  • R 19 is methyl.
  • R z6 is isopropyl.
  • the compound is of Formula (I-i):
  • R 3a is hydrogen or substituted or unsubstituted alkyl.
  • R is hydrogen or - OR B1 .
  • R lla is hydrogen and R llb is hydrogen or -OR B1 .
  • represents a single bond R 5 is alpha (down) and R 6a is hydrogen.
  • R 6a and R 6b are both hydrogen.
  • R 6a is halo, e.g., fluoro, or alkyl.
  • R 6b is halo, e.g., fluoro, or alkyl
  • R 6a is hydrogen
  • R 6a and R 6b are both halo, e.g., fluoro.
  • R 19 is methyl.
  • R z6 is isopropyl.
  • Additional embodiments of Formula (I) include compounds of the following formula:
  • the compound is any one of the following compounds:
  • the compound is any one of the following compounds:
  • the compound is any one of the following compounds:
  • the compound is any one of the following compounds:
  • the compound is any one of the following compounds:
  • the compound is any one of the following compounds:
  • the compound is any one of the following compounds:
  • the compound of the present invention is a pharmaceutically acceptable salt.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a effective amount of a compound of Formula (I).
  • compositions When employed as pharmaceuticals, the compounds provided herein are typically administered in the form of a pharmaceutical composition.
  • Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.
  • the carrier is a parenteral carrier, oral or topical carrier.
  • the present invention also relates to a compound of the present invention or pharmaceutical composition thereof for use as a pharmaceutical or a medicament.
  • the amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • compositions provided herein can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous,
  • the compounds provided herein are preferably formulated as either injectable or oral compositions or as salves, as lotions or as patches all for transdermal administration.
  • compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions.
  • the compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
  • Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like.
  • Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art.
  • the active compound in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
  • Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight.
  • the active ingredients When formulated as a ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example an oil-in-water cream base.
  • Such transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration of stability of the active ingredients or the formulation. All such known transdermal formulations and ingredients are included within the scope provided herein.
  • transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.
  • the compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems.
  • sustained release materials can be found in Remington's Pharmaceutical Sciences.
  • the present invention also relates to the pharmaceutically acceptable formulations of a compound of the present invention.
  • the formulation comprises water.
  • the formulation comprises a cyclodextrin derivative.
  • the most common cyclodextrins are ⁇ -, ⁇ - and ⁇ - cyclodextrins consisting of 6, 7 and 8 cc-l ,4-linked glucose units, respectively, optionally comprising one or more substituents on the linked sugar moieties, which include, but are not limited to, methylated, hydroxyalkylated, acylated, and sulfoalkylether substitution.
  • the cyclodextrin is a sulfoalkyl ether ⁇ -cyclodextrin, e.g., for example, sulfobutyl ether ⁇ - cyclodextrin, also known as Captisol®. See, e.g., U.S. 5,376,645.
  • the formulation comprises hexapropyl- -cyclodextrin. In a more particular embodiment, the formulation comprises hexapropyl- -cyclodextrin (10-50% in water).
  • the present invention also relates to the pharmaceutically acceptable acid addition salt of a compound of the present invention.
  • the acid which may be used to prepare the pharmaceutically acceptable salt is that which forms a non-toxic acid addition salt, i.e., a salt containing pharmacologically acceptable anions such as the hydrochloride, hydroiodide, hydrobromide, nitrate, sulfate, bisulfate, phosphate, acetate, lactate, citrate, tartrate, succinate, maleate, fumarate, benzoate, para-toluenesulfonate, and the like.
  • a non-toxic acid addition salt i.e., a salt containing pharmacologically acceptable anions such as the hydrochloride, hydroiodide, hydrobromide, nitrate, sulfate, bisulfate, phosphate, acetate, lactate, citrate, tartrate, succinate, maleate, fumarate, benzoate, para-toluen
  • Exemplary Formulation 1 - Tablets A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active compound per tablet) in a tablet press.
  • Exemplary Formulation 2 - Capsules A compound of the present invention may be admixed as a dry powder with a starch diluent in an approximate 1: 1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active compound per capsule).
  • 125 mg may be admixed with sucrose (1.75 g) and xanthan gum (4 mg) and the resultant mixture may be blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water.
  • Sodium benzoate (10 mg) flavor, and color are diluted with water and added with stirring. Sufficient water may then be added to produce a total volume of 5 mL.
  • Exemplary Formulation 4 - Tablets A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active compound) in a tablet press.
  • Exemplary Formulation 5 - Injection A compound of the present invention may be dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/mL.
  • Exemplary Formulation 6 - Tablets A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
  • a minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
  • Exemplary Formulation 7 - Tablets A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
  • a minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
  • Exemplary Formulation 8 - Tablets A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
  • a minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
  • Exemplary Formulation 9 - Tablets A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
  • a minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
  • Exemplary Formulation 10 - Tablets A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
  • a minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
  • Injection dose levels range from about 0.1 mg/kg/hour to at least
  • a preloading bolus of from about 0.1 mg/kg to about 10 mg/kg or more may also be
  • the maximum total dose is not expected to exceed about 2 g/day for a 40 to 80 kg human patient.
  • each dose provides from about 0.01 to about 20 mg/kg of the compound provided herein, with preferred doses each providing from about 0.1 to about 10 mg/kg, and especially about 1 to about 5 mg/kg.
  • Transdermal doses are generally selected to provide similar or lower blood levels than are achieved using injection doses.
  • the compounds provided herein When used to prevent the onset of a CNS-disorder, the compounds provided herein will be administered to a subject at risk for developing the condition, typically on the advice and under the supervision of a physician, at the dosage levels described above.
  • Subjects at risk for developing a particular condition generally include those that have a family history of the condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the condition.
  • the compounds and pharmaceutical compositions provided herein find use as therapeutics for preventing and/or treating CNS conditions in mammals including humans and non-human mammals.
  • the present invention includes within its scope, and extends to, the recited methods of treatment, as well as to the compounds for such methods, and to the use of such compounds for the preparation of medicaments useful for such methods.
  • the novel 3a- and 3 ⁇ - hydroxy steroids of the invention may act as negative allosteric modulators (NAM) of NMDA receptor and thus may be useful for preventing and/or treating a broad range of CNS conditions.
  • NAM negative allosteric modulators
  • compounds of the present invention are contemplated as therapeutic agents, e.g., for the treatment of CNS conditions in mammals, such as for the treatment of schizophrenia, depression, bipolar disorder ⁇ e.g., I and/or II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, compulsive disorders, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive compulsive disorder (OCD), pain ⁇ e.g., a painful syndrome or disorder), sleep disorders, memory disorders, dementia, Alzheimer's Disease, a seizure disorder ⁇ e.g., epilepsy), traumatic brain injury (TBI), stroke, addictive disorders ⁇ e.g., addiction to opiates, cocaine, and/or alcohol), autism, Huntington's Disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus.
  • the compounds of the present invention are useful in the
  • a method of treating a mammal susceptible to or afflicted with a condition associated with brain excitability comprises administering an effective amount of one or more of the pharmaceutical compositions described herein.
  • a compound of the present invention as a pharmaceutical, e.g., especially in the treatment or prevention of the aforementioned conditions and diseases.
  • a method of manufacture of a medicament for the treatment or prevention of one of the aforementioned conditions and diseases is provided.
  • the present invention provides a method for preventing, treating, ameliorating or managing a disease or condition which comprises administering to a subject in need of such prevention, treatment, amelioration or
  • the present invention provides a use of a compound of the present invention for the manufacture of a medicament to treat a disease or condition associated with brain excitability.
  • the disease or condition is selected from depression, anxiety, schizophrenia, sleep disorders, memory disorders, and mood disorders.
  • the present invention provides a method of treatment of a mammal, e.g., a human being, to treat a disease associated with brain excitability, including treating said mammal with an effective amount of a compound of the present invention or composition thereof.
  • the present invention provides a combination of a compound of the present invention and another pharmacologically active agent.
  • the compounds provided herein can be administered as the sole active agent or they can be administered in combination with other agents. Administration in combination can proceed by any technique apparent to those of skill in the art including, for example, separate, sequential, concurrent and alternating administration.
  • the compounds provided herein can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization.
  • the compounds provided herein may be isolated and purified by known standard procedures. Such procedures include (but are not limited to) recrystallization, column chromatography, or HPLC. The following schemes are presented with details as to the preparation of representative substituted biarylamides that have been listed herein.
  • the compounds provided herein may be prepared from known or commercially available starting materials and reagents by one skilled in the art of organic synthesis.
  • the enantiomerically pure compounds provided herein may be prepared according to any techniques known to those of skill in the art. For instance, they may be prepared by chiral or asymmetric synthesis from a suitable optically pure precursor or obtained from a racemate by any conventional technique, for example, by chromatographic resolution using a chiral column, TLC or by the preparation of diastereoisomers, separation thereof and regeneration of the desired enantiomer. See, e.g., "Enantiomers, Racemates and Resolutions," by J. Jacques, A. Collet, and S.H. Wilen, (Wiley-Interscience, New York, 1981); S.H. Wilen, A. Collet, and J. Jacques, Tetrahedron, 2725 (1977); E.L. Eliel
  • an enantiomerically pure compound of the present invention may be obtained by reaction of the racemate with a suitable optically active acid or base.
  • suitable acids or bases include those described in Bighley et al., 1995, Salt Forms of Drugs and Adsorption, in Encyclopedia of Pharmaceutical Technology, vol. 13, Swarbrick & Boylan, eds., Marcel Dekker, New York; ten Hoeve & H. Wynberg, 1985, Journal of Organic Chemistry 50:4508-4514; Dale & Mosher, 1973, J. Am. Chem. Soc. 95:512; and CRC Handbook of Optical Resolution via Diastereomeric Salt Formation, the contents of which are hereby incorporated by reference in their entireties.
  • Enantiomerically pure compounds can also be recovered either from the crystallized diastereomer or from the mother liquor, depending on the solubility properties of the particular acid resolving agent employed and the particular acid enantiomer used.
  • the identity and optical purity of the particular compound so recovered can be determined by polarimetry or other analytical methods known in the art.
  • the diasteroisomers can then be separated, for example, by chromatography or fractional crystallization, and the desired enantiomer regenerated by treatment with an appropriate base or acid.
  • the other enantiomer may be obtained from the racemate in a similar manner or worked up from the liquors of the first separation.
  • enantiomerically pure compound can be separated from racemic compound by chiral chromatography.
  • Various chiral columns and eluents for use in the separation of the enantiomers are available and suitable conditions for the separation can be empirically determined by methods known to one of skill in the art.
  • Exemplary chiral columns available for use in the separation of the enantiomers provided herein include, but are not limited to, CHIRALCEL® OB, CHIRALCEL® OB-H, CHIRALCEL® OD, CHIRALCEL® OD-H, CHIRALCEL® OF, CHIRALCEL® OG, CHIRALCEL® OJ and CHIRALCEL® OK.
  • R ⁇ alkyl or -(CH 2 ) 2 _ 5 -COOH
  • reaction mixture was quenched by addition of saturated aqueous NH 4 C1 (50 mL) and extracted with EA (50 mL x 2). The combined organic layers were dried over Na 2 S0 4 and evaporated to dryness to give the desired product (1.84 g, 91%) as a white solid.
  • reaction mixture was poured into saturated aqueous NH 4 CI 4 solution (400 mL) and exacted with EA (300 mL x 2). The combined organic layers were washed with brine (200 mL x 2), dried over sodium sulfate and concentrated in vacuum. The residue was purified by silica gel chromatography eluted with PE: EA (15: 1) to give product 13 (16.0 g, 0.046 mol, 72%) as a white solid.

Abstract

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.

Description

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF
RELATED APPLICATIONS
[0001] The present application claims priority under 35 U.S.C. § 119(e) to U.S.
provisional patent application, U.S. S.N. 61/532,427, filed September 8, 2011, which is incorporated herein by reference.
BACKGROUND
[0002] Brain excitability is defined as the level of arousal of an animal, a continuum that ranges from coma to convulsions, and is regulated by various neurotransmitters. In general, neurotransmitters are responsible for regulating the conductance of ions across neuronal membranes. At rest, the neuronal membrane possesses a potential (or membrane voltage) of approximately -70 mV, the cell interior being negative with respect to the cell exterior. The potential (voltage) is the result of ion (K+, Na+, CI", organic anions) balance across the neuronal semipermeable membrane. Neurotransmitters are stored in presynaptic vesicles and are released as a result of of neuronal action potentials. When released into the synaptic cleft, an excitatory chemical transmitter such as acetylcholine will cause membrane depolarization (change of potential from -70 mV to -50 mV). This effect is mediated by postsynaptic nicotinic receptors which are stimulated by acetylcholine to increase the membrane permeability of Na+ ions. The reduced membrane potential stimulates neuronal excitability in the form of a postsynaptic action potential.
[0003] NMDA receptors are highly expressed in the CNS and are involved in excitatory synaptic transmission and synaptic plasticity as well as excitotoxicity. These receptors are ligand-gated ion channels that admit Ca2+ after binding of the neurotransmitter glutamate and are fundamental to excitatory neurotransmission and normal CNS function. NMDA receptors are heteromeric complexes comprised of NR1, NR2, and/or NR3 subunits and possess distinct recognition sites for exogenous and endogenous ligands. These recognition sites include binding sites for glycine, and glutamate agonists and modulators. These modulators may be useful as therapeutic agents with potential clinical uses as cognitive enhancers and in the treatment of psychiatric disorders in which glutamatergic transmission is reduced or defective (see, e.g., Horak et ah, J. ofNeuroscience, 2004, 24(46), 10318-10325).
[0004] Neuroactive steroids such as pregnenolone sulfate (PS) have been shown to exert direct modulatory effects on several types of neurotransmitter receptors, such as GABAA, glycine, AMPA-kainate, and NMDA receptors. NMDA receptors are positively modulated by PS; however, the degree of modulation varies considerably.
[0005] In addition to PS, several other 3 -hydroxy steroids have been shown to potentiate NMDA receptors (see, e.g., Paul et al., J. Pharm. and Exp. Ther. 1994, 271, 677- 682). Recently, a 3 -hydroxy-ergost-5-ene steroid derivative (1) was reported as positive modulator of NMDA (NRla/NR2A). Compound (1) (also referred to as Org-1) was found to selectively modulate NMDA over GABAA (see, e.g., Madau et al, Program No. 613.2/B87. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009; Connick et al., Program No. 613.1/B86. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009).
Figure imgf000004_0001
[0006] New and improved neuroactive steroids are needed that modulate brain excitability for the prevention and treatment of CNS-related conditions. The compounds, compositions, and methods described herein are directed toward this end.
SUMMARY OF THE INVENTION
[0007] New 3-CC and 3 -hydroxy steroids described herein are potential NMDA receptor modulators and thus are useful for preventing and/or treating a broad range of CNS- related conditions, including but not limited to schizophrenia, depression, bipolar disorder {e.g., I and/or II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, compulsive disorders, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive compulsive disorder (OCD), pain {e.g., a painful syndrome or disorder), sleep disorders, memory disorders, dementia, Alzheimer's Disease, a seizure disorder {e.g., epilepsy), traumatic brain injury, stroke, addictive disorders {e.g., addiction to opiates, cocaine, and/or alcohol), autism, Huntington's Disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus. These compounds are expected to show improved in vivo potency, pharmacokinetic (PK) properties, oral bioavailability, formulatability, stability, and/or safety. [0008] In one aspect, provided are compounds according to Formula (I):
Figure imgf000005_0001
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof;
wherein:
Z is a group of the formula (i), (ii), (iii), (iv), or (v):
Figure imgf000005_0002
T Ι^ 1 , TΙ^ 2, TΙ^ 3, Λ V1 , Λ V2, VΙ , PΚ24 , PκZ5 , PK26 , nη, Ώ κ1, Ώκ2, Pκ3A , PK3B , PK4A , PK4B , PK6A , PK6B , PK7A , PK7B , PKL L A , PKL LB ,
R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein; and the group -XR3b at the C3 position is alpha or beta.
[0009] For example, in certain embodiments, the compound of Formula (I) is of
Formula (I-w):
Figure imgf000005_0003
or a pharmaceutically acceptable salt thereof;
wherein:
Z is a group of the formula (i), (ii), (iii), (iv), or (v):
Figure imgf000006_0001
unsubstituted C -Ce alkylene, a substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, a substituted or unsubstituted hetero Ci-C6 alkylene, a substituted or unsubstituted hetero C2-C6 alkenylene, and a substituted or unsubstituted hetero C2-C6 alkynylene;
L is a substituted or unsubstituted Ci-C6 alkylene, a substituted or unsubstituted C2- C alkenylene, substituted or unsubstituted C2-C6 alkynylene, a substituted or unsubstituted hetero Ci-C6 alkylene, a substituted or unsubstituted hetero C2-C6 alkenylene, or a substituted or unsubstituted hetero C2-C6 alkynylene;
1 2
each instance of X and X is independently -0-, -S-, or -NH-;
R1 is hydrogen or substituted or unsubstituted alkyl;
R3b is hydrogen;
R3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
each instance of R2, Rl la, and Rl lb is independently hydrogen or -ORB1, wherein wherein RB1 is hydrogen or substituted or unsubstituted alkyl, or Rl la and Rl lb are joined to form an oxo (=0) group;
each of R6a and R6b is independently hydrogen, halo, or substituted or unsubstituted alkyl, and represents a single or double bond, provided if a double bond is present, then one of R6a or R6b is absent, and provided if a single bond is present, then the hydrogen at C5 is in the alpha or beta position;
each instance of R19 and R20 is independently hydrogen or -C¾;
and each instance of R23a and R23b is independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R23a and R23b are joined together to form substituted or
unsubstituted C3-C6 cycloalkyl; R 24 is hydrogen or substituted or unsubstituted alkyl;
Y is -0-, -S-, or -NRZ5-;
R is independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR25, -SRZ5, or -N(RZ5)2;
each instance of R Z5 is independently hydrogen or substituted or unsubstituted alkyl; and
each instance of Rz6 is independently hydrogen or substituted or unsubstituted alkyl, or two Rz6 groups are joined to form a C3_6 carbocyclic ring; and
the subscript n is 0 or 1;
provided the following compounds are specifically excluded:
Figure imgf000007_0001
[0010] In certain embodiments, Z is a group of formula:
Figure imgf000007_0002
(iii), RZ6 (iv), or YRZ5 (v).
[0011] In certain embodimen 3 is a group of formula:
Figure imgf000007_0003
wherein p is 1, 2, or 3; and each instance of R and R is, independently, hydrogen, halo, substituted or unsubstituted C^ alkyl, or -OR Z5.
[0012] In certain embodiments, L3 is a group of formula:
Figure imgf000008_0001
wherein w is 0 or 1 and p is 1, 2, or 3, or w is 1 and p is 0, 1, 2, or 3; and each instance of R Z7 and R Z8 is independently hydrogen, halo, substituted or unsubstituted Ci 5
_6 alkyl, or -OR Z .
[0013] In certain embodiments, L is a group of formula
Figure imgf000008_0002
Figure imgf000009_0001
[0016] In certain embodiments, Z is of formula
[0017] In certain embodiments, the group RZ4 is of the formula
Figure imgf000009_0002
Figure imgf000010_0001
[0018] In certain embodiments, Z is of formula
Figure imgf000010_0002
[0019] In certain embodiments, wherein Y is -O- and L3 is an alkylene or heteroalkylene group.
[0020]
Figure imgf000010_0003
Figure imgf000011_0001
[0021] In certain embodiments, Z is of formula YR b .
[0022] In certain embodiments, Y is -O- and L3 is an alkylene or heteroalkylene.
V
[0023] In certain embodiments, the group Y YR is of the formula:
Figure imgf000011_0002
the alpha position. In certain embodiments, -Χ^¾ is -OH. In certain embodiments, R3a is hydrogen. In certain embodiments, R3a is substituted or unsubstituted alkyl. In certain embodiments, R6b is halogen or substituted or unsubstituted alkyl. In certain embodiments, R2 is hydrogen or -ORB1. In certain embodiments, Rl lb is hydrogen or -ORB1, and Rlla is hydrogen. In certain embodiments, Rlla and Rllb together form an oxo group. In certain embodiments, represents a single bond, and the hydrogen at C5 is in the alpha position. In certain embodiments, represents a double bond. In certain embodiments,
R19 is -CH3.
[0025] In another aspect, provided is a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier. In certain embodiments, the compound of the present invention is provided in an effective amount. In certain embodiments, the compound of the present invention is provided in a therapeutically effective amount. In certain embodiments, the compound of the present invention is provided in a prophylactically effective amount.
[0026] In certain aspects, compounds of the present invention are provided as negative allosteric modulators (NAM) of NMDA receptor and thus are useful for preventing and/or treating a broad range of CNS conditions including but not limited to schizophrenia, depression, bipolar disorder (I and II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, compulsive disorders, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive compulsive disorder (OCD), all pain syndromes and disorders, sleep disorders, memory disorders and dementia including Alzheimer's Disease, epilepsy and any seizure disorders, traumatic brain injury (TBI), stroke, addictive disorders including opiates and cocaine and alcohol, autism, Huntington's Disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus. For example, in one aspect, provided is a method of NMDA receptor modulation comprising administering an effective amount of a compound of the present invention to a subject in need thereof. In another aspect, provided is a method of modulating CNS-activity comprising administering an effective amount of acompound of the present invention to a subject in need thereof. In yet another aspect, provided is a method of modulating brain excitability comprising administering an effective amount of acompound of the present invention to a subject in need thereof.
[0027] Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing detailed description, examples, and claims.
DEFINITIONS
Chemical Definitions
[0028] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March 's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern
Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987.
[0029] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et ah, Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et ah, Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw- Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The invention additionally encompasses compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.
[0030] When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example "Q-6 alkyl" is intended to encompass, Q, C2, C3,
C4, C5, C6, Ci_6, Ci_5, Ci^, Ci_3, Ci_2, C2-6, C2_5, C-2-A, C2_3, C3_6, C3_5, C3^, C4-6, C4_5, and C5-6 alkyl.
[0031] The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention. When describing the invention, which may include compounds, pharmaceutical compositions containing such compounds and methods of using such compounds and compositions, the following terms, if present, have the following meanings unless otherwise indicated. It should also be understood that when described herein any of the moieties defined forth below may be substituted with a variety of substituents, and that the respective definitions are intended to include such substituted moieties within their scope as set out below. Unless otherwise stated, the term "substituted" is to be defined as set out below. It should be further understood that the terms "groups" and "radicals" can be considered interchangeable when used herein. The articles "a" and "an" may be used herein to refer to one or to more than one (i.e. at least one) of the grammatical objects of the article. By way of example "an analogue" means one analogue or more than one analogue.
[0032] "Alkyl" refers to a radical of a straight-chain or branched saturated
hydrocarbon group having from 1 to 20 carbon atoms ("Ci_2o alkyl"). In some embodiments, an alkyl group has 1 to 12 carbon atoms ("Ci_12 alkyl"). In some embodiments, an alkyl group has 1 to 10 carbon atoms ("Q-io alkyl"). In some embodiments, an alkyl group has 1 to 9 carbon atoms ("Q-9 alkyl"). In some embodiments, an alkyl group has 1 to 8 carbon atoms ("Ci-8 alkyl"). In some embodiments, an alkyl group has 1 to 7 carbon atoms ("Ci_7 alkyl"). In some embodiments, an alkyl group has 1 to 6 carbon atoms ("Ci_6 alkyl", also referred to herein as "lower alkyl"). In some embodiments, an alkyl group has 1 to 5 carbon atoms ("Ci_5 alkyl"). In some embodiments, an alkyl group has 1 to 4 carbon atoms ("C^ alkyl"). In some embodiments, an alkyl group has 1 to 3 carbon atoms ("Ci_3 alkyl"). In some embodiments, an alkyl group has 1 to 2 carbon atoms ("Ci_2 alkyl"). In some embodiments, an alkyl group has 1 carbon atom ("Ci alkyl"). In some embodiments, an alkyl group has 2 to 6 carbon atoms ("C2_6 alkyl"). Examples of Ci_6 alkyl groups include methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2- butanyl (C5), tertiary amyl (C5), and n-hexyl (C6). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (Cg) and the like. Unless otherwise specified, each instance of an alkyl group is independently optionally substituted, i.e. , unsubstituted (an "unsubstituted alkyl") or substituted (a "substituted alkyl") with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkyl group is unsubstituted C^o alkyl (e.g., -CH ). In certain embodiments, the alkyl group is substituted Ci-w alkyl. Common alkyl abbreviations include Me (-CH3), Et (-CH2CH3), iPr (-CH(CH3)2), nPr (-CH2CH2CH3), n-Bu (-CH2CH2CH2CH3), or i-Bu (-CH2CH(CH3)2).
[0033] As used herein, "alkylene," "alkenylene," and "alkynylene," refer to a divalent radical of an alkyl, alkenyl, and alkynyl group, respectively. When a range or number of carbons is provided for a particular "alkylene," "alkenylene," and "alkynylene" group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain. "Alkylene," "alkenylene," and "alkynylene" groups may be substituted or unsubstituted with one or more substituents as described herein.
[0034] "Alkylene" refers to an alkyl group wherein two hydrogens are removed to provide a divalent radical, and which may be substituted or unsubstituted. Unsubstituted alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2- ), hexylene (-CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted alkylene groups, e.g., substituted with one or more alkyl (methyl) groups, include but are not limited to, substituted methylene (-CH(CH3)-, (-C(CH3)2-), substituted ethylene (-CH(CH3)CH2-,- CH2CH(CH3)-, -C(CH3)2CH2-,-CH2C(CH3)2-), substituted propylene (-CH(CH3)CH2CH2-, - CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, - CH2CH2C(CH3)2-), and the like.
[0035] "Alkenyl" refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds), and no triple bonds ("C2_2o alkenyl"). In some embodiments, an alkenyl group has 2 to 10 carbon atoms ("C^io alkenyl"). In some embodiments, an alkenyl group has 2 to 9 carbon atoms ("C2_g alkenyl"). In some embodiments, an alkenyl group has 2 to 8 carbon atoms ("C2_g alkenyl"). In some embodiments, an alkenyl group has 2 to 7 carbon atoms ("C2_7 alkenyl"). In some embodiments, an alkenyl group has 2 to 6 carbon atoms ("C2_6 alkenyl"). In some embodiments, an alkenyl group has 2 to 5 carbon atoms ("C2_5 alkenyl"). In some embodiments, an alkenyl group has 2 to 4 carbon atoms ("C2^ alkenyl"). In some embodiments, an alkenyl group has 2 to 3 carbon atoms ("C2_3 alkenyl"). In some embodiments, an alkenyl group has 2 carbon atoms ("C2 alkenyl"). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2^ alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2- propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2 6 alkenyl groups include the aforementioned C2^ alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (Cg), octatrienyl (Cg), and the like. Unless otherwise specified, each instance of an alkenyl group is independently optionally substituted, i.e., unsubstituted (an "unsubstituted alkenyl") or substituted (a "substituted alkenyl") with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkenyl group is unsubstituted C2_10 alkenyl. In certain embodiments, the alkenyl group is substituted C2_10 alkenyl.
[0036] "Alkenylene" refers to an alkenyl group wherein two hydrogens are removed to provide a divalent radical, and which may be substituted or unsubstituted. Exemplary unsubstituted divalent alkenylene groups include, but are not limited to, ethenylene (- CH=CH-) and propenylene (e.g., -CH=CHCH2-, -CH2-CH=CH-). Exemplary substituted alkenylene groups, e.g., substituted with one or more alkyl (methyl) groups, include but are not limited to, substituted ethylene (-C(CH3)=CH-, -CH=C(CH3)-), substituted propylene (e.g., -C(CH3)=CHCH2-, -CH=C(CH3)CH2-, -CH=CHCH(CH3)-, -CH=CHC(CH3)2-, - CH(CH3)-CH=CH-,-C(CH3)2-CH=CH-, -CH2-C(CH3)=CH-, -CH2-CH=C(CH3)-), and the like.
[0037] "Alkynyl" refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds), and optionally one or more double bonds (e.g., 1, 2, 3, or 4 double bonds) ("C2_2o alkynyl"). An alkynyl group that has one or more triple bonds and one or more double bonds is also referred to as an "ene-yene" group. In some embodiments, an alkynyl group has 2 to 10 carbon atoms ("C2_io alkynyl"). In some embodiments, an alkynyl group has 2 to 9 carbon atoms ("C2_g alkynyl"). In some embodiments, an alkynyl group has 2 to 8 carbon atoms ("C2_8 alkynyl"). In some embodiments, an alkynyl group has 2 to 7 carbon atoms ("C2_7 alkynyl"). In some embodiments, an alkynyl group has 2 to 6 carbon atoms ("C2_6 alkynyl"). In some embodiments, an alkynyl group has 2 to 5 carbon atoms ("C2_5 alkynyl"). In some embodiments, an alkynyl group has 2 to 4 carbon atoms ("C2^ alkynyl"). In some embodiments, an alkynyl group has 2 to 3 carbon atoms ("C2_3 alkynyl"). In some embodiments, an alkynyl group has 2 carbon atoms ("C2 alkynyl"). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1- butynyl). Examples of C2^ alkynyl groups include, without limitation, ethynyl (C2), 1- propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2_6 alkenyl groups include the aforementioned C2^ alkynyl groups as well as pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (Cg), and the like. Unless otherwise specified, each instance of an alkynyl group is independently optionally substituted, i.e. , unsubstituted (an "unsubstituted alkynyl") or substituted (a "substituted alkynyl") with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkynyl group is unsubstituted C2_10 alkynyl. In certain embodiments, the alkynyl group is substituted C2-io alkynyl.
[0038] "Alkynylene" refers to a linear alkynyl group wherein two hydrogens are removed to provide a divalent radical, and which may be substituted or unsubstituted.
Exemplary divalent alkynylene groups include, but are not limited to, substituted or unsubstituted ethynylene, substituted or unsubstituted propynylene, and the like.
[0039] The term "heteroalkyl," as used herein, refers to an alkyl group, as defined herein, which further comprises 1 or more (e.g. , 1, 2, 3, or 4) heteroatoms (e.g. , oxygen, sulfur, nitrogen, boron, silicon, phosphorus) within the parent chain, wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment. In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 10 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroQ-io alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroCi-9 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1, 2, 3, or 4
heteroatoms ("heteroQ-g alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroC^ alkyl"). In some embodiments, a heteroalkyl group is a group having 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms ("heteroCi-6 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms ("heteroQ-s alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and lor 2 heteroatoms ("heteroC^ alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom ("heteroCi-3 alkyl"). In some
embodiments, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom ("heteroCi-i alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom ("heteroCi alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms ("heteroC2-6 alkyl"). Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an "unsubstituted heteroalkyl") or substituted (a "substituted heteroalkyl") with one or more substituents. In certain embodiments, the heteroalkyl group is an unsubstituted heteroCi-io alkyl. In certain embodiments, the heteroalkyl group is a substituted heteroQ-io alkyl. [0040] The term "heteroalkenyl," as used herein, refers to an alkenyl group, as defined herein, which further comprises one or more (e.g. , 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment. In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 10 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC2- io alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 9 carbon atoms at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC2-9 alkenyl"). In some
embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC2-8 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroC2-7 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1, 2, or 3 heteroatoms ("heteroC2-6 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2
heteroatoms ("heteroC2-5 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and lor 2 heteroatoms ("heteroC2^ alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom ("heteroC2-3 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms ("heteroC2-6 alkenyl"). Unless otherwise specified, each instance of a heteroalkenyl group is independently unsubstituted (an "unsubstituted heteroalkenyl") or substituted (a "substituted heteroalkenyl") with one or more substituents. In certain embodiments, the heteroalkenyl group is an unsubstituted heteroC2-io alkenyl. In certain embodiments, the heteroalkenyl group is a substituted heteroC2-io alkenyl.
[0041] The term "heteroalkynyl," as used herein, refers to an alkynyl group, as defined herein, which further comprises one or more (e.g. , 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment. In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC2- 10 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC2-9 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC2-8 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroC2-7 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1, 2, or 3 heteroatoms ("heteroC2-6 alkynyl"). In some embodiments, a
heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms ("heteroC2-5 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and lor 2 heteroatoms ("heteroC2^ alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom ("heteroC2-3 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms ("heteroC2-6 alkynyl"). Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an "unsubstituted heteroalkynyl") or substituted (a "substituted heteroalkynyl") with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted heteroC2 io alkynyl. In certain embodiments, the heteroalkynyl group is a substituted heteroC2-io alkynyl.
[0042] As used herein, "alkylene," "alkenylene," "alkynylene," "heteroalkylene,"
"heteroalkenylene," and "heteroalkynylene," refer to a divalent radical of an alkyl, alkenyl, alkynyl group, heteroalkyl, heteroalkenyl, and heteroalkynyl group respectively. When a range or number of carbons is provided for a particular "alkylene," "alkenylene,"
"alkynylene," "heteroalkylene," "heteroalkenylene," or "heteroalkynylene," group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain. "Alkylene," "alkenylene," "alkynylene," "heteroalkylene,"
"heteroalkenylene," and "heteroalkynylene" groups may be substituted or unsubstituted with one or more substituents as described herein.
[0043] '"Aryl" refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ("Ce-u aryl"). In some embodiments, an aryl group has six ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms ("Qo aryl"; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms ("C14 aryl"; e.g., anthracyl). "Aryl" also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene. Particularly aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Unless otherwise specified, each instance of an aryl group is independently optionally substituted, i.e. , unsubstituted (an "unsubstituted aryl") or substituted (a "substituted aryl") with one or more substituents. In certain embodiments, the aryl group is unsubstituted C6-i4 aryl. In certain embodiments, the aryl group is substituted Ce_14 aryl.
[0044] In certain embodiments, an aryl group substituted with one or more of groups selected from halo, Ci-Cg alkyl, Ci-Cg haloalkyl, cyano, hydroxy, C Cs alkoxy, and amino.
[0045] Exam les of representative substituted aryls include the following
Figure imgf000020_0001
wherein one of R and R may be hydrogen and at least one of R and R is each independently selected from C Cs alkyl, C Cs haloalkyl, 4-10 membered heterocyclyl, alkanoyl, C Cs alkoxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR58COR59, NR58SOR59 NR58S02R59, COOalkyl, COOaryl, CONR58R59, CONR58OR59, NR58R59, S02NR58R59, S-alkyl, SOalkyl, S02alkyl, Saryl, SOaryl, S02aryl; or R56 and R57 may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or more heteroatoms selected from the group N, O, or S. R60 and R61 are independently hydrogen, C Cs alkyl, CrC4 haloalkyl, C3-C10 cycloalkyl, 4- 10 membered heterocyclyl, C6-Cio aryl, substituted C6-Cio aryl, 5- 10 membered heteroaryl, or substituted 5- 10 membered heteroaryl .
[0046] Other representative aryl groups having a fused heterocyclyl group include the following:
Figure imgf000021_0001
wherein each W is selected from C(R )2, NR , O, and S; and each Y is selected from carbonyl, NR66, O and S; and R66 is independently hydrogen, C Cg alkyl, C3-Q0 cycloalkyl, 4-10 membered heterocyclyl, C6-Cio aryl, and 5-10 membered heteroaryl.
[0047] "Fused aryl" refers to an aryl having two of its ring carbon in common with a second aryl or heteroaryl ring or with a carbocyclyl or heterocyclyl ring.
[0048] "Aralkyl" is a subset of alkyl and aryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group.
[0049] "Heteroaryl" refers to a radical of a 5-10 membered monocyclic or bicyclic
4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-10 membered heteroaryl"). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. "Heteroaryl" includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. "Heteroaryl" also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system. Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
[0050] In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heteroaryl"). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an "unsubstituted heteroaryl") or substituted (a "substituted heteroaryl") with one or more substituents. In certain embodiments, the heteroaryl group is unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is substituted 5-14 membered heteroaryl.
[0051] Exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6- bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
[0052] Examples of representative heteroaryls include the following:
Figure imgf000023_0001
Figure imgf000023_0002
Figure imgf000023_0003
wherein each Y is selected from carbonyl, N, NR , O, and S; and R is independently hydrogen, Q-Cg alkyl, C3-Q0 cycloalkyl, 4-10 membered heterocyclyl, C6-Cio aryl, and 5-10 membered heteroaryl.
[0053] "Heteroaralkyl" is a subset of alkyl and heteroaryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group.
[0054] "Carbocyclyl" or "carbocyclic" refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms ("C^o carbocyclyl") and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms ("C3_g carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C3_6 carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C3_6 carbocyclyl"). In some embodiments, a
carbocyclyl group has 5 to 10 ring carbon atoms ("Cs-io carbocyclyl"). Exemplary C3_6 carbocyclyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3_g carbocyclyl groups include, without limitation, the aforementioned C3_6 carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (Cg), cyclooctenyl (Cg), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (Cg), and the like. Exemplary C3_10 carbocyclyl groups include, without limitation, the
aforementioned C3_g carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-lH-indenyl (C9), decahydronaphthalenyl (Cio), spiro[4.5]decanyl (C10), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic ("monocyclic carbocyclyl") or contain a fused, bridged or spiro ring system such as a bicyclic system ("bicyclic
carbocyclyl") and can be saturated or can be partially unsaturated. "Carbocyclyl" also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently optionally substituted, i.e., unsubstituted (an "unsubstituted carbocyclyl") or substituted (a "substituted carbocyclyl") with one or more substituents. In certain
embodiments, the carbocyclyl group is unsubstituted C3_io carbocyclyl. In certain
embodiments, the carbocyclyl group is a substituted C3_10 carbocyclyl.
[0055] In some embodiments, "carbocyclyl" is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms ("C^o cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C3_g cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C3_6 cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("Cs_6 cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ('¾_½ cycloalkyl"). Examples of C5_6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). Examples of C3_6 cycloalkyl groups include the aforementioned C5_6 cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3_8 cycloalkyl groups include the aforementioned C3_6 cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (Cg). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an
"unsubstituted cycloalkyl") or substituted (a "substituted cycloalkyl") with one or more substituents. In certain embodiments, the cycloalkyl group is unsubstituted C3_io cycloalkyl. In certain embodiments, the cycloalkyl group is substituted C3_io cycloalkyl.
[0056] "Heterocyclyl" or "heterocyclic" refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("3-10 membered heterocyclyl"). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic ("monocyclic heterocyclyl") or a fused, bridged or spiro ring system such as a bicyclic system ("bicyclic heterocyclyl"), and can be saturated or can be partially unsaturated. Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted (an "unsubstituted heterocyclyl") or substituted (a "substituted heterocyclyl") with one or more substituents. In certain embodiments, the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3-10 membered heterocyclyl.
[0057] In some embodiments, a heterocyclyl group is a 5-10 membered non- aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("5-10 membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5- 8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heterocyclyl"). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0058] Exemplary 3-membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl,
tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5- dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl.
Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8- membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as a 5,6-bicyclic heterocyclic ring) include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl,
benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocyclic ring) include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
[0059] Particular examples of heterocyclyl groups are shown in the following illustrative examples:
Figure imgf000026_0001
wherein each W is selected from CR , C(R )2, NR , O, and S; and each Y is selected from NR67, O, and S; and R67 is independently hydrogen, Ci-C8 alkyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl, C6-C10 aryl, 5-10 membered heteroaryl. These heterocyclyl rings may be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl (carbamoyl or amido), aminocarbonylamino, aminosulfonyl, sulfonylamino, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, halogen, hydroxy, keto, nitro, thiol, -S-alkyl, -S-aryl, -S(0)-alkyl,-S(0)-aryl, -S(0)2-alkyl, and -S(0)2-aryl.
Substituting groups include carbonyl or thiocarbonyl which provide, for example, lactam and urea derivatives.
[0060] "Hetero" when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, aryl, e.g,. heteroaryl, cycloalkenyl, e.g,. cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.
[0061] "Acyl" refers to a radical -C(0)R20, where R20 is hydrogen, substituted or unsubstitued alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstitued heteroaryl, as defined herein. "Alkanoyl" is an acyl group wherein R 20 is a group other than hydrogen. Representative acyl groups include, but are not limited to, formyl (-CHO), acetyl (-C(=0)CH3), cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl (-C(=0)Ph), benzylcarbonyl (-C(=0)CH2Ph),— C(O)- Ci-C8 alkyl, -C(O)-(CH2)t(C6-Ci0 aryl), -C(O)-(CH2)t(5-10 membered heteroaryl), -C(O)- (CH2)t(C3-C1o cycloalkyl), and -C(O)-(CH2)t(4-10 membered heterocyclyl), wherein t is an integer from 0 to 4. In certain embodiments, R 21 is Ci-C% alkyl, substituted with halo or hydroxy; or C3-C10 cycloalkyl, 4-10 membered heterocyclyl, C6-C10 aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted Q- C4 alkyl, halo, unsubstituted C C4 alkoxy, unsubstituted C C4 haloalkyl, unsubstituted Q- C4 hydroxyalkyl, or unsubstituted CrC4 haloalkoxy or hydroxy.
[0062] "Acylamino" refers to a radical -NR22C(0)R23, where each instance of R22 and
R23 is independently hydrogen, substituted or unsubstitued alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstitued heteroaryl,, as defined herein, or R 22 is an amino protecting group. Exemplary "acylamino" groups include, but are not limited to, formylamino, acetylamino,
cyclohexylcarbonylamino, cyclohexylmethyl-carbonylamino, benzoylamino and
benzylcarbonylamino. Particular exemplary "acylamino" groups are -NR 24 C(0)-Ci-C8 alkyl, -NR24C(O)-(CH2)t(C6-C10 aryl), -NR24C(O)-(CH2)t(5-10 membered heteroaryl), -NR24C(0)- (CH2)t(C3-Cio cycloalkyl), and -NR24C(O)-(CH2)t(4-10 membered heterocyclyl), wherein t is an integer from 0 to 4, and each R 24 independently represents H or Q-Cg alkyl. In certain embodiments, R 25 is H, Q-Cg alkyl, substituted with halo or hydroxy; C3-Cio cycloalkyl, 4- 10 membered heterocyclyl, C6-C10 aryl, arylalkyl, 5-10 membered heteroaryl or
heteroarylalkyl, each of which is substituted with unsubstituted Q-C4 alkyl, halo,
unsubstituted Q-C4 alkoxy, unsubstituted C C4 haloalkyl, unsubstituted Q-C4 hydroxyalkyl, or unsubstituted C C4 haloalkoxy or hydroxy; and R26 is H, Q-Cg alkyl, substituted with halo or hydroxy; C3-C10 cycloalkyl, 4-10 membered heterocyclyl, C6-C10 aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted Q- C4 alkyl, halo, unsubstituted C C4 alkoxy, unsubstituted C C4 haloalkyl, unsubstituted Q- yl, or unsubstituted Q xyl; provided at least one of R 25
C4 hydroxyalk -C4 haloalkoxy or hydro
and R26 is other than H.
[0063] "Acyloxy" refers to a radical -OC(0)R27, where R27 is hydrogen, substituted or unsubstitued alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstitued heteroaryl, as defined herein.
Representative examples include, but are not limited to, formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl and benzylcarbonyl. In certain embodiments, R 28 is Q- Cg alkyl, substituted with halo or hydroxy; C3-Cio cycloalkyl, 4-10 membered heterocyclyl, C6-Q0 aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted CrC4 alkyl, halo, unsubstituted Q-C4 alkoxy, unsubstituted Q-C4 haloalkyl, unsubstituted C C4 hydroxyalkyl, or unsubstituted Q-C4 haloalkoxy or hydroxy.
[0064] "Alkoxy" refers to the group -OR29 where R29 is substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aryl, or substituted or unsubstitued heteroaryl. Particular alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n- hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, i.e. with between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 and 4 carbon atoms.
[0065] In certain embodiments, R29 is a group that has 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent, selected from the group consisting of amino, substituted amino, C6-C10 aryl, aryloxy, carboxyl, cyano, C3-Q0 cycloalkyl, 4-10 membered heterocyclyl, halogen, 5-10 membered heteroaryl, hydroxyl, nitro, thioalkoxy, thioaryloxy, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(0)2- and aryl-S(0)2-. Exemplary 'substituted alkoxy' groups include, but are not limited to, -O-(CH2)t(C6-C10 aryl), -O-(CH2)t(5-10 membered heteroaryl), -O-(CH2)t(C3-C10 cycloalkyl), and -O-(CH2)t(4-10 membered heterocyclyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocyclyl groups present, may themselves be substituted by unsubstituted Q-C4 alkyl, halo, unsubstituted Q-C4 alkoxy, unsubstituted Q- C4 haloalkyl, unsubstituted Q-C4 hydroxyalkyl, or unsubstituted Q-C4 haloalkoxy or hydroxy. Particular exemplary 'substituted alkoxy' groups are -OCF3, -OCH2CF , -OCH2Ph, -OCH2-cyclopropyl, -OCH2CH2OH, and -OCH2CH2NMe2.
[0066] "Amino" refers to the radical -NH2.
[0067] "Substituted amino" refers to an amino group of the formula -N(R38)2 wherein
R 38 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstitued heteroaryl, or an amino protecting group, wherein at least one of R 38 is not a hydrogen. In certain embodiments, each R 38 is independently selected from hydrogen, Q-Cg alkyl, C3-Cg alkenyl, C3-Cg alkynyl, C6-Q0 aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl, or C3-C10 cycloalkyl; or Q-Cg alkyl, substituted with halo or hydroxy; C3-Cg alkenyl, substituted with halo or hydroxy; C3-Cg alkynyl, substituted with halo or hydroxy, or - (CH2)t(C6-Cio aryl), -(CH2)t(5-10 membered heteroaryl), -(CH2)t(C3-Ci0 cycloalkyl), or - (CH2)t(4-10 membered heterocyclyl), wherein t is an integer between 0 and 8, each of which is substituted by unsubstituted Q-C4 alkyl, halo, unsubstituted Q-C4 alkoxy, unsubstituted Q-C4 haloalkyl, unsubstituted Q-C4 hydroxyalkyl, or unsubstituted Q-C4 haloalkoxy or hydroxy; or both R 38 groups are joined to form an alkylene group.
[0068] Exemplary "substituted amino" groups include, but are not limited to, -NR39-
C Cg alkyl, -NR39-(CH2)t(C6-C10 aryl), -NR39-(CH2)t(5-10 membered heteroaryl), -NR39- (CH2)t(C3-C1o cycloalkyl), and -NR -(CH2)t(4-10 membered heterocyclyl), wherein t is an integer from 0 to 4, for instance 1 or 2, each R independently represents H or Q-Cg alkyl; and any alkyl groups present, may themselves be substituted by halo, substituted or unsubstituted amino, or hydroxy; and any aryl, heteroaryl, cycloalkyl, or heterocyclyl groups present, may themselves be substituted by unsubstituted Q-C4 alkyl, halo, unsubstituted Q- C4 alkoxy, unsubstituted Q-C4 haloalkyl, unsubstituted C C4 hydroxyalkyl, or unsubstituted Q-C4 haloalkoxy or hydroxy. For the avoidance of doubt the term 'substituted amino' includes the groups alkylamino, substituted alkylamino, alkylarylamino, substituted alkylarylamino, arylamino, substituted arylamino, dialkylamino, and substituted dialkylamino as defined below. Substituted amino encompasses both mono substituted amino and disubstituted amino groups.
[0069] "Azido" refers to the radical -N3.
[0070] "Carbamoyl" or "amido" refers to the radical -C(0)NH2.
[0071] "Substituted carbamoyl" or "substituted amido" refers to the radical -
C(0)N(R62)2 wherein each R62 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aryl, substituted or unsubstitued heteroaryl, or an amino protecting group, wherein at least one of R62 is not a hydrogen. In certain embodiments, R62 is selected from H, Q-Cg alkyl, C3-Q0 cycloalkyl, 4-10 membered heterocyclyl, C6-Q0 aryl, aralkyl, 5- 10 membered heteroaryl, and heteroaralkyl; or Ci-Cg alkyl substituted with halo or hydroxy; or C3-Cio cycloalkyl, 4-10 membered heterocyclyl, C6-C10 aryl, aralkyl, 5-10 membered heteroaryl, or heteroaralkyl, each of which is substituted by unsubstituted Q-C4 alkyl, halo, unsubstituted Q-C4 alkoxy, unsubstituted C C4 haloalkyl, unsubstituted Q-C4 hydroxyalkyl, or unsubstituted Q-C4 haloalkoxy or hydroxy; provided that at least one R62 is other than H.
[0072] Exemplary "substituted carbamoyl" groups include, but are not limited to, -
C(O) NR64-Ci-C8 alkyl, -C(O)NR64-(CH2)t(C6-Ci0 aryl), -C(O)N64-(CH2)t(5- 10 membered heteroaryl), -C(O)NR64-(CH2)t(C3-Ci0 cycloalkyl), and -C(O)NR64-(CH2)t(4-10 membered heterocyclyl), wherein t is an integer from 0 to 4, each R64 independently represents H or Cr C8 alkyl and any aryl, heteroaryl, cycloalkyl or heterocyclyl groups present, may themselves be substituted by unsubstituted C C4 alkyl, halo, unsubstituted Q-C4 alkoxy, unsubstituted Q-C4 haloalkyl, unsubstituted C C4 hydroxyalkyl, or unsubstituted Q-C4 haloalkoxy or hydroxy.
[0073] "Carboxy" refers to the radical -C(0)OH.
[0074] "Cyano" refers to the radical -CN.
[0075] "Halo" or "halogen" refers to fluoro (F), chloro (CI), bromo (Br), and iodo (I).
In certain embodiments, the halo group is either fluoro or chloro.
[0076] "Hydroxy" refers to the radical -OH.
[0077] "Nitro" refers to the radical -N02. [0078] "Cycloalkylalkyl" refers to an alkyl radical in which the alkyl group is substituted with a cycloalkyl group. Typical cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, and cyclooctylethyl, and the like.
[0079] "Heterocyclylalkyl" refers to an alkyl radical in which the alkyl group is substituted with a heterocyclyl group. Typical heterocyclylalkyl groups include, but are not limited to, pyrrolidinylmethyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyrrolidinylethyl, piperidinylethyl, piperazinylethyl, morpholinylethyl, and the like.
[0080] "Cycloalkenyl" refers to substituted or unsubstituted carbocyclyl group having from 3 to 10 carbon atoms and having a single cyclic ring or multiple condensed rings, including fused and bridged ring systems and having at least one and particularly from 1 to 2 sites of olefinic unsaturation. Such cycloalkenyl groups include, by way of example, single ring structures such as cyclohexenyl, cyclopentenyl, cyclopropenyl, and the like.
[0081] "Fused cycloalkenyl" refers to a cycloalkenyl having two of its ring carbon atoms in common with a second aliphatic or aromatic ring and having its olefinic
unsaturation located to impart aromaticity to the cycloalkenyl ring.
[0082] "Ethenyl" refers to substituted or unsubstituted -(C=C)-.
[0083] "Ethylene" refers to substituted or unsubstituted -(C-C)-.
[0084] "Ethynyl" refers to -(C≡C)-.
[0085] "Nitrogen-containing heterocyclyl" group means a 4- to 7- membered non- aromatic cyclic group containing at least one nitrogen atom, for example, but without limitation, morpholine, piperidine (e.g. 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (e.g. 2-pyrrolidinyl and 3-pyrrolidinyl), azetidine, pyrrolidone, imidazoline, imidazolidinone, 2-pyrazoline, pyrazolidine, piperazine, and N-alkyl piperazines such as N- methyl piperazine. Particular examples include azetidine, piperidone and piperazone.
[0086] "Thioketo" refers to the group =S .
[0087] Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl,
"substituted" or "unsubstituted" carbocyclyl, "substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl or "substituted" or "unsubstituted" heteroaryl group). In general, the term "substituted", whether preceded by the term "optionally" or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term "substituted" is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
[0088] Exemplary carbon atom substituents include, but are not limited to, halogen, -
CN, -NO2, -N3, -SO2H, -S03H, -OH, -ORaa, -ON(Rbb)2, -N(Rbb)2, -N(Rbb)3 +X , - N(ORcc)Rbb, -SH, -SRaa, -SSRCC, -C(=0)Raa, -C02H, -CHO, -C(ORcc)2, -COaR^, - OC(=0)Raa, -OCOaR^, -C(=0)N(Rbb)2, -OC(=0)N(Rbb)2, -NRbbC(=0)Raa, -NR^CO^, - NRbbC(=0)N(Rbb)2, -C(=NRbb)Raa, -C(=NRbb)ORaa, -OC(=NRbb)Raa, -OC(=NRbb)ORaa, - C(=NRbb)N(Rbb)2, -OC(=NRbb)N(Rbb)2, -NRbbC(=NRbb)N(Rbb)2, -C(=0)NRbbS02Raa, - NRbbS02Raa, -S02N(Rbb)2, -S02Raa, -S02ORaa, -OS02Raa, -S(=0)Raa, -OS(=0)Raa, - Si(Raa)3, -OSi(Raa)3 -C(=S)N(Rbb)2, -C(=0)SRaa, -C(=S)SRaa, -SC(=S)SRaa, -SC(=0)SRaa, -OC(=0)SRaa, -SC(=0)ORaa, -SC(=0)Raa, -P(=0)2Raa, -OP(=0)2Raa, -P(=0)(Raa)2, - OP(=0)(Raa)2, -OP(=0)(ORcc)2, -P(=0)2N(Rbb)2, -OP(=0)2N(Rbb)2, -P(=0)(NRbb)2, - OP(=0)(NRbb)2, -NRbbP(=0)(ORcc)2, -NRbbP(=0)(NRbb)2, -P(RCC)2, -P(RCC)3, -OP(Rcc)2, - OP(Rcc)3, -B(Raa)2, -B(ORcc)2, -BRaa(ORcc), Cn0 alkyl, Ci_i0 perhaloalkyl, C2_i0 alkenyl, C2_io alkynyl, C3_io carbocyclyl, 3-14 membered heterocyclyl, C6-i4 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
or two geminal hydrogens on a carbon atom are replaced with the group =0, =S, =NN(Rbb)2, =NNRbbC(=0)Raa, =NNRbbC(=0)ORaa, =NNRbbS(=0)2Raa, =NRbb, or =NORcc; each instance of Raa is, independently, selected from Ci-w alkyl, Ci-w perhaloalkyl, C2_io alkenyl, C2_10 alkynyl, C3_10 carbocyclyl, 3-14 membered heterocyclyl, C6-i4 aryl, and 5-14 membered heteroaryl, or two Raa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
each instance of Rbb is, independently, selected from hydrogen, -OH, -ORaa, - N(RCC)2, -CN, -C(=0)Raa, -C(=0)N(Rcc)2, -C02Raa, -S02Raa, -C(=NRcc)ORaa, - C(=NRCC)N(RCC)2, -S02N(Rcc)2, -S02Rcc, -S02ORcc, -SORaa, -C(=S)N(RCC)2, -C(=0)SRcc, - C(=S)SRCC, -P(=0)2Raa, -P(=0)(Raa)2, -P(=0)2N(Rcc)2, -P(=0)(NRcc)2, Ci_i0 alkyl, Ci_i0 perhaloalkyl, C2_10 alkenyl, C2_10 alkynyl, C3_10 carbocyclyl, 3-14 membered heterocyclyl, C6-i4 aryl, and 5-14 membered heteroaryl, or two Rbb groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
each instance of Rcc is, independently, selected from hydrogen, C^o alkyl, C^o perhaloalkyl, C2_io alkenyl, C2_io alkynyl, C3_io carbocyclyl, 3-14 membered heterocyclyl, C6-i4 aryl, and 5-14 membered heteroaryl, or two Rcc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
each instance of Rdd is, independently, selected from halogen, -CN, -N02, -N3, - S02H, -S03H, -OH, -ORee, -ON(Rff)2, -N(Rff)2, -N(Rff)3 +X , -N(ORee)Rff, -SH, -SRee, - SSRee, -C(=0)Ree, -C02H, -C02Ree, -OC(=0)Ree, -OC02Ree, -C(=0)N(Rff)2, - OC(=0)N(Rff)2, -NRffC(=0)Ree, -NRffC02Ree, -NRffC(=0)N(Rff)2, -C(=NRff)ORee, - OC(=NRff)Ree, -OC(=NRff)ORee, -C(=NRff)N(Rff)2, -OC(=NRff)N(Rff)2, - NRffC(=NRff)N(Rff)2,-NRffS02Ree, -S02N(Rff)2, -S02Ree, -S02ORee, -OS02Ree, -S(=0)Ree, -Si(Ree)3, -OSi(Ree)3, -C(=S)N(Rff)2, -C(=0)SRee, -C(=S)SRee, -SC(=S)SRee, -P(=0)2Ree, - P(=0)(Ree)2, -OP(=0)(Ree)2, -OP(=0)(ORee)2, d_6 alkyl, d_6 perhaloalkyl, C2_6 alkenyl, C2 6 alkynyl, C3_10 carbocyclyl, 3-10 membered heterocyclyl, C6-io aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups, or two geminal Rdd substituents can be joined to form =0 or =S;
each instance of Ree is, independently, selected from d_6 alkyl, d_6 perhaloalkyl, C2 6 alkenyl, C2_6 alkynyl, C3_10 carbocyclyl, C6-io aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups;
ff
each instance of R is, independently, selected from hydrogen, d_6 alkyl, d_6 perhaloalkyl, C2-6 alkenyl, C2_6 alkynyl, C3_10 carbocyclyl, 3-10 membered heterocyclyl, C6- ff
10 aryl and 5-10 membered heteroaryl, or two R groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups; and
each instance of Rgg is, independently, halogen, -CN, -N02, -N3, -S02H, -S03H, - OH, -Od_6 alkyl, -ON(d_6 alkyl)2, -N(d_6 alkyl)2, -N(d_6 alkyl)3 +X- -NH(d_6 alkyl)2 +X~, -NH2(d-6 alkyl) +X~ -NH3 +X , -N(Od_6 alkyl)(d-6 alkyl), -N(OH)(d-6 alkyl), -NH(OH), -SH, -SCi_6 alkyl, -SS(Ci_6 alkyl), -C(=0)(Ci_6 alkyl), -C02H, -C02(Ci_6 alkyl), -OC(=0)(d_6 alkyl), -OC02(d 6 alkyl), -C(=0)NH2, -C(=0)N(d_6 alkyl)2, - OC(=0)NH(Ci_6 alkyl), -NHC(=0)( Ci_e alkyl), -N(Ci_e alkyl)C(=0)( Ci_6 alkyl), - NHC02(d 6 alkyl), -NHC(=0)N(d_6 alkyl)2, -NHC(=0)NH(d 6 alkyl), -NHC(=0)NH2, -C(=NH)0(Ci_6 alkyl) ,-OC(=NH)(Ci_6 alkyl), -OC(=NH)OCi_6 alkyl, -C(=NH)N(d_6 alkyl)2, -C(=NH)NH(Ci_6 alkyl), -C(=NH)NH2, -OC(=NH)N(Ci_6 alkyl)2, - OC(NH)NH(Ci^, alkyl), -OC(NH)NH2, -NHC(NH)N(Ci_6 alkyl)2, -NHC(=NH)NH2, - NHS02(Ci_6 alkyl), -S02N(Ci_6 alkyl)2, -S02NH(Ci_6 alkyl), -S02NH2,-S02Ci_6 alkyl, - S02Od^ alkyl, -OS02Ci_6 alkyl, -SOC^ alkyl, -Si(Ci_6 alkyl)3, -OSi(d_6 alkyl)3 - C(=S)N(Ci_6 alkyl)2, C(=S)NH(d_6 alkyl), C(=S)NH2, -C(=0)S(C^ alkyl), -C(=S)SC^ alkyl, -SC(=S)Sd_6 alkyl, -P(=0)2(C^ alkyl), -P(=0)(d_6 alkyl)2, -OP(=0)(d_6 alkyl)2, - OP(=0)(OCi_6 alkyl)2, Ci_6 alkyl, d_6 perhaloalkyl, C2_6 alkenyl, C2_6 alkynyl, C3_10 carbocyclyl, C6-io aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal Rgg substituents can be joined to form =0 or =S; wherein X~ is a counterion.
[0089] A "counterion" or "anionic counterion" is a negatively charged group associated with a cationic quaternary amino group in order to maintain electronic neutrality. Exemplary counterions include halide ions (e.g., F~, CT, Br , Γ), N03 , C104 , OH~, H2P04 , HS04 , sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene-l-sulfonic acid-5-sulfonate, ethan-l-sulfonic acid-2-sulfonate, and the like), and carboxylate ions (e.g., acetate, ethanoate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, and the like). [0090] Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quarternary nitrogen atoms. Exemplary nitrogen atom substitutents include, but are not limited to, hydrogen, -OH, -ORaa, -N(RCC)2, -CN, - C(=0)Raa, -C(=0)N(Rcc)2, -C02Raa, -S02Raa, -C(=NRbb)Raa, -C(=NRcc)ORaa, - C(=NRCC)N(RCC)2, -S02N(Rcc)2, -S02Rcc, -S02ORcc, -SORaa, -C(=S)N(RCC)2, -C(=0)SRcc, - C(=S)SRCC, -P(=0)2Raa, -P(=0)(Raa)2, -P(=0)2N(Rcc)2, -P(=0)(NRcc)2, d_10 alkyl, d_10 perhaloalkyl, C2_10 alkenyl, C2_10 alkynyl, d-io carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two Rcc groups attached to a nitrogen atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups, and wherein Raa, Rbb, Rcc and Rdd are as defined above.
[0091] In certain embodiments, the substituent present on a nitrogen atom is an amino protecting group (also referred to herein as a nitrogen protecting group). Amino protecting groups include, but are not limited to, -OH, -OR^, -N(RCC)2, -C(=0)Raa, -C(=0)N(Rcc)2, - COaR^, -S02Raa, -C(=NRcc)Raa, -C(=NRcc)ORaa, -C(=NRCC)N(RCC)2, -S02N(Rcc)2, -S02Rcc, -S02ORcc, -SORaa, -C(=S)N(RCC)2, -C(=0)SRcc, -C(=S)SRCC, Ci_i0 alkyl {e.g., aralkyl, heteroaralkyl), C2_io alkenyl, C2_io alkynyl, -io carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R groups, and wherein Raa, Rbb, Rcc and Rdd are as defined herein. Amino protecting groups are well known in the art and include those described in detail in Protecting
Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
[0092] For example, amino protecting groups such as amide groups (e.g., -C(=0)Raa) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3- pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o- nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (Ν'- dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o- nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o- phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o- nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide and o- (benzoyloxymethyl)benzamide.
[0093] Amino protecting groups such as carbamate groups {e.g., -C(=0)ORaa) include, but are not limited to, methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-i-butyl-[9-( 10,10-dioxo-l 0, 10, 10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1- (l-adamantyl)-l-methylethyl carbamate (Adpoc), l, l-dimethyl-2-haloethyl carbamate, l,l-dimethyl-2,2-dibromoethyl carbamate (DB-i-BOC), l,l-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), l-methyl-l-(4-biphenylyl)ethyl carbamate (Bpoc), 1— (3,5— di— i— butylphenyl)-l-methylethyl carbamate (i-Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, i-butyl carbamate (BOC), 1- adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1- isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), /?-nitobenzyl carbamate, p- bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4- methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p- toluenesulfonyl)ethyl carbamate, [2-(l,3-dithianyl)]methyl carbamate (Dmoc), 4- methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2- phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1, 1- dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p- (dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)- 6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl (o- nitrophenyl)methyl carbamate, i-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate,
cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, l,l-dimethyl-3-(N,N- dimethylcarboxamido)propyl carbamate, 1, 1-dimethylpropynyl carbamate, di(2- pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p '-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-l- cyclopropylmethyl carbamate, l-methyl-l-(3,5-dimethoxyphenyl)ethyl carbamate, 1- methyl-l-(p-phenylazophenyl)ethyl carbamate, 1 -methyl- 1-phenylethyl carbamate, 1- methyl-l-(4-pyridyl)ethyl carbamate, phenyl carbamate, /?-(phenylazo)benzyl carbamate, 2,4,6-tri-i-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6- trimethylbenzyl carbamate.
[0094] Amino protecting groups such as sulfonamide groups (e.g., -S(=0)2Raa) include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,- trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5, 6-tetramethyl-4- methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6- trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7, 8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β- trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'- dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide,
trifluoromethylsulfonamide, and phenacylsulfonamide.
[0095] Other amino protecting groups include, but are not limited to, phenothiazinyl-
(10)-acyl derivative, N'-p-toluenesulfonylaminoacyl derivative, N'-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl- 3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-l,l,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted l,3-dimethyl-l,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl- l,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N- allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N- (l-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N- benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N- triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl] amine (MMTr), N-9- phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N- ferrocenylmethylamino (Fcm), N-2-picolylamino N'-oxide, N-1,1- dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N- diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N',N'- dimethylaminomethylene)amine, N,N '-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2- hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo- l-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N- [phenyl(pentaacylchromium- or tungsten)acyl] amine, N-copper chelate, N-zinc chelate, N- nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp),
dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl
phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate,
benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide,
triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys).
[0096] In certain embodiments, the substituent present on an oxygen atom is an oxygen protecting group (also referred to as a hydroxyl protecting group). Oxygen protecting groups include, but are not limited to, -Raa, -N(Rbb)2, -C(=0)SRaa, -C(=0)Raa, -C02Raa, - C(=0)N(Rbb)2, -C(=NRbb)Raa, -C(=NRbb)ORaa, -C(=NRbb)N(Rbb)2, -S(=0)Raa, -SO^, - Si(Raa)3 -P(RCC)2, -P(RCC)3, -P(=0)2Raa, -P(=0)(Raa)2, -P(=0)(ORcc)2, -P(=0)2N(Rbb)2, and - P(=0)(NRbb)2, wherein Raa, Rbb, and Rcc are as defined herein. Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
[0097] Exemplary oxygen protecting groups include, but are not limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl,
(phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p- methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), i-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2- methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2- (trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3- bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4- methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4- methoxytetrahydrothiopyranyl S,S-dioxide, l-[(2-chloro-4-methyl)phenyl]-4- methoxypiperidin-4-yl (CTMP), l,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, l-(2-chloroethoxy)ethyl, 1-methyl-l-methoxyethyl, 1-methyl-l-benzyloxyethyl, 1- methyl-l-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2- (phenylselenyl)ethyl, ί-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), /?-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p- halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3- methyl-2-picolyl N-oxido, diphenylmethyl, p,p '-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, a-naphthyldiphenylmethyl, /7-methoxyphenyldiphenylmethyl, di(p- methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4 '- bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5- dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"- tris(benzoyloxyphenyl)methyl, 3-(imidazol-l-yl)bis(4',4"-dimethoxyphenyl)methyl, 1 , 1- bis(4-methoxyphenyl)- -pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl- 10-oxo)anthryl, l,3-benzodisulfuran-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, i-butyldimethylsilyl (TBDMS), t- butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl,
diphenylmethylsilyl (DPMS), i-butylmethoxyphenylsilyl (TBMPS), formate,
benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3- phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate
(levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p- phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9- fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl /7-methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate, 4-ethoxy-l- napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4- methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2- (methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-
(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro- 4-( 1 , 1 ,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis( 1 , l-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o- (methoxyacyl)benzoate, a-naphthoate, nitrate, alkyl Ν,Ν,Ν',Ν'- tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts).
[0098] In certain embodiments, the substituent present on an sulfur atom is an sulfur protecting group (also referred to as a thiol protecting group). Sulfur protecting groups include, but are not limited to, -Raa, -N(Rbb)2, -C(=0)SRaa, -C(=0)Raa, -C02Raa, - C(=0)N(Rbb)2, -C(=NRbb)Raa, -C(=NRbb)ORaa, -C(=NRbb)N(Rbb)2, -S(=0)Raa, -SOaR^, - Si(Raa)3 -P(RCC)2, -P(RCC)3, -P(=0)2Raa, -P(=0)(Raa)2, -P(=0)(ORcc)2, -P(=0)2N(Rbb)2, and - P(=0)(NRbb)2, wherein Raa, Rbb, and Rcc are as defined herein. Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
[0099] "Compounds of the present invention", and equivalent expressions, are meant to embrace the compounds as hereinbefore described, in particular compounds according to any of the Formula herein recited and/or described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g., hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits.
[00100] These and other exemplary substituents are described in more detail in the
Detailed Description, Examples, and claims. The invention is not intended to be limited in any manner by the above exemplary listing of substituents.
Other definitions
[00101] "Pharmaceutically acceptable" means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
[00102] "Pharmaceutically acceptable salt" refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2- naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4- methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N- methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like. The term "pharmaceutically acceptable cation" refers to an acceptable cationic counter- ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like (see, e.g., Berge, et al, J. Pharm. Sci. 66(1): 1-79 (Jan."77) .
[00103] "Pharmaceutically acceptable vehicle" refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.
[00104] "Pharmaceutically acceptable metabolically cleavable group" refers to a group which is cleaved in vivo to yield the parent molecule of the structural Formula indicated herein. Examples of metabolically cleavable groups include -COR, -COOR,-CONRR and - CH2OR radicals, where R is selected independently at each occurrence from alkyl, trialkylsilyl, carbocyclic aryl or carbocyclic aryl substituted with one or more of alkyl, halogen, hydroxy or alkoxy. Specific examples of representative metabolically cleavable groups include acetyl, methoxycarbonyl, benzoyl, methoxymethyl and trimethylsilyl groups.
[00105] "Prodrugs" refers to compounds, including derivatives of the compounds of the invention,which have cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N- alkylmorpholine esters and the like. Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but in the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are particular prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. Particularly the Ci to alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C7-C12 substituted aryl, and C7-C12 arylalkyl esters of the compounds of the invention.
[00106] "Solvate" refers to forms of the compound that are associated with a solvent or water (also referred to as "hydrate"), usually by a solvolysis reaction. This physical association includes hydrogen bonding. Conventional solvents include water, ethanol, acetic acid and the like. The compounds of the invention may be prepared e.g. in crystalline form and may be solvated or hydrated. Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non- stoichiometric solvates. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates.
Representative solvates include hydrates, ethanolates and methanolates.
[00107] A "subject" to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or a non-human animal, e.g. , a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non- human animal. The terms "human," "patient," and "subject" are used interchangeably herein.
[00108] An "effective amount" means the amount of a compound that, when administered to a subject for treating or preventing a disease, is sufficient to effect such treatment or prevention. The "effective amount" can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated. A "therapeutically effective amount" refers to the effective amount for therapeutic treatment. A "prophylatically effective amount" refers to the effective amount for prophylactic treatment.
[00109] "Preventing" or "prevention" or "prophylactic treatment" refers to a reduction in risk of acquiring or developing a disease or disorder {i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject not yet exposed to a disease- causing agent, or predisposed to the disease in advance of disease onset.
[00110] The term "prophylaxis" is related to "prevention," and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease. Non- limiting examples of prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization; and the administration of an anti-malarial agent such as chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.
[00111] "Treating" or "treatment" or "therapeutic treatment" of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder {i.e., arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof). In another embodiment "treating" or "treatment" refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, "treating" or "treatment" refers to modulating the disease or disorder, either physically, {e.g., stabilization of a discernible symptom), physiologically, {e.g., stabilization of a physical parameter), or both. In a further embodiment, "treating" or "treatment" relates to slowing the progression of the disease.
[00112] As used herein, the term "isotopic variant" refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such
compound. For example, an "isotopic variant" of a compound can contain one or more non- radioactive isotopes, such as for example, deuterium ( 2 H or D), carbon- 13 ( 13 C), nitrogen- 15 (15N), or the like. It will be understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be 2 H/D, any carbon may be 13 C, or any nitrogen may be 15 N, and that the presence and placement of such atoms may be determined within the skill of the art. Likewise, the invention may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e., 3H, and carbon- 14, i.e., 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Further, compounds may be prepared that are substituted with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N, and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. All isotopic variants of the compounds provided herein, radioactive or not, are intended to be encompassed within the scope of the invention.
[00113] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers." Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers."
[00114] Stereoisomers that are not mirror images of one another are termed
"diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers." When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory {i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".
[00115] "Tautomers" refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of π electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
[00116] As used herein a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, an "S" form of the compound is substantially free from the "R" form of the compound and is, thus, in enantiomeric excess of the "R" form. The term "enantiomerically pure" or "pure enantiomer" denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the enantiomer. In certain embodiments, the weights are based upon total weight of all enantiomers or stereoisomers of the compound.
[00117] As used herein and unless otherwise indicated, the term "enantiomerically pure R-compound" refers to at least about 80% by weight R-compound and at most about 20% by weight S-compound, at least about 90% by weight R-compound and at most about 10% by weight S-compound, at least about 95% by weight R-compound and at most about 5% by weight S-compound, at least about 99% by weight R-compound and at most about 1% by weight S-compound, at least about 99.9% by weight R-compound or at most about 0.1% by weight S-compound. In certain embodiments, the weights are based upon total weight of compound.
[00118] As used herein and unless otherwise indicated, the term "enantiomerically pure S-compound" or "S-compound" refers to at least about 80% by weight S-compound and at most about 20% by weight R-compound, at least about 90% by weight S-compound and at most about 10% by weight R-compound, at least about 95% by weight S-compound and at most about 5% by weight R-compound, at least about 99% by weight S-compound and at most about 1% by weight R-compound or at least about 99.9% by weight S-compound and at most about 0.1% by weight R-compound. In certain embodiments, the weights are based upon total weight of compound.
[00119] In the compositions provided herein, an enantiomerically pure compound or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof can be present with other active or inactive ingredients. For example, a pharmaceutical composition comprising enantiomerically pure R-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure R-compound. In certain embodiments, the
enantiomerically pure R-compound in such compositions can, for example, comprise, at least about 95% by weight R-compound and at most about 5% by weight S-compound, by total weight of the compound. For example, a pharmaceutical composition comprising enantiomerically pure S-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure S-compound. In certain embodiments, the enantiomerically pure S-compound in such compositions can, for example, comprise, at least about 95% by weight S-compound and at most about 5% by weight R-compound, by total weight of the compound. In certain embodiments, the active ingredient can be formulated with little or no excipient or carrier.
[00120] The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof.
[00121] Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.
[00122] One having ordinary skill in the art of organic synthesis will recognize that the maximum number of heteroatoms in a stable, chemically feasible heterocyclic ring, whether it is aromatic or non aromatic, is determined by the size of the ring, the degree of unsaturation and the valence of the heteroatoms. In general, a heterocyclic ring may have one to four heteroatoms so long as the hetero aromatic ring is chemically feasible and stable.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
[00123] In certain aspects, provided herein are 3-CC and 3 -hydroxy steroid compounds as NMDA receptor modulators and thus, useful for preventing and/or treating a broad range of CNS conditions, among them, schizophrenia, depression, bipolar disorder (e.g., I and/or II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, compulsive disorders, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive compulsive disorder (OCD), pain (e.g., a painful syndrome or disorder), sleep disorders, memory disorders, dementia, Alzheimer's Disease, a seizure disorder (e.g., epilepsy), traumatic brain injury, stroke, addictive disorders (e.g., addiction to opiates, cocaine, and/or alcohol), autism, Huntington's Disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus. These compounds are expected to show improved in vivo potency, pharmacokinetic properties (PK) properties, oral bioavailability, formulatability, stability, and/or safety. Compounds
[00124] In one aspect, provided herein are compounds according to Formula (I):
Figure imgf000047_0001
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof;
wherein:
Z is a group of the formula (i), (ii), (iii), (iv), or (v):
Figure imgf000047_0002
1 2
L and V are selected from a group consisting of a bond, a substituted or
unsubstituted C\-Ce alkylene, a substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, a substituted or unsubstituted hetero C\- e alkylene, a substituted or unsubstituted hetero C2-C6 alkenylene, and a substituted or unsubstituted hetero C2-C6 alkynylene;
L is a substituted or unsubstituted C\-Ce alkylene, a substituted or unsubstituted C2- C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, a substituted or unsubstituted hetero C\- e alkylene, a substituted or unsubstituted hetero C2-C6 alkenylene, or a substituted or unsubstituted hetero C2-C6 alkynylene;
1 2 X
each instance of X and X is independently -0-, -S-, -N(R )-, wherein each instance of R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group;
R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, -N3, -N02, -SCN, -CN, -ORA1, -SRA1, -N(RA1)2, -N=NRA1, -N=C(RA1)2, -N(ORA1)(RA1),-C(=0)RA1, -C(=0)ORA1, -C(=0)SRA1, -C(=0)N(RA1)2, - C(=0)N(ORA1)(RA1),-OC(=0)RA1, -OC(=0)ORA1, -OC(=0)SRA1, -OC(=0)N(RA1)2, - NRA1C(=0)RA1, -NRA1C(=0)ORA1, -NRA1C(=0)SRA1, -NRA1C(=0)N(RA1)2, -SC(=0)RA2, -SC(=0)ORA1, -SC(=0)SRA1, -SC(=0)N(RA1)2, -OS(=0)2RA2, -OS(=0)2ORA1, -S- S(=0)2RA2, -S-S(=0)2ORA1, -S(=0)RA2, -SOaR^, -NRA1S02RA2, or -S02N(RA1)2, wherein RA1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two RA1 groups are joined to form an substituted or unsubstituted heterocyclic ring; and R^ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or an RA1 group and an RA2 group are joined to form an substituted or unsubstituted heterocyclic ring;
each instance of R2, R4a, R4b, R7a, R7b, Rl la, and Rl lb is independently hydrogen, -OH, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N3, - N02, -SCN, -CN, -ORB1, -SRB1, -N(RB1)2, -N=NRB1, -N=C(RB1)2, -N(ORB1)(RB1), - C(=0)RB1, -C(=0)ORB1, -C(=0)SRB1, -C(=0)N(Rbl)2, -C(=0)N(ORB1)(RB1),-OC(=0)RB1, -OC(=0)ORB1, -OC(=0)SRB1, -OC(=0)N(RB1)2, -NRB1C(=0)RB1, -NRB1C(=0)ORB1, - NRB1C(=0)SRB1, -NRB1C(=0)N(RB1)2, -SC(=0)RB2, -SC(=0)ORB1, -SC(=0)SRB1, - SC(=0)N(RB1)2, -OS(=0)2RB2, -OS(=0)2ORB1, -S-S(=0)2RB2, -S-S(=0)2ORB1, - S(=0)RB2, -S02RB2, -NRB1S02RB2, or -S02N(RB1)2, wherein RB1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R B 1 groups are joined to form an substituted or unsubstituted heterocyclic ring; and R B2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or an R B 1 group and an R B2 group are joined to form an substituted or unsubstituted heterocyclic ring; or optionally wherein each of R4a andR4b, and/or R7a and R7b, and/or Rl la and Rl lb are joined to form an oxo (=0) group;
R3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3b is hydrogen, -C(=0)Rcl, -C(=0)ORcl, -C(=0)SRcl, -C(=0)N(Rcl)2, - S(=0)2RC2, -S(=0)2ORcl, -P(=0)2RC2, -P(=0)2ORcl, -P(=0)(ORcl)2, -P(=0)(RC2)2, or -
P(=0)(R C2 )(OR CI ), wherein R CI is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R CI groups are joined to form an substituted or unsubstituted heterocyclic ring; and R C2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
each of R6a and R6b is independently hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, and represents a single or double bond, provided if a double bond is present in Ring B, then one of R6a or R6b is absent, and provided if a single bond is present in Ring B, then the hydrogen at C5 is in the alpha or beta position;
R14 is hydrogen or substituted or unsubstituted alkyl; R 17
is hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -ORD1, wherein RD1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group;
18 19 20
each instance of R , R , and R is independently hydrogen or substituted or unsubstituted alkyl;
and each instance of R23a and R23b is independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R23a and R23b are joined together to form substituted or
unsubstituted C3-C6 cycloalkyl;
R 24
is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstitued aryl, substituted or unsubstituted heteroaryl, -C(=0)RE1, -C(=0)ORE1, -C(=0)SRE1, -C(=0)N(RE1)2, - S(=0)2RE2, -S(=0)2ORE1, -P(=0)2RE2, -P(=0)2ORE1, -P(=0)(ORE1)2, -P(=0)(RE2)2, or -
P(=0)(R E2 )(OR El ), El
wherein R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting
El
group when attached to a nitrogen atom, or two R groups are joined to form an substituted
E2
or unsubstituted heterocyclic ring; and R is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
Y is -0-, -S-, or -NRZ5-;
R Z4
is independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR25, -SRZ5, or -N(RZ5)2; each instance of R Z5 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R Z5 groups are joined to form a substituted or unsubstituted heterocyclic ring; and
each instance of Rz6 is independently hydrogen or substituted or unsubstituted alkyl, or two Rz6 groups are joined to form a C3_6 carbocyclic ring; and
the subscript n is 0, 1, 2, or 3.
[00125] In certain embodiments, when R3a is H, n is 1, and R19 is Me; then R1 is other than H, alkyl, alkenyl, or alkynyl. In certain embodiments, when R3a is H, R3b is -COMe, R19 is Me, and n is 0; then R1 is OH. In certain embodiments, when R3a is H, n is 0, and R20 is alkyl; then R1 is other than OH. In certain embodiments, when R19 is Me; then R1 is other than H, alkyl, alkenyl, or alkynyl. In certain embodiments, R1 is H; and R19 is other than Me. In certain embodiments, each R1 and R3a is H; and R19 is other than Me.
[00126] In certain embodiments, when R3a is H, then R1 is other than H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. In certain embodiments, when R3a is H, then R1 is substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, -N3, -N02, -SCN, -CN, -ORA1, -SRA1, - N(RA1)2, -N=NRA1, -N=C(RA1)2, -N(ORA1)(RA1),-C(=0)RA1, -C(=0)ORA1, -C(=0)SRA1, - C(=0)N(RA1)2, -C(=0)N(ORA1)(RA1),-OC(=0)RA1, -OC(=0)ORA1, -OC(=0)SRA1, - OC(=0)N(RA1)2, -NRA1C(=0)RA1, -NRA1C(=0)ORA1, -NRA1C(=0)SRA1, - NRA1C(=0)N(RA1)2, -SC(=0)RA2, -SC(=0)ORA1, -SC(=0)SRA1, -SC(=0)N(RA1)2, - OS(=0)2RA2, -OS(=0)2ORA1, -S-S(=0)2RA2, -S-S(=0)2ORA1, -S(=0)RA2, -S02RA2, - NRA1S02RA2, or -S02N(RA1)2.
[00127] In certain further embodiments, the following compounds are specifically excluded:
Figure imgf000052_0001
Figure imgf000052_0002
and pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
Various embodiments ofR3a
[00128] As generally defined above, R3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. It is generally understood that R3a may be in the alpha (down) or beta (up) position. In certain embodiments, R3a is alpha. In certain embodiments, R3a is beta. [00129] In certain embodiments, R3a is hydrogen.
[00130] In certain embodiments, R3a is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C^alkyl, substituted or unsubstituted C^alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted C4_5alkyl, or substituted or unsubstituted Cs^alkyl. Exemplary R3a C^a cyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3- pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n- hexyl (C6), C^ alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g., -CF3, -CH2F, -CHF2> difluoroethyl, and 2,2,2-trifluoro-l,l-dimethyl-ethyl), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups (e.g. , -CH2C1, -CHC12), and Ci-6 alkyl substituted with alkoxy groups (e.g. , -CH2OCH3 and -CH2OCH2CH3). In certain embodiments, R3a is substituted alkyl, e.g., R3a is haloalkyl, alkoxyalkyl, or aminoalkyl. In certain embodiments, R3a is Me, Et, n-Pr, n-Bu, i-Bu, fluoromethyl, chloromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, difluoroethyl, 2,2,2-trifluoro- 1,1 -dimethyl-ethyl, methoxymethyl, methoxyethyl, or ethoxymethyl. In certain
embodiments, R3a is Me, Et, n-Pr, n-Bu, or i-Bu. In certain embodiments, R3a is
methoxymethyl, ethoxymethyl, propoxymethyl, methoxyethyl, or ethoxyethyl. In certain embodiments, R3a is trifluoromethoxymethyl. In certain embodiments, R3a is fluoromethyl, chloromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, or 2,2,2-trifluoro- 1,1 -dimethyl-ethyl. In certain embodiments, R3a is trifluoromethyl.
[00131] In certain embodiments, R3a is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C2_6alkenyl, substituted or unsubstituted C2_3alkenyl, substituted or unsubstituted C3^alkenyl, substituted or unsubstituted C^salkenyl, or substituted or unsubstituted Cs_6alkenyl. In certain embodiments, R3a is ethenyl (C2), propenyl (C3), or butenyl (C4), unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxyl. In certain embodiments, R3a is ethenyl, propenyl, or butenyl, unsubstituted or substituted with alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxy. In certain embodiments, R3a is ethenyl.
[00132] In certain embodiments, R3a is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C2_6alkynyl, substituted or unsubstituted C2_3alkynyl, substituted or unsubstituted C3^alkynyl, substituted or unsubstituted C^salkynyl, or substituted or unsubstituted Cs_6alkynyl. Exemplary substituted or unsubstituted R3a alkynyl groups include, but are not limited to, ethynyl, propynyl, or butynyl, unsubstituted or substituted with alkyl, halo, haloalkyl (e.g., CF3), alkoxyalkyl, cycloalkyl (e.g., cyclopropyl or cyclobutyl), or hydroxyl. In certain embodiments, R3a is selected from the group consisting of
trifluoroethynyl, cyclopropylethynyl, cyclobutylethynyl, and propynyl, fluoropropynyl, and chloroethynyl. In certain embodiments, R3a is ethynyl (C2), propynyl (C3), or butynyl (C4), unsubstituted or substituted with one or more substituents selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, and substituted or unsubstituted heterocyclyl. In certain embodiments, R3a is ethynyl (C2), propynyl (C3), or butynyl (C4) substituted with substituted phenyl. In certain embodiment, the phenyl substitutent is further substituted with one or more substituents selected from the group consisting of halo, alkyl, trifluoroalkyl, alkoxy, acyl, amino or amido. In certain embodiments, R3a is ethynyl (C2), propynyl (C3), or butynyl (C4) substituted with substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, or tetrazolyl.
[00133] In certain embodiments, R3a is ethynyl, propynyl, or butynyl, unsubstituted or substituted with alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxyl. In certain embodiments, R3a is ethynyl or propynyl, substituted with substituted or unsubstituted aryl. In certain embodiments, R3a is ethynyl or propynyl, substituted with phenyl unsubstituted or substituted with halo, alkyl, alkoxy, haloalkyl, trihaloalkyl, or acyl. In certain embodiments, R3a is ethynyl or propynyl, substituted with substituted or unsubstituted carbocyclyl. In certain embodiments, R3a is ethynyl or propynyl, substituted with substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In certain embodiments, R3a is ethynyl or propynyl, substituted with substituted or unsubstituted heteroaryl. In certain embodiments, R3a is ethynyl or propynyl, substituted with substituted or unsubstituted pyridinyl, or pyrimidinyl. In certain embodiments, R3a is ethynyl or propynyl, substituted with substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl. In certain embodiments, R3a is ethynyl or propynyl, substituted with substituted or unsubstituted heterocyclyl. In certain embodiments, R3a is ethynyl or propynyl, substituted with substituted or unsubstituted pyrrolidinyl, piperidinyl, piperazinyl, or mopholinyl. In certain embodiments, R3a is propynyl or butynyl, substituted with hydroxyl or alkoxy. In certain embodiments, R3a is propynyl or butynyl, substituted with methoxy or ethoxy. In certain embodiments, R3a is ethynyl or propynyl, substituted with CI. In certain embodiments, R3a is ethynyl or propynyl, substituted with trifluoromethyl.
[00134] In certain embodiments, R3a is substituted or unsubstituted carbocyclyl, e.g. , substituted or unsubstituted C3_6carbocyclyl, substituted or unsubstituted C3^carbocyclyl, substituted or unsubstituted C4_5 carbocyclyl, or substituted or unsubstituted C5_6 carbocyclyl.
[00135] In certain embodiments, R3a is substituted or unsubstituted heterocyclyl, e.g., substituted or unsubstituted 3-6 membered heterocyclyl, substituted or unsubstituted 3-4 membered heterocyclyl, substituted or unsubstituted 4-5 membered heterocyclyl, or substituted or unsubstituted 5-6 membered heterocyclyl.
[00136] In certain embodiments, R3a is substituted or unsubstituted aryl. In certain embodiments, R3a is substituted or unsubstituted phenyl.
[00137] In certain embodiments, R3a is substituted or unsubstituted heteroaryl, e.g. , optionally substituted 5- to 6-membered heteroaryl.
[00138] Further embodiments of R3a, as a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl groups, are depicted below:
Figure imgf000055_0001
3c Fl Fl
wherein each instance of R is hydrogen, halo, or -OR , wherein R is substituted or unsubstituted alkyl; and each instance of R3d is hydrogen, halo, or substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl.
[00139] In certain embodiments, at least one R3c is hydrogen. In certain embodiments, at least two R3c is hydrogen. In certain embodiments, each R3c is hydrogen. In certain embodiments, at least one R3c is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, at least two R3c are halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each R3c is halogen (e.g., fluoro, to provide the group -CF3). In certain embodiments, at least one R3c is -ORF1 (e.g., OMe or OEt). In certain embodiments, at least two R3c is -ORF1 (e.g., OMe or OEt). In certain embodiments, at least one R3c is hydrogen, F, -OMe, or -OEt. In certain embodiments, one of R3c is F, -OMe, or OEt; and the rest are H. [00140] In certain embodiments, at least one R3d is hydrogen. In certain embodiments, each R2c is hydrogen. In certain embodiments, at least one R3d is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each R3d is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each of R3d is alkyl, e.g., each of R2c is Me. In certain embodiments, one of R3d is alkyl; and the other is hydrogen, e.g., one of R3d is Me; and the other is hydrogen. In certain embodiments, one of R3d is substituted or unsubstituted carbocyclyl, e.g., cyclopropyl or cyclobutyl, and the other is hydrogen. In certain
embodiments, at least one R3d is hydrogen, -F, -Br, -CI, -I, -CH3, -CF3, cyclopropyl, or cyclobutyl. In certain embodiments, each instance of R3d is H. In certain embodiments, each instance of R3d is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each instance of R3d is alkyl, e.g., -CH3, -CF3, -CH2CH2CI. In certain embodiments, each instance of R3d is substituted or unsubstituted carbocyclyl, e.g., cyclopropyl or cyclobutyl. In certain embodiments, R3d is substituted or unsubstituted cyclopropyl. In certain
embodiments, each instance of R3d is hydrogen, -F, -Br, -CI, -I, -CH3, -CF3, -CH2CH2C1, cyclopropyl, or cyclobutyl. In certain embodiments, R3d is Me or CI. In certain embodiments, R3d is substituted or unsubstituted heterocyclyl.
Various embodiments of-X!-R3h
[00141] As generally defined above, for group -X1R3b, X1 is independently -0-, -S-, or -N(R X )-, wherein each instance of R X is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group; and R3b is hydrogen, -C(=0)Rcl, -C(=0)ORcl, -C(=0)SRcl, -C(=0)N(Rcl)2, -S(=0)2Rcl, -S(=0)2ORcl, -P(=0)2Rcl, -P(=0)2ORcl, -P(=0)(ORcl)2, -P(=0)(Rcl)2, or -
P CI CI CI
(=0)(R )(OR ), wherein R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R CI groups are joined to form an substituted or unsubstituted heterocyclic ring. It is generally understood that the group -X^R313 may be in the alpha (down) or beta (up) position. In certain embodiments, the group -X1-R3b is alpha. In certain embodiments, the group -X^R313 is beta.
[00142] In certain embodiments, X1 is -0-. In certain embodiments, X1 is -S-. In certain embodiments, X is -N(R )-. In certain embodiments, R is alkyl. In certain embodiments, R X is Me, Et, or i-Pr. In certain embodiments, R X is H, i.e., wherein XI is - NH-.
[00143] In certain embodiments, R3b is hydrogen. For example, in certain
embodiments, the group -Χ^¾ is -OH. In certain embodiments, the group -Χ^¾ is -SH. In certain embodiments, the group -X1^ is -NH2 or -NHRX.
[00144] In certain embodiments, R3b is -C(=0)Rcl, -C(=0)ORcl, -C(=0)SRcl, -
C(=0)N(Rcl)2, -S(=0)2Rcl, -S(=0)2ORcl, -P(=0)2Rcl, -P(=0)2ORcl, -P(=0)(ORcl)2, - P(=0)(Rcl)2, or -P(=0)(Rcl)(ORcl).
[00145] In certain embodiments, at least one instance of R C 1 is hydrogen or a protecting group, i.e., an oxygen protecting group when attached to an oxygen atom, sulfur protecting group when attached to an sulfur atom, or a nitrogen protecting group when attached to a nitrogen atom. In certain embodiments, at least one instance of R CI is hydrogen.
[00146] In certain embodiments, at least one instance of R C 1 is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C^a cyl, substituted or unsubstituted Ci_2alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted C4_5alkyl, or substituted or unsubstituted Cs^alkyl. Exemplary
C 1
R Ci_6alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso- butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g., -CF , -CH2F, -CHF2> difluoroethyl, and 2,2,2-trifluoro-l,l- dimethyl-ethyl), Q_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups (e.g., -CH2C1, -CHC12), and Q-6 alkyl substituted with alkoxy groups (e.g., -CH2OCH3 and -CH2OCH2CH3).
[00147] In certain embodiments, at least one instance of R C 1 is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C2_6alkenyl, substituted or
unsubstituted C2_3alkenyl, substituted or unsubstituted C3^alkenyl, substituted or
unsubstituted C4_salkenyl, or substituted or unsubstituted Cs^alkenyl. [00148] C 1
In certain embodiments, at least one instance of R is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C2_6alkynyl, substituted or unsubstituted C2_3alkynyl, substituted or unsubstituted C3^alkynyl, substituted or
unsubstituted C4_5alkynyl, or substituted or unsubstituted Cs^alkynyl.
[00149] C 1
In certain embodiments, at least one instance of R is substituted or unsubstituted carbocyclyl, e.g., substituted or unsubstituted C3_6carbocyclyl, substituted or unsubstituted C3^carbocyclyl, substituted or unsubstituted C4_5 carbocyclyl, or substituted or unsubstituted C5_6 carbocyclyl.
[00150] C 1
In certain embodiments, at least one instance of R is substituted or unsubstituted heterocyclyl, e.g. , substituted or unsubstituted 3-6 membered heterocyclyl, substituted or unsubstituted 3-4 membered heterocyclyl, substituted or unsubstituted 4-5 membered heterocyclyl, or substituted or unsubstituted 5-6 membered heterocyclyl.
[00151] C 1
In certain embodiments, at least one instance of R is substituted or unsubstituted aryl, e.g., substituted or unsubstituted phenyl.
[00152] C 1
In certain embodiments, at least one instance of R is substituted or unsubstituted heteroaryl, e.g. , optionally substituted 5- to 6-membered heteroaryl.
[00153] CI
In certain embodiments, two R groups are joined to form a substituted or unsubstituted heterocyclic ring, e.g., a substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl ring.
[00154] In certain embodiments, R3b is -C(=0)Rcl, -C(=0)ORcl, -C(=0)N(Rcl)2 or -
C(=0)N(ORcl)(Rcl), wherein Rcl is as defined herein.
[00155] In certain embodiments, R3b is -C(=0)Rcl, e.g. , for example, wherein Rcl is, for example, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6). In certain embodiments, R3b is -C(=0)CH . In certain embodiments, R3b is - C(=0)(CH2)mC02H, wherein m is an integer between 2 and 5, inclusive. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 5. In certain embodiments, R3b is -C(=0)CH2CH2C(=0)OH.
[00156] In certain embodiments, R3b is
Figure imgf000058_0001
e.g., for example, wherein Rcl is, for example, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6).
[00157] In certain embodiments, R3b is -C(=0)SRcl, e.g., for example, wherein Rcl is, for example, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6).
[00158] In certain embodiments, R3b is -C(=0)N(Rcl)2, e.g., -C(=0)NH2 or -
CI CI
C(=0)NHR , wherein R is, for example, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5),
1 CI CI
tertiary amyl (C5), or n-hexyl (C6), or R is -C(=0)N(R )2 wherein the two R groups are joined to form a substituted or unsubstituted heterocyclic ring, e.g., substituted or
unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl ring.
[00159] In certain embodiments, R3b is -S(=0)2Rcl or -S(=0)2ORcl, wherein Rcl is, for example, hydrogen, or substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3- pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n- hexyl (C6), or substituted or unsubstituted phenyl. In certain embodiments, R3b is - S(=0)2Rcl. In certain embodiments, R3b is -S(=0)2ORcl, e.g., -S03H.
[00160] In certain embodiments, R3b is -P(=0)2Rcl, -P(=0)2ORcl, -P(=0)(ORcl)2, -
P(=0)(Rcl)2, or -P(=0)(Rcl)(ORcl), wherein each Rcl is, for example, independently hydrogen, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6), or substituted or unsubstituted phenyl. In certain embodiments, R3b is -P(=0)2Rcl. In certain embodiments, R1 is -P(=0)2ORcl. In certain embodiments, R3b is -P(=0)(ORcl)2. In certain embodiments, R1 is -P(=0)(Rcl)2. In certain embodiments, R3b is -P(=0)(Rcl)(ORcl).
Various embodiments wherein Z is a group of formula ( i) or ( ii)
[00161] In certain embodiments, Z is a group of formula (i):
Figure imgf000060_0001
[00162] In other embodiments, Z is a group of formula (ii):
Figure imgf000060_0002
1 2
[00163] As generally defined above, L and L is a bond (i.e., in other words, is absent) or is a substituted or unsubstituted C -C alkylene, a substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, a substituted or unsubstituted hetero Ci-Ce alkylene, a substituted or unsubstituted hetero C2-C6 alkenylene, or a substituted or unsubstituted hetero C2-C6 alkynylene.
1 2
[00164] In certain embodiments, L or L is a bond.
1 2
[00165] In certain embodiments, L or L is a substituted or unsubstituted Ci-Ce
1 2
alkylene. In certain embodiments, L or L is a substituted or unsubstituted Ci-C4 alkylene.
1 2
In certain embodiments, L or L is a substituted or unsubstituted Ci-C3 alkylene. In certain
1 2
embodiments, L or L is a substituted or unsubstituted C1-C2 alkylene. In certain
1 2
embodiments, L or L is a substituted or unsubstituted C alkylene. In certain embodiments,
1 2 1 2
L or L is a substituted or unsubstituted C2 alkylene. In certain embodiments, L or L is a
1 2
substituted or unsubstituted C3 alkylene. In certain embodiments, L or L is a substituted or
1 2
unsubstituted C4 alkylene. In certain embodiments, L or L is a substituted or unsubstituted
1 2
C5 alkylene. In certain embodiments, L or L is a substituted or unsubstituted C6 alkylene.
1 2
In certain embodiments, L or L is an alkylene group, as described above, substituted with one or more substituents selected from the group consisting of substituted or unsubstituted
1 2
alkyl and halo. In certain embodiments, L or L is -CH2-, -CHMe-, -CMe2-, -CH2-CH2-, - CF2-CH2-, -CH2-CMe2-, -CH2-CH2-CH2-, or -CH2-CH2-CMe2-.
1 2
[00166] In certain embodiments, L or L is a substituted or unsubstituted C2-C6
1 2
alkenylene. In certain embodiments, L or L is a substituted or unsubstituted C2-C5
1 2
alkenylene. In certain embodiments, L or L is a substituted or unsubstituted C2-C4
1 2
alkenylene. In certain embodiments, L or L is a substituted or unsubstituted C2-C3
1 2
alkenylene. In certain embodiments, L or L is a substituted or unsubstituted C2 alkenylene. 1 2
In certain embodiments, L or L is a substituted or unsubstituted C3 alkenylene. In certain
1 2
embodiments, L or L is a substituted or unsubstituted C4 alkenylene. In certain
1 2
embodiments, L or L is a substituted or unsubstituted C5 alkenylene. In certain
1 2
embodiments, L or L is a substituted or unsubstituted C6 alkenylene. In certain
1 2
embodiments, L or L is an alkenylene group, as described above, substituted with one or more substituents selected from the group consisting of substituted or unsubstituted alkyl and halo.
1 2
[00167] In certain embodiments, L or L is a substituted or unsubstituted C2-C6
1 2
alkynylene. In certain embodiments, L or L is a substituted or unsubstituted C2-C5
1 2
alkynylene. In certain embodiments, L or L is a substituted or unsubstituted C2-C4
1 2
alkynylene. In certain embodiments, L or L is a substituted or unsubstituted C2-C3
1 2
alkynylene. In certain embodiments, L or L is a substituted or unsubstituted C2 alkynylene.
1 2
In certain embodiments, L or L is a substituted or unsubstituted C3 alkynylene. In certain
1 2
embodiments, L or L is a substituted or unsubstituted C4 alkynylene. In certain
embodiments, L1 is a substituted or unsubstituted C5 alkynylene. In certain embodiments, L1
2 1 2 or L is a substituted or unsubstituted C6 alkynylene. In certain embodiments, L or L is an alkynylene group, as described above, substituted with one or more substituents selected from the group consisting of substituted or unsubstituted alkyl and halo.
1 2
[00168] Furthermore, in certain embodiments, L or L is substituted or unsubstituted heteroCi-ealkylene, e.g., substituted or unsubstituted heteroC^alkylene, substituted or unsubstituted heteroC2_3alkylene, substituted or unsubstituted heteroC3^alkylene, substituted or unsubstituted heteroC4_salkylene, or substituted or unsubstituted heteroCs_6alkylene. In
1 2
certain embodiments, L or L is substituted or unsubstituted heteroC2_6alkyenlene, e.g. , substituted or unsubstituted heteroC2_3alkenylene, substituted or unsubstituted heteroC3_ 4alkenylene, substituted or unsubstituted heteroC4_salkenylene, or substituted or unsubstituted
1 2
heteroC5_6alkenylene. In certain embodiments, L or L is substituted or unsubstituted heteroC2_6alkynylene, e.g. , substituted or unsubstituted heteroC2_3alkynylene, substituted or unsubstituted heteroC3^alkynylene, substituted or unsubstituted heteroC4_salkynylene, or substituted or unsubstituted heteroCs_6alkynylene. In any of the above instances, in certain
1 2
embodiments, L or L is heteroalkylene, heteroalkenylene, or hetero alkynylene unsubstituted or substituted with halo (e.g. , fluoro) or substituted or unsubstituted Ci_6 alkyl.
[00169] As generally defined above, R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, -N3, -N02, -SCN, -CN, - ORA1, -SRA1, -N(RA1)2, -N=NRA1, -N=C(RA1)2, -N(ORA1)(RA1),-C(=0)RA1, -C(=0)ORA1, -C(=0)SRA1, -C(=0)N(RA1)2, -C(=0)N(ORA1)(RA1),-OC(=0)RA1, -OC(=0)ORA1, - OC(=0)SRA1, -OC(=0)N(RA1)2, -NRA1C(=0)RA1, -NRA1C(=0)ORA1, -NRA1C(=0)SRA1, - NRA1C(=0)N(RA1)2, -SC(=0)RA2, -SC(=0)ORA1, -SC(=0)SRA1, -SC(=0)N(RA1)2, - OS(=0)2RA2, -OS(=0)2ORA1, -S-S(=0)2RA2, -S-S(=0)2ORA1, -S(=0)RA2, -S02RA2, - NRA1S02RA2, or -S02N(RA1)2, wherein RA1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two RA1 groups are joined to form an substituted or unsubstituted heterocyclic ring; and RA2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or an RA1 group and an R^ group are joined to form an substituted or unsubstituted heterocyclic ring.
[00170] In certain embodiments, R1 is hydrogen.
[00171] In certain embodiments, R1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl. In certain embodiments, R1 is substituted or unsubstituted alkyl, e.g., Me, Et, or i-Pr. In certain embodiments, R1 is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted ethenyl or substituted or unsubstituted propenyl. In certain embodiments, R1 is substituted or unsubstituted alkynyl.
[00172] In certain embodiments, R1 is selected from substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl.
[00173] In certain embodiments, R1 is substituted or unsubstituted aryl, e.g., phenyl.
[00174] In certain embodiments, R1 is substituted or unsubstituted heteroaryl, e.g., a substituted or unsubstituted heteroaryl selected from pyrrolyl, imidazolyl, pyrazolyl, oxazoyl, thiazolyl, isoxazoyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, quinazonyl, quinoxilinyl, naphthyridinyl, indolyl, indazolyl, benzimidazloyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyridopyrimidinyl, or purinyl. In certain embodiments, the heteroaryl group is substituted with one or more groups selected from substituted or unsubstituted alkyl, haloalkyl, alkenyl, substituted or unsubstituted alkynyl, oxo, hydoxy, halo, alkoxy, -S-alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -SO- alkyl, substituted or unsubstituted -S02-alkyl, substituted or unsubstituted -SO-aryl, substituted or unsubstituted -S02-aryl, substituted or unsubstituted -SO-heteroaryl, substituted or unsubstituted -S02-heteroaryl, amino, cyano, and acyl. In certain
embodiments, R1 is imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, or tetrazolyl; each unsubstitued or substituted with one or two groups independently selected from oxo, Me, F, CI, -CN, and -CF3. In certain embodiments, R1 is quinolinyl, isoquinolinyl or purinyl; each unsubstitued or substituted with one or two groups independently selected from oxo, Me, F, CI, -CN, and -CF3.
[00175] In certain embodiments, R1 is -ORA1. In certain embodiments, R1 is -O- quinolinyl, -O-isoquinolinyl,- O-purinyl, each unsubstitued or substituted with one or two groups independently selected from Me, F, CI, -CN, and -CF . In certain embodiments, R1 is -OH or -0-CO-CH2-CH2-C02H.
[00176] In certain embodiments, R1 is -SRA1. In certain embodiments, R1 is S- quinolinyl, -S-isoquinolinyl, or -S-purinyl, each unsubstitued or substituted with one or two groups independently selected from Me, F, CI, -CN, and -CF . In certain embodiments, R1 is -SH.
[00177] In certain embodiments, R1 is -OS(=0)2RA2. In certain embodiments, R1 is -
OS(=0)2ORA1; e.g., -0-S03H. In certain embodiments, R1 is -S-S(=0)2RA2. In certain embodiments, R1 is -S-S(=0)2ORA1; e.g., -S-S03H.
[00178] As generally defined above, R20 is independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 20 is hydrogen. In certain embodiments, R 20 is substituted or unsubstituted alkyl {e.g., -CH ).
[00179] As generally defined above each instance of R23a and R23b is independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R23a and R23b are joined together to form substituted or unsubstituted C3-C6 cycloalkyl. In certain embodiments, each instance of R23a and R23b is hydrogen. In certain embodiments, one of R23a and R23b is halo gen, e.g., fluoro, and the other of R23a and R23b is hydrogen, halogen, or substituted or unsubstituted alkyl. In certain embodiments, each instance of R23a and R23b is halogen, e.g., fluoro. In certain embodiments, each instance of R23a and R23b is independently substituted or unsubstituted alkyl. In certain embodiments, each of R23a and R23b is Me. In certain embodiments, one of R23a and R23b is H. In certain embodiments, one of R23a and R23b is H; and the other is substituted or unsubstituted alkyl. In certain embodiments, one of R23a and R23b is H; and the other is Me or Et. In certain embodiments, R23a and R23b are joined
2' together to form substituted or unsubstituted C3-C6 cycloalkyl. In certain embodiments, R and R23b are joined together to form a substituted or unsubstituted cyclopropyl.
[00180] In certain embodiments, the group
Figure imgf000064_0001
formula
Figure imgf000064_0002
[00181] As generally defined above, X2 is independently -0-, -S-, or -N(RX)-, wherein each instance of R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group.
[00182] In certain embodiments, X2 is -0-. In certain embodiments, X2 is -S-. In
2 X X
certain embodiments, X is -N(R )-. In certain embodiments, R is alkyl. In certain
X X
embodiments, R is Me, Et, or i-Pr. In certain embodiments, R is hydrogen.
1 2 1
[00183] In certain embodiments, X is -O- and X is -0-. In certain embodiments, X
2 1 2 X
is -O- and X is -S-. In certain embodiments, X is -O- and X is -N(R )-. In certain
1 2 1 2 embodiments, X is -S- and X is -0-. In certain embodiments, X is -S- and X is -S-. In
1 2 X I X certain embodiments, X is -S- and X is -N(R )-. In certain embodiments, X is -N(R )-
2 1 X 2
and X is -0-. In certain embodiments, X is -N(R )- and X is -S-. In certain
embodiments, X1 is -N(RX)- and X2 is -N(RX)-. [00184] As generally defined above, R24 is H, substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstitued aryl, substituted or unsubstituted heteroaryl, -C(=0)R El , -C(=0)OR El , - C(=0)SRE1, -C(=0)N(RE1)2, -S(=0)2RE2, -S(=0)2ORE1, -P(=0)2RE2, -P(=0)2ORE1, - P(=0)(ORE1)2, -P(=0)(RE2)2, or -P(=0)(RE2)(ORE1).
[00185] In certain embodiments, R24 is hydrogen.
[00186] In certain embodiments, R24 is substituted or unsubstituted alkyl. In certain embodiments, R 24 is alkyl unsubstituted or substituted with one or more substituents selected from the group consisting of halo or and hydroxyl. In certain embodiments, R 24 is substituted or unsubstitued alkenyl. In certain embodiments, R 24 is substituted or unsubstituted alkynyl.
In certain embodiments, R 24 is substituted or unsubstituted carbocyclyl. In certain
embodiments, R 24 is substituted or unsubstituted heterocyclyl. In certain embodiments, R 24 is substituted or unsubstitued aryl. In certain embodiments, R 24 is substituted or unsubstituted heteroaryl.
[00187] In certain embodiments, R24 is -C(=0)RE1, e.g., R24 is -C(=0)(CH2)pC02H, wherein p is an integer between 2 and 5, inclusive. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, p is 4. In certain embodiments, p is 5. In certain embodiments, R24 is -C(=0)ORE1. In certain embodiments, R24 is -C(=0)SRE1. In certain embodiments, R24 is -C(=0)N(RE1)2. In certain embodiments, R24 is -S(=0)2RE2. In certain embodiments, R24 is -S(=0)2ORE1; e.g., -SO3H. In certain embodiments, R24 is - P(=0)2RE2. In certain embodiments, R24 is -P(=0)2ORE1. In certain embodiments, R24 is - P(=0)(ORE1)2. In certain embodiments, R24 is -P(=0)(RE2)2. In certain embodiments, R24 is - P(=0)(RE2)(ORE1).
[00188] As generally defined above, the subscript n is 0, 1, 2, or 3. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3.
Various embodiments wherein Z is a group of formula (Hi), (iv), or (v)
[00189] In certain embodiments, Z is a group of formula (iii), (iv), or (v):
Figure imgf000065_0001
(v). [00190] In certain embodiments, L3 is substituted or unsubstituted C^alkylene, e.g. , substituted or unsubstituted C^alkylene, substituted or unsubstituted C2_3alkylene, substituted or unsubstituted C3^alkylene, substituted or unsubstituted C4_5alkylene, or substituted or unsubstituted Cs^alkylene. In certain embodiments, L is substituted or unsubstituted C2_6alkyenlene, e.g., substituted or unsubstituted C2_3alkenylene, substituted or unsubstituted C3^alkenylene, substituted or unsubstituted C4_5alkenylene, or substituted or unsubstituted Cs^alkenylene. In certain embodiments, L is substituted or unsubstituted C2 6alkynylene, e.g., substituted or unsubstituted C2_3alkynylene, substituted or unsubstituted C3 4alkynylene, substituted or unsubstituted C^alkynylene, or substituted or unsubstituted C5 6alkynylene. In any of the above instances, in certain embodiments, L is alkylene, alkenylene, or alkynylene unsubstituted or substituted with halo (e.g., fluoro), substituted or
Z5
unsubstituted Ci-β alkyl, and/or -OR .
[00191] Furthermore, in certain embodiments, L3 is substituted or unsubstituted heteroCi-ealkylene, e.g., substituted or unsubstituted heteroC^alkylene, substituted or unsubstituted heteroC2_3alkylene, substituted or unsubstituted heteroC3^alkylene, substituted or unsubstituted heteroC4_salkylene, or substituted or unsubstituted heteroCs_6alkylene. In certain embodiments, L is substituted or unsubstituted heteroC2_6alkyenlene, e.g. , substituted or unsubstituted heteroC2_3alkenylene, substituted or unsubstituted heteroC3^alkenylene, substituted or unsubstituted heteroC4_salkenylene, or substituted or unsubstituted heteroCs- 6alkenylene. In certain embodiments, L is substituted or unsubstituted heteroC2_6alkynylene, e.g. , substituted or unsubstituted heteroC2_3alkynylene, substituted or unsubstituted heteroC3_ 4alkynylene, substituted or unsubstituted heteroC4_salkynylene, or substituted or unsubstituted heteroC5_6alkynylene. In any of the above instances, in certain embodiments, L is heteroalkylene, heteroalkenylene, or hetero alkynylene unsubstituted or substituted with halo
Z5
(e.g., fluoro), substituted or unsubstituted C^ alkyl, and/or -OR .
[00192] In any of the above or below instances, in certain embodiments, at least one
Z5
R is hydrogen.
[00193] In any of the above or below instances, in certain embodiments, at least one
Z5
instance of R is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted Q_ 6alkyl, substituted or unsubstituted C^alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted C^salkyl, or substituted or
Z5
unsubstituted Cs^alkyl. Exemplary R C^alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), Q_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g., -CF3, -CH2F, -CHF2> difluoroethyl, and 2,2,2-trifluoro-l,l-dimethyl-ethyl), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups (e.g., -CH2C1, -CHC12), and Q_6 alkyl substituted with alkoxy groups (e.g., -CH2OCH3 and -CH2OCH2CH3).
[00194] In any of the above or below instances, in certain embodiments, at least one instance of R Z5 is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C2 6alkenyl, substituted or unsubstituted C2_3alkenyl, substituted or unsubstituted C3^alkenyl, substituted or unsubstituted C4_salkenyl, or substituted or unsubstituted Cs^alkenyl.
[00195] In any of the above or below instances, in certain embodiments, at least one instance of R Z5 is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C2 6alkynyl, substituted or unsubstituted C2_3alkynyl, substituted or unsubstituted C3^alkynyl, substituted or unsubstituted C4_5alkynyl, or substituted or unsubstituted Cs^alkynyl.
[00196] In any of the above or below instances, in certain embodiments, at least one instance of R Z5 is substituted or unsubstituted carbocyclyl, e.g., substituted or unsubstituted C3_6carbocyclyl, substituted or unsubstituted C3^carbocyclyl, substituted or unsubstituted C4_ 5 carbocyclyl, or substituted or unsubstituted C5_6 carbocyclyl.
[00197] In any of the above or below instances, in certain embodiments, at least one instance of R Z5 is substituted or unsubstituted heterocyclyl, e.g., substituted or unsubstituted 3-6 membered heterocyclyl, substituted or unsubstituted 3-4 membered heterocyclyl, substituted or unsubstituted 4-5 membered heterocyclyl, or substituted or unsubstituted 5-6 membered heterocyclyl.
[00198] In any of the above or below instances, in certain embodiments, at least one instance of R Z5 is substituted or unsubstituted aryl, e.g., substituted or unsubstituted phenyl.
[00199] In any of the above or below instances, in certain embodiments, at least one instance of R Z5 is substituted or unsubstituted heteroaryl, e.g., optionally substituted 5-6 membered heteroaryl.
[00200] In any of the above or below instances, in certain embodiments, R Z5 is a protecting group, e.g., an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom. Z5
[00201] In certain embodiments, wherein two R are attached to a nitrogen atom, the
Z5
two R groups are joined to form a substituted or unsubstituted heterocyclic ring, e.g., a substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl ring.
[00202] Furthermore, in any of the above or below instances, in certain embodiments, each instance of Rz6 is independently hydrogen, substituted or unsubstituted alkyl, or two Rz6 groups are joined to form a C3_6 carbocyclic ring.
[00203] In certain embodiments, at least one instance of Rz6 is hydrogen.
[00204] In certain embodiments, at least one instance of Rz6 is substituted or unsubstituted alkyl, e.g. , substituted or unsubstituted C^a cyl, substituted or unsubstituted C^alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted C4_5alkyl, or substituted or unsubstituted Cs^alkyl. Exemplary R Ci_6alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso- butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n-hexyl (C6), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g. , -CF , -CH2F, -CHF2> difluoroethyl, and 2,2,2-trifluoro-l, l- dimethyl-ethyl), Q_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups (e.g., -CH2C1, -CHC12), and Q-6 alkyl substituted with alkoxy groups (e.g. , -CH2OCH3 and -CH2OCH2CH3).
[00205] In certain embodiments, two Rz6 groups are joined to form a C3_6 carbocyclic ring, e.g. , for example, a substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, or substituted or unsubstituted cyclohexyl ring.
[00206] In certain embodiments, R24 is substituted or unsubstituted alkyl, e.g. , substituted or unsubstituted C^alkyl, substituted or unsubstituted C^alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted C4_5alkyl, or substituted or unsubstituted Cs^alkyl. Exemplary R C^alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3- pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n- hexyl (C6), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g., -CF3, -CH2F, -CHF2> difluoroethyl, and 2,2,2-trifluoro-l,l-dimethyl-ethyl), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups (e.g., -CH2C1, -CHC12), and Ci_6 alkyl substituted with alkoxy groups (e.g., -CH2OCH3 and -CH2OCH2CH3).
[00207] In certain embodiments, R24 is substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C2-6alkenyl, substituted or unsubstituted C2_3alkenyl, substituted or unsubstituted C3^alkenyl, substituted or unsubstituted C^alkenyl, or substituted or unsubstituted Cs_6alkenyl.
[00208] In certain embodiments, R24 is substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C2-6alkynyl, substituted or unsubstituted C2_3alkynyl, substituted or unsubstituted C3^alkynyl, substituted or unsubstituted C^alkynyl, or substituted or unsubstituted Cs_6alkynyl.
[00209] In certain embodiments, R24 is substituted or unsubstituted carbocyclyl, e.g., substituted or unsubstituted C3_6carbocyclyl, substituted or unsubstituted C3^carbocyclyl, substituted or unsubstituted C4_5 carbocyclyl, or substituted or unsubstituted C5_6 carbocyclyl.
[00210] In certain embodiments, R24 is substituted or unsubstituted heterocyclyl, e.g., substituted or unsubstituted 3-6 membered heterocyclyl, substituted or unsubstituted 3-4 membered heterocyclyl, substituted or unsubstituted 4-5 membered heterocyclyl, or substituted or unsubstituted 5-6 membered heterocyclyl.
[00211] In certain embodiments, R24 is substituted or unsubstituted aryl, e.g., substituted or unsubstituted phenyl.
[00212] In certain embodiments, R24 is substituted or unsubstituted heteroaryl, e.g., optionally substituted 5- to 6-membered heteroaryl.
[00213] In certain embodiments, R Z4 is -OR Z5 , wherein R Z5 is as defined herein, e.g.,
Z5
for example, R is hydrogen, methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6).
[00214] In certain embodiments, R Z4 is -SR Z5 , wherein R Z5 is as defined herein, e.g.,
Z5
for example, R is hydrogen, methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6).
[00215] In certain embodiments, R24 is -N(R25)2, e.g. , R24 is -NH2, or -NHR25, wherein R Z5 is as defined herein, e.g., for example, R Z5 is hydrogen, methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n- pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), or n-hexyl (C6), or R Z4 is -N(R Z5 )2 wherein the two R Z5 groups are joined to form a substituted or unsubstituted heterocyclic ring, e.g., a substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl ring.
[00216] Specific L3 alkylene groups are contemplated herein. For example, in certain embodiments, L is an alkylene group of the formula:
Figure imgf000070_0001
wherein p is 1, 2, or 3; and each instance of R Z7 and R Z8 is, independently, hydrogen, halo, substituted or unsubstituted Ci Z5
_6 alkyl, or -OR . In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3.
[00217] Specific L3 alkenylene groups are also contemplated herein. For example, in certain embodiments, L is an alkenylene group of the formula:
Figure imgf000070_0002
wherein q is 0, 1, or 2; and each instance of R Z7 and R Z8 is, independently, hydrogen, halo, substituted or unsubstituted Ci Z5
_6 alkyl, or -OR . In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2.
[00218] Specific L3 heteroalkylene groups are also contemplated herein, e.g., for example, in certain embodiments, L is a heteroalkylene group of the formula:
Figure imgf000070_0003
wherein w is 0 or 1 and p is 1, 2, or 3, or w is 1 and p is 0, 1, 2, or 3; and each instance of R' and R Z8 is independently hydrogen, halo, substituted or unsubstituted Ci_6 alkyl, or -OR Z5.
[00219] In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, w is 0. In certain embodiments, w is 1. In certain embodiments, w is 0, and p is 1. In certain embodiments, w is 0, and p is 2. In certain embodiments, w is 0, and p is 3. In certain embodiments, w is 1, and p is 1. In certain embodiments, w is 1, and p is 2. In certain embodiments, w is 1, and p is 3. [00220] For example, in certain embodiments wherein w is 0, provided is an L3 heteroalkylene group of the formula:
Figure imgf000071_0001
wherein p and R are as defined herein.
[00221] In certain embodiments wherein w is 1, provided is an L3 heteroalkylene group of the formula:
Figure imgf000071_0002
wherein p, R , and R are as defined herein.
[00222] In certain embodiments, at least one instance of RZ7 is hydrogen. In any of the
Z7
above instances, in certain embodiments, at least one instance of R is halo, e.g. , fluoro. In
Z7
any of the above instances, in certain embodiments, at least one instance of R is substituted or unsubstituted Ci_6 alkyl, e.g. , substituted or unsubstituted C^alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted
Z7
C4_5alkyl, or substituted or unsubstituted Cs^alkyl. Exemplary R C^alkyl groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3- pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n- hexyl (C6), C^ alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g. , -CF3, -CH2F, -CHF2> difluoroethyl, and 2,2,2-trifluoro-l,l-dimethyl-ethyl), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups (e.g. , -CH2C1, -CHC12), and Ci_6 alkyl substituted with alkoxy groups (e.g. , -CH2OCH3 and -CH2OCH2CH3). In any
Z7
of the above instances, in certain embodiments, at least one instance of R is -CH , -CF , - CH2CH (Et), or -CH(CH )2 (iPr). In any of the above instances, in certain embodiments, at
Z7 Z5
least one instance of R is -OR , e.g. , -OH.
[00223] In certain embodiments, at least one instance of RZ8 is hydrogen. In any of the
Z8
above instances, in certain embodiments, at least one instance of R is halo, e.g. , fluoro. In
Z8
any of the above instances, in certain embodiments, at least one instance of R is substituted or unsubstituted Ci_6 alkyl, e.g. , substituted or unsubstituted Ci_2alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted
Z8
C4_5alkyl, or substituted or unsubstituted Cs^alkyl. Exemplary R Chalky! groups include, but are not limited to, substituted or unsubstituted methyl (CO, ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3- pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), n- hexyl (C6), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more fluoro groups (e.g. , -CF3, -CH2F, -CHF2> difluoroethyl, and 2,2,2-trifluoro-l,l-dimethyl-ethyl), Ci_6 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chloro groups (e.g. , -CH2C1, -CHC12), and Ci_6 alkyl substituted with alkoxy groups (e.g. , -CH2OCH3 and -CH2OCH2CH3). In any
Z8
of the above instances, in certain embodiments, at least one instance of R is -CH3, -CF3, - CH2CH (Et), or -CH(CH )2 (iPr). In any of the above instances, in certain embodiments, at
Z8 Z5
least one instance of R is -OR , e.g. , -OH.
224] Exemplary L3 alkylene groups include, but are not limited to:
Figure imgf000072_0001
[00226] Exemplary L heteroalkylene groups include, but are not limited to:
Figure imgf000073_0001
[00227] In certain embodiments, the group wherein L is an alkylene or heteroalkylene group, is of the formula:
Figure imgf000073_0002
Figure imgf000074_0001
In certain embodiments, the group , wherein Y is -O- and L ylene or heteroalkylene group, is of the formula:
Figure imgf000074_0002
^ο-γςΗ
Figure imgf000074_0003
[00229]
Figure imgf000075_0001
In certain embodiments, the group , wherein Y is -NH- and
L is an alkylene or heteroalkylene group, is of the formula
Figure imgf000075_0002
an alkylene or heteroalkylene group, is of the formula:
Figure imgf000076_0001
Figure imgf000076_0002
Various embodiments ofR2, Rlla, and Rllb
[00232] As generally defined above, each instance of R2, Rlla, and Rllb is
independently H, -OH, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N3, -N02, -SCN, -CN, -ORB1, -SRB1, -N(RB1)2, -N=NRB1, - N=C(RB1)2, -N(ORB1)(RB1), -C(=0)RB1, -C(=0)ORB1, -C(=0)SRB1, -C(=0)N(Rbl)2, - C(=0)N(ORB1)(RB1),-OC(=0)RB1, -OC(=0)ORB1, -OC(=0)SRB1, -OC(=0)N(RB1)2, - NRB1C(=0)RB1, -NRB1C(=0)ORB1, -NRB1C(=0)SRB1, -NRB1C(=0)N(RB1)2, -SC(=0)RB2, - SC(=0)ORB1, -SC(=0)SRB1, -SC(=0)N(RB1)2, -OS(=0)2RB2, -OS(=0)2ORB1, -S- S(=0)2RB2, -S-S(=0)2ORB1, -S(=0)RB2, -S02RB2, -NRB1S02RB2, or -S02N(RB1)2, and/or Rl la and Rl lb are joined to form an oxo (=0) group
[00233] In certain embodiments, R2 is H. In certain embodiments, R2 is substituted or unsubstituted alkyl. In certain embodiments, R is substituted or unsubstituted alkenyl. In certain embodiments, R 2 is substituted or unsubstituted alkynyl. In certain embodiments, R 2 is
-OR B 1. In certain embodiments, R 2 is -SRB1. In certain embodiments, R 2 is -N(RB 1 )2. In certain embodiments, R is H, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -OR B 1 , -SR B 1 , or -N(R B 1 )2. In certain embodiments, R is F, CI, Me, Et, n-Pr, methoxy, ethoxy, propoxy, butoxy, ethynyl, hydroxybutynyl, methoxypropynyl, chloroethynyl, or cyclopropynyl. In certain embodiments,
R 2 is CF3, amino, or dimethylamino. In certain embodiments, R 2 is a non-hydrogen group in the alpha position. In certain embodiments, R is a non-hydrogen group in the beta position.
[00234] In certain embodiments, each instance of Rl la and Rllb is hydrogen. In certain embodiments, one of Rl la and Rl lb is hydrogen. In certain embodiments, one of Rl la and Rllb is hydrogen; and the other is -OR B 1 , -SR B 1 , or -N(R B 1 )2. In certain embodiments, one of Rl la and Rl lb is H; and the other is -OH, -OMe, amino, or dialkylamino. In certain
embodiments, Rllb is a non-hydrogen group, and Rlla is hydrogen. In certain embodiments, Rl la is a non-hydrogen group, and Rl lb is hydrogen.
[00235] In certain embodiments, Rl la and Rl lb together form an oxo group.
Various embodiments ofR4a, R4b, R6, R7a, R7h, R14, R17, R18, and R19
[00236] As generally defined above, each instance of R4a, R4b, R7a, and R7b is independently hydrogen, -OH, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N3, -N02, -SCN, -CN, -ORB1, -SRB1, -N(RB1)2, - N=NRB1, -N=C(RB1)2, -N(ORB1)(RB1), -C(=0)RB1, -C(=0)ORB1, -C(=0)SRB1, - C(=0)N(Rbl)2, -C(=0)N(ORB1)(RB1),-OC(=0)RB1, -OC(=0)ORB1, -OC(=0)SRB1, - OC(=0)N(RB1)2, -NRB1C(=0)RB1, -NRB1C(=0)ORB1, -NRB1C(=0)SRB1, - NRB1C(=0)N(RB1)2, -SC(=0)RB2, -SC(=0)ORB1, -SC(=0)SRB1, -SC(=0)N(RB1)2, - OS(=0)2RB2, -OS(=0)2ORB1, -S-S(=0)2RB2, -S-S(=0)2ORB1, -S(=0)RB2, -S02RB2, - NRB1S02RB2, or -S02N(RB1)2, wherein RB1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R B 1 groups are joined to form an substituted or unsubstituted heterocyclic ring; and R B2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or an R B 1 group and an R B2 group are joined to form an substituted or unsubstituted heterocyclic ring; or optionally wherein each of R4a and R4b, and/or R7a and R7b are joined to form an oxo (=0) group.
[00237] In certain embodiments, each instance of R4a and R4b is hydrogen. In certain embodiments, one of R4a and R4b is hydrogen. In certain embodiments, one of R4a and R4b is hydrogen; and the other is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. In certain embodiments, one of R4a and R4b is hydrogen; and the other is Me, Et, ethenyl, ethynyl, propenyl, or propynyl. In certain embodiments, each of R4a and R4b is independently substituted or unsubstituted alkyl. In certain embodiments, each of R4a and R4b is Me.
[00238] In certain embodiments, each instance of R7a and R7b is hydrogen.
[00239] As generally defined above, each of R6a and R6b is independently hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, and represents a single or double bond, provided if a double bond is present in Ring B, then one of R6a or R6b is absent, and provided if a single bond is present in Ring B, then the hydrogen at C5 is in the alpha or beta position.
[00240] In certain embodiments, wherein represents a single bond, each instance of R6a and R6b is hydrogen. In certain embodiments, each instance of R6a and R6b is halo, e.g., fluoro.
[00241] In certain embodiments, wherein represents a single bond, R6a is hydrogen, and R6b is halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. In certain embodiments, R6a is hydrogen, and R6b is halo (e.g., fluoro). In certain embodiments, R6a is hydrogen, and R6b is substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C^alkyl, substituted or unsubstituted C^alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted C4_salkyl, or substituted or unsubstituted C5_6alkyl, e.g., methyl, ethyl, propyl, or isopropyl. In certain embodiments, R6a is hydrogen, and R6b is substituted or unsubstituted alkenyl. In certain embodiments, R6a is hydrogen, and R6b is substituted or unsubstituted alkynyl.
[00242] In certain embodiments, wherein represents a single bond, R6b is hydrogen, and R6a is halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. In certain embodiments, R6b is hydrogen, and R6a is halo (e.g., fluoro). In certain embodiments, R6b is hydrogen, and R6a is substituted or unsubstituted alkyl, e.g. , substituted or unsubstituted C^alkyl, substituted or unsubstituted C^alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted C4_salkyl, or substituted or unsubstituted C5_6alkyl, e.g., methyl, ethyl, propyl, or isopropyl. In certain embodiments, R6b is hydrogen, and R6a is substituted or unsubstituted alkenyl. In certain embodiments, R6b is hydrogen, and R6a is substituted or unsubstituted alkynyl.
[00243] In certain embodiments, wherein represents a double bond, R6a is hydrogen. In certain embodiments, wherein represents a double bond, R6a is halo, e.g., fluoro. In certain embodiments, wherein represents a double bond, R6a is substituted or unsubstituted alkyl, e.g. , substituted or unsubstituted C^alkyl, substituted or unsubstituted Ci_2alkyl, substituted or unsubstituted C2_3alkyl, substituted or unsubstituted C3^alkyl, substituted or unsubstituted C4_5alkyl, or substituted or unsubstituted Cs^alkyl, e.g., methyl, ethyl, propyl, or isopropyl. In certain embodiments, wherein represents a double bond, R6a is substituted or unsubstituted alkenyl. In certain embodiments, wherein
represents a double bond, R6a is substituted or unsubstituted alkynyl.
17
[00244] As generally defined above, R is hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aryl, substituted or unsubstituted heteroaryl, or -ORD1. In certain
17 17
embodiments, R is hydrogen. In certain embodiments, R is halo. In certain embodiments,
17 17
R is substituted or unsubstituted alkyl. In certain embodiments, R is substituted or
17
unsubstituted alkenyl. In certain embodiments, R is substituted or unsubstituted alkynyl. In
17
certain embodiments, R is substituted or unsubstituted carbocyclyl. In certain embodiments,
17 17
R is substituted or unsubstituted heterocyclyl. In certain embodiments, R is substituted or
17
unsubstituted aryl. In certain embodiments, R is substituted or unsubstituted heteroaryl. In certain embodiments, R17 is -ORD1 (e.g. , -OH). [00245] As generally defined above, R14 is H or substituted or unsubstituted alkyl. In certain embodiments, R14 is H. In certain embodiments, R14 is substituted or unsubstituted alkyl {e.g., -CH3).
[00246] As generally defined above, R 18 is independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 18 is hydrogen. In certain embodiments, R 18 is substituted or unsubstituted alkyl {e.g., -CH ).
[00247] As generally defined above, R19 is independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R19 is hydrogen. In certain embodiments, R19 is substituted or unsubstituted alkyl {e.g., -CH ).
[00248] In certain embodiments, R14 is hydrogen, R18 is -CH3 and R19 is -CH3.
[00249] In certain embodiments, R14 is hydrogen, R18 is -CH3 and R19 is hydrogen.
Additional embodiments of Formula (I)
[00250] Various combinations of the above embodiments are futher contemplated herein. For example, in certain embodiments, the compound of Formula (I) is of Formula (I- w):
Figure imgf000080_0001
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R3b is hydrogen. In certain embodiments, the group -Χ^¾ at the C3 position is beta. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R2 is hydrogen or -ORB1. In certain embodiments, Rlla is hydrogen and Rl lb is hydrogen or - ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro. In certain embodiments, R19 is methyl. [00251] In certain embodiments the compound of Formula (I) is of Formula (I-x):
Figure imgf000081_0001
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, the group - OH at the C3 position is beta. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B 1. In certain
embodiments, Rlla is hydrogen and Rllb is hydrogen or -ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro. In certain embodiments, R19 is methyl.
[00252] In certain embodiments, the compound of Formula (I) is of Formula (I-y):
Figure imgf000081_0002
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, the group OH at the C3 position is beta. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B 1. In certain
embodiments, Rlla is hydrogen and Rllb is hydrogen or -ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R a and R are both hydrogen. In certain embodiments, R ) 6a is halo, e.g., fluoro, or alkyl. In certain embodiments, RR6b iiss hhaalloo,, ee..gg..,, fflluuoorrco, or alkyl, and R a is hydrogen. In certain embodiments, R a and R are both halo, e.g., fluoro. [00253] In certain embodiments the compound of Formula (I) is of Formula (I-z):
Figure imgf000082_0001
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, the group - OH at the C3 position is beta. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B 1. In certain
embodiments, Rlla is hydrogen and Rllb is hydrogen or -ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro.
[00254] In certain embodiments, the compound of Formula (I) is of Formula (I-al), (I- a2), or (I-a3):
Figure imgf000082_0002
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R is hydrogen. In certain embodiments, the group -OR at the C3 position is beta. In certain embodiments, R a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R2 is hydrogen or -ORB1. In certain embodiments, Rl la is hydrogen and Rl lb is hydrogen or - ORB 1. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro.
[00255] In certain embodiments, the compound of Formula (I) is of Formula (I-bl), (I- b2), or (I-b3):
Figure imgf000083_0001
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R3b is hydrogen. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R2 is hydrogen or -ORB 1. In certain embodiments, Rl la is hydrogen and Rl lb is hydrogen or -ORB1. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro.
[00256] In certain embodiments, the compound of Formula (I) is of Formula (I-cl), (I- c2), or (I-c3):
Figure imgf000083_0002
(I-cl),
Figure imgf000084_0001
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R3b is hydrogen. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R2 is hydrogen or -ORB1. In certain embodiments, Rlla is hydrogen and Rl lb is hydrogen or -ORB1. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro.
[00257] In certain embodiments, the compound is of Formula (I-d):
Figure imgf000084_0002
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R3b is hydrogen. In certain embodiments, the group -Χ^¾ at the C3 position is beta. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R2 is hydrogen or -ORB1. In certain embodiments, Rlla is hydrogen and Rl lb is hydrogen or - ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro. In certain embodiments, R19 is methyl. In certain embodiments, each R26 is independently hydrogen or methyl. [00258] In certain embodiments, the compound is of Formula (I-e):
Figure imgf000085_0001
(I-e)
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R is hydrogen or - ORB1. In certain embodiments, Rlla is hydrogen and Rllb is hydrogen or -ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro. In certain embodiments, R19 is methyl. In certain embodiments, each R26 is independently hydrogen or methyl.
[00259] In certain embodiments, the compound is of Formula (I-f):
Figure imgf000085_0002
f)
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R3b is hydrogen. In certain embodiments, the group -Χ^¾ at the C3 position is beta. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R2 is hydrogen or -ORB1. In certain embodiments, Rlla is hydrogen and Rl lb is hydrogen or - ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R a and R are both hydrogen. In certain embodiments, R a is halo, e.g., fluoro, or alkyl. In certain embodiments, R is halo, e.g., fluoro, or alkyl, and R a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro. In certain embodiments, R19 is methyl. In certain embodiments, each Rz6 is independently hydrogen or methyl. In certain embodiments, R Z5 is hydrogen or methyl.
[00260] In certain embodiments, the compound is of Formula (I-g):
Figure imgf000086_0001
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R is hydrogen or - ORB1. In certain embodiments, Rlla is hydrogen and Rllb is hydrogen or -ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R6a and R6 are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R is halo, e.g., fluoro, or alkyl, and RD 6aa i ·s hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro. In certain embodiments, R19 is methyl. In certain embodiments, each R26 is independently hydrogen or methyl. In certain embodiments, R25 is hydrogen or methyl.
[00261] In certain embodiments, the compound is of Formula (I-h):
Figure imgf000086_0002
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R3b is hydrogen. In certain embodiments, the group -Χ^¾ at the C3 position is beta. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R2 is hydrogen or -ORB1. In certain embodiments, Rl la is hydrogen and Rl lb is hydrogen or - ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro. In certain embodiments, R19 is methyl. In certain embodiments, Rz6 is isopropyl.
[00262] In certain embodiments, the compound is of Formula (I-i):
Figure imgf000087_0001
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof. In certain embodiments, R3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R is hydrogen or - ORB1. In certain embodiments, Rlla is hydrogen and Rllb is hydrogen or -ORB1. In certain embodiments, represents a single bond, R5 is alpha (down) and R6a is hydrogen. In certain embodiments, represents a double bond. In certain embodiments, R6a and R6b are both hydrogen. In certain embodiments, R6a is halo, e.g., fluoro, or alkyl. In certain embodiments, R6b is halo, e.g., fluoro, or alkyl, and R6a is hydrogen. In certain embodiments, R6a and R6b are both halo, e.g., fluoro. In certain embodiments, R19 is methyl. In certain embodiments, Rz6 is isopropyl.
[00263] Additional embodiments of Formula (I) include compounds of the following formula:
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000089_0002
Figure imgf000090_0001
ĨVll-e)
Figure imgf000091_0001
XI
Figure imgf000092_0001
[00264] In certain embodiments the compound is any one of the following compounds:
Figure imgf000092_0002
Figure imgf000092_0003
91
Figure imgf000093_0001
92
Figure imgf000094_0001
Figure imgf000094_0002
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
, or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[00265] In certain embodiments the compound is any one of the following compounds:
Figure imgf000098_0002
Figure imgf000098_0003
Figure imgf000098_0004
Figure imgf000098_0005
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000101_0002
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[00266] In certain embodiments the compound is any one of the following compounds:
Figure imgf000102_0001
Figure imgf000103_0001
, or
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[00267] In certain embodiments the compound is any one of the following compounds:
Figure imgf000103_0002
102
Figure imgf000104_0001
Figure imgf000105_0001
, or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[00268] In certain embodiments the compound is any one of the following compounds:
Figure imgf000105_0002
Figure imgf000105_0003
Figure imgf000106_0001
Figure imgf000106_0002
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[00269] In certain embodiments the compound is any one of the following compounds:
Figure imgf000106_0003
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[00270] In certain embodiments the compound is any one of the following compounds:
Figure imgf000107_0001
, or
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or a combination thereof.
[00271] In certain embodiments, the compound of the present invention is a pharmaceutically acceptable salt.
Pharmaceutical Compositions
[00272] In another aspect, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a effective amount of a compound of Formula (I).
[00273] When employed as pharmaceuticals, the compounds provided herein are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.
[00274] In one embodiment, with respect to the pharmaceutical composition, the carrier is a parenteral carrier, oral or topical carrier.
[00275] The present invention also relates to a compound of the present invention or pharmaceutical composition thereof for use as a pharmaceutical or a medicament.
[00276] Generally, the compounds provided herein are administered in a
therapeutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
[00277] The pharmaceutical compositions provided herein can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous,
intramuscular, and intranasal. Depending on the intended route of delivery, the compounds provided herein are preferably formulated as either injectable or oral compositions or as salves, as lotions or as patches all for transdermal administration.
[00278] The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
[00279] Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
[00280] Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As before, the active compound in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
[00281] Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight. When formulated as a ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example an oil-in-water cream base. Such transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration of stability of the active ingredients or the formulation. All such known transdermal formulations and ingredients are included within the scope provided herein.
[00282] The compounds provided herein can also be administered by a transdermal device. Accordingly, transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.
[00283] The above-described components for orally administrable, injectable or topically administrable compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.
[00284] The above-described components for orally administrable, injectable, or topically administrable compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington's The Science and Practice of Pharmacy, 21st edition, 2005, Publisher: Lippincott Williams & Wilkins, which is incorporated herein by reference.
[00285] The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.
[00286] The present invention also relates to the pharmaceutically acceptable formulations of a compound of the present invention. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β- and γ- cyclodextrins consisting of 6, 7 and 8 cc-l ,4-linked glucose units, respectively, optionally comprising one or more substituents on the linked sugar moieties, which include, but are not limited to, methylated, hydroxyalkylated, acylated, and sulfoalkylether substitution. In certain embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, e.g., for example, sulfobutyl ether β- cyclodextrin, also known as Captisol®. See, e.g., U.S. 5,376,645. In certain embodiments, the formulation comprises hexapropyl- -cyclodextrin. In a more particular embodiment, the formulation comprises hexapropyl- -cyclodextrin (10-50% in water).
[00287] The present invention also relates to the pharmaceutically acceptable acid addition salt of a compound of the present invention. The acid which may be used to prepare the pharmaceutically acceptable salt is that which forms a non-toxic acid addition salt, i.e., a salt containing pharmacologically acceptable anions such as the hydrochloride, hydroiodide, hydrobromide, nitrate, sulfate, bisulfate, phosphate, acetate, lactate, citrate, tartrate, succinate, maleate, fumarate, benzoate, para-toluenesulfonate, and the like.
[00288] The following formulation examples illustrate representative pharmaceutical compositions that may be prepared in accordance with this invention. The present invention, however, is not limited to the following pharmaceutical compositions.
[00289] Exemplary Formulation 1 - Tablets : A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active compound per tablet) in a tablet press.
[00290] Exemplary Formulation 2 - Capsules: A compound of the present invention may be admixed as a dry powder with a starch diluent in an approximate 1: 1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active compound per capsule).
[00291] Exemplary Formulation 3 - Liquid: A compound of the present invention
(125 mg) may be admixed with sucrose (1.75 g) and xanthan gum (4 mg) and the resultant mixture may be blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water. Sodium benzoate (10 mg), flavor, and color are diluted with water and added with stirring. Sufficient water may then be added to produce a total volume of 5 mL.
[00292] Exemplary Formulation 4 - Tablets : A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active compound) in a tablet press.
[00293] Exemplary Formulation 5 - Injection : A compound of the present invention may be dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/mL. [00294] Exemplary Formulation 6 - Tablets : A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
90-150 mg tablets (30-50 mg of active compound per tablet) in a tablet press.
[00295] Exemplary Formulation 7 - Tablets : A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
30-90 mg tablets (10-30 mg of active compound per tablet) in a tablet press.
[00296] Exemplary Formulation 8 - Tablets : A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
0.3-30 mg tablets (0.1-10 mg of active compound per tablet) in a tablet press.
[00297] Exemplary Formulation 9 - Tablets : A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
150-240 mg tablets (50-80 mg of active compound per tablet) in a tablet press.
[00298] Exemplary Formulation 10 - Tablets : A compound of the present invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into
270-450 mg tablets (90-150 mg of active compound per tablet) in a tablet press.
[00299] Injection dose levels range from about 0.1 mg/kg/hour to at least
10 mg/kg/hour, all for from about 1 to about 120 hours and especially 24 to 96 hours. A preloading bolus of from about 0.1 mg/kg to about 10 mg/kg or more may also be
administered to achieve adequate steady state levels. The maximum total dose is not expected to exceed about 2 g/day for a 40 to 80 kg human patient.
[00300] For the prevention and/or treatment of long-term conditions the regimen for treatment usually stretches over many months or years so oral dosing is preferred for patient convenience and tolerance. With oral dosing, one to five and especially two to four and typically three oral doses per day are representative regimens. Using these dosing patterns, each dose provides from about 0.01 to about 20 mg/kg of the compound provided herein, with preferred doses each providing from about 0.1 to about 10 mg/kg, and especially about 1 to about 5 mg/kg. [00301] Transdermal doses are generally selected to provide similar or lower blood levels than are achieved using injection doses.
[00302] When used to prevent the onset of a CNS-disorder, the compounds provided herein will be administered to a subject at risk for developing the condition, typically on the advice and under the supervision of a physician, at the dosage levels described above.
Subjects at risk for developing a particular condition generally include those that have a family history of the condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the condition.
Methods of Treatment and Use
[00303] Earlier studies (see, e.g., Gee et al., European Journal of Pharmacology,
136:419-423 (1987)) demonstrated that certain 3cc-hydroxylated steroids are orders of magnitude more potent as modulators of the GRC than others had reported (see, e.g., Majewska et ah, Science 232:1004-1007 (1986); Harrison et ah, J Pharmacol. Exp. Ther. 241:346-353 (1987)). Majewska et al. and Harrison et al. taught that 3cc-hydroxylated-5- reduced steroids are only capable of much lower levels of effectiveness. In vitro and in vivo experimental data have now demonstrated that the high potency of these steroids allows them to be therapeutically useful in the modulation of brain excitability via the GRC (see, e.g., Gee et al, European Journal ofPharmacology, 136:419-423 (1987); Wieland et al,
Psychopharmacology 118(1):65-71 (1995)).
[00304] Various synthetic steroids have also been prepared as neuroactive steroids.
See, for example, U.S. Patent No. 5,232,917, which discloses neuroactive steroid compounds useful in treating stress, anxiety, insomnia, seizure disorders, and mood disorders, that are amenable to GRC-active agents, such as depression, in a therapeutically beneficial manner. Furthermore, it has been previously demonstrated that these steroids interact at a unique site on the GRC which is distinct from other known sites of interaction {e.g., barbiturates, benzodiazepines, and GABA) where therapeutically beneficial effects on stress, anxiety, sleep, mood disorders and seizure disorders have been previously elicited (see, e.g., Gee, K.W. and Yamamura, H.I., "Benzodiazepines and Barbiturates: Drugs for the Treatment of Anxiety, Insomnia and Seizure Disorders, " in Central Nervous System Disorders, Horvell, ed., Marcel-Dekker, New York (1985), pp. 123-147; Lloyd, K.G. and Morselli, P.L., "Psychopharmacology of GABAergic Drugs," in Psychopharmacology: The Third Generation of Progress, H.Y. Meltzer, ed., Raven Press, N.Y. (1987), pp. 183-195; and Gee et al, European Journal of Pharmacology, 136:419-423 (1987). These compounds are desirable for their duration, potency and oral activity (along with other forms of administration).
[00305] Accordingly, the compounds and pharmaceutical compositions provided herein find use as therapeutics for preventing and/or treating CNS conditions in mammals including humans and non-human mammals. Thus, and as stated earlier, the present invention includes within its scope, and extends to, the recited methods of treatment, as well as to the compounds for such methods, and to the use of such compounds for the preparation of medicaments useful for such methods. It is contemplated that the novel 3a- and 3β- hydroxy steroids of the invention may act as negative allosteric modulators (NAM) of NMDA receptor and thus may be useful for preventing and/or treating a broad range of CNS conditions.
[00306] In one aspect, compounds of the present invention are contemplated as therapeutic agents, e.g., for the treatment of CNS conditions in mammals, such as for the treatment of schizophrenia, depression, bipolar disorder {e.g., I and/or II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, compulsive disorders, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive compulsive disorder (OCD), pain {e.g., a painful syndrome or disorder), sleep disorders, memory disorders, dementia, Alzheimer's Disease, a seizure disorder {e.g., epilepsy), traumatic brain injury (TBI), stroke, addictive disorders {e.g., addiction to opiates, cocaine, and/or alcohol), autism, Huntington's Disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus. In certain embodiments, the compounds of the present invention are useful in the treatment of depression, anxiety, mood disorders, sleep disorders, memory disorders, traumatic brain injury, stroke, epilepsy, and schizophrenia.
[00307] In another aspect, provided is a method of treating a mammal susceptible to or afflicted with a condition associated with brain excitability, which method comprises administering an effective amount of one or more of the pharmaceutical compositions described herein.
[00308] In yet another aspect, provided is the use of a compound of the present invention as a pharmaceutical, e.g., especially in the treatment or prevention of the aforementioned conditions and diseases. [00309] In still yet another aspect, provided is a method of manufacture of a medicament for the treatment or prevention of one of the aforementioned conditions and diseases.
[00310] In still yet another aspect, the present invention provides a method for preventing, treating, ameliorating or managing a disease or condition which comprises administering to a subject in need of such prevention, treatment, amelioration or
management, a prophylactically or therapeutically effective amount of a compound of the present invention, or the pharmaceutical composition thereof.
[00311] In yet another aspect, the present invention provides a use of a compound of the present invention for the manufacture of a medicament to treat a disease or condition associated with brain excitability. In one embodiment, the disease or condition is selected from depression, anxiety, schizophrenia, sleep disorders, memory disorders, and mood disorders.
[00312] In yet another aspect, the present invention provides a method of treatment of a mammal, e.g., a human being, to treat a disease associated with brain excitability, including treating said mammal with an effective amount of a compound of the present invention or composition thereof.
[00313] In yet another aspect, the present invention provides a combination of a compound of the present invention and another pharmacologically active agent.
[00314] The compounds provided herein can be administered as the sole active agent or they can be administered in combination with other agents. Administration in combination can proceed by any technique apparent to those of skill in the art including, for example, separate, sequential, concurrent and alternating administration.
EXAMPLES
[00315] In order that the invention described herein may be more fully understood, the following examples are set forth. The synthetic and biological examples described in this application are offered to illustrate the compounds, pharmaceutical compositions and methods provided herein and are not to be construed in any way as limiting their scope.
Materials and Methods
[00316] The compounds provided herein can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization.
[00317] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and P. G. M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein.
[00318] The compounds provided herein may be isolated and purified by known standard procedures. Such procedures include (but are not limited to) recrystallization, column chromatography, or HPLC. The following schemes are presented with details as to the preparation of representative substituted biarylamides that have been listed herein. The compounds provided herein may be prepared from known or commercially available starting materials and reagents by one skilled in the art of organic synthesis.
[00319] The enantiomerically pure compounds provided herein may be prepared according to any techniques known to those of skill in the art. For instance, they may be prepared by chiral or asymmetric synthesis from a suitable optically pure precursor or obtained from a racemate by any conventional technique, for example, by chromatographic resolution using a chiral column, TLC or by the preparation of diastereoisomers, separation thereof and regeneration of the desired enantiomer. See, e.g., "Enantiomers, Racemates and Resolutions," by J. Jacques, A. Collet, and S.H. Wilen, (Wiley-Interscience, New York, 1981); S.H. Wilen, A. Collet, and J. Jacques, Tetrahedron, 2725 (1977); E.L. Eliel
Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and S.H. Wilen Tables of Resolving Agents and Optical Resolutions 268 (E.L. Eliel ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972, Stereochemistry of Organic Compounds, Ernest L. Eliel, Samuel H. Wilen and Lewis N. Manda (1994 John Wiley & Sons, Inc.), and Stereoselective Synthesis A Practical Approach, Mihaly Nogradi (1995 VCH Publishers, Inc., NY, NY).
[00320] In certain embodiments, an enantiomerically pure compound of the present invention may be obtained by reaction of the racemate with a suitable optically active acid or base. Suitable acids or bases include those described in Bighley et al., 1995, Salt Forms of Drugs and Adsorption, in Encyclopedia of Pharmaceutical Technology, vol. 13, Swarbrick & Boylan, eds., Marcel Dekker, New York; ten Hoeve & H. Wynberg, 1985, Journal of Organic Chemistry 50:4508-4514; Dale & Mosher, 1973, J. Am. Chem. Soc. 95:512; and CRC Handbook of Optical Resolution via Diastereomeric Salt Formation, the contents of which are hereby incorporated by reference in their entireties.
[00321] Enantiomerically pure compounds can also be recovered either from the crystallized diastereomer or from the mother liquor, depending on the solubility properties of the particular acid resolving agent employed and the particular acid enantiomer used. The identity and optical purity of the particular compound so recovered can be determined by polarimetry or other analytical methods known in the art. The diasteroisomers can then be separated, for example, by chromatography or fractional crystallization, and the desired enantiomer regenerated by treatment with an appropriate base or acid. The other enantiomer may be obtained from the racemate in a similar manner or worked up from the liquors of the first separation.
In certain embodiments, enantiomerically pure compound can be separated from racemic compound by chiral chromatography. Various chiral columns and eluents for use in the separation of the enantiomers are available and suitable conditions for the separation can be empirically determined by methods known to one of skill in the art. Exemplary chiral columns available for use in the separation of the enantiomers provided herein include, but are not limited to, CHIRALCEL® OB, CHIRALCEL® OB-H, CHIRALCEL® OD, CHIRALCEL® OD-H, CHIRALCEL® OF, CHIRALCEL® OG, CHIRALCEL® OJ and CHIRALCEL® OK.
Synthetic procedures
[00322] General processes for preparing compounds of the present invention are provided as further embodiments of the invention and are illustrated in generalized schemes
1-13 and Examples 1-36. For the purpose of Scheme 1-13, if not defined, R' is alkyl, R 23 is
R23a or R23b. χ1 ; Ll ; Rl ; R3a R3b^ R23a ^ R23b^ ^ ^ described herein.
Figure imgf000117_0001
Scheme 3. Synthesis of 3β-Αηιίηο- and 3 -alkylamino steroids
Figure imgf000118_0001
3-4 (R3b' = alkyl)
Scheme 4. Synthesis of Steroid sulfates
Figure imgf000118_0002
Scheme
Figure imgf000118_0003
R∞ = alkyl or -(CH2)2_5-COOH
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000121_0002
Scheme 12. S nthesis of 3a-Substituted-3 -hydroxy steroids
Figure imgf000122_0001
12-4
Scheme 13. S nthesis of 3a-Substituted-3 -hydroxy steroids
Figure imgf000122_0002
Figure imgf000122_0003
1 2 3
Figure imgf000123_0001
Figure imgf000123_0002
Figure imgf000123_0003
A_001_3 ST-200-A-001
[00323] Preparation of Compound 2: To a solution of ketone 1 (50.0 g, 0.17 mol, 1.0 eq) and ethylene glycol (62 mL) in toluene (600 mL) was added p-toluenesulfonic acid (1.4 g, 7.28 mmol). The reaction mixture was heated at reflux overnight with a Dean-Stark trap. LCMS showed the starting material was consumed completely. The mixture was cooled to room temperature, diluted with ethyl acetate (500 mL), and washed with saturated aqueous sodium bicarbonate (300 mL x 2) and brine (300 mL x 2). The organic phase was dried over sodium sulfate and concentrated in vacuum to afford crude product 2 (64.0 g, 100%) which was directly used in the next step without further purification. 1H NMR: (400 MHz, CDC13) δ 5.35 (d, J=5.6 Hz, IH), 3.97-3.82 (m, 4H), 3.59-3.47 (m, IH), 2.34-2.21(m, 2H), 2.06-1.94 (m, 2H), 1.90-1.74 (m, 3H), 1.73-1.64 (m, IH), 1.63-1.33 (m, 10H), 1.32-1.19 (m, IH), 1.14- 1.03 (m, IH), 1.01 (s, 3H), 0.99-0.93 (m, IH), 0.86 (s, 3H).
[00324] Preparation of Compound 3: To a solution of compound 2 (32 g, 96 mmol, 1.0 eq) in dry CH2C12 (1200 mL) was added Dess-Martin (81 g, 192 mmol, 2.0 eq) in portions at 0 °C. Then the reaction mixture was stirred at room temperature for 3 h. TLC (PE:EA = 3: 1) showed the starting material was consumed completely. The mixture was quenched with saturated aqueous NaHC03/Na2S203 = 1:3 (1 L). The organic phase was washed with brine (500 mL) and dried over Na2S04> and the solvent was evaporated to afford crude product 3 (33.0 g, 100%), which was directly used in the next step without further purification. 1H NMR: (400 MHz, CDC13) δ 5.34 (d, J=5.2 Hz, 1H), 3.77-4.00 (m, 4H), 3.19- 3.39 (m, 1H), 2.83 (dd, J=16.44, 2.13 Hz, 1H), 2.38-2.59 (m, 1H), 2.21-2.37 (m, 1H), 1.95- 2.09 (m, 3H), 1.54-1.73 (m, 4H), 1.74-1.90 (m, 2H), 1.37-1.51 (m, 3H), 1.21-1.34 (m, 2H), 1.19 (s, 3H), 0.98-1.12 (m, 1H), 0.83-0.93 (m, 3H).
[00325] Preparation of MAD: To a solution of compound 5 (96 g, 436 mmol, 1.0 eq) in toluene (300 mL) was added a solution of AlMe3 (109 mL, 218 mmol, 0.5 eq, 2 M in hexane) at room temperature, at which time the methane gas was evolved immediately. The resulting mixture was stirred at room temperature for 1 h and used as a solution of MAD in toluene in the next step without any purification.
[00326] Preparation of Compound 4: To a solution of MAD (218 mmol, 2.3 eq, freshly prepared) in toluene (300 mL) was added dropwise a solution of compound 4 (33 g, 96 mmol, 1.0 eq) in toluene (100 mL) at -78 °C during a period of 1 h under nitrogen. Then the reaction mixture was stirred for 30 min, a solution of MeMgBr (205 mL, 288 mmol, 3.0 eq, 1.4 M in toluene) was added dropwise at -78 °C. The reaction mixture was warmed to -40 °C and stirred at this temperature for 3 h. TLC (PE:EA = 3: 1) showed that the starting material was consumed completely. The mixture was poured into saturated aqueous NH4C1 solution (200 mL) and extracted with EA (150 mL x 2). The combined organic phases were dried over Na2S04> and the solvent was evaporated to afford crude product. The crude product was purified by silica gel chromatography eluted with PE:EA (15: 1) to give the product (7.64 g, 22%) as white powder.
1H NMR: (400 MHz, CDC13) δ 5.30 (d, J=5.2 Hz, 1H), 3.75-4.04 (m, 4H), 2.42 (d, J=13.6 Hz, 1H), 1.88-2.12 (m, 3H), 1.73-1.86 (m, 2H), 1.64-1.72 (m, 2H), 1.52-1.63 (m, 4H), 1.35- 1.51 (m, 4H), 1.19-1.32 (m, 1H), 1.12-1.18 (m, 1H), 1.10 (s, 3H), 0.99-1.03 (m, 3H), 0.92- 0.98 (m, 1H), 0.86 (s, 3H).
[00327] Compound INT A: To a solution of compound 4 (6.0 g, 17.3 mmol, 1.0 eq) in
THF (200 mL) was added aqueous HC1 solution (35 mL, 1 M) and acetone (35 mL). The reaction mixture was stirred at room temperature overnight. TLC (PE:EA = 3: 1) indicated that the reaction was complete. Then the reaction mixture was diluted with EA (200 mL), washed with saturated aqueous NaHC03 solution (200 mL), dried over Na2S04 and evaporated under reduced pressure to give the product (5.2 g, 99.2%). 1H NMR: (400 MHz, CDC13) δ 5.27 (d, J=6.8 Hz, 1H), 2.45-2.35 (m, 2H), 2.09-1.84 (m, 4 H), 1.82-1.57 (m, 6H), 1.50-1.35 (m, 4H), 1.26-1.08 (m, 4H), 1.05 (s, 3 H), 0.95 (s, 3 H), 0.86 (s, 3 H).
[00328] Compound A_001_l: To a solution of PPh3CH3Br (28.3 g, 79.35 mmol) in THF (50 mL) was added a solution of t-BuOK (8.96 g, 79.35 mmol) in THF (20 mL) at room temperature. After stirring for 1 h, INT A (4.0 g, 13.22 mmol) dissolved in THF (10 mL) was added dropwise. The reaction mixture was refluxed for 3 h. The reaction mixture was cooled to room temperature and quenched with Sat. NH4C1, extracted with EA. The combined organic layer was washed with brine, dried and concentrated to give the crude product, which was purified by a flash column chromatography (PE/EA=15/1) to afford compound A_001_l (3.2 g, Y=80%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 5.32 (d, J=5.2 Hz, 1H), 4.65-4.64 (m, 2H), 2.50-2.42 (m, 2H), 2.27-2.22 (m, 1H), 2.07-1.97 (m, 1H), 1.87-1.68 (m, 4H), 1.68-1.49 (m, 7H), 1.40-1.15 (m, 4H), 1.12 (s, 3H), 1.05 (s, 3H), 1.04-0.96 (m, 1H), 0.80 (s, 3H).
[00329] Preparation of Compound A_001_2: To a solution of compound A_001_l (300 mg, 1.0 mmol, 1.0 eq) and methyl propiolate (250 mg, 3.0 mmol, 3.0 eq) in CH2CI2 (5 mL) was added dropwise Et2AlCl (4 mL, 4.0 mmol, 4.0 eq, 1 M in toluene) with stirring at 25 °C, then the reaction mixture was stirred overnight. TLC (PE/EA = 3/1) indicated that the starting material was consumed completely. The solution was washed with saturated aqueous NaHC03 (5 mL), dried over Na2S04 and concentrated under reduced pressure to provide the crude product which was purified by silica gel chromatography eluted with PE:EA (15: 1) to give the desired product (200 mg, 52%) as a white powder. 1H NMR: (400 MHz, CDC13) δ 7.03-6.97 (m, 1H), 5.86 (dd, J1=1.2Hz, J2=15.6Hz, 1H), 5.35 (d, J=1.2Hz, 1H), 5.32 (d, J=5.2Hz, 1H), 3.72 (s, 3H), 2.87 (d, J=6.8 Hz, 2H), 2.42 (d, J=13.2 Hz, 1H), 2.13-1.95 (m, 3H), 2.00-1.40 (m, 11H), 1.40-1.20 (m, 4H), 1.11 (s, 3H), 1.06 (s, 3H), 0.90-0.82 (m, 3H), 0.78 (s, 3H).
[00330] Preparation of Compound A_001_3: To a solution of compound A_001_2 (192 mg, 0.5 mmol, 1.0 eq) in EA (5 mL) was added Pd/C (5%, 40 mg) under N2. The suspension was degassed under vacuum and purged with H2 several times. Then the mixture was stirred under H2 balloon at 30 °C for 1 h. TLC (PE:EA = 3: 1) showed that the reaction was complete. The suspension was filtered through a pad of celite and the pad was washed with EA (5 mL x 2). The combined filtrates were concentrated to dryness to give the product (185 mg, 95%) as a white powder. 1H NMR: (400 MHz, CDC13) δ 5.31 (d, J=4.4Hz, 1H), 3.67 (s, 3H), 2.42 (d, J=13.2 Hz, 1H), 2.35-2.28 (m, 2H), 2.02-1.92 (m, 2H), 1.90-1.60 (m, 6H), 1.55-1.30 (m, 6H), 1.30-1.13 (m, 5H), 1.12 (s, 3H), 1.02(s, 3H), 1.00-0.75 (m, 4H), 0.58 (s, 3H).
[00331] Preparation of Compound ST-200-A-001: To a solution of compound A_001_3 (150 mg, 0.386 mmol, 1.0 eq) in THF (5 mL) was added dropwise MeLi (2 mL, 3.200 mmol, 8.3 eq, 1.6 M in THF) at -78 °C under nitrogen. After the addition the reaction mixture was warmed to -40 °C and stirred for 1 h. TLC (PE:EA = 3: 1) showed that the reaction was complete. The reaction mixture was quenched with saturated aqueous NH4C1 (10 mL), extracted with EA (10 mL x 2). The combined organic layers were concentrated under reduced pressure to provide the crude product which was purified by silica gel chromatography eluted with PE:EA (10: 1) to give product (91 mg, 60%) as a white powder. 1H NMR: (400 MHz, CDC13) δ 5.31 (d, J=5.6Hz, 1H), 2.43 (d, J=13.2 Hz, 1H), 2.05-1.95 (m, 2H), 1.90-1.60 (m, 6H), 1.21 (s, 6H), 1.12 (s, 3H), 1.11-1.04 (m, 1H), 1.03 (s, 3H), 1.01-0.92 (m, 2H), 0.58 (s, 3H).
Example 2. Preparation of Compound ST-200-A-003
Figure imgf000126_0001
A 003 3
Figure imgf000126_0002
ST-200-A-003 [00332] Preparation of Compound A_003_l : To a solution of Ph3PEtBr (12.25 g, 33.00 mmol, 10.0 eq) in dry THF (15 mL) was added dropwise a solution of i-BuOK (3.70 g, 33.00 mmol, 10.0 eq) in dry THF (10 mL) under N2 at 0 °C. The mixture was stirred at room temperature for 1.5 h. Then a solution of INT A (1.00 g, 3.31 mmol, 1.0 eq) in THF (10 mL) was added dropwise and the resulting mixture was stirred at 70 °C for 4 h. TLC (PE:EA = 3: 1) indicated that the starting material was consumed completely. The reaction was quenched with saturated aqueous NH4C1 solution (50 mL) and extracted with EA (30 mL x 2). The combined organic phases were dried over Na2S04 and concentrated in vacuum. The residue was purified by column chromatography on silica gel (eluent: PE: EA = 12: 1) to give the product (900 mg, 90.9%) as a white powder. 1H NMR: (400 MHz, CDC13) δ 5.32 (d, J=5.2Hz, 1H), 5.15-5.12 (m, 1H), 2.44-2.30 (m, 3H), 2.29-2.21 (m, 1H), 2.05-1.97 (m, 2H), 1.81-1.45 (m, 14H), 1.30-1.15 (m, 3 H), 1.12 (s, 3H), 1.02 (s, 3H), 0.95-1.01 (m, 1H), 0.90 (s, 3H).
[00333] Preparation of Compound A_003_2 : To a solution of compound A_003_l (1.00 g, 3.20 mmol, 1.0 eq) and methyl propiolate (0.67 g, 8.00 mmol, 2.5 eq) in dry DCM (15 mL) was added dropwise a solution of Et2AlCl (12.8 mL, 12.8 mmol, 4.0 eq, 1 M in toluene) with stirring at 0 °C. Then the reaction was warmed to room temperature and stirred overnight. TLC (PE:EA = 5: 1) indicated that the starting material was consumed completely. The mixture was quenched with saturated aqueous NaHC03 solution (30 mL) and extracted with DCM (30 mL x 2). The combined organic phases were dried over Na2S04 and concentrated in vacuum. The residue was purified by column chromatography on silica gel (eluent: PE:EA = 10: 1) to give product (1.00 g, 78.7%) as white powder. 1H NMR: (400 MHz, CDC13) δ 6.97-6.91 (m, 1 H) 5.82 (d, J=16 Hz, 1 H), 5.42-5.41 (m, 1H), 5.32 (d, J=5.2Hz, 1H), 3.73 (s, 3 H), 3.04-3.00 (m, 1 H), 2.43 (d, J=12.8 Hz, 1H), 2.11-1.97 (m, 3H), 1.88-1.50 (m, 12H), 1.40-1.20 (m, 3 H), 1.21-1.26 (m, 1H), 1.18 (d, J=6.78 Hz, 3H), 1.12 (s, 3H), 1.04 (s, 3H), 0.82 (s, 3H).
[00334] Preparation of Compound A_003_3: To a solution of compound A_003_2 (160 mg, 0.40 mmol) in EA (15 mL) was added Pd/C (30 mg, 5%). Then the reaction was stirred under 15 psi of H2 pressure at room temperature for 2 h. TLC (PE/EA = 3/1) showed that the starting material was consumed completely. And then the reaction mixture was filtered and the filtrate was evaporated under reduced pressure to give the product (150 mg, 92.8%). 1H NMR: (400 MHz, CDC13) δ 5.32 (d, J=5.2Hz, 1H), 3.67 (s, 3 H), 2.48-1.96 (m, 7H), 1.90-1.62 (m, 5H), 1.60 -1.55 (m, 7H), 1.11 (s, 3H), 1.03-0.99 (m, 3 H), 0.95-0.93 (m, 2H), 0.70-0.66 (m, 2 H).
[00335] Preparation of Compound ST-200-A-003: To a solution of compound A_003_2 (100 mg, 0.25 mmol, 1.0 eq) in dry THF (1 mL) under N2 protection was added dropwise MeLi (1.56 mL, 2.50 mmol, 1.6 M in THF) at -78 °C and the mixture was stirred at this temperature for 30 min. TLC (PE:EA = 3: 1) showed that the reaction was complete. The reaction mixture was quenched with saturated aqueous NH4C1 (5 mL) and extracted with EA (5 mL x 2). The combined organic layers were concentrated under reduced pressure to provide the crude product, which was purified by silica gel chromatography eluted with PE:EA (10: 1) to give the product (45 mg, 45%) as a white powder. 1H NMR: (400 MHz, CDC13) δ 5.30 (d, J=5.2Hz, 1H), 2.42 (d, J=12 Hz, 1 H), 2.02-1.98 (m, 3 H), 1.92-1.66 (m, 3 H), 1.61-1.56 (m, 2 H), 1.55-1.54 (m, 2H), 1.53-1.23 (m, 11 H), 1.20 (s, 6H), 1.10 (s, 3 H), 1.05 (s, 3H), 1.02 (s, 3 H), 0.95-0.90 (m, 3 H), 0.68 (s, 3 H).
Example 3. Preparation of Compound ST-200-A-007
Figure imgf000128_0001
ST-200-A-007 [00336] Preparation of Compound INT E: To a solution of 9-BBN (0.5 M in THF, 133 mL, 66.6 mmol, 10.0 eq) under ice-bath, a solution of A_001_l (2.0 g, 6.66 mmol, 1.0 eq) in THF (10 mL) was added dropwise. The reaction mixture was heated to 60 °C and stirred for 20 h. The mixture was cooled to 0 °C and 10% aqueous NaOH solution (20 mL) followed by 30% aqueous Η202 (30%, 10 mL) was added. The mixture was stirred for 2 h at 0 °C and then extracted with EA (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2S04 and concentrated in vacuum to give the crude product, which was purified by a flash column chromatography eluted by PE/EA (10/1) to afford INT E (1.0 g, 47%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 5.30 (d, J=5.2Hz, 1H), 3.75- 3.71 (dd, J/=10.4Hz, J2=6.8Hz, 1H), 3.58-3.53 (dd, J,=10.4Hz, J2=7.6Hz, 1H), 2.43-2.41 (d, J=10.4Hz, 1H), 2.02-1.96 (m, 2H), 1.91 -1.75 (m, 3H), 1.72-1.44 (m, 10H), 1.33-1.20 (m, 5H), 1.18 (s, 3H), 1.06 (s, 3H), 1.04-0.99 (m, 1H), 0.67 (s, 3H).
[00337] Preparation of Compound INT B: To a solution of INT E (100 mg, 0.314 mmol, 1.0 eq) in DCM (10 mL) under ice -bath, Dess-Martin reagent (265 mg, 0.628 mmol, 2.0 eq) was added. The reaction mixture was warmed to room temperature and stirred for 2 h. The mixture was poured into a solution of NaS203 (4.5 g) and NaHC03 (1.5 g) in water (20 mL), extracted with EA (20 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2S04 and concentrated in vacuum to give the crude product (100 mg, 100%) which was used directly in the next step without further purification.
[00338] Preparation of Compound A_007_l: A mixture of INT B (100 mg, 0.316 mmol, 1.0 eq) and Ph3P=CHCOOCH3 (634 mg, 1.89 mmol, 6.0 eq) in toluene (10 mL) was stirred for 3 h at 80 °C and then concentrated in vacuum. The residue was purified by a flash column chromatography eluted by PE/EA (12/1) to afford product A_007_l (65 mg, 55.2%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 6.99-6.93 (dd, J,=16 Hz, J2=8.4Hz, 1H), 5.82-5.77 (dd, J,=15.6 Hz, J2=1.2Hz, 1H), 5.30 (d, J=5.2Hz, 1H), 3.73 (s, 3H), 2.42 (d, J=12.4Hz, 1H), 2.14-2.11 (m, 1H), 2.05-1.99 (m, 2H), 1.98-1.41 (m, 15H), 1.29-1.24 (m, 2H), 1.12-1.14 (m, 1H), 1.12 (s, 3H), 1.06 (s, 3H), 1.02-0.95 (m, 1H), 0.66 (s, 3H).
[00339] Preparation of Compound A_007_2: A mixture of compound A_007_l (65 mg, 0.174 mmol, 1.0 eq) and Pd/C (5%, 20 mg) in EA (5 mL) was stirred for 2 h at room temperature under H2 (1 atm). The mixture was filtered and the filtrate was concentrated in vacuum to give product A_007_2 (65 mg, 100%) which was used directly in the next step without further purification. [00340] Preparation of Compound ST-200-A-007: To a solution of A_007_2 (65 mg, 0.17 mmol, 1.0 eq) in THF (2 mL) at -78 °C, CH3Li (1.6 M in THF, 1 mL, 1.7 mmol, 10.0 eq) was added dropwise under nitrogen. The reaction mixture was warmed to room temperature and stirred for 1 h. The mixture was quenched with saturated aqueous NH4C1 (10 mL) and then extracted with EA (5 mL x 2). The combined organic layers were washed with brine (5 mL), dried over Na2S04 and concentrated in vacuum to give the crude product, which was purified by a flash column chromatography (eluent: PE/EA = 8/1) to afford ST-200-A-007 (27 mg, 41%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 5.30 (d, J=5.2Hz, 1H), 2.42 (d, J=15.2 Hz, 1H), 2.02-1.96 (m, 2H), 1.86 -1.38 (m, 14H), 1.25-1.14 (m, 4H), 1.21 (s, 6H), 1.11 (s, 3H), 1.09-1.05 (m, 2H) 1.02 (s, 3H), 1.01-0.94 (m, 3H), 0.61 (s, 3H).
Example 4. Preparation of Compound ST-200-A-011
Figure imgf000130_0001
ST-200-A-011
[00341] Preparation of Compound INT D: To a solution of INT A (2.00 g, 6.58 mmol, 1.0 eq) in MeOH (30 mL) and THF (15 mL) was added CeCl3.7H20 (2.45 g, 6.58 mmol, 1.0 eq). The reaction mixture was stirred at room temperature for 10 min. Then NaBH4 (0.50 g, 13.16 mmol, 2.0 eq) was slowly added and the resulting mixture was stirred for 30 min at room temperature. TLC (PE/EA = 3/1) showed that the reaction was complete. The reaction mixture was quenched by addition of saturated aqueous NH4C1 (50 mL) and extracted with EA (50 mL x 2). The combined organic layers were dried over Na2S04 and evaporated to dryness to give the desired product (1.84 g, 91%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 5.30 (d, J=5.2 Hz, IH), 3.65 (t, J=8.6 Hz, IH), 2.43 (d, J= 13.2 Hz, IH), 2.09-1.97 (m, 3H), 1.97-1.68 (m, 3H), 1.64-1.38 (m, 5H), 1.31-1.20 (m, 2H), 1.19-1.16 (m, IH), 1.11 (s, 3H), 1.11-1.04 (m, IH), 1.03 (s, 3H), 1.01-0.93 (m, 2H), 0.88-0.84 (m, IH), 0.76 (s, 3H).
[00342] Preparation of Compound A_011_l: To a solution of INT D (500 mg, 1.63 mmol, 1.0 eq) in DCM (10 mL) was added methyl propiolate (325 mg, 3.30 mmol, 2.0 eq) and NMM (287 mg, 3.30 mmol, 2.0 eq) in turn. The reaction mixture was stirred at room temperature for two days. TLC (PE/EA = 3/1) showed that the reaction was complete. The reaction mixture was washed with saturated aqueous NaHC03 (20 mL) and brine (20 mL), dried over Na2S04 and evaporated to dryness to give the crude product. The residue was purified by silica gel chromatography eluted with PE: EA (15: 1) to give the desired product (274 mg, 43%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 7.54 (d, J= 12.8 Hz, IH), 5. 29 (d, J=5.2 Hz, IH), 5.24 (d, J= 12.8 Hz, IH), 3.88 (t, J=8.2 Hz, IH), 3.68 (s, 3H), 2.42 (d, J= 13.2 Hz, IH), 2.19-2.09 (m, IH), 2.00-1.89 (m, 2H), 1.88-1.84 (m, IH), 1.80-1.70 (m, 2H), 1.62-1.50 (m, 5H), 1.49-1.41 (m, 2H), 1.39-1.29 (m, IH), 1.19-1.10 (m, 2H), 1.11 (s, 3H), 1.02 (s, 3H), 1.00-0.91 (m, 2H), 0.79 (s, 3H).
[00343] Preparation of Compound A_011_2: To a solution of compound A_011_1 (50 mg, 0.128 mmol) in EA (5 mL) was added 5% Pd/C (50%, 25 mg) under argon. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 balloon at room temperature for 4 h. TLC (PE/EA = 3/1) showed that the starting material was consumed completely. Then the suspension was filtered through a pad of celite and the pad was washed with EA (5 mL x 3). The combined filtrates were concentrated to dryness to give the product (48 mg, 96%) as a white solid which was used directly in the next step without purification. 1H NMR: (400 MHz, CDC13) δ 5.30 (d, J=5.2 Hz, IH), 3.77-3.69 (m, 2H), 3.66 (s, 3H), 3.32 (t, J=8.4 Hz, IH), 2.56 (t, J=6.4 Hz, 2H), 2.42 (d, J= 12.4 Hz, IH), 2.00-1.89 (m, 4H), 1.81-1.67 (m, 2H), 1.57-1.44 (m, 6H), 1.43-1.32 (m, IH), 1.30-1.13 (m, 4H), 1.11 (s, 3H), 1.02 (s, 3H), 0.99-0.91 (m, 2H), 0.74 (s, 3H).
[00344] Preparation of Compound ST-200-A-011: To a solution of compound A_011_2 (60 mg, 0.16 mmol, 1.0 eq) in anhydrous THF (5 mL) was added dropwise MeLi (1 mL, 1.60 mmol, 10.0 eq, 1.6 M in Et20) at -78 °C under N2. The reaction mixture was stirred at -78 °C for 30 min and then warmed to room temperature for another 30 min. TLC (PE/EA = 3/1) showed that the starting material was consumed completely. The reaction mixture was quenched with saturated aqueous NH4C1 (5 mL). The resulting solution was extracted with EA (5 mL x 3). The combined organic layers were washed with brine (10 mL), and dried over Na2S04 and concentrated in vacuum. The residue was purified by silica gel
chromatography eluted with PE: EA (10: 1) to give the target product (25 mg, 42%) as white solid. 1H NMR: (400 MHz, CDC13) δ 5.29 (d, J=4.8Hz, IH), 3.80-3.62 (m, 2H), 3.27 (t, J=8.4 Hz, IH), 2.39 (d, J= 13.2 Hz, IH), 2.05-1.86 (m, 4H), 1.76-1.64 (m, 3H), 1.59-1.37 (m, 8H), 1.27-1.20 (m, IH), 1.19 (s, 6H), 1.12-1.08 (m, 2H), 1.07 (s, 3H), 0.99 (s, 3H), 0.98-0.89 (m, 2H), 0.72 (s, 3H).
Example 5. Preparation of Compound ST-200-A-013
Figure imgf000132_0001
INT E ST-200-A-013
[00345] To a solution of INT E (150 mg, 0.471 mmol, 1.0 eq) in DMSO (1 mL) was added KOH (53 mg, 0.942 mmol, 2.0 eq) and 2,2-dimethyloxirane (340 mg, 4.717 mmol, 10.0 eq). The reaction mixture was stirred at 50 °C for 16 h. TLC (PE/EA =3/1) showed the starting material was consumed completely. The mixture was cooled to room temperature, diluted with ethyl acetate (20 mL), and washed with saturated aqueous NH4C1 (10 mL x 2) and water (10 mL x 2). The organic phase was dried over sodium sulfate and concentrated in vacuum to afford the crude product which was purified by column chromatography followed by prep-HPLC purification to afford pure product ST-200-A-013 (14 mg, 8%). 1H NMR (400MHz, CDC13) δ 5.30 (d, J=5.2Hz, IH), 3.57-3.48 (m, IH), 3.38-3.35 (m, IH), 3.20 (s, 2H), 2.42-2.40 (m, IH), 2.03-1.85 (m, 3H), 1.76 (m, 4H), 1.55-1.43 (m, 4H), 1.25 (s, 3H), 1.28-1.25 (m, 6H), 1.17-1.13 (m, 2H), 1.11 (s, 3H), 1.06-0.96 (m, 5H), 0.92-0.79 (m, 2H), 0.65 (s, 3H).
Example 6. Preparation of Compound ST-200-A-017
Figure imgf000133_0001
INT D ST-200-A-017
[00346] To a solution of compound INT D (150 mg, 0.49 mmol, 1.0 eq) and 2, 2- dimethyloxirane (1.5 g, 20.8 mol, 42.0 eq) in DMSO (3 mL) was added KOH (56 mg, 1.0 mmol, 2.0 eq), then the reaction mixture was stirred at 60 °C for 5 h. TLC (PE:EA = 3: 1) indicated that the reaction was complete. The solution was cooled to room temperature, diluted with water (10 mL), extracted with EA (5 mL x 2). The combined organic layers were concentrated under reduced pressure to provide the crude product which was purified by pre- HPLC to give the product (6.6 mg, 3.5%) as a white powder. 1H NMR: (400 MHz, CDC13) δ 5.30 (d, J=5.2Hz, 1H), 3.33 (t, J=8.0Hz, 1H), 3.29-3.22 (m, 2H), 2.40-2.50 (m, 2H), 2.05- 1.85 (m, 4H), 1.82-1.65 (m, 2H), 1.60-1.35 (m, 9H), 1.34- 1.22 (m, 1H), 1.20-1.15 (m, 6H), 1.14-1.11 (m, 1H), 1.12 (s, 3H), 1.05 (s, 3H), 0.90-1.00 (m, 2H), 0.79 (s, 3H).
Example 7. Preparation of Compound ST-200-A-021
Figure imgf000133_0002
A_001_3 ST-200-A-021
[00347] To a solution of compound A_001_3 (150 mg, 0.39 mmol, 1.0 eq) in THF/H20
(4 mL, 1/1), LiOH (90 mg, 2.20 mmol, 5.6 eq) was added. The reaction was stirred at room temperature overnight. TLC (PE/EA = 3/1) showed that compound A_001_3 was consumed completely. The mixture was diluted with water (3 mL), washed with MTBE (5 mL x 2) and then acidified to pH = 4 with 1 M aqueous HC1. The precipitate was collected by filtration and dried in vacuum to give the product (54 mg, 37.3%). 1H NMR: (400 MHz, CDC13) δ 5.30 (d, J=5.2 Hz, 2H), 2.43-2.37 (m, 1H), 2.37-2.33 (m, 2H), 2.05-1.93 (m, 2H), 1.90-1.79 (m, 2H), 1.78-1.61 (m, 6H), 1.61-1.50 (m, 6H), 1.50-1.37 (m, 3H), 1.34-1.13 (m, 4 H), 1.12 (s, 3H), 1.02 (s, 3H), 0.93-1.01 (m, 3H), 0.61 (s, 3H). Example 8. Preparation of Compounds ST-200-A-022 and ST-200-A-023
Figure imgf000134_0001
[00348] Preparation of Compound 7: To a solution of ketone 6 (16.7 g, 52.71 mmol, 1.0 eq) and ethylene glycol (20 mL) in toluene (450 mL) was added p-toluenesulfonic acid (418 mg, 2.20 mmol). The reaction mixture was heated at reflux overnight with a Dean-Stark trap. LCMS showed the starting material was consumed completely. The mixture was cooled to room temperature, diluted with ethyl acetate (400 mL), and washed with saturated aqueous sodium bicarbonate (200 mL x 2) and brine (200 mL x 2). The organic phase was dried over sodium sulfate and concentrated in vacuum to afford crude product 7 (19.0 g, 100%) which was directly used in the next step without further purification. 1H NMR: (400 MHz, CDC13) δ 5.34 (d, J=5.2 Hz, 2H), 4.00-3.85 (m, 4H), 3.53-3.51 (m, 1H), 2.28-2.22(m, 2H), 2.12-2.00 (m, 1H), 1.99-1.95 (m, 1H), 1.86-1.73 (m, 5H), 1.71-1.44 (m, 8H), 1.29 (s, 3H), 1.08 (s, 3H), 1.07 (s, 3H), 1.06-0.92 (m, 1H), 0.77 (s, 3H).
[00349] Preparation of Compound 8: To a solution of compound 7 (19.0 g, 52.71 mmol, 1.0 eq) in dry CH2C12 (700 mL) was added Dess-Martin (45.0 g, 105.42 mmol, 2.0 eq) in portions at 0 °C. Then the reaction mixture was stirred at room temperature for 3 h. TLC (PE/EA = 3/1) showed the starting material was consumed completely. The mixture was quenched with saturated aqueous NaHC03/Na2S203 (1 L, 1/3). The organic phase was washed with brine (500 mL) and dried over Na2S04j and the solvent was evaporated under reduced pressure to afford crude product 8 (19.0 g, 100%), which was directly used in the next step without further purification. 1H NMR: (400 MHz, CDC13) δ 5.33 (d, J=5.2 Hz, 2H), 4.01-3.85 (m, 4H), 3.34-3.21 (m, 1H), 2.82 (dd, J=16.31, 2.01 Hz, 1H), 2.59-2.40 (m, 1H), 2.37-2.25 (m, 1H), 2.13-1.95 (m, 5H), 1.87-1.41 (m, 13H), 1.30 (s, 3H), 1.21-1.15 (m, 5H), 0.81 (s, 3H).
[00350] Preparation of Compound 9: To a solution of MAD (158 mL, 158 mmol, 3.0 eq, 1 M in toluene, prepared via the method as described in the synthesis of ST-200-A- 001) was added a solution of compound 8 (19.0 g, 52.71 mmol, 1.0 eq) in toluene at -78 °C under nitrogen. Then the reaction mixture was stirred at this temperature for 30 min. A solution of MeMgBr (53 mL, 159 mmol, 3.0 eq, 3 M in Et20) was added dropwise at -78 °C. The reaction mixture was warmed to -40 °C and stirred at this temperature for 3 h. TLC (PE:EA = 3: 1) showed that the starting material was consumed completely. The mixture was poured into saturated aqueous NH4C1 solution (300 mL) and extracted with EA (150 mL x 2). The combined organic phases were dried over Na2S04> and the solvent was evaporated under reduced pressure to afford crude product. The crude product was purified by silica gel chromatography eluted with PE:EA (15: 1) to give the product (7.70 g, 39%) as a white powder. 1H NMR: (400 MHz, CDC13) δ 5.31 (d, J=5.2 Hz, 2H), 4.01-3.85 (m, 4H), 2.42 (d, J=12 Hz, 1H), 2.04-1.96 (m, 1H), 1.96-1.95 (m, 2H), 1.85-1.66 (m, 5H), 1.66-1.61 (m, 2H), 1.61 -1.36 (m, 7H), 1.33 (s, 3H), 1.26-1.13 (m, 3H), 1.11 (s, 3H), 1.05 (s, 3 H), 0.91-1.00 (m, 2 H), 0.80 (s, 3 H).
[00351] Preparation of Compound INT C: To a solution of compound 9 (2.7 g, 7.21 mmol, 1.0 eq) in THF (20 mL) was added aqueous HC1 solution (10 mL, 1 M) and acetone (10 mL). The reaction mixture was stirred at room temperature overnight. TLC (PE:EA = 3: 1) indicated that the reaction was complete. Then the reaction mixture was diluted with EA (50 mL), washed with saturated aqueous NaHC03 solution (50 mL x 2), dried over Na2S04 and evaporated under reduced pressure to give the product (2.10 g, 88.2%) as a white powder. 1H NMR: (400 MHz, CDC13) δ 5.31 (d, J=5.2 Hz, 2H), 2.55-2.50 (m, IH), 2.40 (d, J=12Hz, IH), 2.20 -2.19 (m, IH), 2.15-2.10 (m, 3H), 2.08-1.94 (m, 3H), 1.83-1.76 (m, IH), 1.74 -1.65 (m, 3H), 1.62 (s, 3H), 1.61-1.39 (m, 7H), 1.30-1.13 (m, 4H), 1.12 (s, 3H), 1.01 (s, 3H), 0.61- 0.65 (m, 3H).
[00352] Preparation of Compound A_022_l: To a solution of INT C (700 mg, 2.1 mmol, 1.0 eq) in MeOH (10 mL) and THF(5 mL) was added NaBH4 (160 mg, 4.2 mmol, 2.0 feq) was added in five portions. The reaction mixture was stirred at room temperature for 1 h. TLC (PE/EA = 3/1) showed the starting material was consumed completely. The mixture was quenched with saturated aqueous NH4C1 (50 mL) and extracted with EA (20 mL x 2). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over sodium sulfate and concentrated in vacuum to afford the desired product A_022_l (600 mg, 86%).
[00353] Preparation of Compounds ST-200-A-022 and ST-200-A-023: To solution of A_022_l (570 mmol, 1.717 mmol, 1.0 eq) in DCM (15 mL) was added TEA (867 mg, 8.585 mmol, 5.0 eq) and DMAP (63 mg, 0.515 mmol, 0.3 eq). Then BzCl (961 mg, 6.867 mmol, 4.0 eq) was added dropwise. The resulting mixture was stirred at room temperature for 16 h and then neutralized by addition of 1 M aqueous HC1. The aqueous layer was separated and extracted with DCM (10 mL x 3). The combined organic layers were washed with saturated aqueous NaHC03 (10 mL) and brine (10 mL), dried over sodium sulfate and concentrated in vacuum. The residue was purified by silica gel chromatography eluted with PE: EA (15: 1) to give product (360 mg, 46.6%) as a write solid which was applied to the SFC separation to afford the target ST-200-A-022 (100 mg) and ST-200-A-023(70 mg). 1H
NMR(ST-200-A-022): (400 MHz, CDC13) δ 8.06 (d, J=7.2 Hz, 2H), 7.61-7.50 (m, IH), 7.49- 7.40 (m, 2H), 5.30 (d, J=5.2 Hz, 2H), 5.19-5.08 (m, IH), 2.40 (d, J=12Hz, IH), 2.03-1.86 (m, 3H), 1.85-1.64 (m, 5H), 1.58-1.30 (m, 7H), 1.27 (d, J=6.0 Hz, 3H), 1.23-1.06 (m, 6H), 1.01- 0.83 (m, 5H), 0.68 (s, 3H). 1H NMR(ST-200-A-023): (400 MHz, CDC13) δ 8.01 (d, J=8.4Hz, 2H), 7.58-7.50 (m, IH), 7.47-7.39 (m, 2H), 5.31 (d, J=6.0 Hz, 2H), 5.24-5.14 (m, IH), 2.43 (d, J=13.2Hz, IH), 2.05-1.87 (m, 4H), 1.82-1.61 (m, 5H), 1.55-1.38 (m, 4H), 1.36 (d, J=6.0 Hz, 3H), 1.29-1.14 (m, 4H), 1.12 (s, 3H), 1.04-0.95 (m, 4H), 0.74 (s, 3H) Example 9. Preparation of Compound ST-200-C-001
Figure imgf000137_0001
ST-200-A-001 ST-200-C-001
[00354] To a solution of compound ST-200-A-001 (65 mg, 0.167 mmol, 1.0 eq) in ethanol (10 mL) was added Pd/C (10%, 15 mg) under N2. The suspension was degassed under vacuum and purged with H2 several times. Then the mixture was stirred under 50 psi of hydrogen pressure at 60 °C for 24 h. TLC (PE:EA = 3: 1) showed that the reaction was complete. The suspension was filtered through a pad of celite and the pad was washed with ethanol (5 mL x 2). The combined filtrates were concentrated to dryness to give the crude product, which was purified by silica gel chromatography eluted with PE:EA (10: 1) to give the product (28 mg, 43%) as a white powder. 1H NMR: (400 MHz, CDC13) δ 1.90-1.87 (m, 1H), 1.75-1.60 (m, 4H), 1.82-1.65 (m, 2H), 1.55-1.30 (m, 12H), 1.27-1.23 (m, 6H), 1.22 (s, 6H), 1.18-0.95 (m, 8H), 0.82 (s, 3H), 0.72 -0.65 (m, 1H), 0.55 (s, 3H).
Example 10. Preparation of Compounds ST-200-C-003 and ST-200-C-003A
Figure imgf000137_0002
ST-200-C-003 ST-200-C-003A
[00355] To a solution of compound ST-200-A-003 (40.0 mg, 0.10 mmol, 1.0 eq) in
EtOH (30 mL) was added Pd/C (10 mg). The mixture was stirred at 60 °C overnight under 50 psi of hydrogen pressure. 1H NMR indicated that the reaction was complete. Then the mixture was filtered through a pad of celite and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: PE:EA = 2: 1) to afford the pure product ST-200-C-003 (12.0 mg, 29.8%) and ST-200-C-003A (0.8 mg, 2.3 %) as a white powder. 1H NMR (ST-200-C-003): (400 MHz, CDC13) δ 1.97-1.83 (m, 2H), 1.65-1.55 (m, 7H), 1.55-1.42 (m, 4H), 1.41-1.2841 (m, 6H), 1.27-1.21 (m, 5H), 1.20 (s, 6H), 1.16-0.95 (m, 7H), 0.92 (d, J=6.27 Hz, 3 H), 0.81 (s, 3 H), 0.65 (s, 3 H). 1H NMR (ST- 200-C-003A): (400 MHz, CDC13) δ 1.98-1.79 (m, 4H), 1.64-1.53 (m, 6H), 1.52 -1.29 (m, 7H), 1.25-1.22 (m, 6H), 1.22 (s, 3H), 1.20 (s, 3H), 1.05 (s, 3H), 0.96 (s, 3H), 0.91 (d, J=6.53 Hz, 3H), 0.86-0.80 (m, 2H), 0.65 (s, 3H).
Example 11. Preparation of Compound ST-200-C-007
Figure imgf000138_0001
C 007 2 ST-200-C-007 [00356] Preparation of Compound 10: A mixture of compound 1 (28.0 g, 0.097mol, 1.0 eq) and Pd/C (3.5 g) in ethanol (400 mL) was hydrogenated at room temperature overnight under 40 psi of hydrogen pressure. The suspension was filtered through a pad of celite and the pad was washed with ethanol (20 mL x 3). The combined filtrates were concentrated to dryness to give the product (28.0 g, 0.097 mol, 100%) as the white solid. 1H NMR (400 MHz, CDC13) δ 3.63-3.53 (m, 1H), 2.42 (dd, J=19.2, 8.4 Hz, 1H), 2.11-2.06 (m, 1H), 19.6-1.87 (m, 1H) , 1.83-1.09 (m, 18H) , 1.04-0.91 (m, 2H) , 0.85 (s, 3H) , 0.82 (s, 3H).
[00357] Preparation of Compound 11: To a solution of compound 10 (28.0 g, 0.097 mol, 1.0 eq) and ethylene glycol (30 mL) in toluene (300 mL) was added p-toluenesulfonic acid (0.7 g, 3.64 mmol). The reaction mixture was heated at reflux overnight with a Dean- Stark trap. LCMS showed the starting material was consumed completely. The mixture was cooled to room temperature, diluted with ethyl acetate (250 mL), and washed with saturated aqueous sodium bicarbonate (100 mL x 2) and brine (100 mL x 2). The organic phase was dried over sodium sulfate and concentrated in vacuum to afford crude product 11 (30.0 g, 0.090 mol, 93%) which was directly used in the next step without further purification. 1H NMR: (400 MHz, CDC13) 54.02-3.78 (m, 4H), 3.68-3.48 (m, 1H), 2.04-1.92 (m, 1H), 1.80- 1.54 (m, 8H), 1.46 -1.32 (m, 5H), 1.31-1.19(m, 5H), 1.14-1.05 (m, 1H), 1.02-0.86 (m, 2H), 0.83 (s, 3 H), 0.80 (s, 3 H), 0.72-0.61 (m, 1 H).
[00358] Preparation of Compound 12: To a solution of compound 11 (30.0 g, 0.090 mol, 1.0 eq) in dry DCM (300 mL) was added Dess-Martin oxidant (76.0 g, 0.180 mol, 2.0 eq) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min and then at room temperature for 2 h. LCMS showed the starting material was consumed completely. The mixture was quenched with a mixed aqueous solution of saturated NaHC03/Na2S03 (200 mL, 1/3) and then diluted with DCM (250 mL). The organic layer was washed with saturated aqueous sodium bicarbonate (100 mL x 2) and brine (100 mL x 2), dried over sodium sulfate and concentrated in vacuum to afford crude product 12 (24.0 g, 0.072 mol, 80%) which was directly used in the next step without further purification.
[00359] Preparation of Compound 13: To a solution of MAD (2.16 mol, 3.0 eq, prepared via the method as described in synthesis of ST-200-A-001) in dry toluene (300 mL) was added dropwise compound 12 (24.0 g, 0.072 mol, 1.0 eq) at -78 °C and the mixture was stirred at -78 °C for 30 min under nitrogen. Then MeMgBr (72 mL, 2.16 mol, 3.0 eq, 3 M in ether) was added dropwise at -78 °C and the resulting mixture was stirred at the same temperature for 2 h. LCMS showed the starting material was consumed completely. The reaction mixture was poured into saturated aqueous NH4CI4 solution (400 mL) and exacted with EA (300 mL x 2). The combined organic layers were washed with brine (200 mL x 2), dried over sodium sulfate and concentrated in vacuum. The residue was purified by silica gel chromatography eluted with PE: EA (15: 1) to give product 13 (16.0 g, 0.046 mol, 72%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 3.95-3.88 (m, 2 H), 3.87-3.82 (m, 2 H), 2.02- 1.92 (m, 1 H) , 1.84-1.73 (m, 1 H), 1.71-1.50 (m, 9 H), 1.50-1.43 (m, 1 H) ,1.42-1.33 (m, 4 H), 1.33-1.28 (m 1 H), 1.27-1.19 (m, 7 H) ,1.08-0.88 (m, 2 H) , 0.83 (s, 3 H) ,0.81 (s, 3 H).
[00360] Preparation of Compound INT G: A mixture of compound 13 (16.0 g, 46.0 mmol, 1.0 eq) in 1 M aqueous HC1 (60 mL), acetone (60 mL) and THF (350 mmL) was stirred at room temperature overnight, and then diluted with water (200 mL) and neutralized with solid NaHC03 until no CO2 was evolved. The mixture was extracted with EA (300 mL x 2). The combined organic layers were washed with brine (200 mL x 2), dried over sodium sulfate and concentrated in vacuum to afford product INT G (14.0 g, 46.0 mmol, 100%) as a white solid.
1H NMR: (400 MHz, CDC13) δ 2.44 (dd, J=19.20, 8.41 Hz, 1 H), 2.13-2.01 (m, 1 H) ,1.98- 1.89 (m, 1 H) , 1.85-1.76 (m, 2 H), 1.69-1.60 (m, 3 H), 1.59-1.42 (m, 5 H) ,1.33-1.13 (m, 10 H), 1.08-0.94 (m, 2 H), 0.86 (s, 3 H), 0.84 (s, 3 H), 0.68-0.77 (m, 1 H).
[00361] Preparation of Compound 14: To a solution of PPh3CH3Br (1.4 g, 3.94 mmol, 5.0 eq) in THF (10 mL) was added a solution of t-BuOK (442 mg, 3.94 mmol, 5.0 eq) in THF (5 mL) at room temperature. After stirring for 1 h, a solution of INT G (0.2 g, 0.657 mmol, 1.0 eq) in THF (5 mL) was added dropwise. The reaction mixture was refluxed for 3 h, then cooled room temperature and quenched with saturated aqueous NH4C1 (50 mL), extracted with EA (20 mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate and concentrated in vacuum to give the crude product, which was purified by a flash column chromatography (eluent: PE/EA = 15/1) to afford compound 14 (180 mg, 90%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 4.62 (d, J=6.4Hz, 2H), 2.51-2.44 (m, 1H), 2.24-2.22 (m, 1H), 1.82-1.78 (m, 1H), 1.75-1.30 (m, 9H), 1.29-1.11 (m, 11H), 1.03-0.95 (m, 3H), 0.83 (s, 3H), 0.77 (s, 3H), 0.72-0.68 (m, 1H).
[00362] Preparation of Compound INT I: To a solution of 9-BBN (0.5 M in THF, 50 mL, 25.00 mmol, 8.0 eq) under ice-bath, a solution of compound 14 (0.95 g, 3.14 mmol, 1.0 eq) in THF (10 mL) was added dropwise. The reaction mixture was heated to 60 °C and stirred for 20 h. The mixture was cooled to 0 °C and 10% aqueous NaOH solution (20 mL) followed by 30% aqueous H202 (10 mL) was added. The resulting mixture was stirred for 2 h at 0 °C and then extracted with EA (10 mL x 2). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuum to give the crude product, which was purified by a flash column chromatography (eluent: PE/EA = 10/1) to afford INT I (0.63 g, 63%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 3.74-3.69 (dd, J1=10.4Hz, J2=6.8Hz, 1H), 3.56-3.52 (dd, J1=10.4Hz, J2=7.6Hz, 1H), 1.86-1.80 (m, 2H), 1.69-1.44 (m, 11H), 1.41-1.26 (m, 4H), 1.25-1.21 (m, 5H), 1.19-0.99 (m, 5H), 0.93-0.91 (m, 5H), 0.81 (s, 3H), 0.74-0.68 (m, 1H), 0.64 (s, 3H).
[00363] Preparation of Compound INT J: To a solution of INT I (500 mg, 1.56 mmol, 1.0 eq) in DCM (20 mL) under ice -bath, Dess-Martin reagent (1.3 g, 3.12 mmol, 2.0 eq) was added. The reaction mixture was warmed to room temperature and stirred for 2 h. The mixture was poured into a solution of NaS203 (5 g) and NaHC03 (1.5 g) in water (20 mL), extracted with EA (20 mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate and concentrated in vacuum to give the crude product (500 mg, 100%), which was used directly in the next step without further purification.
[00364] Preparation of Compound C_007_l : A mixture of INT J (500 mg, 1.57 mmol, 1.0 eq) and Ph3P=CHCOOCH3 (3.1 g, 8.27 mmol, 6.0 eq) in toluene (30 mL) was stirred for 3 h at 80 °C. The mixture was concentrated in vacuum and the residue was purified by a flash column chromatography (eluent: PE/EA=12/1) to afford product C_007_l (188 mg, 32%) as a white solid.
[00365] Preparation of Compound C_007_2: A mixture of compound C_007_l (188 mg, 0.5 mmol, 1.0 eq) and Pd/C (5%, 60 mg) in EA (10 mL) was stirred for 2 h at room temperature under H2 (1 atm). The mixture was filtered and the filtrate was concentrated in vacuum to give product C_007_2 (189 mg, 100%), which was used directly in the next step without further purification.
[00366] Preparation of Compound ST-200-C-007: To a solution of compound C_007_2 (100 mg, 0.26 mmol, 1.0 eq) in THF (2 mL) at -78 °C, CH3Li (1.6 M in THF, 1.6 mL, 2.6 mmol, 10.0 eq) was added dropwise under nitrogen. The reaction mixture was warmed to room temperature and stirred for 1 h. Saturated aqueous NH4C1 (10 mL) was added to quench the reaction and the mixture was extracted with EA (10 mL x 2). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuum to give the crude product, which was purified by a flash column chromatography (eluent: PE/EA = 8/1) to afford the target ST-200-C-007 (32.7 mg, 32.7%) as a white solid. 1H NMR: (400 MHz, CDC13) δ 1.82-1.81 (m, 1H), 1.75-1.57 (m, 7H), 1.56- 1.26 (m, 10H), 1.24 (s, 3H), 1.20 (s, 6H), 1.18-0.83 (m, 10H), 0.81 (s, 3H), 0.71-0.66 (m, 1H), 0.58 (s, 3H).
Example 12. Preparation of Compound ST-200-C-011
Figure imgf000142_0001
ST-200-C-011
[00367] Preparation of Compound INT H: To a solution of INT G (1.00 g, 3.28 mmol, 1.0 eq) in MeOH (20 mL) and THF (8 mL) was added CeCl3.7H20 (1.22 g, 3.28 mmol, 1.0 eq). Then NaBH4 (0.25 g, 6.56 mmol, 2.0 eq) was added in five portions and the mixture was stirred at room temperature for 1 h. The reaction slurry was quenched with saturated aqueous NH4C1 (50 mL) and extracted with EA (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate and concentrated in vacuum to give the desired product (0.97 g, 97%) as a white solid. 1H NMR: (400MHz, CDC13) δ 3.62 (t, J=8.4 Hz, 1H), 2.10-2.04 (m, 1H), 1.79-1.77 (m, 1H), 1.70-1.35 (m, 13H), 1.31-1.15 (m, 11H), 1.14-0.84 (m, 5H), 0.81 (s, 3H), 0.72 (s, 3H), 0.70-0.61 (m, 1H)
[00368] Preparation of Compound C_011_l: To a solution of INT H (500 mg, 1.63 mmol, 1.0 eq) in DCM (20 mL), NMM (830 mg, 8.21 mmol, 5.0 eq) and methyl propiolate (690 mg, 8.21 mmol, 5.0 eq) were added. The mixture was stirred at room temperature for 16 h, then washed with water (30 mL) and brine (30 mL), dried over sodium sulfate and concentrated in vacuum. The residue was purified by silica gel chromatography eluted with PE: EA (15: 1) to give the product (500 mg, 78.6%) as a white solid. 1H NMR: (400MHz, CDC13) δ= 7.53 (d, J=12.4 Hz, 1H), 5.24 (d, J=12.4 Hz, 1H), 3.86 (t, J=8.4 Hz, 1H), 3.68 (s, 3H), 2.18-2.06 (m, 1H), 1.84-1.81 (m, 1H), 1.70-0.85 (m, 30H), 0.81 (s, 3H), 0.78 (s, 3H), 0.72-0.64 (m, 1H).
[00369] Preparation of Compound C_011_2: To a solution of C_011_1 (500 mg, 1.289 mmol, 1.0 eq) in EA (20 mL) was added Pd/C (10%, 50 mg). The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred at 30 °C for 16 h under 30 psi of hydrogen pressure. TLC (PE/EA = 3/1) showed the reaction was complete. The suspension was filtered through a pad of celite and the pad was washed with EA (20 mL x 5). The combined filtrates were concentrated in vacuum to give the product (430 mg, 85.5%) as a white solid.
[00370] Preparation of Compound ST-200-C-011 : To a solution of C_011_2 ( 100 mg, 0.256 mmol, 1.0 eq) in dry THF (1 mL), MeLi (1.3 mL, 2.048 mmol, 8.0 eq) was added dropwise at -78 °C under N2. The resulting mixture was stirred at this temperature for 0.5 h, and then the temperature was allowed to warm to room temperature and stirred at this temperature for another 1 h. TLC (PE/EA = 3/1) showed the reaction was complete. The mixture was quenched with saturated aqueous NH4C1 and extracted with EA (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuum. The residue was purified by silica gel chromatography eluted with PE:EA (10: 1) to give the product (30 mg, 30%) as a white solid. 1H NMR (400MHz, CDC13) 53.86 (s, 1H), 3.78-3.61 (m, 2H), 3.29 (t, J=8.3 Hz, 1H), 2.10-1.95 (m, 1H), 1.90-1.81 (m, 1H), 1.74 (t, J=5.6 Hz, 2H), 1.69-1.61 (m, 3H), 1.55-1.28 (m, 9H), 1.24-1.22 (m, 9H), 1.22- 0.83 (m, 8H), 0.81 (s, 3H), 0.74 (s, 3H), 0.69-0.62 (m, 1H).
Example 13. Preparation of Compound ST-200-C-013
Figure imgf000143_0001
INT I ST-200-C-013
[00371] To a solution of INT I (150 mg, 0.469 mmol, 1.0 eq) in DMSO (1 mL) was added KOH (53 mg, 0.937 mmol, 2.0 eq) and 2,2-dimethyloxirane(337 mg, 4.687 mmol, 10.0 eq). The reaction mixture was stirred at 50 °C for 16 h. TLC (PE/EA = 10/1) showed the starting material was consumed completely. The mixture was cooled to room temperature, diluted with ethyl acetate (20 mL) and washed with saturated aqueous NH4C1 (10 mL x 2) and water (10 mL x 2). The organic phase was dried over sodium sulfate and concentrated in vacuum to afford crude product which was purified by column chromatography followed by prep-HPLC to afford pure product.ST-200-C-013(26 mg, 15.8%). 1H NMR: (400 MHz, CDC13) δ 3.72 (dd, J=7.3, 9.3 Hz, 1H), 3.35 (dd, J=6.8, 9.3 Hz, 1H), 3.21 (s, 2H), 2.34 (s, 1H), 1.84-1.80 (m, 1H), 1.79-1.63 (m, 5H), 1.54-1.27 (m, 8H), 1.25 (s, 3H), 1.19 (s, 6H), 1.18-0.83 (m, 7H), 0.81 (s, 3H), 0.74-0.65 (m, 1H), 0.63 (s, 3H)
Figure imgf000144_0001
ST-200-C-017 ST-200-C-017A
[00372] A solution of ST-200-A-017 (60 mg, 0.159 mmol, 1.0 eq) and Pd/C (10 mg) in
EtOH (10 mL) was stirred at 50 °C under 50 psi of hydrogen pressure for 16 h. The reaction solution was filtered through a pad of celite and the filtrate was concentrated in vacuum. The residue was purified by silica gel chromatography eluted by PE:EA (20: 1) to give ST-200-C- 017(21 mg) and ST-200-C-017A (4.6 mg) as a white solid. 1H NMR (ST-200-C-017): (400 MHz, CDC13) δ 3.73-3.71 (m, 1H), 3.31 (t, J=8.4Hz, 1H), 3.27-3.22 (m, 2H), 2.48 (s, 1H), 2.01-1.91 (m, 1H), 1.88-1.84 (m, 1H), 1.68-1.52 (m, 4H), 1.51-1.49 (m, 4H), 1.47-1.42 (m, 1H), 1.31 - 1.24 (m, 7H), 1.20-1.83 (m, 6H), 1.15-1.10 (m, 1H), 1.03-0.95 (m, 2H), 0.90-0.85 (m, 1H), 0.81 (s, 3H), 0.65 (s,3H), 0.70-0.61 (m, 1H). 1H NMR (ST-200-C-017a): (400 MHz, CDC13) δ 3.33 (t, J=8.4Hz, 1H), 3.27-3.22 (m, 2H), 2.45 (s, 1H), 2.10-1.91 (m, 1H), 1.89- 1.78 (m, 3H), 1.69-1.61 (m, 1H), 1.58-1.51 (m, 1H), 1.50-1.30 (m, 7H), 1.29-1.24 (m, 5H), 1.20 (s, 3H), 1.29-1.10 (m, 8H), 1.09-1.01 (m, 1H), 0.98 (s, 3H), 0.75 (s, 3H). Exam le 15. Preparation of Compounds 3-alpha-A2 and 3-beta-A2
Figure imgf000145_0001
[00373] Preparation of compound BB-2: Under nitrogen a solution of BB-1 (1.75 g, 4.06 mmol) in THF (35 mL), prepared as described in Steroids (2006) 71: 18, was cooled to 0°C. Methylmagnesium chloride (22% (w/w) in THF, 19.5 mL, 58.1 mmol) was added dropwise. Stirring at 0°C was continued for 15 minutes and reaction mixture was allowed to warm to room temperature and stirring was continued for two hours. Saturated aqueous NH4CI (5 mL) was added slowly. Precipitate formed and was dissolved by addition of water (10 mL). EtOAc (50 mL) and brine (20 mL) were added. Layers were separated. Aqueous layer was extracted with EtOAc (2 x 50 mL). Combined organic layers were dried with Na2S04 and solvents were removed in vacuo. Residue was coevaporated with
dichloromethane (50 mL). BB-2 (1.54 g, 3.95 mmol, 97%) was obtained as an off-white solid. 1HNMR (400 MHz, CDC13): 5(ppm): 5.32 - 5.43 (1H, m), 3.46 - 3.61 (1H, m), 1.20 (3H, s), 1.19 (3H, s), 1.01 (3H, s), 0.93 (3H, d, J = 6.6 Hz), 0.68 (3H, s).
[00374] Preparation of compound BB-3: Under nitrogen in an oven dried flask a solution of oxalyl chloride (0.622 mL, 7.26 mmol) in dichloromethane (19 mL) was cooled to -78°C. Dimethyl sulfoxide (0.60 mL, 8.47 mmol) was added slowly. After 25 minutes a solution of BB-2 (0.470 g, 1.209 mmol) in CHC13 (38 mL) was added dropwise over 25 minutes The solution was stirred at -78°C for 2.5 hours. Triethyl amine (3.36 ml, 24.19 mmol) was added dropwise at -78°C. Stirring was continued 15 minutes. Cooling bath was removed and stirring was continued for lOmin. Aqueous saturated NH4C1 (10 mL) was added and reaction mixture was stirred for 5 minutes. Dichloromethane (50 mL) and water (20 mL) were added. Layers were separated and organic layer was washed with water (20 mL).
Combined aqueous layers were diluted with brine (20 mL) and were extracted with EtOAc (2 x 75 mL). Combined organic layers were dried with Na2S04 and solvents were removed in vacuo. Flash chromatography (heptane, 5% - 30% EtOAc) afforded BB-3 (238 mg,
0616 mmol, 51%) as a white solid. 1HNMR (400 MHz, CDC13): 5(ppm): 5.31 - 5.38 (1H, m), 3.22 - 3.34 (1H, m), 2.83 (1H, dd, J = 16.4 Hz, 2.1 Hz), 2.41 - 2.54 (1H, m), 2.25 - 2.34 (1H, m), 1.95 - 2.08 (3H, m), 1.82 -1.93 (1H, m), 1.21 (3H, s), 1.20 (3H, s), 1.19 (3H, s), 0.94 (3H, d, J = 6.5 Hz), 0.71 (3H, s).
[00375] Preparation of compounds 3-a-OH A2 and 3- 2-OH A2: In a glove box in a flame dried flask, THF (degassed, 3 mL) was added to anhydrous cerium(III) chloride (0.319 g, 1.29 mmol). The suspension was stirred at RT overnight. The white, fine suspension was taken out of the glove box. THF (dry, 1 mL) was added and thew mixture was stirred under argon for 15 minutes at RT. Under argon the white, fine suspension was cooled to - 78°C. At this temperature methyllithium, 1.6M in Et20 (0.79 mL, 1.27 mmol) was added dropwise. A yellow suspension formed and was stirred at -78°C for 1.5h. A solution of BB-3 (0.100 g, 0.259 mmol) in THF (dry, 2mL) was added dropwise over 5min. The colour of the reaction mixture changed from yellow to brown. Reaction mixture was stirred at -78°C for 45min. Cooling bath was removed and reaction mixture was stirred for lOmin. 5% aq. AcOH (2mL) was added. Reaction mixture turned into a colourless, clear solution. EtOAc (lOmL) was added. Mixture was allowed to warm to RT. Layers were separated and aq. layer was extracted with EtOAc (2xl0mL). Combined org. layers were dried with sodium sulfate and solvents were removed in vacuo. Flash chromatography (H, 5%-20% EtOAc) afforded compound A2 (3or-OH) (33 mg, 0.082 mmol; 63.5%) and compound A2 (3/2-OH) (13 mg, 0.032 mmol; 25.0%). (3«-OH): 1H-NMR (400 MHz, CDC13): 5(ppm): 5.43 - 5.38 (m, 1H), 2.46 - 2.37 (m, 1H), 2.05 - 1.80 (m, 4H), 1.73 - 1.23 (m, 15H), 1.22 (s, 3H), 1.20 (s, 3H), 1.19 (s, 3H), 1.18 - 0.99 (m, 9H), 0.98 (s, 1H), 0.94 (d, / = 6.5 Hz, 3H), 0.68 (s, 3H). (3j3- OH): 1H-NMR (400 MHz, CDC13): 5(ppm): 5.34 - 5.28 (m, 1H), 2.47 - 2.38 (m, 1H), 2.07 - 1.92 (m, 3H), 1.91 - 1.66 (m, 3H), 1.63 - 1.24 (m, 13H), 1.20 (s, 3H), 1.19 (s, 3H), 1.18 - 1.12 (m, 3H), 1.11 (s, 3H), 1.10 - 1.02 (m, 2H), 1.01 (s, 3H), 1.00 - 0.94 (m, 1H), 0.93 (d, J = 6.5 Hz, 3H), 0.91 - 0.82 (m, 1H), 0.68 (s, 3H).
Example 16. Preparation of Compounds 3-alpha-A28 and 3-beta-A28
Figure imgf000147_0001
[00376] In a glove box in a flame dried flask THF (degassed, 1.5mL) was added to anhydrous cerium(III) chloride (0.207 g, 0.841 mmol). The suspension was stirred at RT overnight. The white, fine suspension was taken out of the glove box and stirred under argon for 15min. Under argon the white, fine suspension was cooled to -78°C. At this temperature ethyllithium, 0.5M in benzene/cyclohexane (1.68 mL, 0.841 mmol) was added dropwise. A yellow suspension formed and was stirred at -78°C for 30min. A solution of BB-3 (0.065 g, 0.168 mmol) in THF (dry, 1.5mL) was added dropwise over 3 min. The colour of the reaction mixture changed from yellow to brown. Reaction mixture was stirred at -78°C for 45min. A brown, milky suspension was obtained, TLC (H/E; 2: 1) showed complete conversion of the starting material and formation of a more polar spot. Cooling bath was removed and reaction mixture was stirred for lOmin. 5% aq. AcOH (2mL) was added. After addition of brine (2mL), reaction mixture turned into a colourless, clear solution. EtOAc (5mL) was added. Mixture was allowed to warm to RT. Layers were separated and aq. layer was extracted with EtOAc (2x5mL). Combined org. layers were dried with sodium sulfate and solvents were removed in vacuo. 60 mg of a white solid were obtained. Seperation on silicagel impregnated with AgN03 (H, 5%-20% EtOAc) afforded compound A28 (3tf-OH) (6 mg, 0.014 mmol; 8.56%) and compound A28 (3/?-OH) (4 mg, 0.0096 mmol; 5.71%). (3«-OH): 1H-NMR (400 MHz, CDC13): 5(ppm): 5.45 - 5.38 (m, 1H), 2.40 - 2.33 (m, 1H), 2.05 -1.93 (m, 2H), 1.92 - 1.80 (m, 2H), 1.75 - 1.23 (m, 15H), 1.20 (s, 3H), 1.19 (s, 3H), 1.18 - 0.98 (m, 7H), 0.97 (s, 3H), 0.96 - 0.90 (m, 6H), 0.89 - 0.81 (m, 2H), 0.68 (s, 3H). (3/2-OH): 1H-NMR (400 MHz, CDC13): 5(ppm): 5.33 - 5.25 (m, 1H), 2.41 - 2.31 (m, 1H), 2.06 - 1.93 (m, 3H), 1.90 - 1.78 (m, 1H), 1.77 - 1.23 (m, 20H), 1.20 (s, 3H), 1.19 (s, 3H), 1.17 - 1.05 (m, 5H), 1.03 (s, 3H), 1.01 - 0.95 (m, 1H), 0.93 (d, J = 6.5 Hz, 3H), 0.92 - 0.88 (m, 1H), 0.84 (t, J = 7.4 Hz, 3H), 0.67 (s, 3H). Example 17. Preparation of Compound B6
Figure imgf000148_0001
[00377] Preparation of compound B6a. Acetic anhydride (15.36 ml, 164 mmol) was added to a suspension of Stigmasterol (22.5 g, 54.5 mmol) in pyridine (90 ml) under nitrogen atmosphere, and the mixture was incubated at room temperature for 42h.
TLC[heptane(2):ethyl acetate(l)] showed complete conversion to a higher eluting product after p-anisaldehyde staining. Water (300 ml) was added to the reaction mixture to quench the excess acetic anhydride. After stirring for lh, the white solid was filtered and thoroughly washed with water (9x 250 ml). The white solid was dried in a vacuum oven at 40°C in presence of a beaker of sodium hydroxide over the weekend to obtain product B6a (24.63 g, 54.2 mmol, Yield=99 ) as white powder. B6a was used as such in the following
experiment(s). 1HNMR (400 MHz, CDC13) 5(ppm): 5.38-5.37 (1H, m), 5.15 (1H, dd, J=15.1, 8.6 Hz), 5.01 (1H, dd, J=15.1, 8.6 Hz), 4.64-4.56 (1H, m), 2.33-2.31 (2H, m), 2.03 (3H, s), 1.90-1.82 (2H, m), 1.75-1.65 (1H, m), 1.02 (6H, t, J=3.2 Hz), 0.86-0.78 (9H, m), 0.68 (3H, s).
[00378] Preparation of compound B6b. Bromine (1.754 ml, 34.1 mmol) was added to a solution of iodobenzene (3.66 ml, 32.7 mmol) in n-heptane (100 ml) and the solution was coold to -5°C under nitrogen atmosphere. A solution of Stigmasteryl acetate B6a (13.5 g, 29.7 mmol) in n-heptane (700 ml) was also cooled to -5°C under nitrogen atmosphere, stirred vigorously, and the solution prepared above was added dropwise over a period of 2.5h under a nitrogen atmosphere to maintain the solution a pale yellow color. The resulting solution was stirred overnight and then filtered. TLC[heptane(9):ethyl acetate(l)] showed complete conversion to a slightly lower eluting product after vanillin staining. The solution was concentrated under vacuum until dryness. The residue was purified by column (900 g) chromatography [heptane (95): diisopropyl ether(5)]. The pure product containing fractions were collected and evaporated under reduced pressure to obtain B6b (9.06 g, 14.7 mmol, Yield=50 ) as a white powder. B6b was used as such in the following experiment(s).
1HNMR (400 MHz, CDC13) 5(ppm): 5.48 (1H, sep, J=5.4 Hz), 5.15 (1H, dd, J=15.1, 8.6 Hz), 5.02 (1H, dd, J=15.1, 8.6 Hz), 4.84 (1H, brd), 2.05 (3H, s), 1.46 (3H, s), 1.01 (3H, d, J=6.6 Hz), 0.90-0.79 (15H, m), 0.72 (3H, s).
[00379] Preparation of compound B6c. A solution of 5a,6p-Dibromostigmastan-3p- yl acetate B6b (8.11 g, 13.20 mmol) in molecular sieves dried dichloromethane (240 ml) and pyridine (3.05 ml, 37.7 mmol) was cooled in a liquid nitrogen / ethyl acetate bath. A stream of ozone rich oxygen was passed into the solution through a sintered glass sprayer for one hour. The color of reaction mixture turned slightly blue. TLC[heptane(9):ethyl acetate(l)] showed complete conversion of the starting material under UV254. The ozonolysis reaction was stopped. The reaction mixture was immediately poured into a mixture of glacial acetic acid (33.2 ml, 581 mmol) and zinc, dust (21.57 g, 330 mmol) and stirred at room temperature overnight. The solution was filtered, washed successively with water (200 ml), 10% aqueous sodium hydrogen carbonate (200 ml), 5% aqueous sodium hydroxide (200 ml) and brine (200 ml), and then dried over anhydrous sodium sulfate. Evaporation of the solvent afforded crude Cholest-5-en-3P-ol-22-al B6c which was purified by flash column (300 g) chromatography [heptane(100=>90):ethyl acetate(0=>10)]. The product containing fractions were collected and evaporated under reduced pressure to obtain Cholest-5-en-3P-ol-22-al B6c (2.58 g, 6.93 mmol, Yield=53 ) as a white powder. B6c was used as such in the following experiment(s). 1HNMR (400 MHz, CDC13) 5(ppm): 9.57 (IH, d, J=3.3 Hz), 5.38 (IH, brd), 4.65-4.56 (IH, m), 2.41-2.28 (3H, m), 2.04 (3H, s), 2.03-1.92 (2H, m), 1.91-1.81 (3H, m), 1.13 (3H, d, J=6.8 Hz), 1.03 (3H, s), 0.73 (3H, s).
[00380] Preparation of compound B6d. To a solution of (methoxymethyl)triphenyl- phosphonium chloride (0.789 g, 2.30 mmol) in dry THF (6.4 mL) at -10°C under an atmosphere of argon was added n-BuLi 1.6M in hexanes (1.342 mL, 2.15 mmol). The solution was stirred for 5 min at room temperature, followed by addition of B6c (0.2 g, 0.54 mmol) in dry THF (1.3 mL). The mixture was stirred for 30 min at room temperature. The reaction mixture was poured in saturated aqueous NH4C1 (75 mL) and extracted twice with CH2CI2 (50 mL). The combined organic layers were washed with brine dried on Na2S04 and the crude product was purified by flash column chromatography (silica, heptane/ethylacetate, 1:0 -> 88: 12) to afford B6d (103 mg, 0.29 mmol, yield = 54%). B6d was obtained as 1: 1 E/Z- mixture according to NMR. 1HNMR (400 MHz, CDC13) 5(ppm): 6.24 (0.5H, d, J=12.6 Hz), 5.74 (0.5H, d, J=6.2 Hz), 5.34 (IH, brd), 4.59 (0.5H, dd, J=12.5, 9.3 Hz), 4.17 (0.5H, dd, J=9.8, 6.3 Hz), 3.58-3.46 (IH, m), 3.55 (1.5H, s), 3.47 (1.5H, s), 2.67-2.54 (0.5H, m), 2.33- 2.18 (2H, m), 2.04-1.78 (6H, m), 1.77-1.65 (IH, m), 1.04 (1.5H, d, J=6.6 Hz), 1.01 (3H, s), 0.98 (1.5H, d, J=6.7 Hz), 0.72 (1.5H, s), 0.69 (1.5H, s).
[00381] Preparation of compound B6e. Acetic anhydride (0.079 mL, 0.84 mmol) was added to a suspension of B6d (0.1 g, 0.279 mmol) in pyridine (3 mL) under nitrogen atmosphere, and the mixture was incubated at room temperature for 42h. Water (60 mL) was added to the reaction mixture to quench the excess acetic anhydride. After stirring for lh, the white solid was filtered and thoroughly washed with water (9x 250 mL). The white solid was dried in a vacuum oven at 40°C overnight to obtain product B6e (111 mg, 0.28 mmol, Yield=99%). 1HNMR (400 MHz, CDC13) 5(ppm): 6.24 (0.5H, d, J=12.6 Hz), 5.73 (0.5H, d, J=6.2 Hz), 5.37 (IH, brd), 4.66-4.55 (IH, m), 4.59 (0.5H, dd, J=12.5, 9.3 Hz), 4.17 (0.5H, dd, J=9.8, 6.3 Hz), 3.55 (1.5H, s), 3.47 (1.5H, s), 2.66-2.54 (0.5H, m), 2.35-2.28 (2H, m), 2.03 (3H, s), 2.02-1.91 (3H, m), 1.90-1.81 (2H, m), 1.77-1.66 (IH, m), 1.04 (1.5H, d, J=6.6 Hz), 1.02 (3H, s), 0.99 (1.5H, d, J=6.6 Hz), 0.72 (1.5H, s), 0.69 (1.5H, s). [00382] Preparation of compound B6f. To a solution of B6e (0.111 g, 0.28 mmol) in acetone (9 mL) was added 0.1 M aqueous HC1 (1 mL, 0.10 mmol). The resulting white suspension was stirred for lh at room temperature, followed by lh at 70°C and at room temperature overnight. The mixture heated at 70°C for 2h, cooled to room temperature and diluted with H20 (50 mL). The reaction mixture was evaporated until dryness, coevaporated with MeOH (50 mL) and CH2C12 (10 mL). This seems to be a mixture of the desired product and the dimethyl acetal. To a solution of this mixture (0.12 g, 0.28 mmol) in acetone (10 mL) was added 0.1 M aqueous HC1 (1 mL, 0.10 mmol). The resulting white suspension was stirred for 2h at 70°C. 1,4-Dioxane (5 mL) was added, which caused the insoluble to dissolve. The reaction mixture was heated to 70°C for another 2h, allowed to cool to room temperature and stirred over the weekend. The reaction mixture was diluted with H20 (50 mL) and extracted with CH2C12 (3x50 mL). The combined organic layers were washed with brine, dried on Na2S04 and the solvents evaporated. The crude product was coevaporated with CH2C12 (10 mL) to yield B6f (119 mg, 0.31 mmol, yield = 111%). 1HNMR (400 MHz, CDC13) 5(ppm): 9.75 (1H, m), 5.37, (1H, brd), 4.66-.454 (1H, m), 2.47 (1H, dd, J=15.8, 2.4 Hz), 2.36-2.28 (2H, m), 2.17 (1H, ddd, J=15.8, 9.3, 3.3 Hz), 2.03 (3H, s), 1.02 (3H, d, J=6.4 Hz), 1.02 (3H, s), 0.70 (3H, s).
[00383] Preparation of compound B6g. Compound B6f (0.11 g, 0.285 mmol) was dissolved in t-butanol (5 mL), dry THF (1 mL) and 2-methyl-2-butene (0.512 mL, 4.84 mmol). The solution was stirred and cooled with an iced bath. A solution of NaC102 (0.028 g, 0.313 mmol) and K2HP04 (0.043 g, 0.313 mmol) in demineralized Water (3 ml) was slowly added to the solution over a period of 5 minutes and the mixture was stirred 2 h at 0°C. The mixture was stirred at room temperature overnight. Extra NaC102 (0.028 g, 0.313 mmol) and K2HP04 (0.043 g, 0.313 mmol) dissolved in H20 (3 mL) was added slowly to the reaction mixture and stirring was continued for 2h. The reaction mixture was poured into saturated aqueous NH4C1 (250 mL) and extracted three times with CH2C12 (75 mL). The combined organic layers were dried over Na2S04, filtered and evaporated under reduced pressure. The white solid residue (2.26 g, 163%) was triturated in petroleum ether 40-60 (10 mL). The white solid was filtered, washed twice with petroleum ether 40-60 (5 mL) and dried on air for 0.5h to obtain B6f (0.089 g, 0.22 mmol, Yield=78%). 1HNMR (400 MHz, CDC13) 5(ppm): 10.0 (1H, bs), 5.37 (1H, brd), 4.66-4.55 (1H, m), 2.53-2.44 (1H, m), 2.36-2.26 (2H, m), 2.04 (3H, s), 1.04 (3H, d, J=6.4 Hz), 1.02 (3H, s), 0.72 (3H, s). [00384] Preparation of compound B6h. To a solution of B6g (0.09 g, 0.224 mmol) in CH2C12 (10 mL) were added oxalyl chloride (0.048 mL, 0.56 mmol) and DMF (cat). The solution was stirred for 2h at room temperature. The reaction mixture was diluted with dry MeOH (150 mL, 3703 mmol) and stirred at 40°C till all solids were dissolved. The reaction mixture was evaporated till dryness and the crude product was purified by flash column chromatography (silica, heptane/ethylacetate, 1:0 -> 95:5) and coevaporated with THF twice to afford B6h (85 mg, 0.20 mmol, yield = 91%). 1HNMR (400 MHz, CDC13) 5(ppm): 5.37 (1H, brd), 4.66-4.55 (1H, m), 3.66 (3H, s), 2.43 (1H, dd, J=14.1, 2.9 Hz), 2.38-2.25 (2H, m), 2.04 (3H, s), 1.02 (3H, s), 0.99 (3H, d, J=6.2 Hz), 0.72 (3H, s).
[00385] Preparation of compound B6. A solution of B6h (0.085 g, 0.20 mmol) in dry THF (3 mL) was cooled to 0°C under an atmosphere of argon. MeMgCl 3.0M in THF (0.68 mL, 2.04 mmol) was added drop wise using a syringe. The reaction mixture was stirred for lh at 0°C, followed by 2h at room temperature. MeMgCl 3.0M in THF (0.68 mL, 2.04 mmol) was added again at room temperature and stirring was continued overnight. The reaction mixture was quenched with saturated aqueous NH4C1 (75 mL) and extracted three times with CH2C12 (3x50 mL).The combined organic layers were washed with brine dried on Na2S04 and the crude product was purified by flash column chromatography (silica,
heptane/ethylacetate, 1:0 -> 4: 1) to afford B6 (45 mg, 0.12 mmol, yield = 59%) as a white fluffy solid. 1HNMR (400 MHz, CDC13) 5(ppm): 5.35 (1H, brd), 3.53 (1H, sep, J=5.1 Hz), 2.34-2.17 (2H, m), 2.03 (1H, dt, J=12.6, 3.3 Hz), 2.01-1.94 (1H, m), 1.93-1.79 (3H, m), 1.23 (6H, s), 1.06 (3H, d, J=6.5 Hz), 1.01 (3H, s), 0.72 (3H, s).
Example 18. Preparation of Compound B7
Figure imgf000152_0001
[00386] Preparation of compound B7d: Cholest-5-en-3p-ol-22-al B7c (1.33 g, 3.57 mmol) was dissolved in t-butanol (75ml), tetrahydrofuran (dry) (15 ml) and 2-methyl-2- butene (13.22 ml, 125 mmol). The solution was stirred and cooled with an iced bath. A freshly prepared solution of sodium chlorite (0.355 g, 3.93 mmol) and potassium phosphate, monobasic, p. a. (0.534 g, 3.93 mmol) in demineralized water (45 ml) was slowly added to the solution over a period of 30 minutes and the mixture was stirred 2 hour at 0°C. The ice bath was removed, the temperature of the mixture was raised to room temperature, and stirred overnight. TLC [heptane (2): ethyl acetate(l)] showed partial conversion to a lower eluting product after vanillin staining. Extra sodium chlorite (0.355 g, 3.93 mmol) and potassium phosphate, monobasic, p. a. (0.534 g, 3.93 mmol) dissolved in water (45 ml) was added slowly to the reaction mixture and stirring was continued for 2h. TLC[heptane(2):ethyl acetate(l)] showed complete conversion to a lower eluting product after vanillin staining. The reaction mixture was poured into saturated aqueous ammonium chloride (250 ml) and extracted three times with dichloromethane (100 ml). The combined organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was twice stripped with toluene (50 ml) followed by dichloromethane (50 ml). The white solid residue (2.26 g, 163%) was triturated in petroleum ether 40-60 (10 ml) for 0.5h. The white solid was filtered, washed twice with petroleum ether 40-60 (10 ml) and dried on air (leaving the vacuum pump on) for 0.5h to obtain B7d (1.27 g, 3.26 mmol, Yield=91%) as a white powder. B7d was used as such in the following experiment(s). 1HNMR (400 MHz, CDC13) 5(ppm): 10.31 (1H, bs), 5.37 (1H, brd), 4.65-4.56 (1H, m), 2.47-2.39 (1H, m), 2.36-2.26 (2H, m), 2.04 (3H, s), 2.01-1.92 (2H, m), 1.90-1.76 (3H, m), 1.24 (3H, d, J=6.8 Hz), 1.02 (3H, s), 0.71 (3H, s).
[00387] Preparation of compound B7e. Carboxylic acid B7d (0.1 g, 0.257 mmol) was dissolved in dichloromethane (10 ml). Oxalyl chloride (0.044 mL, 0.515 mmol) and Ν,Ν-dimethylformamide (one drop) were added, and the reaction mixture was stirred for lh. A sample of the reaction was poured out in methanol, evaporated until dryness, and anayzed on TLC[heptane(3):ethyl acetate(l)] which showed complete conversion to the methyl ester after vanillin staining. The reaction mixture was diluted with methanol (50 mL, 1234 mmol) (dried on mol. sieves), evaporated under reduced pressure, stripped with anhydrous toluene, and dichloromethane. The residue was purified by flash column (4 g) chromatography
[heptane(99=>80):ethyl acetate(l=>20)]. The product containing fractions were collected and evaporated under reduced pressure to obtain B7e (0.104 g, 0.257 mmol, Yield=100%). B7e was stripped with toluene (2x 5 ml), dichloromethane (2x 5 ml) and anhydrous tetrahydrofuran (2x 5 ml) and used as such in the next reaction step. 1HNMR (400 MHz, CDC13) 5(ppm): 5.37 (1H, brd), 4.65-4.56 (1H, m), 3.65 (3H, s), 2.47-2.38 (1H, m), 2.36- 2.26 (2H, m), 2.03 (3H, s), 2.01-1.92 (2H, m), 1.90-1.82 (2H, m), 1.19 (3H, d, J=6.8 Hz), 1.02 (3H, s), 0.69 (3H, s).
[00388] Preparation of compound B7. Methyl ester B7e (0.104 g, 0.258 mmol) was dissolved in tetrahydrofuran (dry) (2.6 ml) and cooled in an ice bath under argon. After 20 minutes, methylmagnesium chloride 3.0M in THF (0.861 ml, 2.58 mmol) was added dropwise via a syringe. Some gas evolution was observed. After stirring the reaction mixture for 0.5h, the cooling bath was removed, and stirring was continued for 2h. TLC
[heptane(3):ethyl acetate(l)] showed complete conversion of the starting material to two lower eluting products after vanillin staining. Stirring was continued for lh. The reaction mixture was poured out into saturated aqueous solution of ammonium chloride (75 ml) under stirring and extracted with dichloromethane (3x 50 ml). The extracts were combined, dried over sodium sulfate and evaporated. The residue was triturated in methanol (2 ml) for 0.5h, the white solid was filtered, and the filter residue was washed with methanol (2 ml). Almost no material was left on the filter, most of it was present in the filtrate. Filtrate and filter residue were combined and purified by flash column chromatography [heptane (99=>70): ethyl acetate (1=>30)]. The product containing fractions were collected and evaporated under reduced pressure. The residue was dried at 40°C in a vacuum oven overnight to obtain B7 (0.044 g, 0.122 mmol, Yield=47 ) as a white solid. 1HNMR (400 MHz, CDC13) 5(ppm): 5.35 (1H, m), 3.53 (1H, sep, J=5.2 Hz), 2.34-2.19 (2H, m), 2.10 (1H, dt, J=12.6, 3.4 Hz), 2.03-1.88 (2H, m), 1.88-1.79 (2H, m), 1.20 (3H, s), 1.15 (3H, s), 1.00 (3H, s), 0.98 (3H, d, J=6.9 Hz), 0.73 (3H, s).
Example 19. Preparation of Compound B8
Figure imgf000155_0001
[00389] Preparation of compound B8b. In a flame dried round bottom flask, a solution of NaHMDS (0.070 ml, 0.349 mmol) in tetrahydrofuran (dry) (1 ml) was added to a solution of silyloxyphosphonate ester B8a (0.143 g, 0.403 mmol) in tetrahydrofuran (dry) (1 ml) at -78°C. The solution was stirred for 15 minutes at -78°C under argon atmosphere. Then a solution of Cholest-5-en-3P-ol-22-al B7c (0.1 g, 0.268 mmol) in tetrahydrofuran (dry) (1 ml) was slowly added via a syringe. The reaction mixture was slowly warmed to room temperature and stirred for 20h. TLC[heptane(3):ethyl acetate(l)] showed partial conversion to an higher eluting product after vanillin staining. The reaction mixture was quenched by the addition of aqueous saturated ammonium chloride (50 ml) and extracted with
dichloromethane (3x 50 ml). The combined organic layers were washed with water (50 ml), dried over sodium sulfate, and concentrated in vacuo. The residue was purified by flash column (4 g) chromatography [heptane(100=>90): diisopropyl ether (0=>10)]. The product containing fractions were collected and evaporated under reduced pressure to afford product B8b (0.117 g, 0.187 mmol, Yield=70 ) as white powder. According to NMR a 7:3 mixture of E- and Z-isomers was obtained. 1HNMR (400 MHz, CDC13) 5(ppm): 5.70 (1H, d, J=10.4 Hz), 5.23 (1H, brd), 5.17-5.13 (1H, m), 4.51-4.40 (1H, m), 4.11-4.00 (2H, m), 3.16-3.07 (0.3H[Z-isomer], m), 2.68-2.57 (0.7H[E-isomer], m), 2.20-2.10 (2H, m), 1.89 (3H, s), 1.89- 1.77 (2H, m), 1.75-1.67 (2H, m), 0.89-0.85 (6H, m), 0.84-0.77 (10H, m), 0.59 (0.9H[Z- isomer], s), 0.57 (2.1H[E-isomer], s), 0.05-0.00 (6H, m). [00390] Preparation of compound B8c. Glacial acetic acid (0.060 ml, 1.047 mmol) and cesium fluoride (0.080 g, 0.524 mmol) were added to a suspension of B8b (0.1 g, 0.175 mmol) in acetonitrile (anhydrous) (4 ml) under nitrogen atmosphere at 0°C. The resulting mixture was stirred at 0°C for 30 min and at room temperature for 2h. LCMS-NQAD (acid) showed little conversion of the starting material to a product with unclear product mass. Dichloromethane (2 ml) was added to the reaction mixture, and the reaction mixture immediately turned to a yellow clear solution. The reaction mixture was stirred overnight. Extra cesium fluoride (0.080 g, 0.524 mmol) was added to the reaction mixture and stirring was continued for 24h. Extra cesium fluoride (0.080 g, 0.524 mmol) was added to the reaction mixture again and stirring was continued for 4h. Although TLC [heptane(3):ethyl acetate(l)] showed still a little bit of starting material present in the reaction mixture, the reaction mixture was diluted with dichloromethane (75 ml) and washed with saturated aqueous sodium hydrogen carbonate (50 ml). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash column (25 g) chromatography [heptane(100=>90): ethyl acetate(0=>10)] to remove the remaining starting material (only visible on TLC). The product containing fractions were collected and evaporated under reduced pressure to afford product B8c (0.051 g, 0.111 mmol, Yield=64 ). 1HNMR (400 MHz, CDC13) 5(ppm): 5.37 (1H, brd), 4.65-4.55 (1H, m), 4.31, (2H, q, J=7.1 Hz), 2.89 (1H, dd, J=16.8, 3.0 Hz), 2.57 (1H, dd, J=16.8, 9.9 Hz), 2.37-2.25 (2H, m), 2.04 (3H, s), 2.09-1.91 (2H, m), 1.90-1.77 (3H, m), 1.37 (3H, t, J=7.1 Hz), 1.02 (3H, s), 0.97 (3H, d, J=6.5 Hz), 0.72 (3H, s).
[00391] Preparation of compound B8d. A solution of B8c (0.051 g, 0.111 mmol) in dichloromethane (1 ml) was cooled in an ice bath under nitrogen atmosphere for 0.5h.
Diethylamino sulfur trifluoride (DAST) (0.027 ml, 0.222 mmol) was added and the reaction mixture was allowed to warm to room temperature and stirred overnight. Extra
diethylamino sulfur trifluoride (DAST) (0.027 ml, 0.222 mmol) was added and stirring was continued for 20h. TLC[heptane(3):ethyl acetate(l)] showed still no complete consumption of the starting material after vanillin staining. LCMS-ELSD (base): 47% product at rt= 3.43 with m/z(+)= 421, corresponds to desired product were acetate group is eliminated [M- CH COOH+H]+. The reaction mixture was diluted with dichloromethane (50 ml) and washed with saturated sodium hydrogen carbonate (50 ml). The aqueous layer was separated and twice extracted with dichloromethane (50 ml). The extracts were combined with the former organic layer, dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by flash column chromatography [heptane(100=>90):ethyl acetate(0=>90)] . The product containing fractions were collected, evaporated under reduced pressure and stripped with dichloromethane (5 ml) to afford product B8d (0.027 g, 0.056 mmol, Yield=51%). 1HNMR (400 MHz, CDC13) 5(ppm): 5.37 (1H, brd), 4.65-4.55 (1H, m), 4.32, (2H, q, J=7.1 Hz), 2.37-2.28 (2H, m), 2.27-2.09 (1H, m), 2.03 (3H, s), 2.04-1.92 (2H, m), 1.90-1.81 (3H, m), 1.35 (3H, t, J=7.1 Hz), 1.06 (3H, d, J=6.1 Hz), 1.02 (3H, s), 0.88 (6H, t, J=6.8 Hz), 0.70 (3H, s).
[00392] Preparation of compound B8. Compound B8d (0.027 g, 0.056 mmol) was dissolved in tetrahydrofuran (dry) (1 ml) under argon atmosphere. The mixture was cooled in an ice bath for 15 minutes and lithium aluminium hydride, 2.4M in THF (0.047 ml, 0.112 mmol) was added gradually. Some gas evolution was observed. The reaction mixture was cooled and stirred for lh. TLC[heptane(3):ethyl acetate(l)] showed complete conversion to mainly one lower eluting product after vanillin staining. The ice bath was removed and stirring was continued for lh. The reaction mixture was quenched with saturated aqueous ammonium chloride (50 ml) and extracted three times with dichloromethane (50 ml). The combined extracts were dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by flash column (4 g silica) chromatography
[heptane(100=>85):ethyl acetate(0=>15)]. The product containing fractions were collected and evaporated under reduced pressure. The residue was transfered to a vial (4 ml) with methanol and the methanol was evaporated at 37°C under a stream of nitrogen. The residue was dried at 40°C in a vacuum oven overnight to afford product B8 (0.011 g, 0.028 mmol, Yield=49 ).1HNMR (400 MHz, CDC13) 5(ppm): 5.35 (1H, m), 3.71 (2H, t, J=12.8 Hz), 3.58-3.48 (1H, m), 2.35-2.18 (2H, m), 2.15-1.93 (3H, m), 1.92-1.73 (5H, m), 1.70-1.40 (9H, m), 1.08 (3H, d, J=6.5 Hz), 1.01 (3H, s), 0.72 (3H, s).
Example 20. Preparation of Compound B10
Figure imgf000157_0001
[00393] In a flame dried flask under argon a solution of BB-1 (100 mg, 0.23 mmol) and titanium (IV) isopropoxide (0.07 mL, 0.23 mmol) in THF (dry, 2 mL) was cooled to 0°C. Ethylmagnesium bromide (1.0M in THF, 1.16 mL) was added dropwise. Reaction mixture was stirred at 0°C for 15 minutes, TLC (H/E; 2: 1) showed starting material and two new spots. Reaction mixture was allowed to warm to RT and stirring was continued for lh, Reaction mixture was then cooled to 0°C and ethylmagnesium bromide (1.0M in THF, 1.16 mL) was added dropwise. Reaction mixture was stirred at 0°C for 15 minutes, TLC (H/E; 2: 1) showed complete conversion and a single new spot. The reaction mixture was diluted with Et20 (2mL). Aq. sat. NH4C1 (2 mL) and H20 (2 mL) were added at 0°C. Solids were filtered off over cotton and the filter cake was washed with Et20 (10 mL). The colourless layers were separated and the aq. layer was extracted with Et20 (20 mL) and a mixture of Et20 and EtOAc (20 mL; 1: 1). Org. layers were dried with Na2S04 and solvents were removed in vacuo. 125 mg of a white solid were obtained. Flash chromatography (heptane, 5%-30% EtOAc) afforded compound B10 (37 mg, 0.096 mmol; 41.2%). IH-NMR (400 MHz, CDC13) 5(ppm): 5.36-5.35 (m, 1H), 3.58 - 3.46 (m, 1H), 2.32 - 2.21 (m, 2H), 2.03 - 1.93 (m, 2H), 1.91 - 1.80 (m, 3H) 1.77 (s, 1H), 1.69 - 1.37 (m, 10H), 1.34 - 0.82 (m, 9H), 1.01 (s, 3H), 0.93 (d, J = 6.6 Hz, 3H), 0.75 - 0.71 (m, 2H), 0.69 (s, 3H), 0.46 - 0.39 (m, 2H).
Example 21. Preparation of Compounds B13a-B14
Figure imgf000158_0001
[00394] Preparation of compound B13a. To a solution of BB-2 (762 mg, 1.961 mmol) in Pyridine (15 ml) at 0°C was added acetic anhydride (0.185 ml, 1.961 mmol) and DMAP (23.95 mg, 0.196 mmol) (a slightly yellowish suspension which slowly dissolves). The mixture was stirred at RT overnight. TLC (Heptane / EtOAc 2: 1) showed full conversion. The RM was diluted with EtOAc (100 ml) and water (100 ml) and the layers were separated. The water layer was extracted with EtOAc (2x). The organic layers were combined and washed with water (3x) and brine, dried with Na2S04 and concentrated. The obtained solid was co-evaporated three times with toluene, EtOH and DCM. The material was purified by flash chromatography (40 gr silica, 4-40% EtOAc in heptane, loaded with DCM). Compound B13a (687 mg, 1.595 mmol; 81%) was obtained as a white solid. 1HNMR (300MHz, CDC13): 5(ppm): 5.37 (1H, d, 5.1 Hz), 4.60 (1H, m), 1.99 (3H, s), 1.20 (6H, s), 1.01 (3H, s), 0.93 (3H, d, J = 6.6 Hz), 0.68 (3H, s).
[00395] Preparation of compound B13b. To a solution of compound B 13a (687 mg, 1.595 mmol) in Dichloromethane (8.5 ml) under nitrogen, was added TMS-N3 (0.233 ml, 1.755 mmol), followed by BF3.OEt2 (0.842 ml, 3.19 mmol). The mixture was stirred at RT for 2 hours. TLC showed almost complete conversion into a higher eluting spot. Impurities present. Stirred for another 30 minutes after which the RM was diluted with 2M NaOH (25 ml) and DCM (25 ml). The layers were separated. The water layer was extracted with DCM (2x). The organic layers were combined and washed with brine, dried over Na2S04 and concentrated and purified by flash chromatgraphy (40 gr silica, 4-40% EtOAc in heptane, loaded with DCM to give compound B13b (660 mg, 1.376 mmol; 86%). 1HNMR (300MHz, CDC13): 5(ppm): 5.37 (1H, d, 4.8 Hz), 4.60 (1H, m), 2.03 (3H, s), 1.20 (6H, s), 1.01 (3H, s), 0.93 (3H, d, J = 6.6 Hz), 0.68 (3H, s).
[00396] Preparation of compound B13. To a solution of compound B13b (660 mg, 1.448 mmol) in Diethyl ether (dry) (15 ml) at 0°C under argon, was added LiAlH4 in Et20 (0.797 ml, 3.19 mmol) (white suspension was formed). The mixture was stirred for 30 minutes at 0°C and for 1 hour at RT, after which TLC showed complete conversion of the SM into a low eluting spot (amine). The mixture was cooled to 0°C again and WATER (0.057 ml, 3.19 mmol) and NaOH, 4M solution in water (0.797 ml, 3.19 mmol) were added. Stirred for 30 minutes at RT and filtered over Celite with diethyl ether and THF. The organic layer was dried with Na2S04 and the solvent evaporated. The crude product was purified by gravity column chromatography (100 gr silica, loaded with DCM). First, the column was eluted with DCM:MeOH (95:5), to flush off all the impurities. Then, the column was eluted with
DCM:7M NH3 in MeOH (95:5), to obtain compound B13 (400 mg, 1.032 mmol; 71.2%). 1HNMR (300MHz, CDC13): 5(ppm): 5.35 (1H, d, 5.1 Hz), 3.51 (1H, m), 1.07 (6H, s), 1.01 (3H, s), 0.93 (3H, d, J = 6.6 Hz), 0.68 (3H, s).
[00397] Preparation of compound B14. Compound B13 (50 mg, 0.129 mmol) was dissolved in Tetrahydrofuran (dry) (2 ml) by slightly heating, then Mel (8.07 μΐ, 0.129 mmol) (1 mL from a stock solution of 81 microliter Mel in 10 mL of THF) and K2C03 (21.39 mg, 0.155 mmol) were added. Stirring overnight at rt. The solid was filtered off, washed with water and dried. The mixture was purified on a 12g pre-packed flash column (GraceResolve™) run in DCM/7N NH3 in MeOH 97.5/2.5 15 ml/min, 1 min. fractions.
Compound B14 (18 mg, 0.045 mmol, 34.7%) was thus obtained. 1HNMR (400MHz, CDC13): 5(ppm): 5.35 (IH, d, 4.8 Hz), 3.53 (IH, m), 2.30 (3H, s), 1.02 (9H, s), 0.93 (3H, d, J = 6.6 Hz), 0.68 (3H, s).
Example 22. Preparation of Compound B17
Figure imgf000160_0001
[00398] Preparation of compound B17a. l-(3-Dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (EDCI) (0.282 g, 1.468 mmol), and l-hydroxy-7- azabenzotriazole (HOAt) (0.018 g, 0.133 mmol) were added at 0°C to a solution of 3β- hydroxy cholenic acid (0.5 g, 1.335 mmol), Ν,Ο-dimethylhydroxylamine hydrochloride (0.143 g, 1.468 mmol), and N,N-diisopropylethylamine (0.256 ml, 1.468 mmol) in dichloromethane (15 ml) under nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature over the weekend. Extra l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (EDCI) (0.282 g, 1.468 mmol) and l-hydroxy-7- azabenzotriazole (HOAt) (0.018 g, 0.133 mmol) were added and stirring was continued for 2h. The reaction was diluted with dichloromethane (100 ml), washed with 0.5N aqueous potassium hydrogen sulfate (75 ml), and saturated aqueous sodium hydrogen carbonate (75 ml), dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by flash column (4 g silica) chromatography[heptane(80=>66):ethyl
acetate(20=>33)]. The product containing fractions were collected and evaporated under reduced pressure. The residue was stripped with methanol and dried at 40°C overnight to afford B17a (0.495 g, 1.185 mmol, Yield=89%) as a white powder. 1HNMR (400 MHz, CDC13) 5(ppm): 5.36-5.35 (IH, m), 3.69 (3H, s), 3.58-3.48 (IH, m), 3.18 (3H, s), 2.49-2.41 (1H, m), 2.37-2.20 (3H, m), 2.03-1.96 (2H, m), 1.96-1.75 (4H, m), 1.01 (3H, s), 0.95 (3H, d, J=6.5 Hz), 0.69 (3H, s).
[00399] Preparation of compound B17b. Under argon atmosphere, B17a (0.2 g, 0.479 mmol) was dissolved in Tetrahydrofuran (dry) (5 ml) and cooled to -75°C.
Methylmagnesium bromide 3.0M in diethylether (0.798 ml, 2.394 mmol) was added dropwise (exothermic, temperature raised to -40°C). After the addition, the reaction mixture dropped down to -75°C. The cooling bath was removed and the reaction mixture was allowed to warm to room temperature over a period of 20 minutes, and stirred 5h.
TLC[heptane(2):ethyl acetate(l)] showed complete conversion to a higher eluting product after vanillin staining. The reaction mixture was quenched by addition of a saturated aqueous ammonium chloride (75 ml) and extracted with dichloromethane (2x 75 ml). The combined extracts were dried over sodium sulfate and evaporated under reduced pressure. The residue was purified via flash column (4 g) chromatography [heptane (80=>66):ethyl acetate
(20=>33)]. The product containing fractions were collected and evaporated under reduced pressure. The residue was stripped with methanol and dried at 40°C overnight to afford B17b (0.117 g, 0.314 mmol, Yield=66 ) as a white solid. The product was used as such in the next step. 1HNMR (400 MHz, CDC13) 5(ppm): 5.36-5.34 (1H, m), 3.56-3.48 (1H, m), 2.50-2.30 (2H, m) 2.30-2.19 (2H, m), 2.14 (3H, s), 2.02-1.94 (2H, m), 1.90-1.81 (3H, m), 1.01 (3H, s), 0.91 (3H, d, J=6.5 Hz), 0.67 (3H, s).
[00400] Preparation of compound B17. Compound B 17b (0.117 g, 0.314 mmol) was dissolved in ethanol (Abs) (5 ml) under nitrogen atmosphere and cooled to 0°C. Sodium borohydride (0.018 g, 0.471 mmol) was added in one portion (beware for foaming) and the reaction mixture was allowed to warm slowly to room temperature. After stirring for 3h, TLC[heptane(2):ethyl acetate(l)] showed complete consumption of the starting material after vanillin staining. Excess sodium borohydride was decomposed with a saturated aqueous solution of ammonium chloride (50 ml). The reaction mixture was extracted with
dichloromethane (3x 50 ml). The extracts were combined, dried over sodium sulfate and evaporated under reduced pressure. The residue was dried at 40°C in a vacuum oven overnight to afford B17 (0.105 g, 0.280 mmol, Yield=89 ) as a white solid. 1HNMR (400 MHz, CDC13) 5(ppm): 5.36-5.34 (1H, m), 3.75 (1H, q, J=5.8 Hz), 3.53 (1H, sep, J=5.5 Hz), 2.32-2.20 (2H, m), 2.02-1.95 (2H, m), 1.90-1.79 (3H, m), 1.19 (3H, dd, J=6.1, 2.1 Hz), 1.01 (3H, s), 0.93 (3H, d, J=5.5 Hz), 0.68 (3H, s). Example 2 Preparation of Compound B18
Figure imgf000162_0001
TCI [5255-17-4] B18
[00401] 3P-hydroxy cholenic acid (0.1 g, 0.267 mmol) was suspended in
tetrahydrofuran (dry) (5 ml) under argon atmosphere. Lithium aluminium hydride, 2.4M in THF (0.222 ml, 0.534 mmol) was added gradually. Some gas evolution was observed. The reaction mixture was heated to 60°C and stirred overnight. TLC[heptane(2):ethyl acetate(l)] showed complete conversion to a higher eluting product after molybdenum staining. Ethyl acetate (50 ml) and water (50 ml) were added carefully to destroy the excess reagent. The insoluble was filtered and washed with ethyl acetate (3x 5 ml). The washings were combined with the filtrate and the organic phase was separated. The aqueous phase was twice more extracted with ethyl acetate (25 ml), and the combined extracts were washed with brine (75 ml), dried over sodium sulfate and evaporated under reduced pressure to afford product B 18 (0.032 g, 0.089 mmol, Yield=33 ) as white powder.1HNMR (400 MHz, CDC13) 5(ppm): 5.36-5.35 (IH, m), 3.65-3.58 (2H, bs), 3.57-3.48 (IH, m), 2.32-2.20 (2H, m), 2.03-1.93 (2H, m), 1.89-1.79 (3H, m), 1.01 (3H, s), 0.94 (3H, d, J=6.5 Hz), 0.68 (3H, s).
Figure imgf000162_0002
[00402] Preparation of compound C12. Compound C12e (300 mg, 0.720 mmol) was dissolved in Tetrahydrofuran (dry) (7 ml) and cooled to 4°C under Argon. Then,
Methylmagnesium chloride, 3M in THF (2.400 ml, 7.20 mmol) was added via a syringe at such a speed that the temperature did not exceed 7°C. Stirring at 4°C for 20 min and then at rt. After 2h, TLC revealed complete reaction. The rx was dropped onto a stirred saturated solution of NH4C1 and extracted with EtOAc (2x). Some MeOH was added to assure that all the product dissolves in the organic layer. The extract was dried (Brine, Na2S04) and evaporated. The residue was stirred in a little MeOH (~5 ml) and the white solid was filtered off and dried: Compound C12 (168 mg, 0.448 mmol; 62.3%).1HNMR (400MHz, DMSO-D6): 5(ppm): 5.36 (1H, d, 4.6 Hz), 4.61 (1H, d, J=4.3 Hz), 4.03 (1H, s), 3.26 (1H, m), 2.32 (1H, m), 1.03 (6H, s), 0.87 (3H, d, J=6.6 Hz), 0.65 (3H, s).
[00403] Preparation of compound C32a. Compound C12e (74 mg, 0.178 mmol) was dissolved in Ethanol (Abs) (10 ml) and Palladium, 10% On Charcoal (18.90 mg, 0.018 mmol) was added. The rx was flushed with nitrogen and consecutively with hydrogen. It was stirred vigorously at rt. LCMS after 2h indicated complete conversion whereas TLC did not show any change. The rx was again flushed with nitrogen and the Pd/C was filtered off through a fritted tube (3 frits). Still Pd/C in the filtrate. The EtOH was evaporated and the residue was dissolved in DCM and filtered through a small cotton plug. This gave a clear solution. DCM was evaporated to give compound C32a (68 mg, 0.162 mmol; 91% yield). Used as such without further purification. 1HNMR (400MHz, CDC13): 5(ppm): 4.68 (1H, m), 3.66 (3H, s), 2.02 (3H, s), 0.91 (3H, d, J=6.6 Hz), 0.66 (3H, s).
[00404] Preparation of compound C32. Compound C32a (68 mg, 0.162 mmol) was dissolved in Tetrahydrofuran (dry) (1.5 ml) and cooled to 0°C under argon. Then,
Methylmagnesium chloride (0.541 mL, 1.624 mmol) was added. Vigorous gas evolution is seen. Stirring at 0°C and after 3 min. at rt. A little more methylmagnesium chloride (0.1 mL, 0.300 mmol) was added after 2 hours. Stirring overnight at rt. Next day, the rx was poured into 50 ml of sat. aq. NH4C1 and extracted 3x with EtOAc. EtOAc dried (brine, sulfate) and evaporated. The residue was purified by column chromatography: The crude mixture was dissolved in DCM with a few drops MeOH to aid dissolution and applied to a pre-packed flash silica column. It was eluted 30 ml/min fractions of 30 sec. with: 5 min 100% heptane; 20 min 0 => 20% EtO Ac/heptane and 20 min 20% EtO Ac/Heptane isocratic. The product fractions were combined, the solvent evaporated and the white solid residue was triturated in Et20, filtered off and dried to give compound C32 (25 mg, 0.063 mg; 38.8% yield). 1HNMR (400MHz, CDC13): 5(ppm): 3.58 (1H, m), 1.19 (6H, s), 0.91 (3H, d, J=6.6 Hz), 0.66 (3H, s).
[00405] Preparation of compound C33a. Compound C12 (110 mg, 0.294 mmol) was suspended in Toluene (dry) (7 ml) and l-methyl-4-piperidone (1.666 mg, 0.015 mmol) and Aluminium isopropoxide (93 mg, 1.028 mmol) were added. Stirring at reflux temp, for 4h. TLC: still s.m. present. More Aluminium isopropoxide (100 mg, 0.884 mmol) was added. Continue reflux. After 2 h, more Aluminium isopropoxide (100 mg, 0.884 mmol) was added. Continue reflux for 3h. Then the last amount ofAluminium isopropoxide (100 mg, 0.884 mmol) was added. Reflux for 2h more. Then the rx was allowed to cool to rt, diluted with EtOAc and extracted with IN HC1 to remove the 3. The yellow-colored aqueous layer was extracted 2x with EtOAc. The combined EtOAc fractions was washed with IN HC1 (3x), dried (brine, sulfate) and evaporated. The residue was stripped with DIPE to leave behind a white powder. This crude mixture was purified on a 40 g pre-packed flash column
(GraceResolve™) applied in CHC13 with a little MeOH; run in a gradient 30 ml/min: 2 min 100% Heptane; 38 min 0 => 20% Heptane/EtOAc; 10 min 20% Heptane/EtOAc; fraction size 30 sec. Product C33a (84 mg, 0.225 mmol; 77%) was thus obtained. 1HNMR (400MHz, CDCI3): (ppm): 5.82 (1H, s), 1.20 (6H, s), 0.93 (3H, d, J=6.5 Hz), 0.73 (3H, s).
[00406] Preparation of compound C33b. Compound C33a (84 mg, 0.225 mmol) was dissolved in Ethanol (25 ml) and flushed with nitrogen. Then, Palladium on calcium carbonate, (-10% as Pd; 23.99 mg, 0.023 mmol, 10 %) was added and the rx was again flushed with nitrogen. Then the rx was flushed with hydrogen and vigorously stirred under hydrogen. After 3h, TLC indicated completion of the reaction. It was again flushed with nitrogen and the catalyst was filtered off over hyflo, the EtOH evaporated. The mixture was purified on a 12g pre-packed flash column (GraceResolve™) run isocratic in Heptane/EtOAc 9/1; sample applied in DCM; 15 ml/min 1 min fraction- size; Product C33b (40 mg, 0.107 mmol; 47.4%) was thus obtained. 1HNMR (400MHz, CDC13): 5(ppm): 2.60 (1H, t, J=14.4 Hz), 1.20 (6H, s), 0.93 (3H, d, J=6.5 Hz), 0.70 (3H, s).
[00407] Preparation of compound C33. Compound C33b (5 mg, 0.013 mmol) was dissolved in Tetrahydrofuran (dry) (1 ml) and cooled to -78°C. Then, K-Selectride (0.020 mmol, 0.020 ml) was added and the reaction mixture was stirred for 6 hours under nitrogen. The reaction was stopped by the addition of a 10% NaOH solution (0.1 mL) followed by the addition of 30% hydrogen peroxide solution (0.2 mL). The reaction mixture was warmed to room temperature and stirring was continued for 30 minutes. The mixture was extracted with ethyl acetate, the combined organic layers were washed with brine, dried over Na2S04, filtered and evaporated. The crude product was purified by flash column chromatography using 2: 1 Heptane/EtOAc. Compound C33 (2.2 mg, 0.00502 mmol; 37.6%) was thus obtained. LCMS: 83% pure, contains 17% of the 3 -OH isomer. 1HNMR (400MHz, CDC13): 5(ppm): 4.12 (1H, t, J=2.7 Hz), 1.20 (6H, s), 0.92 (3H, d, J=6.6 Hz), 0.67 (3H, s).
Example 25. Preparation
Figure imgf000165_0001
[00408] Compound C33b (40 mg, 0.107 mmol) was dissolved in tetrahydrofuran (dry)
(1 ml) under argon and cooled to -78°C. Then, Methyllithium 1,6M (0.320 mmol, 0.200 ml) was added. Stirring at -78°C. TLC after 2h: still much s.m. present. The rx was allowed to reach r.t. slowly. TLC after lh: still much s.m. present and a thick precipitate present, more Tetrahydrofuran (dry) (1 mL) was added to aid dissolution. After 30 min; the rx was almost completely dissolved. Continue stirring for lh. TLC: s.m. still present but 90+% conversion. The rx was stirred 30 min. longer and then quenched. Sat. aq. NH4C1 was added and the product was extracted with DCM (3x). 32 mg yield (crude). Tha aq. layer was saturated with NaCl and extracted again this time with EtOAc (3x). Now 36 mg crude product. The mixture was purified on a 12g pre-packed flash column (GraceResolve™) run in a gradient 15 ml/min: 2 min 100% Heptane; 28 min 0 => 15% Heptane/EtOAc; 20 min 15%
Heptane/EtOAc; fraction size 60 sec. The product D15 (11 mg, 0.027 mmol; 25.05%) was thus obtained. 1HNMR (400MHz, CDC13): 5(ppm): 1.21 (3H, s), 1.20 (6H, s), 0.92 (3H, d, J=6.5 Hz), 0.67 (3H, s).
Example 26. Preparation of D10 and D16
Figure imgf000166_0001
D16 (3p-OH) + D16 (3a-OH)
29.6%
[00409] Preparation of 3-alpha-D16 compound. Compound DlOa (68 mg, 0.182 mmol) was dissolved in Tetrahydrofuran (dry) (2 ml) under argon and cooled to 0°C. Then, Methylmagnesium chloride (0.605 ml, 1.815 mmol) was added. After 10 min, the rx was stirred at rt for 3h. The rx was then added to 100 mL of sat. aq. NH4C1, rx vessel rinsed with THF and DCM, and stirred for 0.5h with DCM. The product was extracted twice more with DCM. DCM dried (brine, sulfate) and evaporated and Purification on a silica column run in 30 ml/min fractions 30 sec. Grandient: 5 min 100% heptane; 25 min 100/0 H/EtOAc => 80/20 heptane/EtOAc; 20 min 80/20 heptane/EtOAc. Compound D16 (3tf-OH) (21 mg, 0.054 mmol; 29.6%) was thus obtained. 1HNMR (400MHz, CDC13): 5(ppm): 1.19 (9H, s), 0.91 (3H, d, J=6.6 Hz), 0.66 (3H, s).
[00410] Preparation of 3-beta-D16 compound. Compound DlOa (57 mg, 0.152 mmol) was dissolved in Toluene (dry) (1 ml) under argon and cooled to -78°C. Then, MAD, 0.4 M solution in toluene (1.141 ml, 0.456 mmol) was added. After 10 min. stirring at -78°C, Methyllithium, 1.6 M solution in diethyl ether (0.285 ml, 0.456 mmol) was added. Stirring for 2h at -78°C under argon. After 2h at that temperature, the reaction was allowed to stir and warm to rt. After 2 additional hour it was quenched by adding it to saturated NH4C1. The rx vessel was rinsed with EtOAc. Product extracted with EtOAc (2x). EtOAc dried (brine, Na2S04) and evaporated. The mixture was purified on a 12g pre-packed flash column (GraceResolve™) applied in DCM and run in a gradient 30 ml/min: 5 min 100% Heptane; 25 min 0 => 15% Heptane/EtOAc; 20 min 15% Heptane/EtOAc; fraction size 30 sec. Product D16 (3β-Οϋ) (35 mg, 0.090 mmol; 58.8%) was thus obtained. 1HNMR (400MHz, CDC13): δ(ρρηι): 1.23 (3H, s), 1.20 (6H, s), 0.91 (3H, d, J=6.6 Hz), 0.66 (3H, s).
[00411] Preparation of compound DIOa. Compound C32 (222 mg, 0.589 mmol) was dissolved in Chloroform (dry) (15 ml) by slightly heating. Then the solution was cooled in a water bath (did not crystallize upon cooling) and PCC (191 mg, 0.884 mmol) was added. Stirring while still in the water-bath. TLC after lh: -60-70% conversion. Stirring overnight. The solution was then transferred to a separatory funnel and the deposit was extensively washed with DCM and added to the separatory funnel. Washing with 0.5N KHS04. The aq. phase was washed with DCM, org. phase combined and dried over Na2S04 (no brine) and evaporated. The mixture was purified on a 12g pre-packed flash column (GraceResolve™) run in a gradient 30 ml/min: 5 min 100% H; 25 min 0 => 15% H/EA; 20 min 15% H/EA; fraction size 30 sec. 100 tubes. Coumpound DIOa (132 mg, 0.352 mmol; 59.8%) was thus obtained. 1HNMR (400MHz, CDC13): 5(ppm): 1.20 (6H, s), 0.92 (3H, d, J=6.6 Hz), 0.69 (3H, s).
[00412] Preparation of compound D10. Compound DIOa (73 mg, 0.195 mmol) was dissolved in tetrahydrofuran (dry) (2 ml) under argon and trifluoromethyltrimethylsilane (0.086 ml, 0.585 mmol) and Cesium fluoride (2.96 mg, 0.019 mmol) were added. Stirring at rt. The solution became slightly yellow slowly. TLC after 3h: full conversion. The rx was diluted with DCM and extracted with water. No phase separation. Brine (equal volume) was added. Good separation. The aq. layer was again extracted with DCM; DCM combined and dried (Na2S04) and evaporated. 103 mg crude product (102%). Flash column on a 12g prepacked column run in 30 min. gradient from 0 => 2.5% DIPE in heptane. The impure TMS- intermediate was thus obtained as an impure mixture of the 3a- and 3 ?-OH products and used as such: The intermediate was dissolved in 1,4-Dioxane (4 ml) and IN HC1 (1 mL, 1.000 mmol) is added. Stirring at rt. TLC after lh: s.m. gone. Water was added and the product was extracted with DCM 3x and dried over Na2S04 and evaporated. The crude product was purified on a C18-column run in a gradient of MeCN/water 95/5 => 0/100 12 min then 12 min isocratic 100% water. Compound D10 (14 mg, 0.030 mmol; 22.9%) was thus obtained. 1HNMR (400MHz, CDC13): 5(ppm): 1.19 (6H, s), 0.91 (3H, d, J=6.6 Hz), 0.67 (3H, s). Example 27. Preparation of Compound Dl
Figure imgf000168_0001
[00413] In a flame dried tube a colorless clear solution of compound D13a (97 mg,
0.250 mmol) and Trifluoromethyltrimethylsilane (0.119 ml, 0.749 mmol) in THF (dry, ImL) was cooled to 0°C under argon. Cesium fluoride (20 mg, 0.132 mmol) was added. Reaction mixture stayed colorless and was stirred at 0°C for 5 min. Cooling bath was removed and stirring was continued at RT for 1.5h. Reaction mixture had turned brown-yellow, TLC (Heptane/EtOAc, 1: 1) complete conversion. Reaction mixture was left standing at RT overnight. H20 (ImL) and EtOAc (5mL) were added. Layers were separated and aq. layer was extracted with EtOAc (2x5mL). Combined org. layers were dried with Na2S04 and solvents were removed in vacuo. Flash chromatography (Heptane, 5% -20% EtOAc) afford the impure 3-OTMS intermediate. This was used as such: Aq. HCl (IN, ImL) was added to a solution of the 3-OTMS intermediate in THF (ImL). Reaction mixture was stirred at RT overnight, TLC (H/E; 1: 1) complete conversion. Solvents were removed in vacuo. A yellow solid was obtained, Purification by flash chromatography (Heptane; 15%-35% EtOAc) afforded compound Dl (36 mg, 0.078 mmol; 31.4%). 1H-NMR (400 MHz, CDC13): (ppm): 1.20 (6H, s), 0.96 (3H, s), 0.89 (3H, d, J=10.6 Hz), 0.65 (3H, s).
Example 28. Preparation of D2a-D2 compounds
Figure imgf000169_0001
[00414] Preparation of compound D2a. Under an atmosphere of argon, compound BB-la (1 g, 2.57 mmol) was dissolved in methanol (25 ml), and palladium, 10% on activated carbon (0.137 g, 0.129 mmol) was added. The argon atmosphere was replaced by hydrogen (balloon) and the reaction mixture was vigorously stirred at room temperature overnight. The reaction mixture was filtered over hyflo and the filter residue was washed with methanol (50 ml) and dichloromethane (2x 50 ml). The filtrate and washings were combined and evaporated under reduced pressure to afford product D2a (1.01 g, 2.57 mmol, Yield=100%) as white powder. 1HNMR (400 MHz, CDC13) 5(ppm): 3.66 (3H, s), 3.59 (1H, oct, J=5.1 Hz), 2.35 (1H, ddd, J=15.4, 10.3, 5.1 Hz), 2.21 (1H, ddd, J=15.8, 9.5, 6.3 Hz), 1.94 (1H, dt, J=12.4, 3.3 Hz), 0.91 (3H, d, J=6.4 Hz), 0.65 (3H, s), 0.62 (1H, ddd, J=14.8, 8.1, 4.1 Hz).
[00415] Preparation of compound D2b. A suspension of pyridinium chlorochromate
(PCC) (0.969 g, 4.49 mmol) in dichloromethane (10 ml) (dried over molecular sieves) was cooled to 0°C under nitrogen atmosphere. A solution of D2a (0.585 g, 1.498 mmol) in dichloromethane (5 ml) (dried over molecular sieves) was added gradually. After stirring for lh, a color change from orange to dark brown was observed. The ice bath was removed and stirring was continued for 3.5h. TLC[heptane(2):ethyl acetate(l)] showed complete clean conversion to a higher eluting product after vanillin staining. The reaction mixture was diluted with a 2: 1 mixture of heptane/ethyl acetate (15 ml), eluted over a short pad of silica (30 g) and the pad was twice rinsed with heptane/ethyl acetate/dichloromethane 2: 1: 1 (60 ml). The elute was washed with 0.5N aqueous potassium hydrogen sulfate (90 ml). The washing was back extracted with dichloromethane (90 ml) and this extract was combined with the former organic layer, dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was stripped twice with dichloromethane to afford D2b (0.555 g, 1.428 mmol, Yield=95 ) as a white solid. 1HNMR (400 MHz, CDC13) 5(ppm): 3.66 (3H, s), 2.04-1.94 (2H, m), 1.91-1.74 (2H, m), 1.73-1.66 (1H, m), 1.01 (3H, s), 0.92 (3H, d, J=6.4 Hz), 0.64 (3H, s).
[00416] Preparation of compound D2c. Under an atmosphere of argon,
dibromomethane (1.268 ml, 18.01 mmol) was added to a stirred suspension of zinc (3.99 ml, 57.9 mmol) in tetrahydrofuran (dry) (30 ml) (slightly exothermic). The mixture was cooled to -40°C in a dry ice / acetonitrile bath and stirring for 10 minutes. Titanium(IV) chloride (1.533 ml, 13.90 mmol) was added gradually at such a rate that the temperature did not exceed - 30°C (very exothermic). The dry ice / acetonitrile bath was removed and the mixture was stirred in an ice bath for 4h at an internal temperature between 0-5°C. Part of the black suspension (~3 ml) was added at room temperature to a solution of D2b (0.1 g, 0.257 mmol) in tetrahydrofuran (dry) (10 ml). The mixture was stirred for 10 minutes. TLC [Heptane (2) : ethyl acetate (1)] showed mainly starting material present in the reaction mixture after molybdenum staining. Another part of the suspension (~3 ml) was added and stirring was continued for 5 minutes. TLC [Heptane (2): ethyl acetate(l)] showed still mainly starting material present in the reaction mixture after molybdenum staining. The rest of the suspension was added and after stirring for 5 minutes, TLC [Heptane (2): ethyl acetate(l)] showed complete conversion of the starting material to mainly one very apolar product after molybdenum staining. The reaction mixture was poured out in saturated aqueous sodium hydrogen carbonate (100 ml) (beware for foaming) and extracted three times with ethyl acetate (100 ml). The combined extracts were washed with brine (150 ml), dried over sodium sulfate and evaporated under reduced pressure. The residue was chromatographed on silica gel (12 g flash column) using an eluent with gradient of 0-5% diisopropyl ether in heptane to provide D2c (0.058 g, 0.150 mmol, Yield=58%) as a white solid product. 1HNMR (400 MHz, CDC13) 5(ppm): 4.55 (2H, brd), 3.66 (3H, s), 2.35 (1H, ddd, J=15.4, 10.3, 5.1 Hz), 2.21 (1H, ddd, J=15.8, 9.7, 6.4 Hz), 2.19-2.09 (2H, m), 2.06-1.71 (6H, m), 1.69-1.61 (1H, m), 0.91 (3H, d, J=6.4 Hz), 0.85 (3H, s), 0.69-0.60 (1H, m), 0.65 (3H, s).
[00417] Preparation of compound D2d. To a solution of D2c (0.058 g, 0.150 mmol) in dry dichloromethane (2 ml) (dried on molsieves) was added potassium carbonate (anhydrous) (0.027 g, 0.195 mmol) under nitrogen atmosphere. The resulting mixture was cooled in an ice/water bath, and solid 3-chloroperoxybenzoic acid (70-75%) (mCPBA) (0.039 g, 0.158 mmol) was added in a one portion. The reaction mixture was stirred overnight.
TLC[heptane(9):ethyl acetate(l)] showed partial clean conversion after vanillin staining. Extra potassium carbonate (anhydrous) (0.027 g, 0.195 mmol) and 3-chloroperoxybenzoic acid (70-75%) (m-CPBA) (0.039 g, 0.158 mmol) was added and stirring was continued for 2h. TLC[heptane(9):ethyl acetate(l)] showed complete conversion after vanillin staining. The reaction mixture was filtered and the precipitated benzoate salt was washed with
dichloromethane (2x 5ml). The solvent was removed in vacuo to afford D2d (0.060 g, 0.149 mmol, Yield=99%) as a white solid residue. According to NMR a 2: 1 mixture of a-O- and β- O-diastereoisomers was obtained. 1HNMR (400 MHz, CDC13) 5(ppm): 3.66 (3H, s), 2.62 (0.33H[a-diastereoisomer], d, J=4.8 Hz), 2.61 (0.33H[a-diastereoisomer], d, J=4.9 Hz), 2.57 (0.33H[P-diastereoisomer], bs), 2.35 (1H, ddd, J=15.4, 10.3, 5.1 Hz), 2.21 (1H, ddd, J=15.7, 9.4, 6.3 Hz), 2.10-1.99 (1H, m), 1.99-1.92 (1H, m), 0.91 (3H, d, J=6.4 Hz), 0.86 (1Η[β- diastereoisomer], s,), 0.84 (2H[a-diastereoisomer], s), 0.66 (3H, s).
[00418] Preparation of compound D2e (a-OH and β-ΟΗ). A mixture of D2d (0.055 g, 0.137 mmol) in methanol (extra dry) (5.5 ml) was heated until a clear colorless solution was obtained. The solution was allowed to cool to room temperature under a nitrogen atmosphere and sodium methoxide, 5.4M (30 wt.%) solution in methanol (0.239 mmol, 0.080 ml) was added. The reaction mixture was heated to reflux and stirred overnight.
TLC[heptane(4):ethyl acetate(l)] showed complete conversion after vanillin staining, product not visible. The reaction mixture was poured out in a saturated aqueous solution of ammonium chloride (50 ml) and three times extracted with dichloromethane (50 ml). The combined extracts were dried over sodium sulfate and evaporated. According to TLC, a very polar product was formed. The methyl ester moiety was hydrolyzed to the carboxylic acid due to presence of water in the reaction mixture. The residue was dissolved in
dichloromethane (10 ml). Oxalyl chloride (0.078 g, 0.612 mmol, 0.053 ml) and N,N- dimethylformamide (cat.) were added, and the reaction mixture was stirred for 2h. A sample was poured out in methanol, evaporated until dryness, and analyzed on TLC
[dichloromethane(98):methanol(2)] which showed complete conversion to the methyl ester after molybdenum staining. The reaction mixture was diluted with methanol (150 ml) (dried on mol. sieves), and evaporated under reduced pressure at 40°C. The residue was purified by flash column (12 g) chromatography [heptane (100=>80) : ethyl acetate(0=>20)]. Two product fractions were obtained, which were separately collected and evaporated under reduced pressure to afford D2e (a-OH) (0.035 g, 0.081 mmol, Yield=33 ) and D2e (β-ΟΗ) (0.032 g, 0.074 mmol, Yield=30 ) as white solids. D2e (a-OH) and D2e (β-ΟΗ) were used as such in the following experiment.D2e (a-OH): 1HNMR (400 MHz, CDC13) 5(ppm): 3.66 (3H, s), 3.38 (3H, s), 3.18 (2H, s), 2.35 (IH, ddd, J=15.4, 10.3, 5.1 Hz), 2.21 (IH, ddd, J=15.7, 9.4, 6.3 Hz), 2.02 (IH, bs), 1.94 (IH, dt, J=12.3, 3.0 Hz), 1.90-1.73 (2H, m), 0.91 (3H, d, J=6.4 Hz), 0.74 (3H, s), 0.65 (3H, s).D2e (β-ΟΗ): 1HNMR (400 MHz, CDC13) 5(ppm): 3.66 (3H, s), 3.39 (3H, s), 3.37 (2H, d, J=4.3 Hz), 2.54 (IH, bs), 2.35 (IH, ddd, J=15.4, 10.3, 5.1 Hz), 2.21 (IH, ddd, J=15.8, 9.5, 6.3 Hz), 1.95 (IH, dt, J=12.5, 3.0 Hz), 1.90- 1.73 (2H, m), 0.91 (3H, d, J=6.4 Hz), 0.83 (3H, s), 0.65 (3H, s).
[00419] Preparation of compound D2 (a-OH). In a flame dried round bottom flask (100 ml), D2e (a-OH) (0.035 g, 0.081 mmol) was dissolved in tetrahydrofuran (dry) (1 ml) and cooled in an ice bath under argon for 0.5h. Methylmagnesium chloride 3.0M in THF (0.805 mmol, 0.268 ml) was added via a syringe. Some gas evolution was observed. After stirring the reaction mixture for 2h, TLC[heptane(l):ethyl acetate(l)] showed complete conversion of the starting material to a lower eluting product after molybdenum staining. The reaction mixture was partitioned between a saturated aqueous solution of ammonium chloride (20 ml) and dichloromethane (20 ml) and left for two days. The organic layer was separated and the aqueous layer was twice more extracted with dichloromethane (20 ml). The extracts were combined, dried over sodium sulfate and evaporated. The residue was purified by flash column (12 g) chromatography [heptane(100=>80):ethyl acetate(0=>20)]. The product containing fractions were collected and evaporated under reduced pressure at 40°C. The residue was transferred to a vial as a solution in dichloromethane / methanol and evaporated at 37°C under a stream of nitrogen. The white solid residue was dried at 45°C in a vacuum oven overnight to afford D2 (a-OH) (0.025 g, 0.055 mmol, Yield=68 ) as white powder. 1HNMR (400 MHz, CDC13) 5(ppm): 3.38 (3H, s), 3.18 (2H, s), 1.98 (IH, bs), 1.95 (IH, dt, J=12.5, 3.2 Hz), 1.88-1.79 (IH, m), 1.68-1.61 (IH, m), 1.20 (3H, s), 1.19 (3H, s), 0.91, (3H, d, J=6.5 Hz), 0.74 (3H, s), 0.65 (3H, s).
[00420] Preparation of compound D2 (β-ΟΗ). In a flame dried round bottom flask (100 ml), D2e (β-ΟΗ) (0.035 g, 0.081 mmol) was dissolved in tetrahydrofuran (dry) (1 ml) and cooled in an ice bath under argon for 0.5h. Methylmagnesium chloride 3.0M in THF (0.805 mmol, 0.268 ml) was added via a syringe. Some gas evolution was observed. After stirring the reaction mixture for 2h, TLC[heptane(l):ethyl acetate(l)] showed complete conversion of the starting material to a lower eluting product after molybdenum staining. The reaction mixture was partitioned between a saturated aqueous solution of ammonium chloride (20 ml) and dichloromethane (20 ml) and left for two days. The organic layer was separated and the aqueous layer was twice more extracted with dichloromethane (20 ml). The extracts were combined, dried over sodium sulfate and evaporated. The residue was purified by flash column (12 g) chromatography [heptane (100=>80): ethyl acetate (0=>20)]. The product containing fractions were collected and evaporated under reduced pressure at 40°C. The residue was transferred to a vial as a solution in dichloromethane / methanol and evaporated at 37°C under a stream of nitrogen. The white solid residue was dried at 45°C in a vacuum oven overnight to afford D2 (β-ΟΗ) (0.018 g, 0.039 mmol, Yield=53 ) as white powder. 1HNMR (400 MHz, CDC13) 5(ppm): 3.40 (3H, s), 3.39 (1H, d, J=9.2 Hz), 3.36 (1H, d, J=9.2 Hz), 2.51 (1H, bs), 1.96 (1H, dt, J=12.4, 3.1 Hz), 1.89-1.77 (1H, m), 1.20 (6H, s), 0.91, (3H, d, J=6.5 Hz), 0.83 (3H, s), 0.65 (3H, s).
Example 29. Preparation of 3-alpha-D3 and 3-beta-D6
Figure imgf000173_0001
[00421] Preparation of compound D6a. To a solution of 18-crown-6 (0.315 g, 1.192 mmol) and KHF2 (0.233 g, 2.98 mmol) in dry DMF (7.5 mL) under an argon atmosphere was added D5c (0.3 g, 0.745 mmol) The reaction mixture was heated till 150°C overnight. More KHF2 (0.233 g, 2.98 mmol) was added and heating was continued for 8 h. The mixture was cooled to room temperature poured out in H20 (150 mL) and stirred with EtOAc (100 mL) for 30 min. The aqueous layer was extracted twice with EtOAc (200 mL). The combined organic layers were washed with brine (2x) dried over Na2S04, filtered and evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica, heptane/ethylacetate, 1:0 -> 85: 15) to afford product D6a (71 mg, 0.17 mmol, yield=23 ). According to NMR D6a was obtained as a 3: 1 cis/trans mixture. 1HNMR (400 MHz, CDC13) 5(ppm): 4.18 (1.5H [cis-isomer (β-ΟΗ)], d, J= 47.8 Hz), 4.15 (0.5H [trans-isomer (a-OH)], d, J= 48 Hz), 3.66 (3H, s), 2.35 (1H, ddd, J=15.4 ,10.3, 5.2 Hz), 2.21 (1H, ddd, J=15.8, 9.5, 6.3 Hz), 0.98 (3H, s), 0.91 (3H, d, J=6.4 Hz), 0.65 (3H, s).
[00422] Preparation of compound D6 (β-ΟΗ) and D3 (a-OH). Compound D6a (0.071 g, 0.168 mmol) was coevaporated with toluene (50 mL) and dissolved in dry THF (2 mL) under an atmosphere of argon and cooled to 0°C. MeMgCl 3.0M in THF (0.560 mL, 1.680 mmol,) was added using a syringe. The reaction mixture was stirred for 2 h at 0°C. The reaction mixture was quenched with saturated aqueous NH4C1 (50 mL) and extracted three times with CH2CI2 (100 mL).The combined organic layers were washed with brine dried on Na2S04 and the crude product was purified by flash column chromatography (silica, heptane/ethylacetate, 1:0 -> 85: 15) to afford D6 (β-ΟΗ) (23 mg, 0.05 mmol, yield = 32%) and D3 (a-OH) (8 mg, 0.007 mmol, yield = 4%). D6 (β-ΟΗ): 1HNMR (400 MHz, CDC13) 5(ppm): 4.19 (2H, d, J= 47.8 Hz), 2.00-1.94 (1H, m), 1.76-1.69 (1H, m), 1.20 (6H, s), 0.98 (3H, s), 0.91 (3H, d, J=6.5 Hz), 0.65 (3H, s). D3 (a-OH): 1HNMR (400 MHz, CDC13) 5(ppm): 4.15 (2H, d, J= 47.8 Hz), 1.96 (1H, dt, J=12.4, 3.2 Hz), 1.89-1.78 (1H, m), 1.20 (3H, s), 1.19 (3H, s), 0.92 (3H, d, J=6.5 Hz), 0.76 (3H, s), 0.65 (3H, s).
Figure imgf000174_0001
[00423] Preparation of compound D4a. BB-3 (0.448 g, 1.153 mmol) was suspended in EtOH (abs) (12 mL) and MeOH (6 mL) under an atmosphere of argon and palladium, 10% on activated carbon (0.012 g, 0.012 mmol) was added. The argon atmosphere was replaced by hydrogen (atmospheric) and the reaction mixture was vigorously stirred at room
temperature for 2h. Stirring was continued for 3 days. The reaction mixture was filtered over hyflo and evaporated till dryness. The residue was suspended in acetic acid (5 mL), EtOAc (5 mL) and 1,4-dioxane (5 mL) and heated till a clear solution was obtained. The reaction mixture was cooled to room temperature and palladium, 10% on activated carbon (0.012 g, 0.012 mmol) was added under an Argon atmosphere. The argon atmosphere was replaced by hydrogen (atmospheric) and the reaction mixture was vigorously stirred at room temperature overnight. The reaction mixture was filtered over hyflo and washed with MeOH (2x50 mL) and CH2CI2 (50 mL). The solvents were evaporated and the residue triturated with saturated aqueous NaHC03, filtered off and dried in a vacuum oven at 40°C overnight to afford D4a (385 mg, 0.99 mmol, yield = 85%) as a white solid. 1HNMR (400 MHz, CDC13) 5(ppm): 3.59 (IH, sep, J=5.3 Hz), 1.96 (IH, dt, J=9.3, 3.1 Hz), 1.98-1.75 (2H, m), 1.71 (IH, dt, J=13.2, 3.4 Hz), 1.65 (IH, dq, J=13.0, 3.4 Hz), 1.19 (6H, s), 0.91, (3H, d, J=6.5 Hz), 0.80 (3H, s), 0.65 (3H, s).
[00424] Preparation of compound D4b. To an ice cooled solution of pyridinium chlorochromate (PCC) (0.248 g, 1.152 mmol) in dry CH2CI2 (4 mL) under a nitrogen atmosphere was added a suspension of D4a (0.3 g, 0.768 mmol) in dry CH2CI2 (4 mL). The solid material was added drop wise redissolved as a solution in dry CHCI3 (4mL). The reaction mixture was stirred for 30 min at 0°C, followed by 2h at room temperature. Again pyridinium chlorochromate (PCC) (0.248 g, 1.152 mmol) was added in one portion at room temperature, and the reaction mixture was stirred overnight. The reaction mixture was eluted over a short pad of sand, silica (5 g) and hyflo, and the pad was rinsed with CH2CI2 (100 mL). The elute was washed twice with aqueous 0.5N KHSO4 (100 ml). The combined washings were extracted once with CH2CI2 (100 mL), and the combined organic layers were dried over Na2S04, filtered and evaporated under reduced pressure to afford D4b (306 mg, 0.79 mmol, yield = 103%) an orange/brown solid.1HNMR (400 MHz, CDC13) 5(ppm): 2.38 (IH, td, J=14.5, 6.4 Hz), 2.32-2.21 (2H, m), 2.15-1.93 (3H, m), 1.90-1.79 (IH, m), 1.75-1.65 (IH, m), 1.20 (6H, s), 1.01 (3H, s), 0.92 (3H, d, J=6.4 Hz), 0.78-0.64 (IH, m), 0.68 (3H, s).
[00425] Preparation of compound D4c. In a flame dried reaction tube, a solution of
D4b (0.1 g, 0.257 mmol) and (trifluoromethyl)trimethylsilane (0.053 mL, 0.34 mmol) in dry THF (2.5 mL) was cooled to 0°C under argon. CsF (spatula tip) was added and the reaction mixture was stirred at 0°C for 5 minutes. The cooling bath was removed and stirring was continued at room temperature overnight. Extra (trifluoromethyl)trimethylsilane (0.053 ml, 0.34 mmol) and CsF (spatula tip) were added to the reaction mixture and stirring under argon atmosphere was continued for 3h. H20 (50 mL) and EtOAc (50 mL) were added. Layers were separated after stirring for 30 minutes. The aqueous layer was extracted twice with EtOAc (50 mL). The combined organic layers were dried with Na2S04 and solvents were removed in vacuo. D4c (163 mg, 0.31 mmol, yield = 119%) was obtained as a light yellow oil. 1HNMR (400 MHz, CDC13) 5(ppm): 2.04-1.92 (1H, m), 1.90-1.68 (2H, m), 1.09 (3H, s), 1.08 (3H, s), 0.80 (3H, s), 0.73 (3H, s), 0.55 (3H, s), 0.03 (12H, m).
[00426] Preparation of compound D4. To a solution of D4c (0.137 g, 0.258 mmol) in 1,4-dioxane (8 mL) was added 1 M aqueous HCl (2 mL, 2.0 mmol). The yellow solution was stirred for 3h at room temperature. The reaction mixture was diluted with H20 (50 mL) and extracted with CH2C12 (3x50 mL). The combined organic layers were washed with saturated aqueous NaHC03, brine, dried on Na2S04 and the solvents evaporated. The crude product was purified by flash column chromatography (silica, heptane/EtOAc, 1:0 -> 4: 1) and crystallized from CH2C12 to afford D4 (44 mg, 0.10 mmol, yield = 37%) as a white solid. 1HNMR (400 MHz, CDC13) 5(ppm): 2.09-2.02 (1H, m), 1.98 (1H, s), 1.96 (1H, dt, J=12.8, 3.4 Hz), 1.88-1.77 (2H, m), 1.72-1.61 (3H, m), 1.20 (3H, s), 1.19 (3H, s), 0.92 (3H, d, J=6.6 Hz), 0.85(3H, s), 0.65 (3H, s).
Example 31. Preparation of compound D5
Figure imgf000176_0001
[00427] Preparation of compound D5a. To a solution BB-1 (2 g, 5.15 mmol) and
Al(iPrO)3 (3.68 g, 18.01 mmol) in dry toluene (80 mL) was added l-methyl-4-piperidone (29.1 g, 257 mmol, 29.7 mL). The solution was stirred at reflux for 3 h. The reaction mixture was cooled to room temperature and diluted with aqueous 0.5 M HCl (80 mL), brine (80 mL) and Et20 (120 mL). The organic layer was extracted with EtOAc (3x100 mL). The combined organic layers were dried with Na2S04, filtered and the solvents were removed in vacuo. The residue was diluted with aqueous 1 M HCl (250 mL) and extracted with EtOAc (2x250 mL). The organic solvents were washed with brine, dried with Na2S04 and evaporated till dryness. The crude product was purified by flash column chromatography (silica,
heptane/ethylacetate, 1:0 -> 9: 1) and coevaporated with CH2C12 to afford D5a (1.27 g, 3.27 mmol, yield = 64%). 1HNMR (400 MHz, CDC13) 5(ppm): 5.72 (1H, s), 3.67 (3H, s), 2.48-
2.17 (6H, m), 2.02 (1H, dt, J=9.6, 3.8 Hz), 1.94-1.75 (3H, m), 1.69 (1H, td, J=14.0, 4.7 Hz),
1.18 (3H, s), 0.92 (3H, d, J=6.4 Hz), 0.71 (3H, s).
[00428] Preparation of compound D5b. A suspension of D5a (1.26 g, 3.26 mmol) in absolute EtOH (150 mL) was heated till the starting material was dissolved. The solution was cooled to room temperature and made under an argon atmosphere. Palladium on calcium carbonate, 10% (w/w) (cat.) was added, and hydrogen (atmospheric) was flushed through the reaction mixture for 15 minutes. The reaction mixture was stirred at room temperature under hydrogen atmosphere overnight. The reaction mixture was flushed with argon, the solids were filtered over Celite/silica gel, and the filter was washed with EtOH (75 ml). The solvents were removed in vacuo and the crude product was purified by flash column chromatography (silica, heptane/ethylacetate, 1:0 -> 9: 1) to obtain product D5b (1.12 g, 2.16 mmol, Yield=75%). According to NMR D5b was obtained as a 3: 1 cis/trans mixture.1HNMR (400 MHz, CDC13) 5(ppm): 3.67 (3H, s), 2.70 (1H, t, J=14.2 Hz), 1.02 (2H[cis-isomer], s), 1.00 (lH[trans-isomer], s), 0.92 (3H, d, J=6.4 Hz), 0.68 (3H, s).
[00429] Preparation of compound D5c. To a solution of trimethylsulfoxonium iodide
(0.747 g, 3.39 mmol) in dry DMSO (10 mL) under an nitrogen atmosphere was added NaH (60% dispersion in mineral oil) (0.075 g, 3.13 mmol) in 1 portion. The reaction mixture was stirred for 30 min and a solution of D5b (1.014 g, 2.61 mmol) in dry THF (10 mL) was added. The reaction mixture was stirred for lh, followed by the addition of extra
trimethylsulfoxonium iodide (0.747 g, 3.39 mmol) and NaH (60% dispersion in mineral oil) (0.075 g, 3.13 mmol). The mixture stirred for 2 h. The reaction mixture was partitioned between saturated aqueous NH4C1 (150 mL) and CH2C12 (150 mL). The aqueous layer extracted with CH2CI2 (100 mL) and the combined organic layers were washed with brine, dried on Na2S04 and evaporated till dryness. The crude product was purified by flash column chromatography (silica, heptane/ethylacetate, 1:0 -> 88: 12) to afford product D5c (1 g, 2.48 mmol, Yield=75%). According to NMR D5c was obtained as a cis/trans mixture. 1HNMR (400 MHz, CDC13) 5(ppm): 3.67 (3H, s), 2.64-2.60 (2H, m), 2.42-2.30 (2H, m), 2.27-2.16 (1H, m), 0.99 (3H, s), 0.92 (3H, d, J=6.4 Hz), 0.66 (3H, s).
[00430] Preparation of compound D5d. To a suspension of D5c (0.1 g, 0.248 mmol) in MeOH (2.5 mL) under a nitrogen atmosphere was added KOtBu (0.056 g, 0.497 mmol) in one portion. The reaction mixture was heated till reflux for 3 hours and cooled to room temperature overnight. The mixture was diluted with CH2CI2 (5 mL) and poured out in saturated aqueous NH4C1 (25 mL). The aqueous layer was extracted with CH2CI2 (3x 25 mL). The combined organic layers were dried over Na2S04, filtered and evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica, heptane/ethylacetate, 1:0 -> 9: 1) and coevaporated with CH2CI2 (5 mL) to afford product D5d (0.08 g, 0.18 mmol, Yield=74 ). According to NMR D5d was obtained as a -2: 1 cis/trans mixture. 1HNMR (400 MHz, CDC13) 5(ppm): 3.66 (3H, s), 3.39 (2H [cis-isomer (β-ΟΗ)], s), 3.38 (1H [trans-isomer (a-OH)], s), 3.24-3.12 (2H [cis-isomer (β-ΟΗ) / trans-isomer (a-OH)], m), 2.35 (1H, ddd, J=15.4, 10.3, 5.1 Hz), 2.21 (1H, ddd, J=15.8, 9.5, 6.3 Hz), 2.04 (1H, bs), 1.98-1.92 (1H, m), 1.92-1.75 (3H, m), 0.96 (3H, s), 0.91 (3H, d, J=6.4 Hz), 0.64 (3H, s).
[00431] Preparation of compound D5. In a flame dried round bottom flask (100 mL) D5d (0.080 g, 0.184 mmol) was dissolved in dry THF (3 mL) under an atmosphere of nitrogen and cooled to 0°C. MeMgCl 3.0M in THF (0.614 mL, 1.841 mmol) was added using a syringe The reaction mixture was stirred for 1.5 h at 0°C. The reaction mixture was quenched with saturated aqueous NH4C1 (20 mL) and extracted three times with CH2CI2 (3x20 mL).The combined organic layers were washed with brine dried on Na2S04 and the crude product was purified by flash column chromatography (silica, heptane/ethylacetate, 1:0 -> 85: 15) to afford D5 (36 mg, 0.08 mmol, yield = 45%). 1HNMR (400 MHz, CDC13) 5(ppm): 3.39 (3H, s), 3.22 (1H, d, J=9.0 Hz), 3.20 (1H, d, 9.0 Hz), 1.20 6H, s), 0.97 (3H, s), 0.91 (3H, d, J=6.5 Hz), 0.65 (3H, s). Example 32. Preparation of C3-alpha-D13 and C3-beta-D13 compounds
Figure imgf000179_0001
[00432] Under argon at 0°C methyllithium, 1.6M in diethyl ether (0.26 mL, 0.412 mmol) was added dropwise to a solution of D13a (0.080 g, 0.206 mmol) in THF (dry, ImL). A white precipitate formed upon addition. THF (dry, 5mL) was added. Stirring at 0°C was continued for lOmin. Reaction mixture was alllowed to warm to RT and stirring was continued for lh, TLC (H/E,l: l) showed starting material and two more polar spots.
Methyllithium, 1.6M in diethyl ether (0.39 mL, 0.618 mmol) was added at RT under argon. Stirring was continued overnight. Reaction mixture had turned into a yellow solution. Solvent was removed in vacuo. THF (dry, ImL) was added under argon at RT. Methyllithium, 1.6M in diethyl ether (0.26 mL, 0.412 mmol) was added dropwise and reaction mixture was stirred at RT for 3h. Aq. sat. ammonium chloride (lOmL), H20 (5mL) and diethyl ether (20mL) were added. Layers were separated and aq. layer was extracted with diethyl ether (2x25mL). Combined org. layers were dried with sodium sulfate and solvents were removed in vacuo. Flash chromatography (H, 5% -25% EtOAc) afforded 13 mg of the 3beta-hydroxy
diastereoisomer and 12 mg of the 3alpha-hydroxy diastereoisomer. Compound D13 (3ar-OH)
(12 mg, 0.030 mmol; 14.4%) and compound D13 (3/?-OH) (13 mg, 0.032 mmol; 15.6%). (3a-OH): 1H-NMR (400 MHz, CDC13): 5(ppm): 2.03 - 1.92 (m, 2H), 1.90 - 1.79 (m, 2H), 1.78 - 1.70 (m, 1H), 1.63 - 0.99 (m, 25H), 1.25 (s, 3H), 1.20 (s, 3H), 1.19 (s, 3H), 0.93 (s, 3H), 0.91 (d, J = 6.5 Hz, 3H), 0.64 (s, 3H). (3/?-OH): 1H-NMR (400 MHz, CDC13): 5(ppm): 2.00 - 1.78 (m, 4H), 1.67 - 0.99 (m, 25H), 1.22 (s, 3H), 1.20 (s, br, 6H), 0.96 (s, 3H), 0.94 - 0.86 (m, 4H), 0.65 (s, 3H).
Example 33. Preparation of compounds C3-alpha and C3-beta D14
Figure imgf000180_0001
D14 (β-ΟΗ)
[00433] In a flame dried reaction tube (20 mL) D4b (0.1 g, 0.257 mmol) was dissolved in dry THF (3 mL) under an atmosphere of argon and cooled to -10°C. MeMgCl 3.0M in THF (0.86 mL, 2.57 mmol) was added drop wise using a syringe MeMgCl 3.0M in THF (0.68 mL, 2.04 mmol). The reaction mixture was coming up to room temperature during 1.5 h and stirred for 2h at room temperature. The reaction mixture was poured into a stirred solution of saturated aqueous NH4C1 (100 mL) and extracted three times with CH2CI2 (3x75 mL).The combined organic layers were washed with brine dried on Na2S04 and the crude product was purified by flash column chromatography (silica, heptane/ethylacetate, 1:0 -> 4: 1) to afford D14 (a-OH) (28 mg, 0.07 mmol, yield = 27%) and D14 (β-ΟΗ) (21 mg, 0.05 mmol, yield = 20%) both as a white solid. D14 (a-OH): 1HNMR (400 MHz, CDC13) 5(ppm): 1.95 (IH, dt, J=12.3, 3.1 Hz), 1.89-1.77 (IH, m), 1.65 (IH, dq, J=12.7, 3.3 Hz), 1.20 (9H, s), 0.92 (3H, d, J=6.5 Hz), 0.75 (3H, s), 0.78-0.69 (IH, m), 0.65 (3H, s). D14 (β-ΟΗ): 1HNMR (400 MHz, CDCI3) 5(ppm): 1.96 (IH, dt, J=12.5, 3.3 Hz), 1.89-1.77 (IH, m), 1.25 (3H, s), 1.20 (3H, s), 1.19 (3H, s), 0.92 (3H, d, J=6.5 Hz), 0.81(3H, s), 0.65 (3H, s), 0.70-0.61 (IH, m).
Figure imgf000180_0002
Figure imgf000181_0001
(a) H2S04, MeOH, reflux overnight, 97%; (b) Jones reagent, acetone, 0°C 30 min, 60%; (c) HCI, MeOH, rt overnight, 44%; (d) Ac20, pyridine, 70°C, overnight, 92%; (e) DAST(neat), 40°C, 4 days, 42%; (f) HCI, MeOH, THF, rt overnight; (g) Dess-Martin periodinane, CH2CI2, rt overnight; (h) MeMgBr, THF, 0°C.
Figure imgf000181_0002
Figure imgf000181_0003
Figure imgf000182_0001
(a) H2S04, MeOH, reflux overnight, 97%; (b) Jones reagent, acetone, 0°C 30 min, 60%; (c) HCI, MeOH, rt overnight, 44%; (d) Ac20, pyridine, 70°C, overnight, 92%; (e) DAST(neat), cat. fuming H2S04; (f) HCI, MeOH, THF, rt overnight; (g) Dess-Martin periodinane, CH2CI2, rt overnight; (h) MeMgBr, THF, 0°C.
Example 36. Synthesis of 6-beta-methyl analogs
Figure imgf000182_0002
Figure imgf000182_0003
Figure imgf000182_0004
(a) Ethane-1 ,2-diol, cat.TsOH, toluene, reflux overnight; (b) Ac20, pyridine, rt overnight; (c) BH3, THF, NaOH/ H202, 0°C then rt; (d) Dess-Martin periodinane, CH2CI2, rt overnight; (e) methyltriphenylphosphonium bromide, potassium tert-butoxide, THF, room temperature; (f) TCDI, DMAP, CH2CI2, 40 °C; (g) Ph3SnH, AIBN, toluene, 1 10 °C; (h) potassium carbonate, MeOH,rt overnight; (i) MeMgBr, THF, 0 °C.
Figure imgf000183_0001
(a) 3M HCI, acetone; (b)(ethyl)-triphenylphosphonium bromide, t-BuOK, THF, 65°C; (e) methylacrylate, EtAICI2, DCM, rt; (f) 10% Pd/C, H2, EtOAc; (g) MeMgBr, THF, 0 °C.
Assay Methods
[00434] Compounds of the present invention can be evaluated using various in vitro and in vivo assays described in the literature; examples of which are described below.
[00435] The following examples are offered to illustrate the biological activity of the compounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting the scope thereof.
NMDA modulation activity assay
[00436] The compounds of the invention are or can be tested for their NMDA modulation activity using the assay described by Paul et ah, in J. Pharm. and Exp. Ther. 1994, 271, 677-682. The assay protocol is reproduced below.
(1) Cell culture [00437] Hippocampal neurons from 19-day-old Sprague-Dawley rat embryos are maintained in primary culture, as described previously (Segal, J. NeurophysioL 50 1249- 1264, 1983). Briefly, hippocampal tissue is dissected and mechanically disrupted and the cell suspension is plated onto poly-L-lysine (Sigma, St. Louis, MO)-coated, glass-bottom, 35-mm culture dishes that contained modified Eagle's medium with Earle's salts supplemented with 10% fetal bovine serum, 10% horse serum and 2 mM glutamine (Sigma). N3 serum supplement (modified from Guthrie et ah, Brain Res. 420 313-323, 1987) consisted of:
bovine serum albumin, 0.001%; transferrin, 20 mg/liter; insulin, 10 mg/liter; selenium, 60 nM; corticosterone, 40 μg/liter; triiodothyronine, 20 μg/liter; progesterone, 40 nM; and putrescine, 200 μ , which is added to the media. Cells are incubated in a humidified atmosphere that contained 10% C02 and 90% air. Culture media that lacked fetal bovine serum is added every 7 days after plating. The cells are used after 7 to 14 days in culture.
(2) Measurement of intracellular Ca++
[00438] Cultures are washed three times with buffer that contained (in millimolar quantities) the following: NaCl, 145; KC1, 2.5; HEPES, 10; CaCl2, 1; and glucose, 10 (adjusted to pH 7.4 with NaOH and to an osmolality of 315-325 mOsm with sucrose). The cultures are then incubated with fura-2 acetoxymethyl ester 2 to 5 μΜ for 30 to 45 min in the dark at 37°C. After the incubation period, the cultures are again ished three times with buffer and allowed to stand for > 15 mm to permit complete hydrolysis of the ester. The neuron of interest is perfused with buffer at a rate of approximately 250 μΐ/min (37 °C). The perfusion device consisted of a water-jacketed array of 10 tubes that emptied into a common tip positioned approximately 500 μιη from the cell. All solutions contained 0.5 μΜ tetrodotoxin to eliminate voltage-sensitive Na+ currents and 2 to 5 μΜ glycine to saturate the strychnine- insensitive glycine site on NMDA receptors.
[00439] [Ca++] is measured by microspectrofluorimetry with the Ca++ sensitive indicator fura-2 (Groden et ah, Cell Calcium 12: 279-287, 1991). The neurons are illuminated on a Nikon inverted microscope with a dual- wavelength illumination-photometry system (SPEX-DM3000 AR-CM, SPEX Industries, Edison, NJ).
[00440] Excitation of fura-2 occurred at 340 and 380 nm with emitted light monitored at 510 nm. The neurons are visualized by phase-contrast microscopy and are easily identified by their characteristic morphology. Light reaching the photomultiplier is limited to that emitted by the cell of interest by a pinhole. The photon counts are stored in digital form for subsequent analysis. Calibration is carried out as described by Grynkiewicz et at. (J. Biol. Chem. 280, 34440-3450, 1985). The fluorescence ratio at saturating Ca++ (RmaJ is determined in situ by bathing the cells in buffer that contained (in millimolar quantities) the following: KC1, 130; NaCl, 17; HEPES, 10; glucose, 10; CaCl2, 2; and ionomycin, 0.015 (pH 7.2, 37°C. Some calibration buffers contained 10 μΜ carbonyl cyanide-m-chlorophenyl-hydrazone to uncouple mitochondrial oxidative phosphorylation. For the determination of the fluorescence ratio at zero Ca++ (RminJ, the buffer is modified so that 3 mM EGTA and 80 μ EGTA acetoxymethyl ester is substituted for CaCl2. An apparent ¾ of 285 nM (Groden et at., 1991) is used for [Ca++]; calculations.
Electrophysiology assay
[00441] The compounds of the invention are or can be tested in electrophysiology assay as described by Petrovic et ah, in /. Neuroscience 160 (2009) 616-628. The assay protocol is reproduced below.
(1) Hippocampal cultures
[00442] Primary dissociated hippocampal cultures are prepared from 1-to 2-day-old postnatal rats. Animals are decapitated, and the hippocampi are dissected. Trypsin digestion, followed by mechanical dissociation, is used to prepare cell suspension. Single cells are plated at a density of 500,000 cells/cm on 31- or 12-mm polylysine-coated glass coverslips. Neuronal cultures are maintained in NeurobasalTM-A (Invitrogen, Carlsbad, CA, USA) medium supplemented with glutamine (0.5 mM) and B27 Serum- Free Supplement
(Invitrogen).
(2) Transfection and maintenance of HEK293 cells
[00443] HEK293 cells (American Type Culture Collection, ATTC No. CRL1573,
Rockville, MD, USA) are cultured in Opti-MEM® I (Invitrogen) with 5% fetal bovine serum at 37 °C and transfected with NRl-la/NR2B/green fluorescent protein (GFP) plasmids as described
previously (Cais et ah, Neuroscience 151: 428-438, 2008). Briefly, equal amounts (0.3 μg) of cDNAs coding for NRl, NR2 and GFP (pQBI 25, Takara, Otsu, Shiga, Japan) are mixed with 0.9 μΐ Matra-A Reagent (IBA, Gottingen, Germany) and added to confluent HEK293 cells on a 24- well plate. After trypsinization, the cells are resuspended in Opti-MEM® I containing 1% fetal bovine serum supplemented with 20mM MgC12,l mM D,L-2-amino-5- phosphonopentanoic acid and 3 mM kynurenic acid and plated on 30-mm polylysine-coated glass coverslips. The following genes encoding NMDAR subunits are used: NRl-la
(GenBank accession no. U08261) (Hollmann et al, Neuron 10:943-954 1993) and NR2B (GenBank accession no. M91562) (Monyer et al., Science, 256: 1217-1221, 1992).
(3) Recording from cultured cells and drug application
[00444] Experiments are performed 24-48 h after the end of HEK293 transfection; neurons maintained in culture for 5-8 days are used. Whole-cell voltage-clamp recordings are made with a patch-clamp amplifier after a capacitance and series resistance (<10 ΜΩ) compensation of 80 -90 . Agonist-induced responses are low-pass filtered at 1 kHz with an eight-pole Bessel filter (Frequency Devices, Haverhill, MA, USA), digitally sampled at 5 kHz and analyzed using pCLAMP software version 9 (Axon Instruments). Patch pipettes (3- 4 ΜΩ) pulled from borosilicate glass are filled with Cs+ based intracellular solution (Cs-ICS) containing (in mM) 125 gluconic acid, 15 CsCl, 5 EGTA, 10 Hepes, 3 MgC12, 0.5 CaC12, and 2 ATP-Mg salt (pH-adjusted to 7.2 with CsOH). Extracellular solution (ECS) contained (in mM) 160 NaCl, 2.5 KCl, 10 Hepes, 10 glucose, 0.2 EDTA and 0.7 CaC12 (pH-adjusted to 7.3 with NaOH). In some experiments, the concentration of CaCl2 is lowred to 0.2 mM (with no EDTA) or increased to 2 mM as indicated. Glycine (10 μΜ), an NMDAR coagonist, is present in the control and test solutions. Tetrodotoxin (0.5 μΜ) and bicuculline
methochloride (10 μΜ) are used in experiments on cultured hippocampal neurons. The solutions of compounds of invention are made from freshly prepared 20 mM stock in dimethyl sulfoxide (DMSO). The same concentration of DMSO is maintained in all ECSs. A microprocessor-controlled multibarrel fast perfusion system, with a time constant of solution exchange around cells of -10 ms, is used to apply test and control solutions (Vyklicky et al., J Physiol Lond 470:575-600 1990).
[00445] The compounds of the invention are prepared according to synthetic methods described herein and their purity is tested by using conventional methods known to one skilled in the art..
NMDA binding in vitro
[00446] Compounds can be screened to determine their potential as modulators of
NMDA binding in vitro. These assays are or can be performed in accordance with the above discussed procedures. In vivo Pharmacology.
[00447] Male NSA mice weighing between 15-20 g are obtained from Harlan Sprague-
Dawley (San Diego, CA). Upon arrival they are housed in standard polycarbonate cages (4 per cage) containing a sterilized bedding material in a room of constant temp (23.0° + 2.5 °C) with a 12 h (07.00-19.00 light) light/dark cycle. Food (Teklad LM 485) and water are freely available. Mice are acclimated a minimum of 4 days prior to experimentation.
Hanging Wire Test
[00448] The hanging-wire test used a custom-built apparatus that consisted of a metal wire (2 mm diameter) suspended horizontally above a padded surface (25 cm). Mice are held by the base of the tail, their forepaws placed in contact with the wire, and then released. Animals are required to bring both hindpaws in contact with the wire within 5 sec in order to be scored as a pass. Results are treated quantally.
Drug Metabolism and Pharmacokinetics: HERG assay
[00449] HEK 293 cells which stably express the HERG potassium channel are used for electrophysiological study. The methodology for stable transfection of this channel in HEK cells can be found elsewhere (Zhou et al., Biophys. J. 74:230-41, 1998). Before the day of experimentation, the cells are harvested from culture flasks and plated onto glass coverslips in a standard Minimum Essential Medium (MEM) medium with 10% Fetal Calf Serum (FCS). The plated cells are stored in an incubator at 37 °C maintained in an atmosphere of 95%02/5%C02. Cells are studied between 15-28 hrs after harvest.
[00450] HERG currents are studied using standard patch clamp techniques in the whole-cell mode. During the experiment the cells are superfused with a standard external solution of the following composition (mM); NaCl, 130; KC1, 4; CaCl2, 2; MgCl2, 1;
Glucose, 10; HEPES, 5; pH 7.4 with NaOH. Whole-cell recordings are made using a patch clamp amplifier and patch pipettes which have a resistance of 1-3 MOhm when filled with the standard internal solution of the following composition (mM); KC1, 130; MgATP, 5; MgCl2, 1.0; HEPES, 10; EGTA 5, pH 7.2 with KOH. Only those cells with access resistances below 15 MOhm and seal resistances >lGOhm are accepted for further experimentation. Series resistance compensation was applied up to a maximum of 80%. No leak subtraction is done. However, acceptable access resistance depended on the size of the recorded currents and the level of series resistance compensation that can safely be used. [00451] Following the achievement of whole cell configuration and sufficient time for cell dialysis with pipette solution (>5 min), a standard voltage protocol is applied to the cell to evoke membrane currents. The voltage protocol is as follows. The membrane is depolarized from a holding potential of -80 mV to +40 mV for 1000ms. This was followed by a descending voltage ramp (rate 0.5 mV msec-1) back to the holding potential. The voltage protocol is applied to a cell continuously throughout the experiment every 4 seconds (0.25 Hz). The amplitude of the peak current elicited around -40mV during the ramp is measured. Once stable evoked current responses are obtained in the external solution, vehicle (0.5% DMSO in the standard external solution) is applied for 10-20 min by a peristalic pump. Provided there were minimal changes in the amplitude of the evoked current response in the vehicle control condition, the test compound of either 0.3, 1, 3, or 10 mM is applied for a 10 min period. The 10 min period included the time which supplying solution was passing through the tube from solution reservoir to the recording chamber via the pump. Exposing time of cells to the compound solution was more than 5 min after the drug concentration in the chamber well reached the attempting concentration. There is a subsequent wash period of a 10-20 min to assess reversibility. Finally, the cells is exposed to high dose of dofetilide (5 mM), a specific IKr blocker, to evaluate the insensitive endogenous current.
[00452] All experiments are performed at room temperature (23 + 1°C). Evoked membrane currents were recorded on-line on a computer, filtered at 500-1 KHz (Bessel -3dB) and sampled at 1-2 KHz using the patch clamp amplifier and a specific data analyzing software. Peak current amplitude, which occurred at around -40 mV, is measured off line on the computer.
[00453] The arithmetic mean of the ten values of amplitude is calculated under vehicle control conditions and in the presence of drug. Percent decrease of IN in each experiment was obtained by the normalized current value using the following formula: IN = (1- ID/IC )xl00, where ID is the mean current value in the presence of drug and IC is the mean current value under control conditions. Separate experiments are performed for each drug
concentration or time-matched control, and arithmetic mean in each experiment is defined as the result of the study. Drug Metabolism and Pharmacokinetics: Half -life in human liver microsomes (HLM)
[00454] Test compounds (1 μΜ) are incubated with 3.3 mM MgCl2 and 0.78 mg/mL
HLM (HLlOl) in 100 mM potassium phosphate buffer (pH 7.4) at 37 °C on the 96-deep well plate. The reaction mixture is split into two groups, a non-P450 and a P450 group. NADPH is only added to the reaction mixture of the P450 group. An aliquot of samples of P450 group is collected at 0, 10, 30, and 60 min time point, where 0 min time point indicated the time when NADPH was added into the reaction mixture of P450 group. An aliquot of samples of non-P450 group is collected at -10 and 65 min time point. Collected aliquots are extracted with acetonitrile solution containing an internal standard. The precipitated protein is spun down in centrifuge (2000 rpm, 15 min). The compound concentration in supernatant is measured by LC/MS/MS system. The half-life value is obtained by plotting the natural logarithm of the peak area ratio of compounds/ internal standard versus time. The slope of the line of best fit through the points yields the rate of metabolism (k), and is converted to a half-life value using following equation: Half-life = In 2 / k.
Example 37. NMDA potentiation data
[00455] The whole-cell patch-clamp technique was used to investigate the effects of compounds (0.1 mM and 1.0 mM) on the NMDA receptor (GRIN1 / GRIN2A subunits) expressed in HEK cells. NMDA / Glycine peak and steady-state currents were recorded from stably transfected cells expressing the NMDA receptor and the modulatory effects of the test items on these currents were investigated.
[00456] Cells were stably transfected (Lipofectamine™) with human GRTN1 (variant
NRl-3). These cells were transiently transfected with GRIN2A cDNA and CD 8 (pLeu) antigene cDNA. About 24-72 hours following transfection 1 μΐ Dynabeads M-45 CD8 was added to identify successfully transfected cells (Jurman et ah, Biotechniques (1994) 17:876- 881). Cells were passaged to a confluence of 50-80%. Whole cell currents were measured with HEKA EPC-10 amplifiers using PatchMaster software. Cell culture dishes for recordings were placed on the dish holder of the microscope and continuously perfused (1 ml/min) with bath solution. All solutions applied to cells including the pipette solution were maintained at room temperature (19°C - 30°C). After formation of a Gigaohm seal between the patch electrodes and transfected individual HEK 293 cells (pipette resistance range: 2.5 MW - 6.0 MW; seal resistance range:>l GW) the cell membrane across the pipette tip was ruptured to assure electrical access to the cell interior (whole-cell patch-configuration). Once a stable seal could be established NMDA inward currents were measured upon application of 30 μΜ NMDA (and 5.0 μΜ Glycine) to patch-clamped cells (2 applications) for 5 s. The cells were voltage clamped at a holding potential of -80 mV.
Figure imgf000190_0001
Figure imgf000191_0001
C25H42O2I
Figure imgf000192_0001
Figure imgf000193_0001
C27H45F3O2I
Figure imgf000195_0001
OTHER EMBODIMENTS
[00457] In the claims articles such as "a," "an," and "the" may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
[00458] Furthermore, the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms "comprising" and "containing" are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
[00459] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any claim, for any reason, whether or not related to the existence of prior art.
[00460] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.

Claims

What is claimed is:
1. A compound of Formula:
Figure imgf000198_0001
or a pharmaceutically acceptable salt thereof;
wherein:
Z is a group of the formula (i), (ii), (iii), (iv), or (v)
Figure imgf000198_0002
L 1 and V 2 are selected from a group consisting of a bond, a substituted or
unsubstituted Ci-C6 alkylene, a substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, a substituted or unsubstituted hetero Ci-C6 alkylene, a substituted or unsubstituted hetero C2-C6 alkenylene, and a substituted or unsubstituted hetero C2-C6 alkynylene;
L is a substituted or unsubstituted Ci-C6 alkylene, a substituted or unsubstituted C2- C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, a substituted or unsubstituted hetero Ci-C6 alkylene, a substituted or unsubstituted hetero C2-C6 alkenylene, or a substituted or unsubstituted hetero C2-C6 alkynylene;
each instance of X 1 and X 2 is independently -0-, -S-, or -NH-;
R1 is hydrogen or substituted or unsubstituted alkyl;
R3b is hydrogen; R3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
each instance of R2, Rl la, and Rl lb is independently hydrogen or -ORB 1, wherein wherein RB 1 is hydrogen or substituted or unsubstituted alkyl, or Rl la and Rl lb are joined to form an oxo (=0) group;
each of R6a and R6b is independently hydrogen, halo, or substituted or unsubstituted alkyl, and represents a single or double bond, provided if a double bond is present, then one of R6a or R6b is absent, and provided if a single bond is present, then the hydrogen at C5 is in the alpha or beta position;
each instance of R19 and R20 is independently hydrogen or -CH3;
and each instance of R23a and R23b is independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R23a and R23b are joined together to form substituted or
unsubstituted C3-C6 cycloalkyl;
24
R is hydrogen or substituted or unsubstituted alkyl;
Y is -0-, -S-, or -NRZ5-;
Z4
R is independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR25, -SRZ5, or -N(RZ5)2;
Z5
each instance of R is independently hydrogen or substituted or unsubstituted alkyl; and
each instance of Rz6 is independently hydrogen or substituted or unsubstituted alkyl, or two Rz6 groups are joined to form a C3_6 carbocyclic ring; and
the subscript n is 0 or 1 ;
provided the following compounds are specifically excluded:
Figure imgf000199_0001
Figure imgf000200_0001
and ΗΟ
The compound of claim 1 wherein Z is a group of formula:
Figure imgf000200_0002
3. The compound of claim 2, wherein L3 is a group of formula:
Figure imgf000200_0003
wherein p is 1, 2, or 3; and each instance of RZ7 and RZ8 is, independently, hydrogen, halo, substituted or unsubstituted C 1-6 alkyl, or -OR .
4. The compound of claim 2, f formula:
Figure imgf000200_0004
wherein w is 0 or 1 and p is 1, 2, or 3, or w is 1 and p is 0, 1, 2, or 3; and each instance of R Z7 and R is independently hydrogen, halo, substituted or unsubstituted Ci_6 alkyl, or -OR Z5
The compound of claim 2, wherein L3 is a group of formula:
Figure imgf000200_0005
6. The co
Figure imgf000201_0001
7. The compound of claim 2, wherein L is a group of formula:
Figure imgf000201_0002
8. The compound of claim 1, wherein Z is of formula
Figure imgf000201_0003
9. The compound of claim 8, wherein the group
Figure imgf000201_0004
is of the formula:
Figure imgf000201_0005
Figure imgf000202_0001
The compound of claim 1, Z is of formula
Figure imgf000203_0001
11. The compound of claim 10, wherein Y is -O- and L is an alkylene or heteroalkylene group.
Figure imgf000203_0002
The compound of claim 1, wherein Z is of formula
Figure imgf000203_0003
14. The compound of claim 13, wherein Y is -O- and L is an alkylene or heteroalkylene. I 3 pZ6
V
The compound of claim 14, wherein the group Y YRZ5 is of the formula:
Figure imgf000204_0001
16. The compound of claim 1, wherein the group -Χ^¾ is in the beta position, and R3a is in the alpha position.
17. The compound of claim 1, wherein -Χ^¾ is -OH.
18. The compound of claim 1, wherein R3a is hydrogen.
The compound of claim 1, wherein R a is substituted or unsubstituted alkyl.
20. The compound of claim 1, wherein represents a double bond and R a is halo or substituted or unsubstituted alkyl
The compound of claim 1, wherein R is halo or substituted or unsubstituted alkyl
22. The compound of claim 1, wherein R is hydrogen.
23. The compound of claim 1, wherein R is -OR .
24. The compound of claim 1, wherein Rl lb is hydrogen or -ORB, and Rlla is hydro gen.
The compound of claim 1, wherein Rl la and Rllb together form an oxo group.
26. The compound of claim 1, wherein z z represents a single bond, and the hydrogen at C5 is in the alpha position.
27. The compound of claim 1, wherein z z represents a double bond.
28. The compound of claim 1, wherein R19 is -CH3.
29. The compound of claim 1, wherein the compound is selected from the group consisting of:
Figure imgf000205_0001
Figure imgf000205_0002
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000207_0002
Figure imgf000208_0001
Figure imgf000208_0002
Figure imgf000209_0001
208
Figure imgf000210_0001
Figure imgf000210_0002
Figure imgf000210_0003
Figure imgf000210_0004
Figure imgf000211_0001
, and pharmaceutically acceptable salts thereof.
The compound of claim 1, wherein the compound is selected from the group consisting of:
Figure imgf000211_0002
Figure imgf000211_0003
Figure imgf000211_0004
Figure imgf000212_0001
and pharmaceutically acceptable salts thereof.
31. The compound of claim 1, wherein the compound is selected from the group consisting of:
Figure imgf000212_0002
Figure imgf000212_0003
Figure imgf000213_0001
Figure imgf000213_0002
Figure imgf000213_0003
and pharmaceutically acceptable salts thereof.
32. The compound of claim 1, wherein the compound is selected from the group consisting of: 212
Figure imgf000214_0001
Figure imgf000214_0002
Figure imgf000215_0001
Figure imgf000215_0002
, and pharmaceutically acceptable salts thereof.
33. The compound of claim 1, wherein the compound is selected from the group consisting of: 214
Figure imgf000216_0001
Figure imgf000216_0002
Figure imgf000216_0003
Figure imgf000216_0004
Figure imgf000217_0001
and pharmaceutically acceptable salts thereof.
Figure imgf000217_0002
35. The compound of claim 1, wherein the compound is selected from the group consisting of:
Figure imgf000217_0003
Figure imgf000218_0001
36. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound of any one of the preceding claims.
37. A method for preventing, treating, ameliorating or managing a disease or condition which comprises administering to a patient in need of such prevention, treatment,
amelioration or management, a prophylactically or therapeutically effective amount of a compound or pharmaceutical composition of any one of the preceding claims.
38. The method according to claim 37, wherein the disease or condition is schizophrenia, depression, bipolar disorder (I and II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, compulsive disorders, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive compulsive disorder (OCD), all pain syndromes and disorders, sleep disorders, memory disorders and dementia including Alzheimer's Disease, epilepsy and any seizure disorders, traumatic brain injury (TBI), stroke, addictive disorders including opiates and cocaine and alcohol, autism, Huntington's Disease, insomnia, Parkinson's disease, withdrawal syndromes, or tinnitus.
39. The method according to claim 38, wherein the disease or condition is schizophrenia.
40. The method according to claim 38, wherein the disease or condition is traumatic brain injury (TBI).
41. The method according to claim 38, wherein the disease or condition is stroke.
PCT/US2012/054261 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof WO2013036835A1 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
EP23171488.2A EP4245369A3 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
BR112014005373-1A BR112014005373B1 (en) 2011-09-08 2012-09-07 Neuroactive steroid compounds, compositions and uses thereof
CA2848212A CA2848212C (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
FIEP12766766.5T FI2753632T3 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
HRP20230747TT HRP20230747T1 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
ES12766766T ES2951664T3 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions and uses thereof
PL12766766.5T PL2753632T3 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
AU2012304412A AU2012304412A1 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
SI201232034T SI2753632T1 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
LTEPPCT/US2012/054261T LT2753632T (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
DK12766766.5T DK2753632T3 (en) 2011-09-08 2012-09-07 NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF
CN201280054927.2A CN103958540B (en) 2011-09-08 2012-09-07 Neuroactive steroids, composition, and application thereof
US14/343,603 US20150158903A1 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
JP2014529913A JP6205362B2 (en) 2011-09-08 2012-09-07 Nerve stimulating steroids, compositions, and uses thereof
RU2014113548A RU2665571C2 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions and uses thereof
RS20230525A RS64332B1 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
EP12766766.5A EP2753632B1 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
HK15100472.0A HK1200173A1 (en) 2011-09-08 2015-01-15 Neuroactive steroids, compositions, and uses thereof
AU2017204452A AU2017204452B2 (en) 2011-09-08 2017-06-29 Neuroactive Seroids, Compositions, and Uses Thereof
US16/114,791 US10759828B2 (en) 2011-09-08 2018-08-28 Neuroactive steroids, compositions, and uses thereof
AU2019227507A AU2019227507B2 (en) 2011-09-08 2019-09-10 Neuroactive steroids, compositions, and uses thereof
US16/942,235 US20210147470A1 (en) 2011-09-08 2020-07-29 Neuroactive steroids, compositions, and uses thereof
AU2021204183A AU2021204183B2 (en) 2011-09-08 2021-06-21 Neuroactive steroids, compositions, and uses thereof
US17/707,303 US20230192756A1 (en) 2011-09-08 2022-03-29 Neuroactive steroids, compositions, and uses thereof
AU2023203028A AU2023203028A1 (en) 2011-09-08 2023-05-15 Neuroactive steroids, compositions, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532427P 2011-09-08 2011-09-08
US61/532,427 2011-09-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/343,603 A-371-Of-International US20150158903A1 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof
US16/114,791 Continuation US10759828B2 (en) 2011-09-08 2018-08-28 Neuroactive steroids, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
WO2013036835A1 true WO2013036835A1 (en) 2013-03-14

Family

ID=46964032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/054261 WO2013036835A1 (en) 2011-09-08 2012-09-07 Neuroactive steroids, compositions, and uses thereof

Country Status (20)

Country Link
US (4) US20150158903A1 (en)
EP (2) EP2753632B1 (en)
JP (5) JP6205362B2 (en)
CN (3) CN107936076B (en)
AU (5) AU2012304412A1 (en)
BR (1) BR112014005373B1 (en)
CA (1) CA2848212C (en)
DK (1) DK2753632T3 (en)
ES (1) ES2951664T3 (en)
FI (1) FI2753632T3 (en)
HK (1) HK1200173A1 (en)
HR (1) HRP20230747T1 (en)
HU (1) HUE062616T2 (en)
LT (1) LT2753632T (en)
PL (1) PL2753632T3 (en)
PT (1) PT2753632T (en)
RS (1) RS64332B1 (en)
RU (1) RU2665571C2 (en)
SI (1) SI2753632T1 (en)
WO (1) WO2013036835A1 (en)

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333216A (en) * 2013-06-04 2013-10-02 苏州大学 5alpha-6-ketone-cholestane analogue and applications thereof
WO2014160480A1 (en) 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
WO2014169836A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169833A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
WO2014169831A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US20160022701A1 (en) * 2013-03-13 2016-01-28 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016057713A1 (en) 2014-10-07 2016-04-14 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
US9365611B2 (en) 2013-04-17 2016-06-14 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US9480692B2 (en) 2011-04-06 2016-11-01 Virginia Commonwealth University Sulfated-oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
WO2017007840A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
WO2017149052A1 (en) * 2016-03-02 2017-09-08 Patheon Austria Gmbh Co. & Kg Process and intermediates for the production of 17(20)-ene b-seco steroids
WO2017173358A1 (en) 2016-04-01 2017-10-05 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) * 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018064649A1 (en) * 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
US10144759B2 (en) 2004-10-25 2018-12-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US10201550B2 (en) 2015-07-06 2019-02-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3319610A4 (en) * 2015-07-06 2019-03-06 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
IT201700100483A1 (en) * 2017-09-07 2019-03-07 Dipharma Francis Srl SELECTIVE OXIDATION OF IODESEXICOLIC ACID
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10251894B2 (en) 2012-11-30 2019-04-09 The Regents Of The University Of California Anticonvulsant activity of steroids
US10272097B2 (en) 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)
US10322139B2 (en) 2012-01-23 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
US10323059B2 (en) 2013-07-19 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10426837B2 (en) 2015-01-26 2019-10-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10435431B2 (en) 2011-10-14 2019-10-08 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10759828B2 (en) 2011-09-08 2020-09-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10799463B2 (en) 2015-12-22 2020-10-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US10857105B2 (en) 2017-03-15 2020-12-08 MordernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11203569B2 (en) 2017-03-15 2021-12-21 Modernatx, Inc. Crystal forms of amino lipids
US11220476B2 (en) 2015-09-17 2022-01-11 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3852764A4 (en) * 2018-09-19 2022-06-15 ModernaTX, Inc. Sterol analogs and uses thereof
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
EP3829589A4 (en) * 2018-07-31 2022-07-27 The Research Foundation for the State University of New York Methods of activating microglial cells
US11406646B2 (en) 2016-08-02 2022-08-09 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2022261510A1 (en) 2021-06-11 2022-12-15 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2023049295A1 (en) 2021-09-22 2023-03-30 Sage Therapeutics, Inc. Deuterated positive nmda-modulating compounds and methods of use thereof
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
US11969506B2 (en) 2018-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
WO2017019524A1 (en) * 2015-07-30 2017-02-02 Intercept Pharmaceuticals, Inc. Methods for preparation of bile acids and derivatives thereof
KR20180082457A (en) 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 Injectable neuro-steroid agents containing nanoparticles
MX2019001669A (en) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Methods and compositions for treatment of epileptic disorders.
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN109280069B (en) * 2017-07-19 2020-09-04 青岛海洋生物医药研究院股份有限公司 3 beta-hydroxy-ergosta-5-ene steroid derivative and pharmaceutical use thereof
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN116589521A (en) 2019-01-08 2023-08-15 成都康弘药业集团股份有限公司 Steroid compound, application and preparation method thereof
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
JP2023503928A (en) 2019-12-06 2023-02-01 マリナス ファーマシューティカルズ， インコーポレイテッド Ganaxolone for use in the treatment of tuberous sclerosis
CN113387991A (en) * 2020-03-13 2021-09-14 苏州朗科生物技术股份有限公司 Method and compound for synthesizing dydrogesterone
CN112679571A (en) * 2020-12-24 2021-04-20 广西壮族自治区中国科学院广西植物研究所 Mogrol derivative monomer, and preparation method and application thereof
CN115624555A (en) * 2022-02-24 2023-01-20 中国药科大学 Application of hyodeoxycholic acid in preparation of antidepressant drug

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079385A (en) * 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH08268917A (en) * 1995-03-31 1996-10-15 D D S Kenkyusho:Kk Antitumor agent having high transition to cancer tissue
FR2850023A1 (en) * 2003-01-17 2004-07-23 Mapreg Treating acute lesions or degenerative diseases of the nervous system, e.g. Alzheimer's disease, spinal-cerebral trauma or pain, using 3-methoxypregnenolone or derivatives having microtubule stabilizing action

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594323A (en) * 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
EP0701444B1 (en) 1993-05-24 2010-04-07 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
EP0752860B1 (en) 1994-02-14 2000-08-23 Euro-Celtique S.A. Androstanes and pregnanes for allosteric modulation of gaba receptor
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
ES2155543T3 (en) * 1994-11-23 2001-05-16 Cocensys Inc ANDROSTAN AND PREGNAN SERIES FOR ALLOSTERIC MODULATION OF THE GABA RECEIVER.
IL122348A0 (en) 1995-06-06 1998-04-05 Cocensys Inc Neuroactive steroids of the androstane and pregnane series
WO1997000884A1 (en) 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
IL139241A0 (en) 1998-05-13 2001-11-25 Novo Nordisk As Meiosis regulating compounds
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
GB9910934D0 (en) * 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (en) 2000-12-29 2002-04-11 Novel gabaa modulating neurosteroids
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
WO2003039480A2 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
JP2005511713A (en) 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア Treatment for age-related macular degeneration
CN102727501A (en) 2002-03-27 2012-10-17 菲特法姆股份有限公司 Uses of sapogenins and their derivatives
NZ547897A (en) 2002-03-27 2008-02-29 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
WO2004055201A2 (en) 2002-12-13 2004-07-01 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
CA2643732C (en) 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
ES2710288T3 (en) * 2006-04-22 2019-04-24 Neurmedix Inc Medications and uses
GB0619860D0 (en) * 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
ES2400026T3 (en) 2007-06-20 2013-04-05 Auspex Pharmaceuticals, Inc. N-arylpyridinones substituted as fibrotic inhibitors
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059239A2 (en) * 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
CA2703497A1 (en) 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
CN102762207A (en) 2008-05-09 2012-10-31 爱莫里大学 NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2011014661A2 (en) 2009-07-29 2011-02-03 The University Of Chicago Liver x receptor agonists
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (en) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille AMINOSTEROIDAL COMPOUNDS FOR LOCAL TOPICAL APPLICATION FOR CUTANEO-MUCOUS DECOLONIZATION OF STAPHYLOCOCCUS AUREUS
KR101692275B1 (en) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
WO2012142039A1 (en) 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
WO2012166617A2 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
EP2736919A4 (en) 2011-07-29 2015-01-14 Univ California NOVEL 17ß-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
SI2753632T1 (en) 2011-09-08 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN108976272B (en) 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3, 3-disubstituted 19-norpregnane compounds, compositions, and uses thereof
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
WO2014028942A2 (en) 2012-08-17 2014-02-20 Trueex Group Llc Interoffice bank offered rate financial product and implementation
KR102400891B1 (en) 2012-12-18 2022-05-20 워싱톤 유니버시티 Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
CN105073119A (en) 2013-01-23 2015-11-18 司菲埃拉制药私人有限公司 Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
MX2015009773A (en) 2013-01-29 2016-08-05 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof.
RU2021111681A (en) 2013-03-13 2021-05-11 Сейдж Терапьютикс, Инк. NEUROACTIVE STEROIDS, COMPOSITIONS AND THEIR APPLICATION
PT3461834T (en) 2013-03-13 2021-09-10 Sage Therapeutics Inc Neuroactive steroids
JP6628745B2 (en) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド Oxysterols and methods of using same
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
KR20170065637A (en) 2014-10-07 2017-06-13 세이지 테라퓨틱스, 인크. Neuroactive compounds and methods of use thereof
LT3319611T (en) 2015-07-06 2021-05-10 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA42409A (en) 2015-07-06 2018-05-16 Sage Therapeutics Inc OXYSTEROLS AND THEIR METHODS OF USE
SG10202002655VA (en) 2015-07-06 2020-05-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
EP3642217A4 (en) 2017-06-23 2021-06-16 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
EA202091144A1 (en) 2017-11-10 2020-09-16 Маринус Фармасьютикалз, Инк. GANAXOLONE FOR USE IN THE TREATMENT OF HEREDITARY EPILEPTIC DISEASES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079385A (en) * 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH08268917A (en) * 1995-03-31 1996-10-15 D D S Kenkyusho:Kk Antitumor agent having high transition to cancer tissue
FR2850023A1 (en) * 2003-01-17 2004-07-23 Mapreg Treating acute lesions or degenerative diseases of the nervous system, e.g. Alzheimer's disease, spinal-cerebral trauma or pain, using 3-methoxypregnenolone or derivatives having microtubule stabilizing action

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
"CRC Handbook of Optical Resolution via Diastereomeric Salt Formation"
"Handbook of Chemistry and Physics"
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
"Remington's The Science and Practice of Pharmacy", 2005, PUBLISHER: LIPPINCOTT WILLIAMS & WILKINS
"Stereoselective Synthesis A Practical Approach, Mihdly Nogradi", 1995, VCH PUBLISHERS, INC.
BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, pages 1 - 79
BIGHLEY ET AL.: "Encyclopedia of Pharmaceutical Technology", vol. 13, 1995, MARCEL DEKKER, article "Salt Forms of Drugs and Adsorption"
BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24
CAIS ET AL., NEUROSCIENCE, vol. 151, 2008, pages 428 - 438
CARRUTHERS: "Some Modem Methods of Organic Synthesis", 1987, CAMBRIDGE UNIVERSITY PRESS
CONNICK ET AL.: "Program No. 613 1/B86", 2009 NEUROSCIENCE MEETING PLANNER. CHICAGO, IL: SOCIETY FOR NEUROSCIENCE, 2009
CONNICK ET AL.: "Program No. 613 1/B86", 2009 NEUROSCIENCE MEETING PLANNER. CHICAGO, IL: SOCIETY FOR NEUROSCIENCE, 2009, XP002686783 *
CROSS A D ET AL: "Steroids CCLXXIN<1>. Biologically-active labile ethers IV<2>. The synthesis of 22-oxa-25-azacholesterol and related compounds", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 5, no. 5, 1 May 1965 (1965-05-01), pages 585 - 598, XP023431635, ISSN: 0039-128X, [retrieved on 19650501], DOI: 10.1016/0039-128X(65)90154-6 *
DALE; MOSHER, J. AM. CHEM. SOC., vol. 95, 1973, pages 512
E.L. ELIEL: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL
ELIEL: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL
ERNEST L. ELIEL; SAMUEL H. WILEN; LEWIS N. MANDA: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY & SONS, INC
GEE ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 136, 1987, pages 419 - 423
GEE ET AL., EUROPEAN JOURNAL OFPHARMACOLOGY, vol. 136, 1987, pages 419 - 423
GEE, K.W.; YAMAMURA, H.I.: "Central Nervous System Disorders", 1985, MARCEL-DEKKER, article "Benzodiazepines and Barbiturates: Drugs for the Treatment of Anxiety, Insomnia and Seizure Disorders", pages: 123 - 147
GRODEN ET AL., CELL CALCIUM, vol. 12, 1991, pages 279 - 287
GRYNKIEWICZ, J. BIOL. CHEM., vol. 280, 1985, pages 34440 - 3450
GUTHRIE ET AL., BRAIN RES., vol. 420, 1987, pages 313 - 323
HARRISON ET AL., J PHARMACOL. EXP. THER., vol. 241, 1987, pages 346 - 353
HOLLMANN ET AL., NEURON, vol. 10, 1993, pages 943 - 954
HORAK ET AL., J. OF NEUROSCIENCE, vol. 24, no. 46, 2004, pages 10318 - 10325
J. JACQUES; A. COLLET; S.H. WILEN: "Enantiomers, Racemates and Resolutions", 1981, WILEY-INTERSCIENCE
JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE
JURMAN ET AL., BIOTECHNIQUES, vol. 17, 1994, pages 876 - 881
KHRIPACH V A ET AL: "Synthesis of (24S)-hydroxy-and (24S)-24,25-epoxycholesterol analogues, potential agonists of nuclear LXR receptors", RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 32, no. 6, 1 December 2006 (2006-12-01), pages 586 - 594, XP019453952, ISSN: 1573-9163, DOI: 10.1134/S1068162006060124 *
LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS, INC.
LARRY K. STEINRAUF ET AL: "Synthesis and evaluation of sulfur-containing steroids against methylmercuric chloride toxicity", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 67, no. 12, 1 December 1978 (1978-12-01), pages 1739 - 1743, XP055043400, ISSN: 0022-3549, DOI: 10.1002/jps.2600671228 *
LLOYD, K.G; MORSELLI, P.L.: "Psychopharmacology: The Third Generation of Progress", 1987, RAVEN PRESS, article "Psychopharmacology of GABAergic Drugs", pages: 183 - 195
MADAU ET AL.: "Program No. 613.2/B87", 2009 NEUROSCIENCE MEETING PLANNER. CHICAGO, IL: SOCIETY FOR NEUROSCIENCE, 2009
MAJEWSKA ET AL., SCIENCE, vol. 232, 1986, pages 1004 - 1007
MONYER ET AL., SCIENCE, vol. 256, 1992, pages 1217 - 1221
NAGANO H ET AL: "CHEMISTRY AND BIOCHEMISTRY OF CHINESE DRUGS. PART II. HYDROXYLATED STEROLS, CYTOTOXIC TOWARDS CANCEROUS CELLS: SYNTHESIS AND TESTING", JOURNAL OF CHEMICAL RESEARCH, SCIENCE REVIEWS LTD, GB, vol. 9, 1 January 1977 (1977-01-01), pages 218, XP009025681, ISSN: 0308-2342 *
PAUL ET AL., J. PHANN. AND EXP. THER., vol. 271, 1994, pages 677 - 682
PAUL ET AL., J. PHARM. AND FXP. THER., vol. 271, 1994, pages 677 - 682
PETROVIC ET AL., J. NEUROSCIENCE, vol. 160, 2009, pages 616 - 628
S.H. WILEN: "Tables of Resolving Agents and Optical Resolutions", vol. 268, 1972, UNIV. OF NOTRE DAME PRESS
S.H. WILEN; A. COLLET; J. JACQUES, TETRAHEDRON, vol. 2725, 1977
SEGAL, J. NEUROPHYSIOL, vol. 50, 1983, pages 1249 - 1264
SMITH; MARCH: "March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS, INC.
STEROIDS, vol. 71, 2006, pages 18
T. W. GREENE; P. G. M. WUTS: "Protecting Groups in Organic Synthesis", 1991, WILEY
T. W. GREENE; P. G. M. WUTS: "Protecting Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
TEN HOEVE; H. WYNBERG: "Journal of Organic Chemistry", vol. 50, 1985, pages: 4508 - 4514
THOMAS SORRELL: "Organic Chemistry", 1999, UNIVERSITY SCIENCE BOOKS
VYKLICKY ET AL., J PHYSIOL LOND, vol. 470, 1990, pages 575 - 600
WIELAND ET AL., PSYCHOPHARMACOLOGY, vol. 118, no. L, 1995, pages 65 - 71
WILEN ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725
WILEN: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268
ZHOU ET AL., BIOPHYS../., vol. 74, 1998, pages 230 - 41

Cited By (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144759B2 (en) 2004-10-25 2018-12-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US11384115B2 (en) 2004-10-25 2022-07-12 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US10844089B2 (en) 2004-10-25 2020-11-24 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9480692B2 (en) 2011-04-06 2016-11-01 Virginia Commonwealth University Sulfated-oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US10759828B2 (en) 2011-09-08 2020-09-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10435431B2 (en) 2011-10-14 2019-10-08 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US11426417B2 (en) 2012-01-23 2022-08-30 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
US10322139B2 (en) 2012-01-23 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
US10251894B2 (en) 2012-11-30 2019-04-09 The Regents Of The University Of California Anticonvulsant activity of steroids
JP2020062050A (en) * 2013-03-13 2020-04-23 セージ セラピューティクス， インコーポレイテッド Neuroactive steroids, compositions, and uses thereof
US10227375B2 (en) 2013-03-13 2019-03-12 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
JP2016513663A (en) * 2013-03-13 2016-05-16 セージ セラピューティクス， インコーポレイテッド Nerve stimulating steroids and methods of use thereof
US20160022701A1 (en) * 2013-03-13 2016-01-28 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3932932A1 (en) * 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroactive steriods and methods of use thereof
AU2019201275B2 (en) * 2013-03-13 2020-10-15 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
EP3461834A1 (en) * 2013-03-13 2019-04-03 Sage Therapeutics, Inc. Neuroactive steroids
JP2016514967A (en) * 2013-03-13 2016-05-26 セージ セラピューティクス， インコーポレイテッド Nerve stimulating steroids, compositions and uses thereof
US11905309B2 (en) 2013-03-13 2024-02-20 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
US11104701B2 (en) 2013-03-13 2021-08-31 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
WO2014160480A1 (en) 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
AU2021200205B2 (en) * 2013-03-13 2022-09-01 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
AU2014243773B2 (en) * 2013-03-13 2018-12-13 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
JP2018030890A (en) * 2013-03-13 2018-03-01 セージ セラピューティクス， インコーポレイテッド Neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US11241446B2 (en) 2013-04-17 2022-02-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10023606B2 (en) 2013-04-17 2018-07-17 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CN108440633A (en) * 2013-04-17 2018-08-24 萨奇治疗股份有限公司 19- goes the disubstituted C21-N- pyrazolyls steroids of first C3,3- and its application method
WO2014169836A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169833A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
US10822370B2 (en) 2013-04-17 2020-11-03 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10172871B2 (en) 2013-04-17 2019-01-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
WO2014169831A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
CN105339381B (en) * 2013-04-17 2018-04-27 萨奇治疗股份有限公司 19- goes the dibasic C21-N- pyrazolyls steroids of first C3,3- and its application method
US11261211B2 (en) 2013-04-17 2022-03-01 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US9365611B2 (en) 2013-04-17 2016-06-14 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US11344563B2 (en) 2013-04-17 2022-05-31 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US9512165B2 (en) 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10391106B2 (en) 2013-04-17 2019-08-27 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US10377790B2 (en) 2013-04-17 2019-08-13 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10342810B2 (en) 2013-04-17 2019-07-09 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US11912737B2 (en) 2013-04-17 2024-02-27 Sage Therpeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CN103333216A (en) * 2013-06-04 2013-10-02 苏州大学 5alpha-6-ketone-cholestane analogue and applications thereof
US10323059B2 (en) 2013-07-19 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11046728B2 (en) 2013-07-19 2021-06-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10272097B2 (en) 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)
US11612609B2 (en) 2013-12-24 2023-03-28 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
US10786517B2 (en) 2013-12-24 2020-09-29 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
US10723758B2 (en) 2014-06-18 2020-07-28 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP4306114A1 (en) * 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP2017518323A (en) * 2014-06-18 2017-07-06 セージ セラピューティクス， インコーポレイテッド Oxysterols and methods of use
EP3157528A4 (en) * 2014-06-18 2017-12-27 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10745436B2 (en) 2014-06-18 2020-08-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11780875B2 (en) 2014-06-18 2023-10-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US20170304321A1 (en) * 2014-10-07 2017-10-26 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
AU2021200721B2 (en) * 2014-10-07 2023-06-01 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
WO2016057713A1 (en) 2014-10-07 2016-04-14 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11542297B2 (en) 2014-10-16 2023-01-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11530237B2 (en) 2014-10-16 2022-12-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11945836B2 (en) 2014-11-27 2024-04-02 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11147877B2 (en) 2015-01-26 2021-10-19 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10426837B2 (en) 2015-01-26 2019-10-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11124538B2 (en) 2015-02-20 2021-09-21 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
RU2742333C2 (en) * 2015-07-06 2021-02-04 Сейдж Терапьютикс, Инк. Oxysteroles and methods of using them
US10765685B2 (en) 2015-07-06 2020-09-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
RU2744267C2 (en) * 2015-07-06 2021-03-04 Сейдж Терапьютикс, Инк. Oxysteroles and methods of using them
AU2021218227B2 (en) * 2015-07-06 2023-08-03 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3812392A1 (en) 2015-07-06 2021-04-28 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3828194A1 (en) * 2015-07-06 2021-06-02 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP4316591A3 (en) * 2015-07-06 2024-04-24 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017007840A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10201550B2 (en) 2015-07-06 2019-02-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN113292623A (en) * 2015-07-06 2021-08-24 萨奇治疗股份有限公司 Pregnansterol and methods of use thereof
US11732000B2 (en) 2015-07-06 2023-08-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP4316591A2 (en) 2015-07-06 2024-02-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2016289967B2 (en) * 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2016289971B2 (en) * 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2016289965B2 (en) * 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2016289971C1 (en) * 2015-07-06 2022-12-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3319612A4 (en) * 2015-07-06 2019-03-06 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3319611A4 (en) * 2015-07-06 2019-03-06 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3319610A4 (en) * 2015-07-06 2019-03-06 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2021218228B2 (en) * 2015-07-06 2023-11-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2021218230B2 (en) * 2015-07-06 2023-11-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11220476B2 (en) 2015-09-17 2022-01-11 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
US10869875B2 (en) 2015-10-26 2020-12-22 MAX BioPharma, Inc. Oxysterols and Hedgehog signaling
US10799463B2 (en) 2015-12-22 2020-10-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2017149052A1 (en) * 2016-03-02 2017-09-08 Patheon Austria Gmbh Co. & Kg Process and intermediates for the production of 17(20)-ene b-seco steroids
US11554125B2 (en) 2016-03-08 2023-01-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11884697B2 (en) 2016-04-01 2024-01-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3436022A4 (en) * 2016-04-01 2019-11-27 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017173358A1 (en) 2016-04-01 2017-10-05 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2017240157B2 (en) * 2016-04-01 2022-10-20 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11878995B2 (en) 2016-05-06 2024-01-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11407782B2 (en) 2016-05-06 2022-08-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10781231B2 (en) 2016-07-07 2020-09-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2021232833B2 (en) * 2016-07-07 2023-09-28 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2017292870B2 (en) * 2016-07-07 2021-10-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) * 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11279730B2 (en) 2016-07-07 2022-03-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3919502A1 (en) * 2016-07-07 2021-12-08 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
TWI752976B (en) * 2016-07-07 2022-01-21 美商賽吉醫療公司 Oxysterols and methods of use thereof
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11406646B2 (en) 2016-08-02 2022-08-09 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
AU2017337121B2 (en) * 2016-09-30 2022-01-27 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as NMDA modulators
US11926646B2 (en) 2016-09-30 2024-03-12 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
WO2018064649A1 (en) * 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11851457B2 (en) 2016-10-18 2023-12-26 Sage Therapeutics Oxysterols and methods of use thereof
US11613556B2 (en) 2016-10-18 2023-03-28 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
US11203569B2 (en) 2017-03-15 2021-12-21 Modernatx, Inc. Crystal forms of amino lipids
US10857105B2 (en) 2017-03-15 2020-12-08 MordernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
IT201700100483A1 (en) * 2017-09-07 2019-03-07 Dipharma Francis Srl SELECTIVE OXIDATION OF IODESEXICOLIC ACID
US11969506B2 (en) 2018-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
EP3829589A4 (en) * 2018-07-31 2022-07-27 The Research Foundation for the State University of New York Methods of activating microglial cells
EP3852764A4 (en) * 2018-09-19 2022-06-15 ModernaTX, Inc. Sterol analogs and uses thereof
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US11597698B2 (en) 2019-09-19 2023-03-07 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US11571432B2 (en) 2019-09-30 2023-02-07 Eliem Therapeutics (UK) Ltd Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US11090314B2 (en) 2019-09-30 2021-08-17 Eliem Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2022261510A1 (en) 2021-06-11 2022-12-15 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
WO2023049295A1 (en) 2021-09-22 2023-03-30 Sage Therapeutics, Inc. Deuterated positive nmda-modulating compounds and methods of use thereof
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Also Published As

Publication number Publication date
FI2753632T3 (en) 2023-08-02
US10759828B2 (en) 2020-09-01
JP6205362B2 (en) 2017-09-27
BR112014005373A2 (en) 2017-06-13
AU2012304412A1 (en) 2014-03-27
CN107936076A (en) 2018-04-20
US20230192756A1 (en) 2023-06-22
AU2023203028A1 (en) 2023-06-01
EP2753632A1 (en) 2014-07-16
DK2753632T3 (en) 2023-07-10
RS64332B1 (en) 2023-08-31
CN113956315A (en) 2022-01-21
AU2017204452B2 (en) 2019-06-20
HK1200173A1 (en) 2015-07-31
LT2753632T (en) 2023-07-10
EP4245369A3 (en) 2023-11-22
AU2021204183B2 (en) 2023-02-23
RU2018129752A (en) 2019-03-20
JP6777773B2 (en) 2020-10-28
PL2753632T3 (en) 2023-09-11
AU2021204183A1 (en) 2021-07-15
ES2951664T3 (en) 2023-10-24
JP2014526469A (en) 2014-10-06
JP2023040180A (en) 2023-03-22
HUE062616T2 (en) 2023-11-28
CN107936076B (en) 2021-10-15
RU2014113548A (en) 2015-10-20
AU2019227507A1 (en) 2019-09-26
EP2753632B1 (en) 2023-05-10
CA2848212C (en) 2022-03-29
US20210147470A1 (en) 2021-05-20
PT2753632T (en) 2023-08-17
CN103958540B (en) 2017-12-05
RU2665571C2 (en) 2018-08-31
SI2753632T1 (en) 2023-08-31
CA2848212A1 (en) 2013-03-14
AU2017204452A1 (en) 2017-07-20
AU2019227507B2 (en) 2021-04-01
EP4245369A2 (en) 2023-09-20
CN103958540A (en) 2014-07-30
BR112014005373B1 (en) 2022-04-19
JP2019077717A (en) 2019-05-23
JP2021008504A (en) 2021-01-28
US20180362573A1 (en) 2018-12-20
JP2018021059A (en) 2018-02-08
HRP20230747T1 (en) 2024-01-05
RU2018129752A3 (en) 2022-03-18
US20150158903A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
AU2021204183B2 (en) Neuroactive steroids, compositions, and uses thereof
AU2021204782B2 (en) 3,3 Disubstituted 19-nor pregnane compounds, compositions, and uses thereof
JP2022044802A (en) Neuroactive steroids, compositions, and uses thereof
RU2808165C2 (en) Neuroactive steroids, compositions and their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12766766

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014529913

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2848212

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012304412

Country of ref document: AU

Date of ref document: 20120907

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014113548

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014005373

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 14343603

Country of ref document: US

ENP Entry into the national phase

Ref document number: 112014005373

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140307

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112014005373

Country of ref document: BR

Kind code of ref document: A2

Free format text: APRESENTAR DOCUMENTO DE CESSAO DA PRIORIDADE US 61/532,427 ASSINADO E DATADO CONTENDO, PELO MENOS, NUMERO E DATA DE DEPOSITO DO DOCUMENTO DE PATENTE QUE ESTA SENDO CEDIDO, UMA VEZ QUE O DOCUMENTO ENVIADO NA PETICAO NO 020140009775 NAO APRESENTA OS DADOS IDENTIFICADORES DA PRIORIDADE, CONTEMPLANDO SOMENTE O TITULO NAO POSSIBILITANDO DETERMINAR A QUAL PRIORIDADE ELE SE REFERE.

ENP Entry into the national phase

Ref document number: 112014005373

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140307